<SEC-DOCUMENT>0001731122-25-000724.txt : 20250513
<SEC-HEADER>0001731122-25-000724.hdr.sgml : 20250513
<ACCEPTANCE-DATETIME>20250513163117
ACCESSION NUMBER:		0001731122-25-000724
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		49
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250513
DATE AS OF CHANGE:		20250513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				980608404
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		25940669

	BUSINESS ADDRESS:	
		STREET 1:		630 5TH AVENUE
		STREET 2:		20TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10111
		BUSINESS PHONE:		844-689-3939

	MAIL ADDRESS:	
		STREET 1:		630 5TH AVENUE
		STREET 2:		20TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e6578_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:avxl="http://anavex.com/20250331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02F_US%2DGAAP%2D2024%2D(with%2DECD)_rempres -->
<!-- Field: Set; Name: xdx; ID: xdx_038_avxl_anavex.com_20250331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20241001_20250331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wOS0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DDocumentFiscalYearFocus_2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--09-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000005" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000007" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31" id="xdx2ixbrl0087" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30" id="xdx2ixbrl0089" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2025-01-012025-03-31" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2023-10-012024-03-31" id="xdx2ixbrl0156" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="From2023-10-012024-03-31" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:IssuanceOfCommonShares" contextRef="From2024-10-01to2025-03-31" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommonStockIssuedUponCashlessExerciseOfStockOption" contextRef="From2023-10-012024-03-31" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:ExerciseOfStockOption" contextRef="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:ExerciseOfStockOption" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:ExerciseOfStockOptionAndTaxes" contextRef="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:ExerciseOfStockOptionAndTaxes" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:PurchaseShares" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CashlessExerciseOfStockOption" contextRef="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CashlessExerciseOfStockOption" contextRef="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesWithheldRelatedToAndTaxes" contextRef="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:SharesWithheldRelatedToAndTaxes" contextRef="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:PurchaseShares" contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:CommitmentShares" contextRef="From2023-10-012024-03-31" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:ExerciseOfStockOptions" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:ExerciseOfStockOptions" contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="avxl:ExerciseOfStockOptions" contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20250331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-10-01to2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_custom_MichaelJFoxFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-02</xbrli:startDate>
        <xbrli:endDate>2023-02-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-242022-03-25_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-24</xbrli:startDate>
        <xbrli:endDate>2022-03-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-17_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 14pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 14pt"><b>&#160;SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 18pt"><b>FORM
<span id="xdx_907_edei--DocumentType_c20241001__20250331_zOm20frxATe3"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000013" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 12pt"><b><span id="xdx_902_edei--DocumentQuarterlyReport_c20241001__20250331_z3zPjQjsS93h"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
</b></span><b><span style="font-size: 12pt">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF
1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_90F_edei--DocumentPeriodEndDate_c20241001__20250331_zkmUw7I5poY8"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate">March 31, 2025</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 12pt"><b><span id="xdx_907_edei--DocumentTransitionReport_c20241001__20250331_zAnU2zkJAAl7"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span><b><span style="font-size: 12pt">&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the transition period from _____to _____</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Commission File Number: <span style="text-decoration: underline"><span id="xdx_906_edei--EntityFileNumber_c20241001__20250331_z860AohdtMjl"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000017" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 24pt"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityRegistrantName_c20241001__20250331_zahEyO5tx1n1"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000018" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>&#160;</b>(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20241001__20250331_zJSD2cqHbem2"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20241001__20250331_zBvfGjYplvpb"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000020" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction
    of</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation or organization)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_901_edei--EntityAddressAddressLine1_c20241001__20250331_zlOFijLMxcB1"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000021" name="dei:EntityAddressAddressLine1">630 5th Avenue</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20241001__20250331_zue0CrjJT5Vl"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000022" name="dei:EntityAddressAddressLine2">20th Floor</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressCityOrTown_c20241001__20250331_znaf0eCsnzth"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000023" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20241001__20250331_zcvKH9R3AQD2"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000024" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressCountry_c20241001__20250331_zMlPKoaIFMz3"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000025" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A
<span id="xdx_904_edei--EntityAddressPostalZipCode_c20241001__20250331_zrbJ0nHK4XPl"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">10111</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;(Address of principal executive offices) (Zip
Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">1-<span id="xdx_903_edei--CityAreaCode_c20241001__20250331_zMTmt0e5KXl2"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000027" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_903_edei--LocalPhoneNumber_c20241001__20250331_zNk2DrffgAbl"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000028" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b>(Registrant&#8217;s telephone number,
including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities Registered Pursuant to Section&#160;12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Each Class</span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Each Exchange on Which Registered</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20241001__20250331_z0OjpqNAj4Z8"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000029" name="dei:Security12bTitle">Common Stock
    Par Value $0.001</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20241001__20250331_z1II411NUng"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000030" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SecurityExchangeName_c20241001__20250331_zKIsJ60Qcb4h"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock
    Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>&#160;<b><span id="xdx_90A_edei--EntityCurrentReportingStatus_c20241001__20250331_zRKz3lm4Guel"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000032" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
No</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>
<b><span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20241001__20250331_zE8CxcIl7VZ8"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" id="Fact000033" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span> No</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and
&#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated
    filer</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 44%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 26%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityFilerCategory_c20241001__20250331_zryrvwXQaALf"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000034" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntitySmallBusiness_c20241001__20250331_ztZAlIPZ0nVe"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt:booleantrue" id="Fact000035" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20241001__20250331_zxbulNqxrYNg"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Segoe UI Symbol,sans-serif; margin: 0; text-align: right"><b>&#9744;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Exchange Act).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> <span id="xdx_904_edei--EntityShellCompany_c20241001__20250331_zzDlBzFY0Jk7"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt:booleanfalse" id="Fact000037" name="dei:EntityShellCompany">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares outstanding of each
of the issuer&#8217;s classes of Common Stock, as of the latest practicable date: <span><span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_c20250513_z4BJmcm0BfW6"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-05-13" id="Fact000038" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,371,852</ix:nonFraction></span></span>
shares of Common Stock outstanding as of May 13, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">TABLE OF CONTENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left; padding-top: 0cm; padding-bottom: 0pt; padding-left: 0cm"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I &#8211; FINANCIAL INFORMATION</b></span></a></td>
    <td style="width: 10%; text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1. FINANCIAL STATEMENTS</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4. CONTROLS AND PROCEDURES</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0pt; padding-left: 0cm"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II &#8211; OTHER INFORMATION</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1. LEGAL PROCEEDINGS</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1A. RISK FACTORS</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4. MINE SAFETY DISCLOSURES</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 5. OTHER INFORMATION</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0pt; padding-left: 0cm"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I &#8211; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_002"></span>ITEM 1. FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="margin: 0"></p>



<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>ANAVEX LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">March 31, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_pn3n3_zuJP0RyepWUg" summary="xdx: Statement - Condensed Consolidated Interim Balance Sheets (Unaudited)" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" id="xdx_491_20250331_zxBYqurH3c6e" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" id="xdx_49C_20240930" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="9" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="9" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
Consolidated Interim Balance Sheets</span></td></tr>
<tr style="vertical-align: bottom">
<td colspan="9" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands, except share and per share amounts)</span></td></tr>
<tr style="vertical-align: bottom">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31,</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
30,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--AssetsAbstract_iB_ztSoZ1kXuoT1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_z6HaiXnGMnK6" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzBZA_z9iZJT6GAdL" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact000046" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115,771</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-09-30" id="Fact000047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132,187</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--IncomeTaxesReceivable_i02I_maCzBZA_zjJJl7fDqC72" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
and tax receivables</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2025-03-31" id="Fact000049" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">666</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2024-09-30" id="Fact000050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,449</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzBZA_zF0Aqulvg6W3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" id="Fact000052" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">702</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-09-30" id="Fact000053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">931</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--Assets_i01TI_mtCzBZA_zthG8ZJ6i7u1" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
Assets</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-03-31" id="Fact000055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,139</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-09-30" id="Fact000056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135,567</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_i" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
and Stockholders&#8217; Equity</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesCurrentAbstract_iB_zQkyGE6rW2wa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
Liabilities</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_iI_maCzODo_zjpTVD4pG0we" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
payable</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-03-31" id="Fact000064" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,997</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-09-30" id="Fact000065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,627</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iI_maCzODo_zblFyAjXcaFl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
liabilities - Note 3</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,555</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000068" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,835</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--DeferredIncomeCurrent_iI_maCzODo_zu2EbJmt4Vjc" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
grant income - Note 4</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2025-03-31" id="Fact000070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">829</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2024-09-30" id="Fact000071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">842</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--Liabilities_iTI_mtCzODo_maCzthI_z4aHQ4dXd02d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
Liabilities</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-03-31" id="Fact000073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,381</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-09-30" id="Fact000074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,304</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--CommitmentsAndContingencies_iI_maCzthI_z4l4bjhs3wjd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
and Contingencies - Note 6</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
stock</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized:</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20250331_zZoxsxtj3Ou1" title="Preferred stock, shares authorized"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20240930_zCMehEOWPj0e" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000079" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact000081" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span>
preferred stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20250331_zuulEhMW9Lo" title="Preferred stock, par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20240930_zTj9r48dkamd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000083" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact000085" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_981_eus-gaap--PreferredStockValue_iI_pn3n3_maCzA3o_c20250331_zhYcD784oYI9" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="text-align: right"><span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0087">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98B_eus-gaap--PreferredStockValue_iI_pn3n3_maCzA3o_c20240930_zoAUvWOKCzJb" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="text-align: right"><span style="color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0089">&#8212;</span></span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20250331_zkKt96XnyIa1" title="Common stock, shares authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240930_zywTO0l22uGg" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000091" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact000093" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span>
common stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20250331_zxx8AHdXfqV1" title="Common stock, par value"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20240930_z4ysXSEWVdBe" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000095" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact000097" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
and outstanding:</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pip0_c20250331_z4wZRO3sKhOf" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20250331_zhKCOyE8ilv" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31" id="Fact000099" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000101" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">85,333,652</ix:nonFraction></ix:nonFraction></span></span>
common shares (2024 - <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pip0_c20240930_zrEGTH22Zi3k" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20240930_zzndQFEW9qd4" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30" id="Fact000103" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" id="Fact000105" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">84,795,517</ix:nonFraction></ix:nonFraction></span></span>)</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_98B_eus-gaap--CommonStockValue_iI_pn3n3_maCzA3o_c20250331_zg3ytnMlVJxj" title="Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 84,985,449 common shares (September 30, 2024 - 84,795,517)" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-03-31" id="Fact000107" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td id="xdx_985_eus-gaap--CommonStockValue_iI_pn3n3_maCzA3o_c20240930_z4HPPKMRJWZ8" title="Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 84,985,449 common shares (September 30, 2024 - 84,795,517)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" id="Fact000109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_maCzA3o_zpoPDQnlCga5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
paid-in capital</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2025-03-31" id="Fact000111" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">459,051</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-09-30" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">456,249</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzA3o_z4SnwfO1tlki" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
deficit</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" id="Fact000114" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">359,378</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">336,071</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--StockholdersEquity_iTI_mtCzA3o_maCzthI_zNgCdeLWLZx2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
Stockholders&#8217; Equity</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99,758</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,263</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzthI_z6BHb25PHQC3" style="vertical-align: bottom; background-color: White">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
Liabilities and Stockholders&#8217; Equity</span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117,139</ix:nonFraction></span></td>
<td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135,567</ix:nonFraction></span></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_pn3n3_zAsdx1hFAuJd" summary="xdx: Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_490_20250101__20250331_z4EnEjvw6GA9" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_491_20240101__20240331_zS4QMiknuLBf" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49C_20241001__20250331_zGYqU8L2IKyg" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_493_20231001__20240331_zrk8GTnRSh58" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="17" style="font-weight: bold; text-align: center">Anavex Life Sciences Corp.</td></tr>
<tr style="vertical-align: bottom">
<td colspan="17" style="font-weight: bold; text-align: center">Condensed Consolidated Interim Statements of Operations and Comprehensive Loss</td></tr>
<tr style="vertical-align: bottom">
<td colspan="17" style="font-weight: bold; text-align: center">(in thousands, except share and per share amounts)</td></tr>
<tr style="vertical-align: bottom">
<td colspan="17" style="font-weight: bold; text-align: center">(Unaudited)</td></tr>
<tr style="vertical-align: bottom">
<td colspan="9" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="7" style="font-weight: bold; text-align: center">Three months ended March 31,</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="7" style="font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_z9WBHOC3rC4k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Operating expenses</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzu50_z2CdS3OVYcCh" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td>
<td style="width: 3%; font-weight: bold">&#160;</td>
<td style="width: 1%; font-weight: bold; text-align: left">$</td>
<td style="width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-012025-03-31" id="Fact000128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,621</ix:nonFraction></td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-03-31" id="Fact000129" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,895</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%; font-weight: bold">&#160;</td>
<td style="width: 1%; font-weight: bold; text-align: left">$</td>
<td style="width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-10-01to2025-03-31" id="Fact000130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,767</ix:nonFraction></td>
<td style="width: 1%; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-10-012024-03-31" id="Fact000131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,590</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzu50_zMNSteSWK516" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-03-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,892</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,729</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-10-01to2025-03-31" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,338</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-10-012024-03-31" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,413</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtCzu50_msCzGXF_zygBI6iVWhKg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total operating expenses</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-012025-03-31" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,513</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-03-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,624</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-10-01to2025-03-31" id="Fact000140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,105</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-10-012024-03-31" id="Fact000141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,003</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingIncomeLoss_i01T_mtCzGXF_maCzhpv_z7MpRYCBYZvk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating loss</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-012025-03-31" id="Fact000143" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,513</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000144" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,624</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-10-01to2025-03-31" id="Fact000145" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">26,105</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-10-012024-03-31" id="Fact000146" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24,003</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zjjWFK1wE1N8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other income (expense)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_ecustom--NonOperatingIncomeFromGrants_i01_maCzuag_zfJFyQaVKFE2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Grant income</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0154">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2024-10-01to2025-03-31" id="Fact000155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0156">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzuag_zGc2pYU8iuni" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development incentive income</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2025-01-012025-03-31" id="Fact000158" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2024-01-012024-03-31" id="Fact000159" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">472</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><b><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2024-10-01to2025-03-31" id="Fact000160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">508</ix:nonFraction></b></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2023-10-012024-03-31" id="Fact000161" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,064</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--InterestIncomeExpenseNet_i01_maCzuag_z1oGbqEE7Ib4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest income, net</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2025-01-012025-03-31" id="Fact000163" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,210</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-012024-03-31" id="Fact000164" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,756</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-10-01to2025-03-31" id="Fact000165" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,604</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-10-012024-03-31" id="Fact000166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,764</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzuag_zalNjvgw1K2d" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange gain (loss)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-01-012025-03-31" id="Fact000168" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-012024-03-31" id="Fact000169" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">150</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-10-01to2025-03-31" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">326</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-10-012024-03-31" id="Fact000171" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzuag_maCzhpv_z230u4EXTlba" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total other income, net</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-012025-03-31" id="Fact000173" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,317</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-03-31" id="Fact000174" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,078</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-10-01to2025-03-31" id="Fact000175" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,798</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-10-012024-03-31" id="Fact000176" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,835</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--NetIncomeLoss_iT_mtCzhpv_z3LD8AKAeKS4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss and comprehensive loss</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,196</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,546</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left"><b>$</b></td>
<td style="border-bottom: Black 1pt solid; text-align: right"><b>(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2025-03-31" id="Fact000180" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,307</ix:nonFraction></b></td>
<td style="padding-bottom: 1pt; text-align: left"><b>)</b></td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31" id="Fact000181" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,168</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--EarningsPerShareAbstract_iB_zJ4tqqmGOPX8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Net Loss per share</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pip0_c20250101__20250331_zSUJ7QQ0KFqk" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_pip0_c20250101__20250331_z9YTnyTnEPJe" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-012025-03-31" id="Fact000188" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-012025-03-31" id="Fact000190" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pip0_c20240101__20240331_zyUX6yhB1XWe" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pip0_c20240101__20240331_zfSymdfrOBl6" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-03-31" id="Fact000192" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-03-31" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pip0_c20241001__20250331_ztaJv8gFqyh4" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20241001__20250331_zmo5ZJQWYFD7" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-10-01to2025-03-31" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-10-01to2025-03-31" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.27</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_pip0_c20231001__20240331_zFUqJhM3aZS2" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20240331_zOuftZt0YEKc" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-10-012024-03-31" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-012024-03-31" id="Fact000202" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_z8iCFlQob4V9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Weighted average number of shares outstanding</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20250101__20250331_zZL508lFHI4b" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20250101__20250331_z20mQDwEzsc3" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-012025-03-31" id="Fact000209" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-012025-03-31" id="Fact000211" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">85,073,769</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20240101__20240331_z8IREmIZxM25" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20240101__20240331_zI189XULziGj" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-03-31" id="Fact000213" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-03-31" id="Fact000215" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,464,226</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20241001__20250331_zYe1SYIA8pJ4" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20241001__20250331_zXGgp45Ynmf3" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-10-01to2025-03-31" id="Fact000217" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-10-01to2025-03-31" id="Fact000219" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">84,938,400</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20231001__20240331_zsAO3rGI1x77" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20231001__20240331_zDEcHNfJ9Yvd" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-10-012024-03-31" id="Fact000221" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-012024-03-31" id="Fact000223" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,269,965</ix:nonFraction></ix:nonFraction></span></span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_pn3n3_z64QlECN8Nnk" summary="xdx: Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_49C_20241001__20250331_zsQbvM8WTxe" style="font-weight: bold; text-align: right">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_49B_20231001__20240331_zvIInKCcz0X2" style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="9" style="font-weight: bold; text-align: center">Anavex Life Sciences Corp.</td></tr>
<tr style="vertical-align: bottom">
<td colspan="9" style="font-weight: bold; text-align: center">Condensed Consolidated Interim Statements of Cash Flows</td></tr>
<tr style="vertical-align: bottom">
<td colspan="9" style="font-weight: bold; text-align: center">(in thousands, except share and per share amounts)</td></tr>
<tr style="vertical-align: bottom">
<td colspan="9" style="font-weight: bold; text-align: center">(Unaudited)</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="7" style="font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td>
<td>&#160;</td>
<td colspan="3" style="text-align: center">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zjTJPGnKhTNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows used in Operating Activities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maCzRp4_zktu2VB6ofBd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net loss</td>
<td style="width: 8%; font-weight: bold">&#160;</td>
<td style="width: 1%; font-weight: bold; text-align: left">$</td>
<td style="width: 12%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2025-03-31" id="Fact000228" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,307</ix:nonFraction></td>
<td style="width: 1%; font-weight: bold; text-align: left">)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,168</ix:nonFraction></td>
<td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zNBWRhAJ4xPj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operations:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--ShareBasedCompensation_i02_maCzRp4_zhMa3R1okfW6" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Share based compensation</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-01to2025-03-31" id="Fact000234" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,504</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-03-31" id="Fact000235" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,938</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zypgX5cTxAHh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Changes in working capital balances related to operations:</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCzRp4_zSZYtj5ssN1f" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2024-10-01to2025-03-31" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,783</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2023-10-012024-03-31" id="Fact000241" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,076</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzRp4_zed0mRCL66E3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and deposits</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-10-01to2025-03-31" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">229</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-10-012024-03-31" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">692</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzRp4_zNb8TcyFA2vd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-10-01to2025-03-31" id="Fact000246" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,893</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-10-012024-03-31" id="Fact000247" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">596</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzRp4_zzXjUcXHbQxj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-10-01to2025-03-31" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,720</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-10-012024-03-31" id="Fact000250" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,380</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_403_ecustom--DeferredGrantIncome_i02N_di_msCzRp4_zxOuCUnDukYk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="From2024-10-01to2025-03-31" id="Fact000252" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzRp4_maCzATE_zXffz2j3SLn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash used in operating activities</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-10-01to2025-03-31" id="Fact000255" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,976</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-10-012024-03-31" id="Fact000256" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,974</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zQJ2t9mwpDp8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows provided by Financing Activities</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--IssuanceOfCommonShares_i01_maCzKw3_zyFHhm1ThPLj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Issuance of common shares</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:IssuanceOfCommonShares" contextRef="From2023-10-012024-03-31" id="Fact000262" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,178</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzKw3_zFNL72b7K2h9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Proceeds from exercise of stock options</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2024-10-01to2025-03-31" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,560</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-10-012024-03-31" id="Fact000265" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzKw3_maCzATE_zHIiQiIDmuQc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash provided by (used in) financing activities</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-10-01to2025-03-31" id="Fact000267" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,560</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-10-012024-03-31" id="Fact000268" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,336</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzATE_zMVwlIgX4nC6" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Decrease in cash and cash equivalents during the period</td>
<td style="font-weight: bold">&#160;</td>
<td style="font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-10-01to2025-03-31" id="Fact000270" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,416</ix:nonFraction></td>
<td style="font-weight: bold; text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-10-012024-03-31" id="Fact000271" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,638</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zTZ4K87CZdx8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash and cash equivalents, beginning of period</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" id="Fact000273" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132,187</ix:nonFraction></td>
<td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151,024</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zAKoV3hAFie" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash and cash equivalents, end of period</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31" id="Fact000276" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115,771</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000277" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139,386</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z3Zijdb20job" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Supplemental Cash Flow Information</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--CashPaidForStateAndLocalFranchiseTaxes_i01_zNrcc2cIHKEc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash paid for state and local franchise taxes</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalFranchiseTaxes" contextRef="From2024-10-01to2025-03-31" id="Fact000282" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalFranchiseTaxes" contextRef="From2023-10-012024-03-31" id="Fact000283" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">220</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--CommonStockIssuedUponCashlessExerciseOfStockOption_i01_zKjU8ufyM9n7" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Common stock issued upon cashless exercise of stock option</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:CommonStockIssuedUponCashlessExerciseOfStockOption" contextRef="From2024-10-01to2025-03-31" id="Fact000285" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">460</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; width: 100%; text-align: center"><span style="font-size: 10pt"><b>Anavex Life Sciences Corp.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-size: 10pt"><b>Condensed Consolidated Interim Statements of Changes in Stockholders&#8217; Equity</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-size: 10pt"><b>For the three months ended March 31, 2025 and 2024</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-size: 10pt"><b>(in thousands, except share and per share amounts)</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; text-align: center"><span style="font-size: 10pt"><b>(Unaudited)</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<table cellpadding="0" cellspacing="0" id="xdx_30A_114_pn3n3_zFqBT27LPIu5" summary="xdx: Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zBRQqh3x8zW9" style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zF91jFVkH2Mg" style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_custom--ShareProceedsReceivableMember_zymCeT476cPf" style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zKucZsTAnUy3" style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td id="xdx_4BD_zF0vECYNejba" style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="7" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Common Stock</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Additional</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Share Proceeds</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Accumulated</td>
<td style="font-size: 11pt">&#160;</td>
<td colspan="3" style="font-size: 11pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Shares</td>
<td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Par Value</td>
<td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Paid-in Capital</td>
<td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Receivable</td>
<td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Deficit</td>
<td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Total</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td></tr>
<tr id="xdx_438_c20250101__20250331_eus-gaap--StockholdersEquity_iS_zWpjTWuoeTr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-indent: -10pt">Balance, January 1, 2025</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_987_eus-gaap--SharesOutstanding_iS_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRpjoACMH4b8" title="Balance at beginning, shares" style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000294" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">84,985,449</ix:nonFraction></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000288" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000289" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">459,012</ix:nonFraction></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">348,182</ix:nonFraction></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000292" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110,915</ix:nonFraction></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Shares issued pursuant to exercise of</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zQmfzLb4sb4h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">stock options</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_988_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXFuULrIZqMa" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000302" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">130,700</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">852</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2025-01-012025-03-31" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">852</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to cashless</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_ecustom--ExerciseOfStockOption_zQdf25f3ez0g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">exercise of stock option</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98C_ecustom--ExerciseOfStockOptionShares_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zG2IDS2Wwv8k" title="exercise of stock option, shares" style="text-align: right"><ix:nonFraction name="avxl:ExerciseOfStockOptionShares" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000310" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">500,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:ExerciseOfStockOption" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:ExerciseOfStockOption" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000305" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">459</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:ExerciseOfStockOption" contextRef="From2025-01-012025-03-31" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">460</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares withheld related to cashless</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_ecustom--ExerciseOfStockOptionAndTaxes_zPukn5AM5NA3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">exercise of stock option and taxes</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_989_ecustom--ExerciseOfStockOptionAndTaxesShares_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCyPrJoLT3b7" title="exercise of stock option and taxes, shares" style="text-align: right">(<ix:nonFraction name="avxl:ExerciseOfStockOptionAndTaxesShares" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000318" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="Shares">282,497</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="avxl:ExerciseOfStockOptionAndTaxes" contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember" id="Fact000312" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="avxl:ExerciseOfStockOptionAndTaxes" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000313" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,721</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="avxl:ExerciseOfStockOptionAndTaxes" contextRef="From2025-01-012025-03-31" id="Fact000316" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,722</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zjMY5Wxqt5Ef" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000321" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,449</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-03-31" id="Fact000324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,449</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--NetIncomeLoss_zcAzIrIrV3fe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact000329" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,196</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-03-31" id="Fact000330" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,196</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_433_c20250101__20250331_eus-gaap--StockholdersEquity_iE_zpc83EuDtnjk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 10pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-indent: -10pt">Balance, March 31, 2025</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_981_eus-gaap--SharesOutstanding_iE_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOYOMfqwOCw3" title="Balance at beginning, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">85,333,652</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000333" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">459,051</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000335" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">359,378</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99,758</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-indent: -10pt">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_431_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zV74KtgELDEc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-indent: -10pt">Balance, January 1, 2024</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pip0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2KRosFXFUck" title="Balance at beginning, shares" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000346" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,086,511</ix:nonFraction></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000341" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">437,184</ix:nonFraction></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000343" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">301,691</ix:nonFraction></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135,575</ix:nonFraction></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2023 purchase</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">agreement</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--PurchaseShares_iP3us-gaap--SharesOutstanding_z3yw8vTeOjW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Purchase shares</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98A_ecustom--PurchaseSharesShares_iP3custom--PurchaseShares_pip0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTGV0XmiPcL4" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="avxl:PurchaseSharesShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,500,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:PurchaseShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:PurchaseShares" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000349" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,410</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="avxl:PurchaseShares" contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember" id="Fact000350" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:PurchaseShares" contextRef="From2024-01-012024-03-31" id="Fact000352" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,178</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_ecustom--CommitmentShares_iP3custom--PurchaseSharesShares_z4aYHVJqh4p1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Commitment shares</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_982_ecustom--CommitmentSharesShares_iP3custom--CommitmentShares_pip0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbObuYPTjP74" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000362" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,707</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Shares issued pursuant to exercise of</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_iP3custom--CommitmentSharesShares_zAQ961mtmMvd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">stock options</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_984_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_iP3custom--SharesIssuedPursuantToExerciseOfStockOptions_pip0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZCyXowNFsy8" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">26,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000365" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-01-012024-03-31" id="Fact000368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zYU3Ww70Rb4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000373" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,652</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,652</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--NetIncomeLoss_zllECUR0ilwc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,546</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000382" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,546</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_436_c20240101__20240331_eus-gaap--StockholdersEquity_iE_zWktEUCldpVg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-indent: -10pt">Balance, March 31, 2024</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_984_eus-gaap--SharesOutstanding_iE_pip0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeYh4JuDL7ob" title="Balance at beginning, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">83,616,218</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000385" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">447,345</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_ShareProceedsReceivableMember" id="Fact000386" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000387" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">312,237</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000388" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134,958</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; width: 100%; text-align: center; text-indent: 0pt"><span style="font-size: 10pt"><b>Anavex Life Sciences Corp.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt"><b>Condensed Consolidated Interim Statements of Changes in Stockholders&#8217; Equity</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt"><b>For the six months ended March 31, 2025 and 2024</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt"><b>(in thousands, except share and per share amounts)</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt"><b>(Unaudited)</b></span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="7" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Common Stock</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Additional</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Share Proceeds</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Accumulated</td>
<td style="font-size: 11pt">&#160;</td>
<td colspan="3" style="font-size: 11pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Shares</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Par Value</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Paid-in Capital</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Receivable</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Deficit</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">Total</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td colspan="3" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center">&#160;</td></tr>
<tr id="xdx_434_c20241001__20250331_eus-gaap--StockholdersEquity_iS_z0VPDXGxdpy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-indent: -10pt">Balance, October 1, 2024</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pip0_c20241001__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziH7AjeS8hb7" title="Balance at beginning, shares" style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000398" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">84,795,517</ix:nonFraction></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000392" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000393" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">456,249</ix:nonFraction></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000395" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">336,071</ix:nonFraction></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)</td>
<td style="width: 2%; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="width: 6%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000396" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120,263</ix:nonFraction></td>
<td style="width: 1%; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zcIEAiQ2eCx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">exercise of stock options</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_984_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20241001__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx4iMBiG19Ad" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember" id="Fact000406" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">320,632</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000401" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,560</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-10-01to2025-03-31" id="Fact000404" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,560</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--CashlessExerciseOfStockOption_iP3custom--SharesIssuedPursuantToExerciseOfStockOptionsShares_zwHKOW0o3Vlh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">cashless exercise of stock option</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_988_ecustom--CashlessExerciseOfStockOptionShares_iP3custom--CashlessExerciseOfStockOption_pip0_c20241001__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8x6i9pLWWz8" title="cashless exercise of stock option, shares" style="text-align: right"><ix:nonFraction name="avxl:CashlessExerciseOfStockOptionShares" contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember" id="Fact000414" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">500,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:CashlessExerciseOfStockOption" contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember" id="Fact000408" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:CashlessExerciseOfStockOption" contextRef="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000409" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">459</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:CashlessExerciseOfStockOption" contextRef="From2024-10-01to2025-03-31" id="Fact000412" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">460</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares withheld related to</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">cashless exercise of stock option</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--SharesWithheldRelatedToAndTaxes_iP3custom--CashlessExerciseOfStockOptionShares_zqfMiRCpK515" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">and taxes</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98C_ecustom--SharesWithheldRelatedToAndTaxesShares_iP3custom--SharesWithheldRelatedToAndTaxes_pip0_c20241001__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2Niyq8MvsQg" title="Shares withheld related to cashless exercise of stock option and taxes, shares" style="text-align: right">(<ix:nonFraction name="avxl:SharesWithheldRelatedToAndTaxesShares" contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember" id="Fact000422" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="Shares">282,497</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="avxl:SharesWithheldRelatedToAndTaxes" contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember" id="Fact000416" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="avxl:SharesWithheldRelatedToAndTaxes" contextRef="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000417" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,721</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="avxl:SharesWithheldRelatedToAndTaxes" contextRef="From2024-10-01to2025-03-31" id="Fact000420" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,722</ix:nonFraction></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zzJYQ7pw3xI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000425" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,504</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-10-01to2025-03-31" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,504</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--NetIncomeLoss_zhTkMNjUKDW" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,307</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-10-01to2025-03-31" id="Fact000434" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,307</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_432_c20241001__20250331_eus-gaap--StockholdersEquity_iE_zXr0hhRw2hgc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 2.5pt 10pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-indent: -10pt">Balance, March 31, 2025</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pip0_c20241001__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoVSbEdypro7" title="Balance at ending, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000442" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">85,333,652</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000436" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">459,051</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8212;</span></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">359,378</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000440" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99,758</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-indent: -10pt">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_43A_c20231001__20240331_eus-gaap--StockholdersEquity_iS_zuMUa78uMlgj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-indent: -10pt">Balance, October 1, 2023</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pip0_c20231001__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgLA2o0tlXE1" title="Balance at beginning, shares" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000450" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,066,511</ix:nonFraction></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434,839</ix:nonFraction></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293,069</ix:nonFraction></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000448" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141,852</ix:nonFraction></td>
<td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Shares issued under 2023</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Purchase Agreement</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--PurchaseShares_zS5C9nziVvnb" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Purchase shares</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98F_ecustom--PurchaseSharesShares_pip0_c20231001__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztmOFJUB43L6" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="avxl:PurchaseSharesShares" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="Fact000458" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,500,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:PurchaseShares" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="Fact000452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:PurchaseShares" contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,410</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(<ix:nonFraction name="avxl:PurchaseShares" contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction></td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:PurchaseShares" contextRef="From2023-10-012024-03-31" id="Fact000456" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,178</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--CommitmentShares_zuFikifNEK73" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Commitment shares</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_985_ecustom--CommitmentSharesShares_pip0_c20231001__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeJEcrb66gq7" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="Fact000466" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,707</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td>
<td style="font-size: 11pt; text-align: right">&#160;</td>
<td style="font-size: 11pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--ExerciseOfStockOptions_zrlyfwAPYTUj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">exercise of stock options</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_986_ecustom--ExerciseOfStockOptionsShares_pip0_c20231001__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zevdEQfcRx5k" title="exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:ExerciseOfStockOptionsShares" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="Fact000474" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">46,000</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:ExerciseOfStockOptions" contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000469" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:ExerciseOfStockOptions" contextRef="From2023-10-012024-03-31" id="Fact000472" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zgGpYMXpcxI4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,938</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-03-31" id="Fact000480" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,938</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--NetIncomeLoss_zVpdrxLKiMDa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Net loss</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8212;</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000485" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,168</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31" id="Fact000486" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,168</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_430_c20231001__20240331_eus-gaap--StockholdersEquity_iE_zXih40IpIaxl" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 2.5pt 10pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-indent: -10pt">Balance, March 31, 2024</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pip0_c20231001__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUJ9ppfTb28h" title="Balance at ending, shares" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000494" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">83,616,218</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000488" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000489" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">447,345</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_ShareProceedsReceivableMember" id="Fact000490" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">312,237</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)</td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000492" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134,958</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">&#160;</td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">See Accompanying Notes to Condensed Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Notes to the Condensed Consolidated Interim Financial Statements
<br/>
March 31, 2025 Page 1 <br/>
(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000496" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z9R5f4dEeaZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 	<span id="xdx_82F_zTFTJfB8thWk">Business Description</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s focus is on developing innovative
treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000498" name="us-gaap:BasisOfAccounting"><p id="xdx_80C_eus-gaap--BasisOfAccounting_zexirGCAj3Nb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 2 	<span id="xdx_823_z36cN1o8XQ12">Basis of Presentation</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed consolidated
interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed consolidated
interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are
necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2024 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto
included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2024 filed with the SEC on December 23, 2024.
The Company follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the six months ended March 31,
2025 are not necessarily indicative of the results that may be expected for the year ending September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain immaterial amounts from prior periods have
been reclassified to conform to the current year&#8217;s presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000500" name="avxl:LiquidityPolicyTextBlock"><p id="xdx_848_ecustom--LiquidityPolicyTextBlock_zICIurpE8pEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_zeR0VfVzmDJ9">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenue from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed consolidated interim financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zJ4buRG8koY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div id="xdx_23C_zVJwylXQSzPa" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zNCR73MJBRTe" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_z6PBXy7mJjlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_z9DEHKXvjYL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zo7I0Qyhzetl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Notes to the Condensed Consolidated Interim Financial Statements
<br/>
March 31, 2025 Page 2 <br/>
(Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_237_zXgcIs3YtEL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. The Company will need to obtain effectiveness of a new registration
statement in order to access the funds under the 2023 Purchase Agreement. If the Company is not able to obtain the additional financing
on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000507" name="us-gaap:UseOfEstimates"><p id="xdx_84E_eus-gaap--UseOfEstimates_zvoBFwCpEkv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zrQtwQDPhyT7">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000509" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zyMLo2kqnlP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zwYdubCxIUV4">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These unaudited condensed consolidated interim financial
statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex
Australia&#8221;), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany,
and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances
have been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000511" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zORTeRDCLXV" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zLXB3vMTixZ4">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025 and September 30, 2024, the Company
did not have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_z3A5EVvJPJb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div id="xdx_236_zICqcDfB4Wbh" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_zBstw2ElJPN7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zBlqFUT5TW2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zk3P5nHlXJu" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zby86nMDeBPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Notes to the Condensed Consolidated Interim Financial Statements
<br/>
March 31, 2025 Page 3 <br/>
(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_239_zb6VGuRJPZui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000518" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zEziszRJ3yNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zNJJ33As7Ie7">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025 loss per share excludes <span id="xdx_900_ecustom--DilutiveCommonShares_iI_pip0_c20250331_zd47XwkTDlq1" title="Dilutive common shares"><ix:nonFraction name="avxl:DilutiveCommonShares" contextRef="AsOf2025-03-31" id="Fact000520" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,710,622</ix:nonFraction></span>
(March 31, 2024: <span id="xdx_90B_ecustom--DilutiveCommonShares_iI_pip0_c20240331_zSr7AeeGJm0c" title="Dilutive common shares"><ix:nonFraction name="avxl:DilutiveCommonShares" contextRef="AsOf2024-03-31" id="Fact000522" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,755,114</ix:nonFraction></span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000524" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv2UtPTYfkUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_86C_zhB6e4utZRmk">Recent Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2023, the Financial
Accounting Standards Board (FASB) issued ASU No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221;
This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our
fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30, 2026. The Company is currently
assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000526" name="avxl:AccuredLiabilitiesTextBlock"><p id="xdx_80D_ecustom--AccuredLiabilitiesTextBlock_zfzFq0XHzQRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 3	<span id="xdx_822_zMut58cTdmi9">Accrued Liabilities</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000528" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zTR76Me0xrG8" summary="xdx: Disclosure - Accrued Liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B6_zAYunKXtNpH6" style="display: none">Schedule of principal components of accrued liabilities</span></td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_49C_20250331_zD5WUULJawa9" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_49E_20240930_zfej5vkDkEW2" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_405_ecustom--AccruedInvestigatorPayments_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedInvestigatorPayments" contextRef="AsOf2025-03-31" id="Fact000530" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,459</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedInvestigatorPayments" contextRef="AsOf2024-09-30" id="Fact000531" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">860</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2025-03-31" id="Fact000533" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,200</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2024-09-30" id="Fact000534" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,527</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2025-03-31" id="Fact000536" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,332</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2024-09-30" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">557</ix:nonFraction></td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000539" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,564</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000540" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,891</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_zGSWkP31omT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000542" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,555</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,835</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000545" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_80C_ecustom--OtherIncomeDisclosureTextBlock_zk66xjkPwUGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 4	<span id="xdx_823_z8t8ZdZUxhs9">Other Income</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of March 31, 2025, the
Company had received a $<span id="xdx_90D_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20241001__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zQMM4WfPKBi1" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" contextRef="From2024-10-012025-03-31_custom_MichaelJFoxFoundationMember" id="Fact000547" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant
will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) related to Parkinson&#8217;s
disease. Of the total, $<span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20221001__20230930_zJRplDwq78Q8" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" contextRef="From2022-10-012023-09-30" id="Fact000549" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million was received during the year ended September 30, 2023 and $<span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20201001__20210930_z1MYgO9BrOEj" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" contextRef="From2020-10-012021-09-30" id="Fact000551" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million was received during the year
ended September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income was
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the three and six months ended March 31, 2025, the Company recognized $<span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20250101__20250331_zDkAYP2l8lVj" title="Non operating income from grant"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2025-01-012025-03-31" id="Fact000553" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_906_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20241001__20250331_zHo2UpitGLWa" title="Non operating income from grant"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2024-10-01to2025-03-31" id="Fact000555" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,275</ix:nonFraction></span>, respectively (three and six months ended March 31,
2024: $<span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20240101__20240331_zrxVg7ZPsDB3" title="Non operating income from grant"><span id="xdx_906_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20231001__20240331_zUGWZElgf6F2" title="Non operating income from grant"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2024-01-012024-03-31" id="Fact000557" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2023-10-012024-03-31" id="Fact000559" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span>) of this grant on its statements of operations within grant income. At March 31, 2025 an amount of $<span id="xdx_90E_ecustom--DeferredGrantIncome1_pn5n6_c20241001__20250331_zsnxobGOHehg" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome1" contextRef="From2024-10-01to2025-03-31" id="Fact000561" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million (September 30,
2024: $<span id="xdx_90C_ecustom--DeferredGrantIncome1_pn5n6_c20231001__20240930_zuj6CigMDod5" title="Deferred grant income"><ix:nonFraction name="avxl:DeferredGrantIncome1" contextRef="From2023-10-012024-09-30" id="Fact000563" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized
to other income. The Company will recognize this income on its statements of operations as the related expenditures are incurred to offset
the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:exclude><p id="xdx_23E_zm8UdFt5W7fh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div id="xdx_23E_zLNE87UbZl35" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_zxlsVaOLoSH3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zCHsFgxCVCKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zaqNYqun06Sf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zXzKMJrnKBla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Notes to the Condensed Consolidated Interim Financial Statements
<br/>
March 31, 2025 Page 4 <br/>
(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_234_z1S2AtuEpkFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#8217;s annual income tax return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the three and six
months ended March 31, 2025, the Company recorded research and development incentive income of $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20250101__20250331_zp30BaoA9U6g" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2025-01-012025-03-31" id="Fact000570" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million (AUD <span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20250101__20250331__srt--CurrencyAxis__currency--AUD_zTDPeiu1kqm8" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2025-01-012025-03-31_currency_AUD" id="Fact000572" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million) and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250331_z8oUCNXbqTX9" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2024-10-01to2025-03-31" id="Fact000574" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
million (AUD <span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250331__srt--CurrencyAxis__currency--AUD_zsRczMl4XLp1" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2024-10-012025-03-31_currency_AUD" id="Fact000576" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million), respectively (2024: $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331_za7nMLpByrd5" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2024-01-012024-03-31" id="Fact000578" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million (AUD <span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331__srt--CurrencyAxis__currency--AUD_zgLVuvOeCura" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2024-01-012024-03-31_currency_AUD" id="Fact000580" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million) and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331_z4ZorWOIzI0k" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-10-012024-03-31" id="Fact000582" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million (AUD <span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331__srt--CurrencyAxis__currency--AUD_zu6d9mEiJjA4" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-10-012024-03-31_currency_AUD" id="Fact000584" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million), respectively) in respect
of the Australia R&amp;D credit for eligible research and development expenses incurred during the period. This amount is included within
Other income (expense) on the condensed consolidated interim statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At March 31, 2025, Incentive
and tax receivables includes $<span id="xdx_90B_eus-gaap--OtherReceivables_iI_pn5n6_c20250331_z9JmJrCqRI49" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2025-03-31" id="Fact000586" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million (AUD <span id="xdx_903_eus-gaap--OtherReceivables_iI_pn5n6_c20250331__srt--CurrencyAxis__currency--AUD_zlLn9Cp3He5j" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2025-03-31_currency_AUD" id="Fact000588" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million) (September 30, 2024: $<span id="xdx_902_eus-gaap--OtherReceivables_iI_pn5n6_c20240930_zEnZJCwyNmp" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-09-30" id="Fact000590" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million (AUD <span id="xdx_904_eus-gaap--OtherReceivables_iI_pn5n6_c20240930__srt--CurrencyAxis__currency--AUD_zNr0fI8Ex2wk" title="Incentive and tax receivables"><ix:nonFraction name="us-gaap:OtherReceivables" contextRef="AsOf2024-09-30_currency_AUD" id="Fact000592" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span> million)) relating to Australia
R&amp;D credits earned during the period that are expected to be reimbursed upon filing of the Company&#8217;s annual claim under this
program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Australia R&amp;D credit
program is a self-assessment program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if specific R&amp;D activities are eligible and (iii) if the individual R&amp;D expenditures have nexus to such R&amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right
to review the Company&#8217;s qualifying programs and related expenditures for a period of four years. If such a review were to occur,
the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#8217;s assessments
and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#8217; claims already received.
Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess
penalties and interest on any such adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Currently, the Company&#8217;s
tax incentive claims from 2020 to 2024 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000594" name="avxl:EquityOfferingTextBlock"><p id="xdx_80D_ecustom--EquityOfferingTextBlock_zqtZmkPJVub6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5	<span id="xdx_82B_zTgkX6ypXsza">Equity Offerings</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board of Directors&#160;(the &#8220;Board&#8221;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23B_zFfI2ckDNuki" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div id="xdx_234_zwbUWBCCfv65" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_z0PGduB4MlDk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zGUByqmF9Jxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zW4kx2vrZmM4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_238_zpmPgsdgCA53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Notes to the Condensed Consolidated Interim Financial Statements
<br/>
March 31, 2025 Page 5 <br/>
(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_23E_zLwOum9mo7na" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2023 Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEO1Po9iJstg" title="Value of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000601" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">150</ix:nonFraction></span>.0
million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zenXujBEivod" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000603" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
and agreed to issue up to an additional <span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z5vpIn8uL2r9" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000605" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion,
the $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zIIP2cMT7llb" title="Proceeds from issuance or sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000607" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">150</ix:nonFraction></span>.0 million aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_90C_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230930_zu9HE73auP5a" title="Fair value of the initial commitment"><ix:nonFraction name="avxl:FairValueOfInitialCommitment" contextRef="AsOf2023-09-30" id="Fact000609" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million with
reference to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $<span id="xdx_900_ecustom--IncurredExpenses_iI_pn5n6_c20230930_zIMJ8tyfr997" title="Incurred expenses"><ix:nonFraction name="avxl:IncurredExpenses" contextRef="AsOf2023-09-30" id="Fact000611" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2025, the Company
did not issue any shares of common stock under the 2023 Purchase Agreement (2024: an aggregate of <span id="xdx_90A_ecustom--AggregateCommonShares_pip0_c20241001__20250331_zLIZcf0gdBFl" title="Aggregate common shares"><ix:nonFraction name="avxl:AggregateCommonShares" contextRef="From2024-10-01to2025-03-31" id="Fact000613" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,503,707</ix:nonFraction></span> shares of common stock including
<span id="xdx_901_ecustom--AggregateCommonShares_pip0_c20231001__20240331_zXOO9ZEfGZwe" title="Aggregate common shares"><ix:nonFraction name="avxl:AggregateCommonShares" contextRef="From2023-10-012024-03-31" id="Fact000615" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,500,000</ix:nonFraction></span> shares for an aggregate purchase price of $<span id="xdx_902_ecustom--AggregatePurchasePrice_pn5n6_c20241001__20250331_zYAdxQOcwO46" title="Aggregate purchase price"><ix:nonFraction name="avxl:AggregatePurchasePrice" contextRef="From2024-10-01to2025-03-31" id="Fact000617" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.4</ix:nonFraction></span> million and <span id="xdx_90D_ecustom--CommitmentsShares_pip0_c20241001__20250331_zUC4XvKkVTZi" title="Commitment shares"><ix:nonFraction name="avxl:CommitmentsShares" contextRef="From2024-10-01to2025-03-31" id="Fact000619" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,707</ix:nonFraction></span> commitment shares).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025, there was an unused amount of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20241001__20250331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zFwiDzW8tU1" title="Amount of shares remain available"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-10-012025-03-31_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000621" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">110.8</ix:nonFraction></span>
million under the 2023 Purchase Agreement. The Company will need to obtain effectiveness of a new registration statement in order to access
funds under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2020 Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;2020 Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company could offer and sell shares of common
stock registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2024, no shares
were sold pursuant to the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2024, the Company terminated the 2020
Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and six months ended March 31,
2025, the Company issued a net <span id="xdx_902_ecustom--SharesOfCommonStockIssued_pip0_c20241001__20250331_z6SYGlKymyw7"><ix:nonFraction name="avxl:SharesOfCommonStockIssued" contextRef="From2024-10-01to2025-03-31" id="Fact000622" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">217,503</ix:nonFraction></span>
shares of common stock to the Company&#8217;s Chief Executive Officer upon a net exercise of an option to purchase <span id="xdx_90A_ecustom--OptionToPurchaseShares_pip0_c20241001__20250331_zHGO5UX7pvpj"><ix:nonFraction name="avxl:OptionToPurchaseShares" contextRef="From2024-10-01to2025-03-31" id="Fact000623" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">500,000</ix:nonFraction></span>
shares of common stock at an exercise price of $<span id="xdx_90D_ecustom--ExercisePrice_pip0_c20241001__20250331_zYD2xB8VJOta"><ix:nonFraction name="avxl:ExercisePrice" contextRef="From2024-10-01to2025-03-31" id="Fact000624" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.92</ix:nonFraction></span>
per share. In connection with the exercise, the Company withheld <span id="xdx_90D_ecustom--WthheldShares_pip0_c20241001__20250331_zX7fdpz2XgY2"><ix:nonFraction name="avxl:WthheldShares" contextRef="From2024-10-01to2025-03-31" id="Fact000625" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">47,745</ix:nonFraction></span>
shares of common stock as consideration of the exercise price of $<span id="xdx_90B_ecustom--ExercisePriceConsideration_pn3n3_dm_c20241001__20250331_zxzDYQc6kEOe"><ix:nonFraction name="avxl:ExercisePriceConsideration" contextRef="From2024-10-01to2025-03-31" id="Fact000626" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.46</ix:nonFraction></span>
million and <span id="xdx_904_ecustom--CommonStockAsConsideration_pip0_c20241001__20250331_zh70B5Qc2s3g"><ix:nonFraction name="avxl:CommonStockAsConsideration" contextRef="From2024-10-01to2025-03-31" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">234,752</ix:nonFraction></span>
shares of common stock as consideration for the payment of $<span id="xdx_909_ecustom--WithholdingObligationsExercise_pn5n6_c20241001__20250331_zNY0nl0W2Yha"><ix:nonFraction name="avxl:WithholdingObligationsExercise" contextRef="From2024-10-01to2025-03-31" id="Fact000628" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span>
million in connection with tax withholding obligations associated with the exercise. The shares withheld were based upon a market
price of $9.63 per share as determined by reference to the average high and low sales price reported on the Nasdaq stock exchange on
the date of exercise. At March 31, 2025, the amount of $<span id="xdx_90A_ecustom--AccountsPayable_pn3n3_dm_c20241001__20250331_zvear9CB18Pa"><ix:nonFraction name="avxl:AccountsPayable" contextRef="From2024-10-01to2025-03-31" id="Fact000629" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.3</ix:nonFraction></span>
million in connection with the tax withholding obligations was included in accounts payable on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000631" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_805_eus-gaap--CommitmentsDisclosureTextBlock_z9XnvYLplbN" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 6	<span id="xdx_829_z42y3Yg8aavi">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company leases office space under an operating lease with an initial term of 12 months or less. Under the terms of the office lease, the
Company is required to pay its proportionate share of operating costs. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<ix:exclude><p id="xdx_23B_z4tUEhUT96Zg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div id="xdx_236_zC1JWiRl9qei" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zeKhmD9tsh1l" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zkGmAX3cj3M7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_236_z8wvFdIdkFQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p>

<ix:exclude><p id="xdx_237_zA7iz9darU69" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Notes to the Condensed Consolidated Interim Financial Statements
<br/>
March 31, 2025 Page 6 <br/>
(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_23B_zoVcrYm2Bi2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
operating lease costs were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"></p>

<ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000638" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LeaseCostTableTextBlock_pn3n3_zwSPOL4WLGye" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8BE_z306R9oBMXN" style="display: none">Schedule of operating lease costs</span></td>
<td style="font-style: normal">&#160;</td>
<td colspan="3" id="xdx_49A_20250101__20250331_zXvTohZieOh3" style="font-style: normal; text-align: center">&#160;</td>
<td style="color: gray; font-weight: bold; font-style: normal">&#160;</td>
<td colspan="3" id="xdx_493_20240101__20240331_ziUeuynH9xMc" style="font-weight: bold; text-align: center">&#160;</td>
<td style="color: gray; font-weight: bold; font-style: normal">&#160;</td>
<td colspan="3" id="xdx_495_20241001__20250331_zWoEmaQFPEE1" style="font-weight: bold; text-align: center">&#160;</td>
<td style="color: gray; font-weight: bold; font-style: normal">&#160;</td>
<td colspan="3" id="xdx_493_20231001__20240331_z2IVqBCiBZij" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-style: normal; text-align: center"><span style="font-weight: normal; font-size: 10pt; font-style: normal"><b>2025</b></span></td>
<td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_401_eus-gaap--OperatingLeaseCost_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Operating lease costs</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2025-01-012025-03-31" id="Fact000640" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-012024-03-31" id="Fact000641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-10-01to2025-03-31" id="Fact000642" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-10-012024-03-31" id="Fact000643" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A8_zBV7Ud0dpqk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company made matching contributions under the 401(k) plan as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p>

<ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000645" name="us-gaap:DefinedContributionPlanDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zoNuCoesb418" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B2_zgvvTFOaLGM5" style="display: none">Schedule of contributions under the plan</span></td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_498_20250101__20250331_zo7hRpAFbtJe" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_49C_20240101__20240331_zzIMjpSm5Ag" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_492_20241001__20250331_zvYnMorIwb5b" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_499_20231001__20240331_zt9xe4YEHub6" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months ended March 31</td></tr>
<tr style="vertical-align: bottom">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_401_eus-gaap--PensionContributions_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2025-01-012025-03-31" id="Fact000647" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2024-01-012024-03-31" id="Fact000648" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2024-10-01to2025-03-31" id="Fact000649" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2023-10-012024-03-31" id="Fact000650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">167</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A4_zfSdE6CZo3m6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Litigation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="font-style: normal"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York and it
named the Company and an officer of the Company as Defendants. The complaint was amended on July 12, 2024 (the &#8220;Initial Action&#8221;).
The complaint alleged violations of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect
to certain clinical trials for ANAVEX<sup>&#174;</sup>2-73 related to Rett syndrome. The complaint seeks unspecified damages, as well as
costs, including counsel and expert witness fees, on behalf of a class of investors.&#160;The Company believes the lawsuit is without
merit and the Company denies any liability or wrongdoing and has filed a motion to dismiss the complaint, which is awaiting a decision
by the Court. No amount has been recorded in these condensed consolidated interim financial statements for any loss contingencies associated
with this lawsuit as the Company believes that it is not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants.
The Company believed that this lawsuit was also without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed this complaint subsequent to the filing of the motion to dismiss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the
Company&#8217;s Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint
asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding
the same or similar allegations at issue in the purported class action lawsuit related to disclosures and statements made about certain
clinical trials related to Rett Syndrome. On January 22, 2025, pursuant to a stipulation of the parties, the Court entered an order staying
this purported derivative lawsuit until the motion to dismiss filed by defendants in the Initial Action is decided by the U.S. District
Court for the Southern District of New York.&#160;No amount has been recorded in these condensed consolidated interim financial statements
for any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_237_z15uNQkF0R7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div id="xdx_230_zkoPwQOjLRGb" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_239_zJ3Bo7f58n03" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zgqPMV9q0T21" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zzPefO0FsY4f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_239_zhoFfO3zCc6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Notes to the Condensed Consolidated Interim Financial Statements
<br/>
March 31, 2025 Page 7 <br/>
(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_230_z09BROrQ6yK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On February
14, 2025, another derivative lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations
was filed against the Company (as nominal defendant), an officer of the Company, and members of the Company&#8217;s Board of Directors
in the Supreme Court for the State of New York, County of New York, by another purported shareholder named Evan Levitan. The parties to
that action also have stipulated to a stay of the proceeding until the Court rules on the motion to dismiss in the putative class action
lawsuit pending in the U.S. District Court for the Southern District of New York. The New York state court has not yet entered an order
pursuant to the stipulation of the parties. No amount has been recorded in these condensed consolidated interim financial statements for
any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We know of no
other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which
our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any
of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025 and September 30, 2024, the Company
had <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20250331_zQNhL5vRDmm2" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-03-31" id="Fact000657" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000</ix:nonFraction></span> share purchase warrants outstanding exercisable at $<span id="xdx_90B_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20250331_z99TI7K5dSrc" title="Warrants outstanding weighted average exercise price"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2025-03-31" id="Fact000659" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">12.00</ix:nonFraction></span> per share until <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20250331_zMTbu586Lpxc" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2025-03-31" format="ixt:datemonthdayyearen" id="Fact000661" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 21, 2026</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Share&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2015 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the 2015 Plan was <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT078oDmSJQk" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-03-31_custom_StockOptionPlan2015Member" id="Fact000663" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the 2019 Plan was <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20241001__20250331__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zdlnRZjcpsEc" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2024-10-012025-03-31_custom_StockOptionPlan2019Member" id="Fact000665" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,000,000</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pip0_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zinupTm7xWrl" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member" id="Fact000667" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">406,453</ix:nonFraction></span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20220324__20220325__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zArEo1H39uD5" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2022-03-242022-03-25_custom_StockOptionPlan2022Member" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></span> additional shares of Common Stock will be available for issuance under the 2022 Plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_237_zB8Owgi4EiE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div id="xdx_23F_zRw4zJroN4u3" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zdoKbvclrLjl" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zVFfBvrfd2h2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zCkRMR0FrTYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zu8WnoRecL6b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Notes to the Condensed Consolidated Interim Financial Statements
<br/>
March 31, 2025 Page 8 <br/>
(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_235_znrmvpUugfKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. As at March 31,
2025, <span id="xdx_905_ecustom--OptionIssued_pip0_c20241001__20250331_z6BLsQoqgdX3" title="Option issued"><ix:nonFraction name="avxl:OptionIssued" contextRef="From2024-10-01to2025-03-31" id="Fact000676" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,751,000</ix:nonFraction></span> options had been issued under the 2022 Plan and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zwUxtbOJOy4" title="Option available issue"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-31_custom_StockOptionPlan2022Member" id="Fact000678" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,978,702</ix:nonFraction></span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock option
activity during the six months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000680" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_pn3n3_z9S8O13eYfzg" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_zS9TXJDkRItc" style="display: none">Schedule of stock option activity</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value <br/> ($)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value <br/> ($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2024</span></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoEaPYql32d4" title="Number of options, Outstanding beginning balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000682" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,037,754</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoToyiPYCpNa" title="Weighted average exercise price, Outstanding beginning balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000684" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.80</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3KMRIQOoSy6" title="Weighted average grant date fair value, Outstanding beginning balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000686" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.12</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7FOQOnkEFBb" title="Aggregate intrinsic value, Outstanding beginning balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_StockOptionMember" id="Fact000688" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,825,791</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjgRAX6Toh8k" title="Number of options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember" id="Fact000690" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,483,500</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z55T64KzlfX5" title="Weighted average exercise price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember" id="Fact000692" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">8.58</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbB1KsasrkVc" title="Weighted average grant date fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember" id="Fact000694" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.22</ix:nonFraction></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zb5a8BIaPsmg" title="Number of options, Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember" id="Fact000696" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">820,632</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze0qcpoGZEj4" title="Weighted average exercise price, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember" id="Fact000698" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.46</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBIWuwS0o07c" title="Weighted average grant date fair value, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember" id="Fact000700" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.89</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT0rQLLEcxK3" title="Aggregate intrinsic value, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember" id="Fact000702" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,785,518</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, March 31, 2025</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjgGMNZ5Achc" title="Number of options, Outstanding beginning balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,700,622</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zapl6u6eG3ik" title="Weighted average exercise price, Outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000706" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">7.19</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuLjeaneUI4j" title="Weighted average grant date fair value, Outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000708" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.39</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zddXQqjIO2Kj" title="Aggregate intrinsic value, Outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000710" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,630,198</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable, March 31, 2025</span></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_za09lPpzu9Fi" title="Number of options, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000712" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,346,086</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMW0ks6U2uB" title="Weighted average exercise price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000714" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.03</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvgz0pk0U7Pi" title="Weighted average grant date fair value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.68</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJcdPGwunFEc" title="Aggregate intrinsic value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000718" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,276,704</ix:nonFraction></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AA_z67DJIQfLdm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at March 31, 2025 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000720" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellspacing="0" cellpadding="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlIRqgbamqfc" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_8B0_zOvKWoDBishk" style="display: none">Schedule of summarizes information about stock options</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of exercises prices</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of outstanding </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average remaining contractual life (in</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of vested </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;options</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> years)&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; price</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;options</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; price</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zrnGbCei2rd3" title="Range of exercise prices, lower range limit" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000722" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.92</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z52scwgkvHul" title="Range of exercise prices, upper range limit" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000724" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.00</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zSAurzpUAKbe" title="Number of outstanding options" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000726" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,400,150</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z03dX8ExWOb5" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" id="Fact000728" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.92</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxSls1sXj7db" title="Weighted average exercise price" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000730" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.69</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zPymBH2v5m15" title="Number of vested options" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000732" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,400,150</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zCun6LKsZWab" title="Weighted average exercise price options vested" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.69</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zBiOs6e9ODdl" title="Range of exercise prices, lower range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000736" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.01</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zyoEroYMf3u" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000738" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zffZhWgKcf9d" title="Number of outstanding options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000740" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,197,500</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zurDYdWYyMXc" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" id="Fact000742" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.44</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zSnbeNfoWgk4" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000744" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.41</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zTBZD18vTfej" title="Number of vested options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000746" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,027,916</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zp4vRIlaj22a" title="Weighted average exercise price options vested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.31</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTaxbaDflOLj" title="Range of exercise prices, lower range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000750" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.01</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zWkAAlJQsaI1" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zvuSVhzoEaA" title="Number of outstanding options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000754" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">8,028,972</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zGGjzbtrmZm8" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" id="Fact000756" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.36</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zmu2LkvBC4Ee" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.95</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zaNQFSp8JOn4" title="Number of vested options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000760" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">4,297,519</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zNcGZkFQBZAl" title="Weighted average exercise price options vested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000762" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.39</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z69JunRT9rya" title="Range of exercise prices, lower range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000764" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.01</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zPJraIoaxcNg" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">13.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z1kQsNImJ2p9" title="Number of outstanding options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000768" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,609,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zvfOZMHD6tia" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" id="Fact000770" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.81</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zO46Ji9l9SOg" title="Weighted average exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">10.29</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zFgDHNVAFGqa" title="Number of vested options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000774" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">998,834</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3cdhYlhr5z4" title="Weighted average exercise price options vested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000776" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">10.42</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zXTCt5aJdsId" title="Range of exercise prices, lower range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">13.01</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zGqvDBOJrpa5" title="Range of exercise prices, upper range limit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000780" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">25.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zUkMsMVzpcQ5" title="Number of outstanding options" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000782" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,465,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zqDDFS6JsUe3" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" id="Fact000784" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.97</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zKKvCc09J06j" title="Weighted average exercise price" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">18.18</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zDZG5Pgw9TO1" title="Number of vested options" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000788" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">621,667</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBLqMqPkvQC4" title="Weighted average exercise price options vested" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000790" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">18.34</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZx9d33psFFi" title="Number of outstanding options" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000792" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,700,622</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm0Xt9SnbzZb" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact000794" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.59</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6fSVe9l7uT6" title="Weighted average exercise price" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000796" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">7.19</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKoKRgQHLD6i" title="Number of vested options" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember" id="Fact000798" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,346,086</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPN9U7MMCaic" title="Weighted average exercise price options vested" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact000800" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.03</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zRtWEBMpp0w4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average per share fair value of options
vested at March 31, 2025 was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250331_zQTrzeDgURb6" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-10-01to2025-03-31" id="Fact000802" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.68</ix:nonFraction></span> (September 30, 2024: $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930_zObSEf6I3Arg" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-012024-09-30" id="Fact000804" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.34</ix:nonFraction></span>). At March 31, 2024, the weighted average contractual life of options outstanding
was <span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331_zazaen280lTe" title="Weighted average contractual life of options exercisable"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt-sec:duryear" id="Fact000806" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.59</ix:nonNumeric></span> years (September 30, 2024: <span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zluwOMal5HA3" title="Weighted average contractual life of options exercisable"><ix:nonNumeric contextRef="From2023-10-012024-09-30" format="ixt-sec:duryear" id="Fact000808" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.48</ix:nonNumeric></span> years) and for options exercisable was <span id="xdx_90B_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331_zvyKflAdZpC9" title="Weighted average contractual life of options exercisable"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt-sec:duryear" id="Fact000810" name="avxl:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2">4.16</ix:nonNumeric></span> years (September 30, 2024: <span id="xdx_90C_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zHJ8b0iGmcV3" title="Weighted average contractual life of options exercisable"><ix:nonNumeric contextRef="From2023-10-012024-09-30" format="ixt-sec:duryear" id="Fact000812" name="avxl:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2">4.03</ix:nonNumeric></span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_230_zrc6Ba93BDi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div id="xdx_239_zrikVPUmNlK9" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zrqRwjFA8Yek" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zmqDagQpK8M" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zCFI1pdLY9b7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_237_zteSmIUX2XJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Notes to the Condensed Consolidated Interim Financial Statements
<br/>
March 31, 2025 Page 9 <br/>
(Unaudited)</p></ix:exclude>


<ix:exclude><p id="xdx_238_zXWUvKCLPQ96" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">	The Company recognized share-based compensation expense of $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20241001__20250331_zMQ4RKqp3Old" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-10-01to2025-03-31" id="Fact000819" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million
and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250331_z033PHgEgZIc" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-03-31" id="Fact000821" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million during the three and six months ended March 31, 2025, respectively (three and six months ended March 31, 2024: $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240331_zcoYkVYG7yZi" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-10-012024-03-31" id="Fact000823" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million
and $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20240331_zkKqgmf3ij5i" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-03-31" id="Fact000825" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction></span> million, respectively) in connection with the issuance and vesting 	of stock options in exchange for services. These amounts
have been included in general and 	administrative expenses and research and development expenses on the Company&#8217;s condensed consolidated
interim statements of 	operations as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000827" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zRh3T6c8zy4j" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zGd4iqBHJun4" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsdePd72fJP4" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000829" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">605</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvVUtKpGRobj" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000831" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">979</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zaJVYaJQ91ll" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000833" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,407</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIJV7N6wQDvd" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000835" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,905</ix:nonFraction></td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTkDsIk0arsg" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000837" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">844</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zPPYzqwN8CP1" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000839" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,673</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zsepTg66hEZh" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000841" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,097</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQLcSQjTkXWg" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000843" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,033</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331_zp2UQISywiD7" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-03-31" id="Fact000845" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,449</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zYLvizQYIEQi" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31" id="Fact000847" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,652</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331_zDiBuuC3BI8a" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-01to2025-03-31" id="Fact000849" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,504</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331_zsdD1RzD9ITf" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-03-31" id="Fact000851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,938</ix:nonFraction></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A1_zlExNPLG2s52" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20250331_zmJuvYORp40a" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2025-03-31" id="Fact000853" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.5</ix:nonFraction></span> million in share-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each stock option award is estimated
on the date of grant using the Black Scholes option pricing model. The fair value of share-based compensation charges recognized during
the three and six months ended March 31, 2025 was determined with reference to the quoted market price of the Company&#8217;s shares on
the grant date and based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000855" name="avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zPvDuWDnFQRl" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zqMPwOhpgEG" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20241001__20250331_zoyoowXnU3Bg" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-10-01to2025-03-31" id="Fact000857" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.98</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left">%</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240331_z4ohS6cP5BEc" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-10-012024-03-31" id="Fact000859" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.28</ix:nonFraction></span></td>
<td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250331_zLU1pziZ19Re" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt-sec:duryear" id="Fact000861" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.56</ix:nonNumeric></span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331_zfZGxXDHR0yg" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2023-10-012024-03-31" format="ixt-sec:duryear" id="Fact000863" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.74</ix:nonNumeric></span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250331_zUu6KqaeQfKa" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-10-01to2025-03-31" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">86.49</ix:nonFraction></span></td>
<td style="text-align: left">%</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240331_z1RY5hnHofR7" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-10-012024-03-31" id="Fact000867" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.84</ix:nonFraction></span></td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20241001__20250331_zPt4K6lfFYX6" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-10-01to2025-03-31" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td>
<td style="text-align: left">%</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240331_zA083g62GN2g" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-10-012024-03-31" id="Fact000871" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td>
<td style="text-align: left">%</td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AE_zQjOKf59jhb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" escape="true" id="Fact000873" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zqshjQVK9aVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7	<span id="xdx_822_zAW7x0rQUdWi">Subsequent Events</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates subsequent events occurring
between the most recent balance sheet date and the date the financial statements are available to be issued in order to determine whether
the subsequent events are to be recorded and/or disclosed in the Company&#8217;s financial statements and footnotes. The financial statements
are considered to be available to be issued at the time they are filed with the Securities and Exchange Commission (SEC).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 17, 2025, the Board approved, subject to
stockholder approval, an amendment to the 2022 Plan (the &#8220;Amendment&#8221;). The Amendment, if approved by stockholders, will increase
the number of shares of common stock reserved for issuance under the 2022 Plan by <span id="xdx_904_ecustom--SharesOfCommonStockReservedForIssuance_iI_pip0_c20250417__us-gaap--SubsegmentsAxis__us-gaap--SubsequentEventMember_zxmnbP0IA1ai" title="Shares of common stock reserved for issuance"><ix:nonFraction name="avxl:SharesOfCommonStockReservedForIssuance" contextRef="AsOf2025-04-17_us-gaap_SubsequentEventMember" id="Fact000875" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">4,000,000</ix:nonFraction></span> shares. In addition, the Amendment will establish
a minimum vesting period of one year for all awards granted under the Plan and limit the discretion to accelerate the vesting of awards
upon a separation from service, with limited exceptions permitted. Finally, the Amendment would prohibit liberal share recycling provisions.</p>

</ix:nonNumeric><p id="xdx_81F_zy0Hs60ejCxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_003"></span>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Forward-Looking Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Quarterly Report on Form 10-Q includes forward-looking
statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements
regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and
objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221;
&#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221;
&#8220;potential,&#8221; &#8220;predict&#8221;, &#8220;could,&#8221; &#8220;would,&#8221; &#8220;will,&#8221; &#8220;suggest,&#8221; &#8220;plan&#8221;
and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include,
without limitation, statements regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    in our stock price and in the markets in general;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    conduct preclinical studies and clinical trials for our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise additional
    capital on favorable terms and the impact of such activities on our stockholders and stock price;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to generate
    any revenue or to continue as a going concern;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to execute
    our research and development plan on time and on budget; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our product candidates&#8217;
    ability to demonstrate efficacy or an acceptable safety profile; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain the
    support of qualified scientific collaborators; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability, whether alone
    or with commercial partners, to successfully commercialize any of our product candidates that may be approved for sale; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to identify
    and obtain additional product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reliance on third parties
    in non-clinical studies and clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to defend against
    product liability claims; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to safeguard
    against security breaches; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and
    maintain sufficient intellectual property protection for our product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to comply with
    our intellectual property licensing agreements; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to defend against
    claims of intellectual property infringement; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to comply with
    the maintenance requirements of the government patent agencies; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to protect
    our intellectual property rights throughout the world; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the anticipated start dates,
    durations and completion dates of our ongoing and future clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the anticipated designs
    of our future clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to attract
    and retain qualified employees; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of Fast Track
    designation on receipt of actual U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our anticipated future
    regulatory submissions and our ability to receive regulatory approvals to develop and market our product candidates, including any
    orphan drug or Fast Track designations; </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and likelihood
    of the accomplishment of various scientific, clinical, regulatory filings and approvals and other product development objectives,
    including the timing of a decision by the European Medicines Agency, or EMA, regarding whether to approve the Marketing Authorization
    Application, or MAA, for blarcamesine for the treatment of Alzheimer&#8217;s disease; and</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
        anticipated future cash position and ability to obtain funding for our operations.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking statements largely
on our current expectations and projections about future events, including the responses we expect from the FDA and other regulatory authorities
and financial trends that we believe may affect our financial condition, results of operations, business strategy, preclinical studies
and clinical trials, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions
including without limitation the risks described in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed
with the Securities and Exchange</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><br/>
Commission on December 23, 2024. These risks are not exhaustive. Other sections of this Quarterly Report
on Form 10-Q include additional factors which could adversely impact our business and financial performance. Moreover, we operate in a
very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management
to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination
of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not rely
upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the
forward-looking statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking
statements. Except as required by applicable laws including the securities laws of the United States, we assume no obligation to update
or supplement forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Quarterly Report on Form 10-Q, the
terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company&#8221;, and &#8220;Anavex&#8221; mean Anavex Life Sciences
Corp., unless the context clearly indicates otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Overview and Strategy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage biopharmaceutical
company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;)
diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s focus is on developing innovative
treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes ANAVEX<sup>&#174;</sup>2-73
currently in three different clinical trial indications, and ANAVEX<sup>&#174;</sup>3-71 currently in one clinical trial and several other
compounds in different stages of clinical and pre-clinical development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><img src="image_001.jpg" alt="" style="height: 256px; width: 624px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>* = Orphan Drug Designation by the FDA </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying in sigma-1
receptor (SIGMAR1) binding activities. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative
nature, including Alzheimer&#8217;s disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate
ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development)
of disease. Multiple viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related
cellular processes, in order to ensure survival and replication. Hence, it is possible that SIGMAR1 could also play a role in modulating
the cellular response to viral infection and ameliorate pathogenesis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The SIGMAR1 gene encodes the SIGMAR1 protein, which
is an intracellular chaperone protein with important roles in cellular communication. SIGMAR1 is also involved in transcriptional regulation
at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability
of our compounds to activate quantitatively the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron
Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) target engagement
or receptor occupancy with SIGMAR1 in the brain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_002.jpg" alt="Graphical user interface, diagram&#10;&#10;Description automatically generated" style="height: 416px; width: 624px"/>&#160;
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><i></i>Source: Reyes Setal.,
Sci Rep. 2021 Aug 25; 11(1):17150</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused by chronic
homeostatic imbalances or cellular stress of brain cells. In pediatric diseases, such as Rett syndrome or infantile spasms, chronic cellular
stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases, such as Alzheimer&#8217;s and
Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular insult and hence chronic
cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;) lead to the death of neurons
and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy, a characteristic found in Alzheimer&#8217;s
and Parkinson&#8217;s diseases that results from disorders of protein synthesis, trafficking, folding, processing or degradation in cells.
The clearance of macromolecules in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in
nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized by the presence of amyloid plaques, and neurofibrillary
tangles, which are aggregates of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation
of microglia. With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<sup>&#174;</sup>2-73 (blarcamesine), our approach is to
restore cellular balance (i.e. homeostasis). Therapies that correct defects in cellular homeostasis might have the potential to halt or
delay neurodevelopmental and neurodegenerative disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Program Overview </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX&#174;2-73 (blarcamesine)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe ANAVEX<sup>&#174;</sup>2-73 may offer a
disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1. ANAVEX<sup>&#174;</sup>2-73 is
being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer&#8217;s disease and Parkinson&#8217;s
disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of Part A and Part B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s
patients. This open-label randomized trial in Australia met both primary and secondary endpoints and was designed to assess the safety
and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors,
which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse
the pathological hallmarks observed in Alzheimer&#8217;s disease. In October 2017, we presented positive pharmacokinetic (&#8220;PK&#8221;)
and pharmacodynamic (&#8220;PD&#8221;) data from the Phase 2a clinical trial, which established a concentration-effect relationship between
ANAVEX<sup>&#174;</sup>2-73 and trial measurements. These measures obtained from all patients who participated in the entire 57 weeks include
exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally, the clinical trial appeared
to show that ANAVEX<sup>&#174;</sup>2-73 activity was enhanced by its active metabolite (ANAVEX19-144), which also targets the SIGMAR1
receptor and has a half-life approximately twice as long as the parent molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase 2a
trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX<sup>&#174;</sup>2-73, providing
an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing these Phase
2a trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73 through the Australian Government Department
of Health &#8211; Therapeutic Goods Administration&#8217;s compassionate use Special Access Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a clinical trial. More than 33,000 genes were analyzed
using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients treated
with ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73, among
them variants related to the SIGMAR1, the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that trial participants with the common
SIGMAR1 wild type gene variant, which is estimated to be about 80% of the population worldwide, demonstrated improved cognitive (MMSE)
and functional (ADCS-ADL) scores. The results from this evaluation supported the continued evaluation of genomic information in subsequent
clinical trials, since these signatures can now be applied to neurological indications tested in future clinical trials with ANAVEX<sup>&#174;</sup>2-73
including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia and Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>&#174;</sup>2-73
data met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled trial. This larger Phase 2b/3 double-blind,
placebo-controlled trial of ANAVEX<sup>&#174;</sup>2-73 in early Alzheimer&#8217;s disease commenced in August 2018. The trial enrolled
508 patients, which were treated with a convenient once-daily oral formulation of ANAVEX<sup>&#174;</sup>2-73 for 48 weeks, randomized
1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial took place at 52 sites across North America, Europe and
Australia. Primary and secondary endpoints to assess safety and both cognitive and functional efficacy, were measured through the Alzheimer&#8217;s
Disease Assessment Scale &#8211; Cognitive Subscale test (&#8220;ADAS-Cog&#8221;), Alzheimer&#8217;s Disease Cooperative Study &#8211;
Activities of Daily Living (&#8220;ADCS-ADL&#8221;) and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and function (&#8220;CDR-SB&#8221;).
In addition to these endpoints, the ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 trial design incorporated pre-specified statistical analyses
related to potential genomic precision medicine biomarkers previously identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a clinical trial.
The trial was completed in mid-2022 and, in December 2022, the Company presented topline results from the Phase 2b/3 clinical trial. All
statistical analyses were performed by outside consultancy companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Furthermore, all pre-specified clinical endpoints
were analyzed using a mixed model for repeated measures (MMRM). Under the multiplicity control rule, a trial is successful in meeting
the co-primary endpoints if the significance of each endpoint is P &lt; 0.05, or if the significance of only one co-primary endpoint is
P &lt; 0.025. If only one primary endpoint is significant at an &#945; level of 0.025, then the secondary endpoint will be evaluated
at the same level of 0.025. The trial was successful, the differences in the least-squares mean (LSM) change from baseline to 48 weeks
between the ANAVEX<sup>&#174;</sup>2-73 and placebo groups for ADAS-Cog13 was significant at a level of P &lt; 0.025 and for CDR-SB was
significant at a level of P &lt; 0.025, in the patients with early Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The comparison of individual dose groups vs placebo
also supports blarcamesine&#8217;s efficacy. For the primary endpoint ADAS-Cog13, blarcamesine is significantly better than placebo (&#8722;2.027;
P = 0.0079) as well as for both the 50 mg (&#8722;2.149; P = 0.021) and the 30 mg (&#8722;1.934; P = 0.026) blarcamesine dosage groups
at Week 48, representing that blarcamesine slowed clinical progression at 48 weeks by 36.3% and by 38.5% and 34.6% in 50 mg and 30 mg
groups vs. placebo, respectively. The functional co-primary endpoint, ADCS-ADL, was trending in a positive direction but did not reach
significance at Week 48. The key secondary endpoint CDR-SB was significantly improved vs. placebo (&#8722;0.483, P = 0.0104) as well as
in both 50 mg (&#8722;0.465; P = 0.045) and 30 mg (&#8722;0.502; P = 0.020) groups at Week 48. Clinical Global Impression &#8211; Improvement
(&#8220;CGI-I&#8221;) was also significantly improved vs. placebo (&#8722;0.278, P = 0.004) as well as in both the 50 mg (&#8722;0.314;
P = 0.008) and the 30 mg (&#8722;0.248; P = 0.024) groups at Week 48. The findings are supported by biomarkers, including plasma A&#946;42/40-ratio
and reduction of brain atrophy. Blarcamesine significantly slowed brain atrophy in key regions of interest, including the whole brain
by 37.6%, total grey matter by 63.5%, and lateral ventricles by 25.1%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the respective safety population, common treatment-emergent
adverse events included dizziness, which was transient and mostly mild to moderate in severity, and occurred in 120 participants (35.8%)
during titration and in 76 participants (25.2%) during maintenance with ANAVEX<sup>&#174;</sup>2-73 and 10 (6.0%) during titration and
9 (5.6%) during maintenance with placebo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, we announced the submission of a
Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA), under the centralized procedure, for ANAVEX<sup>&#174;</sup>2-73
for the treatment of Alzheimer&#8217;s disease and, in December 2024, the EMA accepted the submission for scientific review. The MAA,
if approved, would allow direct market access throughout the European Union for oral ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) for the
treatment of Alzheimer&#8217;s disease. A company seeking to market a new pharmaceutical product through the centralized procedure must
file safety data and efficacy data as part of the MAA. After the EMA evaluates the MAA, it provides a recommendation to the European Commission
(&#8220;EC&#8221;) and the EC then approves or denies the MAA. Throughout the scientific review process with the EMA, we may receive feedback
or comments which, while not a conclusive decision, could suggest the application provided is insufficient to support the marketing authorization.
We may not be able to sufficiently address these comments or requests. Alternatively, these comments or requests could lead us to decide,
after consultation with our advisors or the regulatory authorities, to withdraw our MAA for blarcamesine. The Company plans to announce
the results when the EMA review and decision-making is finished and does not plan to provide interim updates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A long-term open label extension study of ANAVEX<sup>&#174;</sup>2-73,
referred to as the ATTENTION-AD trial, was initiated for patients who completed the 48-week Phase 2b/3 placebo-controlled trial referenced
above. This trial extension for a duration of up to 96/144 additional weeks was completed in June 2024. The trial extension demonstrated
that blarcamesine-treated patients continued to accrue&#160;benefit through up to 4&#160;years, as measured by the clinical endpoints
ADAS-Cog13 and ADCS-ADL. Delayed-start analysis of treatment with oral blarcamesine&#160;was significant, reflecting the importance of
early treatment&#160;initiation. No new safety findings were observed&#160;with continued blarcamesine&#160;treatment over three years,&#160;confirming
good comparative safety profile and no associated neuroimaging adverse events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease, which demonstrated significant improvements on behavioral,
histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional data announced in
October 2017 indicated that ANAVEX<sup>&#174;</sup>2-73 induced robust neurorestoration in experimental Parkinsonism. We believe the encouraging
results we have gathered in this preclinical model, coupled with the favorable profile of this product candidate in the Alzheimer&#8217;s
disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 has the potential to treat Parkinson&#8217;s disease dementia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind, randomized,
placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia in Spain and
Australia, to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The trial enrolled
approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30 mg and 50 mg, or placebo.
The ANAVEX<sup>&#174;</sup>2-73 Phase 2 Parkinson&#8217;s disease dementia trial design incorporated genomic precision medicine biomarkers
identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease trial.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (&#8220;CDR&#8221;) computerized assessment system analysis. Treatment with ANAVEX<sup>&#174;</sup>2-73
also resulted in clinically meaningful improvements as measured by the global composite score of Parkinson&#8217;s disease symptom severity,
MDS-Unified Parkinson&#8217;s Disease Rating Scale (&#8220;MDS-UPDRS&#8221;) total score on top of standard of care including dopaminergic
therapy, levodopa and other anti-PD medications after 14 weeks of treatment, suggesting ANAVEX<sup>&#174;</sup>2-73&#8217;s potential capability
of slowing and reversing symptoms that progress in Parkinson&#8217;s disease. In addition, the trial confirmed the precision medicine
approach of targeting SIGMAR1 as a genetic biomarker in response to ANAVEX<sup>&#174;</sup>2-73 may result in improved clinical outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A 48-week OLE ANAVEX2-73-PDD-EP-001 Phase 2 trial
was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001 Phase 2 trial discussed above.
The OLE trial assessed safety, tolerability and efficacy, measuring among others, MDS-Unified Parkinson&#8217;s Disease Rating Scale Parts
I, II, III, REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), CGI-I, as well as cognitive efficacy endpoint Montreal Cognitive
Assessment (MoCA) over a 48-week period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2023, we reported the preliminary ANAVEX2-73-PDD-EP-001
OLE trial data, which demonstrated longitudinal beneficial effects of ANAVEX<sup>&#174;</sup>2-73 on the pre-specified primary and secondary
objectives. Preliminary analysis reveals that ANAVEX<sup>&#174;</sup>2-73 was found to be generally safe and well tolerated, and safety
findings in this trial were consistent with the known safety profile of ANAVEX<sup>&#174;</sup>2-73. In respect to efficacy, across all
efficacy endpoints, patients performed better while on ANAVEX<sup>&#174;</sup>2-73. While all patients were on drug holiday due to COVID-19
between the DB EOT and the OLE Baseline, the respective efficacy endpoints, including the MDS-UPDRS Part II + III and CGI-I, measured
at the end of trial of the double-blind study (DB EOT) and the OLE Baseline, were worsening, as expected in a progressive disease like
Parkinson&#8217;s. However, when patients resumed daily oral ANAVEX<sup>&#174;</sup>2-73 treatment, a consistent improvement was observed
during the extension phase from OLE Baseline through OLE Week 24, and OLE Week 48, respectively. These results are consistent with the
pattern observed for all efficacy measures in the extension phase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate conducting further clinical trials of
ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia after submitting the results of the trial to regulatory authorities to
obtain regulatory guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also with respect to Parkinson&#8217;s disease, in
January 2021, we were awarded a research grant of $1.0 million from&#160;The Michael J. Fox Foundation for Parkinson&#8217;s Research&#160;to
explore utilization of PET imaging biomarkers to enable measurement of target engagement and pathway activation of the SIGMAR1 with clinically
relevant doses including in people with Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The data demonstrated dose related significant
improvements in an array of behavioral and gait paradigms in a mouse model with an MECP2-null mutation that causes neurological symptoms
that mimic Rett syndrome. The study was funded by the International Rett Syndrome Foundation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Rett syndrome program includes several clinical
trials that were conducted in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily formulation
of ANAVEX<sup>&#174;</sup>2-73. The FDA has granted Orphan Drug Designation and the Rare Pediatric Disease (RPD) designation for the treatment
of Rett syndrome. The RPD designation is intended to encourage the development of treatments for rare pediatric diseases. Additionally,
the FDA has granted Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome.
The FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to address unmet medical needs
in the treatment of serious and life-threatening conditions. An earlier application for a proposed Rett syndrome study in the United States
resulted in the FDA requesting additional information. The resulting clinical hold and subsequent partial clinical hold have since been
removed after the Company satisfactorily provided the additional information requested. At the present time, the Company does not plan
to conduct a clinical trial in the United States. The following is a summary of clinical trials conducted by the Company in Rett Syndrome.
The first Phase 2 trial, (ANAVEX<sup>&#174;</sup>2-73-RS-001), took place in the United States, and was completed in December 2020. This
trial was a randomized double-blind, placebo-controlled safety, tolerability, PK and efficacy trial of oral liquid ANAVEX<sup>&#174;</sup>2-73
formulation in 25 adult female patients with Rett syndrome over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific
genomic precision medicine biomarkers. The primary endpoint of the trial was safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was
well-tolerated and demonstrated dose-proportional PK. All secondary efficacy endpoints of the trial showed statistically significant and
clinically meaningful response in the Rett Syndrome Behaviour Questionnaire (&#8220;RSBQ&#8221;) response, when compared to placebo, in
the intent to treat (&#8220;ITT&#8221;) cohort (all participants, p = 0.011). 66.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed
a statistically significant improvement in RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort (all participants,
p = 0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained improvement in CGI-I response throughout the 7-week clinical
trial, when compared to placebo in the ITT cohort (all participants, p = 0.014). Consistent with previous ANAVEX<sup>&#174;</sup>2-73 clinical
trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73 experienced stronger improvements
in the prespecified efficacy endpoints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This clinical trial was funded, in part, by a financial
grant from the International Rett Syndrome Foundation of $0.6 million. No other clinical trials with ANAVEX<sup>&#174;</sup>2-73 related
to Rett syndrome have been conducted in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
second, international trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced in June
2019.</span> This trial took place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2 trial for Rett
syndrome. The trial was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73
in 33 adult patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. Based
upon the input from the successful U.S. Phase 2 Rett syndrome trial (ANAVEX<sup>&#174;</sup>2-73-RS-001), we updated the endpoints for
the AVATAR trial (ANAVEX<sup>&#174;</sup>2-73-RS-002) to appropriately assess the clinically meaningful outcome following International
Conference on Harmonization (ICH) guidelines. These updates were approved by the respective regulatory authorities in the U.K. and in
Australia, respectively, where the AVATAR trial was conducted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The data from the AVATAR trial was released in February
2022. The clinical trial met all primary and secondary efficacy and safety endpoints, with consistent improvements in primary efficacy
endpoint, RSBQ response (p = 0.037), and secondary efficacy endpoints, Anxiety, Depression, and Mood Scale (ADAMS) (p = 0.010) and CGI-I
(p = 0.037) response. Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome
symptoms. Convenient once daily oral liquid doses of up to 30 mg of ANAVEX<sup>&#174;</sup>2-73 were also well tolerated with good medication
compliance. All patients who participated in the trial were eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label
extension protocol and subsequent Compassionate Use Program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The very first trial of ANAVEX<sup>&#174;</sup>2-73
in pediatric Rett syndrome patients, the EXCELLENCE trial, completed enrollment in February 2023. This randomized, double-blind, placebo-controlled
Phase 2/3 trial in pediatric patients with Rett syndrome included trial sites in Canada, Australia, and the United Kingdom. 92 pediatric
patients with Rett syndrome between the ages of 5 through 17 years were treated daily with up to 30 mg ANAVEX<sup>&#174;</sup>2-73. Participants
were randomized 2:1 (ANAVEX<sup>&#174;</sup>2-73:placebo) for 12 weeks, followed by a week 16 safety visit and topline results from this
trial were announced in early January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After 12 weeks, the study showed improvement on the
key co-primary endpoint RSBQ, which is a detailed 45-item questionnaire for assessing multiple Rett syndrome characteristics by the patients&#8217;
caregivers. The other co-primary endpoint, the CGI-I, which represents a less granular assessment by the site investigators using a seven-point
scoring (one=&#8220;very much improved&#8221; to seven=&#8220;very much worse&#8221;), was not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In an ad-hoc analysis, using the predefined mixed-effect
model for repeated measure (MMRM) method, after 12 weeks of treatment, ANAVEX<sup>&#174;</sup>2-73-treated patients improved LS Mean (SE)
-12.93 (2.150) points on their RSBQ total score compared to LS Mean (SE) -8.32 (2.537) points in placebo-treated patients. The LS Mean
difference (SE) of -4.61 (2.439) points between treated and placebo groups did not reach statistical significance (n=77; p=0.063). ANAVEX<sup>&#174;</sup>2-73-treated
patients demonstrated a rapid onset of action with improvements at 4 weeks after treatment with a RSBQ total score LS Mean (SE) -10.32
(2.086) points in the drug-treated group compared to a LS Mean (SE) -5.67 (2.413) points in placebo-treated patients. The LS Mean difference
of -4.65 (2.233) points between treated and placebo groups was statistically significant (n=77; p=0.041).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The key secondary endpoint, the ADAMS, trended favorably.
In the same analysis, scores for all RSBQ and ADAMS subscales improved over the course of the study. Collectively, the RSBQ and ADAMS
demonstrated improvements in multiple areas, impacting positively in particular repetitive movements, nighttime disruptive behaviors,
and social avoidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preliminary review of the safety results indicates
there were no new safety signals in the EXCELLENCE study, reinforcing the favorable and manageable safety profile observed with ANAVEX<sup>&#174;</sup>2-73
to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All patients who participated in the trial were eligible
to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol, which was completed in June 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A high enrollment rate in the Open Label Extension
(&#8220;OLE&#8221;) of over 91% and the high level of requests for the Compassionate Use Program (93%) provide solid numerical evidence
for the reported positive Real World Evidence (RWE) from patients with Rett syndrome under Compassionate Use Authorization. Families whose
children were previously on drug or placebo in the placebo-controlled trial commented favorably on the improvement of their child&#8217;s
daily life due to ANAVEX<sup>&#174;</sup>2-73 treatment in the Compassionate Use Program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i>Other indications</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe preclinical data from our studies also
supports further research into the use of ANAVEX<sup>&#174;</sup>2-73 as a potential platform drug for other neurodegenerative diseases
beyond Alzheimer&#8217;s disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X
syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated significant
improvements in all of these indications in the respective preclinical animal models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a preclinical study sponsored by the Foundation
for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The results
indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced seizures in mice. In a study sponsored
by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73 restored hippocampal brain-derived
neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many neurodevelopmental and neurodegenerative
pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of
BDNF expression could be a contributing factor for the positive preclinical data observed in both neurodevelopmental and neurodegenerative
disorders like Angelman and Fragile X syndromes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data to-date also indicates
that ANAVEX<sup>&#174;</sup>2-73 has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, may play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data on ANAVEX<sup>&#174;</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination in multiple sclerosis disease. Further,
our data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 has the potential to provide protection for oligodendrocytes and oligodendrocyte
precursor cells (&#8220;OPCs&#8221;), as well as central nervous system neurons in addition to helping repair by increasing OPC proliferation
and maturation in tissue culture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data of ANAVEX<sup>&#174;</sup>2-73
in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;). TSC is a rare genetic disorder characterized by the growth
of numerous benign tumors in many parts of the body with a high incidence of seizures. The preclinical data demonstrated that treatment
with ANAVEX<sup>&#174;</sup>2-73 significantly increased survival and reduced seizures in those mice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i>ANAVEX<sup>&#174;</sup>2-73
(blarcamesine)-specific Biomarkers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of some of our clinical trials, we have incorporated
a genomic analysis to better understand potential populations for whom our clinical programs might benefit. A full genomic analysis of
Alzheimer&#8217;s disease patients treated with ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) has helped us identify actionable genetic variants.
A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) and COMT, a gene
involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73 (blarcamesine)
specific biomarker hypothesis. We believe that <i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately 10%-20%
of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant improved
functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73 (blarcamesine),
which are considered independent of Alzheimer&#8217;s disease pathology, as well as multiple endpoints and time-points, provides support
for the potential precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) by using genetic biomarkers identified
within the trial population itself to either confirm the mechanism of action of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) or target patients
who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) treatment. We may in the future utilize such an approach in
certain indications in which ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) is being studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>3-71 is an orally available
clinical drug candidate with a novel mechanism of action via SIGMAR1 activation and M1 muscarinic allosteric modulation, which has been
shown to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable potential
disease modifying treatment for cognitive impairments. We believe it is effective against the major Alzheimer&#8217;s hallmarks in transgenic
(3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial
dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s and other protein-aggregation-related
diseases given its ability to enhance neuroprotection and cognition via SIGMAR1 activation and M1 muscarinic allosteric modulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of ANAVEX<sup>&#174;</sup>3-71
in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation
with the administration of ANAVEX<sup>&#174;</sup>3-71. The FDA has granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>3-71
for the treatment of FTD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>&#174;</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number of astrocytes.
In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease, synaptogenesis is believed to be impaired. Additional
preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71 has the potential
to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed to
play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human Phase
1 clinical trial of ANAVEX<sup>&#174;</sup>3-71. <span style="background-color: white">The Phase 1 clinical trial was a prospective double-blind,
randomized, placebo-controlled trial conducted in Australia. A total of 36 healthy male and female subjects were included. Single escalating
doses of ANAVEX<sup>&#174;</sup>3-71 were administered in order to evaluate the safety, tolerability, and PK of ANAVEX<sup>&#174;</sup>3-71
and the effects of food and gender on its PK in healthy volunteers. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The trial met
its primary and secondary endpoints of safety, with no serious adverse events (&#8220;SAEs&#8221;) or dose-limiting toxicities observed.
ANAVEX<sup>&#174;</sup>3-71 was well tolerated in all cohorts receiving ANAVEX<sup>&#174;</sup>3-71 in single doses ranging from 5 mg to
200 mg daily with no SAEs and no significant lab abnormalities in any subject. In the trial, ANAVEX<sup>&#174;</sup>3-71 exhibited linear
PK. Its pharmacokinetics was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of the drug and food had no
effect on the bioavailability of ANAVEX<sup>&#174;</sup>3-71. The trial also met the secondary objective of characterizing the effect of
ANAVEX<sup>&#174;</sup>3-71 on electrocardiogram (&#8220;ECG&#8221;) parameters. There were no clinically significant ECG parameters throughout
the trial. Participant QTcF measures were normal across all dose groups with no difference between ANAVEX<sup>&#174;</sup>3-71 and placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In October 2023
a peer-reviewed publication in the journal <i>Neurobiology of Aging</i>, titled &#8216;<i>Early treatment with an M1 and sigma-1 receptor
agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology</i>&#8217;, featured the orally
available small molecule ANAVEX<sup>&#174;</sup>3-71 (AF710B). The preclinical study described the potential disease-modifying properties
of ANAVEX<sup>&#174;</sup>3-71 on Alzheimer&#8217;s disease pathology as a possible drug candidate for a potential once daily oral preventive
strategy for Alzheimer&#8217;s disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In January 2024,
in another peer-reviewed publication in the journal <i>Clinical Pharmacology in Drug Development</i>, entitled, &#8216;<i>Population-Based
Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor
Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease&#8217;</i>, reported the population-based
characterization of the PK and food effect of ANAVEX<sup>&#174;</sup>3-71 as part of the single ascending dose study in healthy participants
with the primary objective of assessing dose proportionality of ANAVEX<sup>&#174;</sup>3-71, and to characterize the effect of food on
the PK of ANAVEX<sup>&#174;</sup>3-71. The results from this PK evaluation demonstrated that ANAVEX<sup>&#174;</sup>3-71, at single ascending
doses of 5 to 200 mg, is linear, dose proportional, and time invariant. Food had no effect on the PK of ANAVEX<sup>&#174;</sup>3-71. This
data also expands the safety objectives met in this first-in-human study of ANAVEX<sup>&#174;</sup>3-71, further supporting its drug development
program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based on these
results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven
clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease, evaluating longitudinal effect
of treatment with ANAVEX<sup>&#174;</sup>3-71. The first of these trials is being conducted in Schizophrenia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i>Schizophrenia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In March 2024,
we commenced the U.S. FDA-cleared ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial: a double-blind, placebo-controlled Phase 2 trial in
schizophrenia. The trial consists of two parts to explore multiple ascending doses in individuals with schizophrenia followed by a 28-day
treatment period in a larger cohort. The trial will utilize standard clinical outcome measures for schizophrenia including the Positive
and Negative Symptoms Scale (PANSS), and novel fluid and electrophysiological biomarkers will also be assessed, leveraging several advances
in electroencephalography/event-related potential (EEG/ERP) biomarkers in schizophrenia developed in collaboration with the industry-led
ERP Biomarker Qualification Consortium. In addition to the electrophysiological biomarkers, we are also applying novel neuroinflammatory,
metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX<sup>&#174;</sup>3-71&#8217;s
novel, dual mechanism of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Preliminary
results from Part A of the ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial, consisting of a multiple ascending dose study in 16 participants,
demonstrated a dose-dependent effect of ANAVEX<sup>&#174;</sup>3-71 on two key EEG biomarkers in patients with schizophrenia. The effects
were most pronounced in the higher dose group indicating a dose-dependent pharmacodynamic effect. The observed changes reversed known
electroencephalography (EEG) and ERP biomarker abnormalities associated with schizophrenia. These EEG biomarkers correlate with positive,
negative, and cognitive symptoms of schizophrenia. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In May 2025
we announced the completion of enrollment of Part B of the placebo-controlled Phase 2 study, which includes more participants and a longer
treatment duration, and will provide more comprehensive data on the efficacy and safety of ANAVEX<sup>&#174;</sup>3-71 in schizophrenia.
We expect to report top-line data of the Phase 2 ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial in the second half of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>&#174;</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1-41 is a sigma-1 agonist. Pre-clinical
tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of
endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability. In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41
prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus,
the part of the brain that regulates learning, emotion and memory. These activities involve both muscarinic and SIGMAR1 systems through
a novel mechanism of action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that ANAVEX<sup>&#174;</sup>1-41
has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired,
are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1066</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1066, a mixed sigma-1/sigma-2
ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066 was tested in two preclinical
models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury model of neuropathic
pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored the nociceptive threshold in the affected paw
to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant for two hours. In
a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent directly into the colon and
a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned the nociceptive threshold to control levels in a dose-dependent manner.
Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit with ANAVEX<sup>&#174;</sup>1066 and
a favorable safety profile in a battery of behavioral measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is designed for the treatment
of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at
nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical studies,
this compound revealed antitumor potential. It has also been shown to selectively kill human cancer cells without affecting normal/healthy
cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications highlight the possibility
that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors are highly expressed
in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through
tumor cell membrane reorganization and interactions with ion channels, we believe our drug candidates may play an important role in inhibiting
the processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation
of new blood vessels) and tumor cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is currently in the pre-clinical
and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown
in human testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions with
potential strategic and commercial partners to most effectively advance our programs and increase stockholder value. Further, we may acquire
or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are developing compounds with potential application
to two broad categories and several specific indications, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alzheimer&#8217;s
        disease &#8211; In 2024, an estimated 6.9 million Americans were suffering from Alzheimer&#8217;s disease according to the Alzheimer&#8217;s
        Association<sup>&#174;</sup>. The Alzheimer&#8217;s Association<sup>&#174;</sup> estimates that the annual number of new cases
        of Alzheimer&#8217;s and other dementias is projected to double by 2050. Medications on the market today treat only the symptoms
        of Alzheimer&#8217;s disease and do not have the ability to stop its onset or its progression. We believe that there is an urgent
        and unmet need for both a disease modifying cure for Alzheimer&#8217;s disease as well as for better symptomatic treatments.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parkinson&#8217;s
        disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity,
        and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and deficiency of the neurotransmitter
        dopamine. Parkinson&#8217;s disease currently is estimated to afflict more than 10 million people worldwide, typically middle-aged
        and elderly people. The Parkinson&#8217;s disease market is expected to reach $11.5 billion by 2029, according to GlobalData.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rett
        syndrome &#8211; Rett syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain
        develops, including protein transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis.
        It is considered a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene. Because
        males have a different chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating
        ways. Most of them die before birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe impairments,
        affecting nearly every aspect of the child&#8217;s life; severe mental retardation, their ability to speak, walk and eat, sleeping
        problems, seizures and even the ability to breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000 females.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Schizophrenia - Schizophrenia is a persistent and
    often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide, including
    2.8 million people in the U.S., according to the World Health Organization. It is characterized by three symptom domains: positive symptoms
    (hallucinations and delusions), negative symptoms (difficulty enjoying life and withdrawal from others), and cognitive impairment (deficits
    in memory, concentration, and decision-making). In part due to limitations with current treatments, people living with schizophrenia often
    struggle to maintain employment, live independently, and manage relationships. While current treatments can be effective in managing select
    symptoms, approximately 34% of people do not respond to therapy, with an additional 50-60% experiencing only a partial improvement in
    symptoms or unacceptable side effects.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fragile X &#8211; Fragile X syndrome (FXS) is the
    most prevalent genetic form of intellectual disability and autism spectrum disorder, primarily affecting boys. As with most neurodevelopmental
    disorders, FXS is considered a condition of synaptic development and function. The disease has a range of clinical presentations depending
    on the specific genetic changes associated with an &#8220;expansion&#8221; of the FMR1 gene. The disease is characterized by deficits
    in long-term potentiation and homeostatic plasticity. FXS has been detected in all populations and ethnic groups. Researchers do not know
    the exact number for how many Americans could have full mutation FXS. Studies estimate that the disease affects approximately 1:4,000
    males and 1:6,000 females. Worldwide, more than 1,400,000 people could be affected by FXS.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depression &#8211; Depression is a major cause of
    morbidity worldwide according to the World Health Organization. The global antidepressant drug market is projected to reach $21 billion
    by 2030 according to Allied Market Research. Pharmaceutical treatment for depression has been historically dominated by blockbuster brands.
    However, the dominance of the leading brands is waning, largely due to an increase in the number of approvals for antidepressant drugs.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Epilepsy &#8211; Epilepsy is a common chronic neurological
    disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or
    synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4
    million Americans. Today, epilepsy is often controlled, but not cured, with medications that are categorized as older traditional anti-epileptic
    drugs and second-generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different ways, there is a need for drugs used
    in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Neuropathic Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Malignant Melanoma &#8211; Predominantly a skin cancer,
    malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for a large majority of skin
    cancer deaths. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy.
    According to iHealthcareAnalyst, Inc. the worldwide malignant melanoma market is expected to grow to $7.5 billion by 2029.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prostate Cancer &#8211; Specific to men, prostate
    cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Cancer cells may metastasize from the
    prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase
    to nearly $10.1 billion by the end of 2030 according to Market Research Future.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pancreatic Cancer &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 62,000 new cases of pancreatic cancer will be diagnosed this year and approximately 50,000 patients will die as a result of their cancer, according to the American Cancer Society. Sales predictions by Market Data Forecast predict that the market for the global pharmaceutical treatment of pancreatic cancer will increase to $3.7 billion by 2027.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual Property
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to twenty-seven
(27) issued U.S. patents, twenty-two (22) pending U.S. patent applications, and numerous PCT and ex-U.S. patent applications relating
to our drug candidates, methods associated therewith, and to our research programs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73
and certain anticholinesterase inhibitors composition and method for neuroprotection,&#8221; which claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73,
a synergistic neuroprotective compound, combined with donepezil and other cholinesterase inhibitors. This patent is expected to expire
in June 2034, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own another issued U.S. patent entitled &#8220;A2-73
crystalline polymorph compositions of matter and methods of use thereof&#8221;. It claims crystals of A2-73 freebase or its fumarate salt,
dosage forms and pharmaceutical formulations. This patent is expected to expire in July 2039, absent any patent term extension for regulatory
delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own five issued U.S. patents each with claims directed
to crystalline forms of ANAVEX<sup>&#174;</sup>2-73. The first of these five patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73,
dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease
using them. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. The second of these
five patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment
for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2036, absent any patent term extension
for regulatory delays. The third of these five patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73,
and methods of treating for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037, absent any
patent term extension for regulatory delays. The fourth patent claims method of making certain crystalline forms of ANAVEX<sup>&#174;</sup>2-73.
This patent is expected to expire in October 2036, absent any patent term extension for regulatory delays. The fifth patent claims crystalline
forms of the dihydrogen phosphate salt of ANAVEX<sup>&#174;</sup>2-73 and dosage forms (including transdermal and oral dosage forms) and
pharmaceutical compositions containing the same. This patent is expected to expire in July 2039, absent any patent term extension for
regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own three issued U.S. patents for seizure
treatment. The first of these three patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose
anti-epilepsy drug combined with either: (i) ANAVEX<sup>&#174;</sup>2-73 and its active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii)
ANAVEX<sup>&#174;</sup>19-144. The second of these three patents further claims a combination seizure treatment involving administration
of an anti-epilepsy drug combined with (i) ANAVEX<sup>&#174;</sup>19-144, or (ii) ANAVEX<sup>&#174;</sup>19-144 and ANAVEX<sup>&#174;</sup>2-73.
The third of these three patents claims a dosage form for seizure reduction, comprising (i) ANAVEX<sup>&#174;</sup>19-144, (ii) ANAVEX<sup>&#174;</sup>2-73,
or (iii) a combination of ANAVEX<sup>&#174;</sup>19-144 and ANAVEX<sup>&#174;</sup>2-73; and optionally further comprising a low-dose anti-epilepsy
drug. All three patents are expected to expire in October 2035, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own four issued U.S. patents with claims directed
to treating neurodevelopmental disorders. These patents claim methods for treating a neurodevelopmental disorder, multiple sclerosis,
their related biochemical and functional abnormalities, or loss-of-function associated with a neurodevelopmental disorder, by administering
ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41 (another sigma receptor ligand similar to
ANAVEX<sup>&#174;</sup>2-73), or compositions thereof. All four patents are expected to expire in January 2037, absent any patent term
extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we own one issued U.S. patent with claims
directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in February
2030, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own an issued U.S. patent that claims crystalline
forms of ANAVEX<sup>&#174;</sup>19-144, dosage forms and compositions containing the crystalline forms of ANAVEX<sup>&#174;</sup>19-144,
and methods of treatment for Alzheimer&#8217;s disease. This patent is expected to expire in July 2036, absent any patent term extension
for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, we own two issued U.S. patents with claims
directed to methods of treating cardiac dysfunction with ANAVEX<sup>&#174;</sup>2-73. These patents are expected to expire in July 2038,
absent any patent term extension for regulatory delays. Additionally, we own three issued U.S. patents for the treatment of insomnia,
anxiety, or agitation. The first of the three patents claims methods of treating insomnia or anxiety with ANAVEX<sup>&#174;</sup>2-73,
ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41. This patent is expected to expire in September 2038. The second and
third of the three patents claim dosage forms comprising any of, or any combination of ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
and/or ANAVEX<sup>&#174;</sup>1-41. These patents are expected to expire in July 2037, absent any patent term extension for regulatory
delays.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, we own one issued U.S. patent with claims
directed to a method of treating systolic hypertension using ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2039,
absent any patent term extension for regulatory delays. Additionally, we own one issued U.S. patent with claims directed to pharmaceutical
dosage forms of the (-) enantiomer of ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in July 2036, absent any patent term
extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own three (3) issued U.S. patents related
to ANAVEX<sup>&#174;</sup>1066. The first of these three patents claims methods for treating or preventing pain using the (+) ANAVEX<sup>&#174;</sup>1066
isomer. The second patent claims methods for treating or preventing pain using the (-) ANAVEX<sup>&#174;</sup>1066 isomer. The third patent
claims dosage forms and pharmaceutical compositions comprising the (+) ANAVEX<sup>&#174;</sup>1066 isomer. All three patents are expected
to expire in November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted or pending applications in Australia, Canada, China,
Europe, Japan, and Hong Kong, which are expected to expire after 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>&#174;</sup>3-71, we own
exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71 compound and methods of
treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in April 2030, and January 2030,
respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related patents or applications
that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and South Africa, which are expected
to expire in January 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications and certain
granted foreign patents directed to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional
protection for one or more of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual property
rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business strategy
including the selective development, protection, and exploitation of our intellectual property rights. In addition to filings made with
intellectual property authorities, we protect our intellectual property and confidential information by means of carefully considered
processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements and provisions
for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements provide some form of recourse
in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions
for which important legal principles are unresolved. For more information regarding challenges to our existing or future patents, see
&#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on December
23, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financial Overview </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The following discussion should be read in conjunction
with our condensed consolidated interim financial statements and related notes thereto contained elsewhere in this report. Past operating
results are not necessarily indicative of results that may occur in future periods. The discussion contains forward-looking statements,
which involve a number of risks and uncertainties. See &#8220;Forward Looking Statements&#8221; included elsewhere in this report.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are in the development stage and have not earned
any revenue since our inception in 2004. We do not anticipate earning any revenues until we can establish an alliance with other companies
to develop, co-develop, license, acquire or market our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating costs consist primarily of research
and development activities including the cost of clinical trials and clinical supplies as well as clinical drug manufacturing and formulation.
Research and development expenses also include personnel related costs such as salaries and wages, and third-party contract research organization
(CRO) expenses in support of these clinical trials. Personnel costs include salaries and wages, benefits, and non-cash share-based compensation
charges associated with options and other equity awards granted to employees and consultants who are directly engaged in support of our
research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses consist of personnel
costs, expenses for outside professional services and expenses associated with operating as a public company. Personnel costs consist
of salaries and wages, benefits and share-based compensation for general and administrative personnel. Outside professional services and
public company expenses include expenses related to compliance and reporting, additional insurance expenses, audit and SOX compliance,
expenses associated with patent research, applications and filings, investor and stockholder relations activities and other administrative
expenses and professional services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Comparison of the three- and six- months ended
March 31, 2025 and 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating expenses for the three months ended
March 31, 2025 were $12.5 million, compared to $12.6 million for the comparable three months ended March 31, 2024. Total operating expenses
for the six months ended March 31, 2025 were $26.1 million, compared to $24.0 million for the comparable six months ended March 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses for the three
months ended March 31, 2025 were $9.9 million, as compared to $9.7 million for the three months ended March 31, 2024. Our research and
development expenses for the six months ended March 31, 2025 were $20.3 million, compared to $18.4 million in the comparable six months
ended March 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The increase in research and development expenses
during the three- and six-month periods is primarily related to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 33pt">(i)</td><td style="text-align: justify">an increase of approximately $2.1 million in the three-month period and $3.7 million in the six-month
period over the comparable periods relating to expenditures on the ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial, which trial commenced
in the second quarter of fiscal 2024.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 33pt">(ii)</td><td style="text-align: justify">an increase in personnel costs of $0.9 million for the six-month period related to the addition of new
consultants engaged to assist in the preparation of the submission of our Marketing Authorisation Application (MAA) to the European Medicines
Agency (EMA); and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 33pt">(iii)</td><td style="text-align: justify">an increase of approximately $1.2 million in the six-month period over the comparable period relating
to manufacturing activities of ANAVEX<sup>&#174;</sup>2-73 for potential commercial use, and to support the MAA.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These increases were partially offset by (i) a decrease
of approximately $0.6 million in the three-month period and $1.2 million in the six-month period in expenditures over the comparable periods
relating to our Alzheimer&#8217;s program, as a result of the completion of the Phase 2b/3 clinical trial open label extension and (ii)
a decrease in stock based compensation charges of $0.8 million in the three-month period and $0.9 million in the six-month period due
to a change in estimates associated with milestone-based options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our research and development
expenses for the three- and six-months ended March 31, 2025 and 2024 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Cost of external service providers</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">6,018</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">5,167</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">11,494</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">9,732</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Personnel costs</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">3,010</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">2,862</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">6,674</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">5,610</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Share based compensation</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">844</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,673</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">2,097</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">3,033</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other common costs</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">20</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">27</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">73</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">38</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total research and development costs</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">9,892</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">9,729</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">20,338</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">18,413</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three- and six-months ended March 31, 2025
and 2024, external service provider costs by product candidate was as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>2-73</span></td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">3,232</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">4,180</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">6,752</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">7,991</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>3-71</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">2,693</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">856</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">4,282</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,453</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other product candidates</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">44</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">61</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">286</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">66</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other external service provider costs</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">49</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">70</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">174</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">222</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total external service provider costs</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">6,018</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">5,167</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">11,494</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">9,732</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses were $2.6
million for the three months ended March 31, 2025, as compared to $2.9 million for the same quarter of fiscal 2024. General and
administrative expenses were $5.8 million for the six months ended March 31, 2025, as compared to $5.6 million for the six months
ended March 31, 2024. In both periods, increases in legal fees were offset by a decrease in stock
based compensation charges.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other income (net)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net other income for the three-months ended March
31, 2025 was $1.3 million, as compared to $2.1 million for the comparable three-months ended March 31, 2024. The decrease in other income
is primarily related to a decrease in interest income associated with a change in market wide rates and principal balances held, as well
as decrease in research and development incentive income, as a result of the completion of the open label extensions of our Australian
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net other income for the six months ended March 31,
2025 was $2.8 million as compared to $4.8 million for the comparable six months ended March 31, 2024. The decrease in other income for
the six-month period is also primarily related to a decrease in interest income associated with a change in market wide rates and principal
balances held, as well as decrease in research and development incentive income, as a result of the completion of the open label extensions
of our Australian clinical trials</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for the three-months ended March 31, 2025,
was $11.2 million, or $0.13 per share, as compared to $10.5 million, or $0.13 per share in the comparative quarter of fiscal 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for the six-months ended March 31, 2025,
was $23.3 million, or $0.27 per share, as compared to $19.2 million, or $0.23 per share for the six-months ended March 31, 2024. The increase
in net loss for the quarter and year-to-date periods is primarily related to an increase in research and development expenditures and
a decrease in other income, as discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Working Capital (in thousands)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">March 31,<br/> 2025</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">September 30, 2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Current Assets</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">117,139</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">135,567</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">17,381</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">15,304</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Working Capital</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">99,758</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">120,263</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2025, we had net current assets of $99.8
million, a decrease of approximately $20.5 million from our year ended September 30, 2024. The decrease in net current assets primarily
relates to cash utilized in operations during the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We intend to
continue to use our capital resources to advance our clinical trials for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71, and
to perform the work necessary to prepare for future development of our pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table summarizes cash flows during the six months ended March 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" style="font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net cash flows used in operating activities</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(17,976</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(18,974</td>
<td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash flows provided by financing activities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">1,560</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">7,336</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Decrease in cash and cash equivalents</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(16,416</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">(11,638</td>
<td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash flow used in operating activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities for the six-months
ended March 31, 2025 was $18.0 million, compared to $19.0 million during the comparable period ended March 31, 2024. The principal reason
for this is due to changes in working capital as a result of (i) the receipt of the annual research and development incentive tax refund
during the current quarter, whereas such amount was received in third quarter of fiscal 2024 and (ii) an increase in accrued liabilities
related to activities associated with a large manufacturing run for ANAVEX<sup>&#174;</sup>2-73, which work was not yet invoiced at March
31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash flow provided by financing activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flows from financing activities for the six-month
period ended March 31, 2025 was $1.6 million, compared to cash provided from financing activities of $7.3 million during the comparable
six-month period ended March 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2025, we received
$1.6 million in cash from the exercise of stock options by our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2024, cash provided
by financing activities was primarily attributable to cash received from the issuance of common shares at various market prices under
the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Financings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2023 Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150,000,000
purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant
to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $150.0 million
in value of its shares of Common Stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On any business day and subject to having an effective
registration statement and subject to certain customary conditions, the Company may direct Lincoln Park to purchase up to 200,000 shares
of Common Stock (such purchases, &#8220;Regular Purchases&#8221;). The amount of a Regular Purchase may increase under certain circumstances
based on the market price of the Common Stock; provided, however, that Lincoln Park&#8217;s committed obligation under any Regular Purchase
shall not exceed $4.0 million. The purchase price of shares of Common Stock will be based on the then prevailing market prices of such
shares at the time of sales as described in the 2023 Purchase Agreement. There are no limits on the price per share that Lincoln Park
may pay to purchase Common Stock under the 2023 Purchase Agreement. In addition, if the Company has directed Lincoln Park to purchase
the full amount of Common Stock available as a Regular Purchase on a given day, it may direct Lincoln Park to purchase additional amounts
as &#8220;accelerated purchases&#8221; and &#8220;additional accelerated purchases,&#8221; each as set forth in the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2023 Purchase Agreement limits the Company&#8217;s
sale of shares of Common Stock to Lincoln Park to 15,606,426 shares of Common Stock, representing 19.99% of the shares of the Common Stock
outstanding on the date of the 2023 Purchase Agreement unless (i) stockholder approval is obtained to issue more than such amount or (ii)
the average price of all applicable sales of Common Stock to Lincoln Park under the 2023 Purchase Agreement equals or exceeds the lower
of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average
of the closing price of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2023 Purchase Agreement also prohibits the Company
from directing Lincoln Park to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common Stock
then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership,
at any single point in time, of more than 4.99% of the then total outstanding shares of Common Stock, as calculated pursuant to Section
13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park 75,000 shares of Common Stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
during the year ended September 30, 2023 and agreed to issue up to 75,000 shares pro rata (collectively with the initial commitment shares,
the &#8220;commitment shares&#8221;), when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the $150.0 million aggregate
commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six-months ended March 31, 2025, the Company
did not issue any shares of common stock under the 2023 Purchase Agreement. During the six-month period ended March 31, 2024, the Company
issued to Lincoln Park an aggregate of 1,503,707 shares of Common Stock under the 2023 Purchase Agreement, including 1,500,000 shares
of Common Stock for an aggregate purchase price of $7,411,700 and 3,707 commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 31, 2025, there was an unused amount of $110.8
million under the 2023 Purchase Agreement. The Company will need to obtain effectiveness of a new registration statement in order to access
funds under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have no off-balance sheet
arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>CRITICAL ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We prepare our condensed
consolidated interim financial statements in accordance with accounting principles generally accepted in the United States of America
and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue and expenses, and the related disclosures
of contingent liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable in the
circumstances. Actual results may differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There have been no significant
changes in the critical accounting policies and estimates described in our Annual Report on Form 10-K for the year ended September 30,
2024, as filed with the SEC on December 23, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Please refer to Note 2 &#8220;Recent
Accounting Pronouncements&#8221; in notes to our Condensed Consolidated Interim Financial Statements included in this Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_004"></span>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not required for smaller reporting companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_005"></span>ITEM 4. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Disclosure Controls and
Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We maintain disclosure controls
and procedures that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports
filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules
and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief executive
officer and our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We carried out an evaluation,
under the supervision and with the participation of our management, including our principal executive officer and principal financial
officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) under
the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive
officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Changes in Internal
Control over Financial Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the quarter ended
March 31, 2025, there were no changes to our internal control over financial reporting identified in management&#8217;s evaluation pursuant
to Rules 13a 15(d) or 15d 15 (d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal
controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_006"></span>PART II &#8211; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_007"></span>ITEM 1. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to claims and legal proceedings
that arise during the course of business. The Company is currently subject to the following lawsuits:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York (the &#8220;Initial
Action&#8221;). The complaint was captioned Blum v. Anavex Life Sciences, Corp. et al., case number 1:24-cv-01910, and it named the Company
and Christopher Missling as Defendants. The complaint alleged violations of the Securities and Exchange Act of 1934 associated with disclosures
and statements made with respect to certain clinical trials for ANAVEX<sup>&#174;</sup>2-73 related to Rett syndrome (the &#8220;March
2024 Complaint&#8221;). At a hearing on or about June 13, 2024, the Court named another purported Company shareholder, Quintessa Huey,
as lead plaintiff with respect to the March 2024 Complaint. An Amended Complaint was filed by the appointed lead plaintiff on July 12,
2024, which asserts allegations related to purported violations of Section 10(b) of the Securities Exchange Act tied to disclosures associated
with the same clinical trials related to Rett Syndrome, and which names the Company and Christopher Missling as defendants. The Amended
Complaint seeks unspecified damages, as well as costs, including counsel and expert witness fees, on behalf of a class of investors who
purchased stock of the Company on the NASDAQ during the period February 1, 2022 through January 1, 2024.&#160;The defendants filed a motion
to dismiss the complaint. The motion to dismiss is fully-briefed and awaiting a decision by the Court.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing (case no. 1:2024-cv-03529), a purported shareholder of the Company,
against the same defendants as the March 2024 Complaint. The defendants filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed his complaint subsequent to the filing of the motion to dismiss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), Christopher Missling, and members of the Company&#8217;s
Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder named Denise Deangelis.&#160;The
complaint asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a) of the Securities Exchange
Act regarding the same or similar allegations at issue in the two purported class action lawsuits related to disclosures and statements
made about certain clinical trials related to Rett Syndrome. On January 22, 2025, pursuant to a stipulation of the parties, the Court
entered an order staying this purported derivative lawsuit until the motion to dismiss filed by defendants in the above-referenced class
action (Quintessa Huey) lawsuit is decided by the U.S. District Court for the Southern District of New York.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On February
14, 2025, another derivative lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations
was filed against the Company (as nominal defendant), Christopher Missling, and members of the Company&#8217;s Board of Directors in the
Supreme Court for the State of New York, County of New York, by another purported shareholder named Evan Levitan. The parties to that
action also have stipulated to a stay of the proceeding until the Court rules on the motion to dismiss in the putative class action lawsuit
pending in the U.S. District Court for the Southern District of New York. The New York state court has not yet entered an order pursuant
to the stipulation of the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">We
know of no other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business,
to which our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which
any of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_008"></span>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes to the risk factors
discussed in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024,
filed with the SEC on December 23, 2024 except the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to the Discovery and Development
of Our Current and Future Product Candidates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The marketing approval process for pharmaceutical
products is a lengthy, complex and highly regulated process and we cannot predict the outcome of any interactions with the regulatory
authorities or when we will receive marketing approval, if at all.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The regulatory approval processes of the EMA, the
FDA, and other comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and the approval process can vary
significantly depending on the regulatory authority. Relevant health authorities may, at the time of the filing of the application for
a marketing authorization, or later during their review, impose requirements that can evolve over time, including requiring additional
clinical trials, and such authorities may delay or refuse to grant approval. A finding that our Phase 2b/3 ANAVEX2-73-AD-004 clinical
trial is insufficient to support the current marketing authorization in Alzheimer&#8217;s disease could lead us to decide, after consultation
with regulatory authorities, to voluntarily withdraw our MAA for blarcamesine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In recent years, health authorities have become increasingly
focused on product safety and on the risk/benefit profile of pharmaceutical products, which could lead to more burdensome and costly approval
processes and negatively affect our ability to obtain regulatory approval for products under development. For example, the U.S. Food and
Drug Administration (the &#8220;FDA&#8221;) and the European Medicines Agency (the &#8220;EMA&#8221;), have been implementing strict requirements
for approval, particularly in terms of the volume of data needed to demonstrate a product&#8217;s efficacy and safety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Obtaining and maintaining regulatory approval
of blarcamesine or any future product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory
approval of those product candidates in other jurisdictions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Obtaining and maintaining regulatory approval of blarcamesine
and any future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval
in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on
the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative
review periods different from each other, including additional preclinical studies or clinical trials, as clinical trials conducted in
one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., including
Canada, and certain jurisdictions in the EU, a product candidate must be approved for reimbursement before it can be approved for sale
in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regulatory authorities in jurisdictions outside of
the U.S. have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions and
such regulatory requirements can vary widely from country to country. Obtaining other regulatory approvals and compliance with other regulatory
requirements could result in significant delays, difficulties and costs for us and could require additional preclinical studies or clinical
trials, which could be costly and time-consuming and could delay or prevent the introduction of our products in certain countries. The
foreign regulatory approval process involves all of the risks associated with FDA approval. We do not have experience in obtaining regulatory
approval in international markets or within the United States. If we fail to comply with the regulatory requirements in international
or domestic markets and/or obtain and maintain applicable marketing approvals, our target market will be reduced and our ability to realize
the full market potential of blarcamesine or any future product candidates will be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in U.S. and international trade policies
may adversely impact our business and operating results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The U.S. government has made statements and taken
actions that have led to certain changes and may lead to additional changes to U.S. and international trade policies. For example, President
Trump has imposed or signaled to impose a series of&#160;tariffs&#160;on certain products manufactured outside the United States, including
pharmaceutical products and raw materials and components for pharmaceutical products, and it is unknown whether and to what extent additional&#160;tariffs&#160;(or
other new laws or regulations) will be adopted, or the effect that any such actions would have on us or our industry. Such unfavorable
government policies on international trade, such as export controls, capital controls or&#160;tariffs, may affect the import and export
of materials and products used in our drug development. For example, we have already faced increased costs associated with our imports
of drug products due to newly imposed tariffs on Canada. These policies may also affect the demand for our product candidates, the competitive
position of our product candidates, and clinical manufacturing and future commercial activities. If any new&#160;tariffs, export controls,
legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or if the U.S. government takes retaliatory
trade actions due to the ongoing trade tensions, such changes could have an adverse effect on our business, financial condition and results
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_009"></span>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period covered by this Quarterly Report
on Form 10-Q, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously
reported in a Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_010"></span>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_012"></span>ITEM 5. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Insider Trading Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None of our directors or Section 16 officers informed
us of the <span id="xdx_90E_eecd--Rule10b51ArrAdoptedFlag_dbF_c20241001__20250331_z76xzKeMhlEl"><span id="xdx_909_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20241001__20250331_zCzIXJTZdC57"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt:booleanfalse" id="Fact000876" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt:booleanfalse" id="Fact000877" name="ecd:NonRule10b51ArrAdoptedFlag">adoption</ix:nonNumeric></ix:nonNumeric></span></span>, modification or <span id="xdx_90D_eecd--Rule10b51ArrTrmntdFlag_dbF_c20241001__20250331_z1FdccJUfhRc"><span id="xdx_903_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20241001__20250331_z9u40Wso22Gl"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt:booleanfalse" id="Fact000878" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-10-01to2025-03-31" format="ixt:booleanfalse" id="Fact000879" name="ecd:NonRule10b51ArrTrmntdFlag">termination</ix:nonNumeric></ix:nonNumeric></span></span> of a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement&#8221;
(in each case, as defined in Item 408(a) of Regulation S-K) during the three-month period ended March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ITEM 6. EXHIBITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Number</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 92%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(3)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Articles
    of Incorporation and Bylaws</b></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on April 14, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(31)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rule
    13a-14(a)/15(d)-14(a)Certifications</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><a href="e6578_ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Christopher Missling, PhD.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><a href="e6578_ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Sandra Boenisch</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(32)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
    1350 Certifications</b></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><a href="e6578_ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Christopher Missling, PhD and Sandra Boenisch.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(101)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>XBRL</b></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    INSTANCE DOCUMENT</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION SCHEMA</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-transform: uppercase"><b>&#160;</b></span>&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">** Furnished herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_013"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX LIFE SCIENCES CORP. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; width: 50%; text-indent: 0pt"><span style="font-size: 10pt">/s/Christopher Missling, PhD</span></td>
    <td style="padding: 0pt; width: 50%; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Christopher Missling, PhD</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Executive Officer</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Date: May 13, 2025</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; width: 50%; text-indent: 0pt"><span style="font-size: 10pt">/s/Sandra Boenisch</span></td>
    <td style="padding: 0pt; width: 50%; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Sandra Boenisch, CPA, CGA</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Principal Financial Officer</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Date: May 13, 2025</span></td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e6578_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;<B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on Form 10-Q
for the three months ended March 31, 2025 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e)
and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: May 13, 2025</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Christopher Missling, PhD</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Christopher Missling, PhD</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer, President and Secretary</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e6578_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;<B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on Form 10-Q
for the three months ended March 31, 2025 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e)
and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: May 13, 2025</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Sandra Boenisch</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Principal Financial Officer, Treasurer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>e6578_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of Anavex
Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months ended March 31, 2025 as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the capacities and on the date indicated below,
hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the
best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(1) the Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(2) the information contained in the Report
fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: May 13, 2025</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">/s/Christopher Missling, PhD </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Christopher Missling, PhD</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer, President, Secretary</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer) </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">/s/Sandra Boenisch</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Principal Financial Officer, Treasurer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing certification is being furnished solely
to accompany the Report pursuant to 18 U.S.C. &sect; 1350 and is not being filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic
version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  G # 2(  A$! Q$!_\0
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M,'_/>/\ [[%%T%F2T5%]I@_Y[Q_]]BC[3!_SWC_[[%%T%F2T5%]I@_Y[Q_\
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M/P?.\$YB#2 ?9TV0294*0H4@#@9< ?[U #K+Q;=ZI#'/8Z1NB%P8)#YF\AE
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M=7SO)3[+_P "1[O//N__  %CHO#\DP1EG0*P))*GCIC\\G\C43:0JP-+]H7
M.,;<D\@=B>YI_E:9G/\ ;%UGU^SG_P"*I&ATMB2VL73$\9-L3_[-0X4[:)?^
M!(%.=]6__ 6,.CD7#Q>=G:%*L(R<[B0/H..M2?V$V"3.H"YW87ICZFCR],R6
M_MFZRPP3]G.2/?YJ!'IHQC6;L8Z8MVX_\>H4*?9?^!('.?=_^ L:NARE5)D
MW)N VY.?[I]\8/XU4O;06<_E;PY Y(&/ZU<$6F#=C6+H;OO?Z.>?K\U#0Z5(
M07U>Y8C@;K8G_P!FJ94XN-HI)_XD5&I).\KV_P +,O HP*TOLND?]!2?_P !
M3_C1]ETC_H*3_P#@*?\ &L?8R[K[T:^U79_<S-P*,"M+[+I'_04G_P# 4_XT
M?9=(_P"@I/\ ^ I_QH]C+NOO0>U79_<S-P*,"M+[+I'_ $%)_P#P%/\ C1]E
MTC_H*3_^ I_QH]C+NOO0>U79_<S-P*,"M+[+I'_04G_\!3_C1]ETC_H*3_\
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M_@*?\:/LND?]!2?_ ,!3_C2]C+NOO0_:KL_N9FX%&!6E]ETC_H*3_P#@*?\
M&C[+I'_04G_\!3_C1[&7=?>@]JNS^YF;@48%7%T]KB25K6=6@4[4>2,JS' Y
MQZ<X_"G#2+G*YF@Q_%@-^E5]7J?TR?;P_I%' HP*N_V1=;1^^M]V>>&QC_&E
M.DW/SXF@_P!C(;]:/J]3^F'MX%' HP*O?V3<;O\ 70[<>ASG_"FC2KCY,RP?
M[6 WZ4OJ]3^F/V\"G@48%6SIESM/[V#=GCAL8_QH.FSY?$L./X<@_K1["?\
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M_P /\S-HK2^V:5_T!S_X%-_A1]LTK_H#G_P*;_"L_91_G7X_Y&GM)?RO\/\
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M%^/^1:J3_D?X?YGI>D*4T:R4P>01 @\K.=G XJ[5+2#$VC61@1TA,";%D)+
M8& 2>]7:^WCLCY)[L****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]JR@,I;#2N, <GGUQS4C6^JH 6U2;#,%0B1R&)&?P]*.:;5_>_\ )0M!=O\
MR8C:>[>5'.GW8VQ&,E=P;G'(...E3#4+W.6TN?KG 5@!QCCBFR6^J1LJG59L
MN=J_O'Y;GCVZ'FEFMM6@BDDEU24*A(&)6.[W'/0T_?5W[W_DHO<=MO\ R81+
MR[3:!I<^U"2I"MNR?O9.,<\=NU5;X7=Z8S]@N$*#&-A(Z#V]JK?VG?\ _/\
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M_09B_P# =Z/L&G?]!F+_ ,!WK-HH]I#^1?C_ )AR2_F?X?Y&E]@T[_H,Q?\
M@.]'V#3O^@S%_P" [UFT4>TA_(OQ_P PY)?S/\/\C2^P:=_T&8O_  '>D^P:
M=_T&HO\ P'>LZCM1[2'\B_'_ ##DE_,_P_R.F  0 -D #!QUI"!Z_I4ELT2A
M3,A==H&!_.IFFL\<6[9Z]?T^E>JDFKW1YK;3V*1 _O?I32!_>_2KCS6ASM@Z
MGKC&!^=1F6URX\D[3G'J..*3BNZ_$:D^S*A _O?I32!_>_2KKS63)C[.P.1T
M_P :9)-9E?E@.<CMCC//?_.:AQ7=?B6I/L_P*9 _O_H:80O]_P#0U<DEM"C;
M8R'*@9V\9]1SQ3%FM /FAYR?X<\9^OIQ^M9N*ONOQ+4G;9E,A?[WZ&FD+_?_
M $-:+W6G9&VR.-Q)!;\A3/M&G!<?9F.!Z8)_6I<(_P R_$:G+L_P,XJO]_\
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M)*Y')ZGD&GSK^?\ \E7^0N1_R_\ DS_S(?[6A_Z!&G_]\-_C1_:T7_0(T_\
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M/+D_YYO_ -\FCVU7^DO\@]E3_IO_ #-#^UHO^@1I_P#WPW^-']K1?] C3_\
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M  K#_:/YG_X%_P#;&_[C^7_R7_@#/[;U7_H(W/\ WW1_;>J_]!&Y_P"^Z?\
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M+@\"V4%ON[I0 !_M?W?PS4VJ=_Q_X(_<[?A_P!PB54C0%PL;[T'F-PWKUH9
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M1D\$<CG@_AR*G_L="NTW$[#K@D$9]<5IT54I.3NR(P459%6TLQ:[OWTLA/\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 44ASCY<9]Z;^\_V/UH
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M7WF'M'I1M'I6YY?AC^_K/_?,56]+TOPYJVI06,,VK)),2%9Q%@8!/./I6O\
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MI6&'DDDR!MWD(,ID_)@'L.,]Z2#Q!IQ?_2-/C W$Y1%/0KC(XR>#Z8JY]O\
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M1]]O_032?\);K7_/S%_X#1__ !-:_A?Q'JEYXFL;>>>-HG<A@($4GY2>H&:
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M$_CWJN/#%D YW.9')8N57.X[3Q@<#*C@=,FGV%UK$]\B7-NL5N QD8Q$'/9
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MWOMTA.39GYCEA@X/TXX[5G^5+_SS?_ODT 4?[!\/_P#/A<_^!1_PH_L'P_\
M\^%S_P"!1_PJ]Y4O_/)_^^31Y4O_ #R?_ODT 4?[!\/_ //A<_\ @4?\*T-#
MTC1K?6K66VLYTF5B59K@L!P>V.:;Y4O_ #R?_ODU=TB.0:K;DQN!D\E3Z&@#
ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^Z 5?GZ@=CQ0!?\ M]G]G%Q]JA\ECM$F\;2?3-)/J%I;OY<MQ&),*=F<M@G
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2I?I4/DOZ#\ZG0%4 /44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &@ G # 2(  A$! Q$!_\0
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M!B!WJI_POWQU_P _%C_X"BO/]=_Y&#4O^OJ7_P!#-4* /3_^%^^.O^?BQ_\
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M\!11_P +]\=?\_%C_P" HKS"B@#T_P#X7[XZ_P"?BQ_\!11_POWQU_S\6/\
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MA14@>G_\+]\=?\_%C_X"BC_A?OCK_GXL?_ 45YA10!Z?_P +]\=?\_%C_P"
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M"8JA1QJCAOA:2]6>+L,&DJ6;&\XJ*NBM!0FTC[Q.Z"BBBLAA1110 4444 %
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M'[T+6,</3IU*CA&S9Z.4QIQQBNCS)QR:94C\,:CKYJLO>9^BH****P&%%%%
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MII*\YJS+"BBBD 4444 %/'2F4\5O1W$R6-L$5UN@^(6LE5"V*Y)0#TJU =C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOPV2VDT%M)BV>4B:2(R%/E_NX()]16ZOBWPO=:Y?7-ZS"QNV@UG[,L+$1WZ
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M\4T3%)(W7#*P.""#T(-=UJ&J:-#X5ET2'7FU" WD<FF;K=T?3TR2[.<#+$$
MJNX'&<]*XB\"K?7 2Y^U()&"SX(\T9^]@\C/7GGF@""BBB@ KJ8?!4LNF12'
M4;==3FLFOX=.*-O>!023NQM#%59@O<#W KEJ]"MO$&BK]@UYK_;?66C-I_\
M9_DL6>7RGA5@V-NS:P8Y.<@C'(H XG3](U+5I&33K"YNV4@,((F?&<XS@<=#
M^5/N=#U:RM%NKK3+R"W>0Q+++ RJ7'5<D=>#Q[&M/1]8AL/!_B*P-P\5U?-:
MB)5!^=4=BP)'3J.M=JGC73[KQ=JURDL]_P#:]2TV6T@*MF?RF&X#=PI[#..M
M 'G%_H.KZ5$LNH:7>6D;$!7G@9 202!DCK@'CVK1T/PK+K6G37@NXX AF"*Z
MD^9Y4+3/TZ8"J/JXKJO%EBVF?#^ZAEU&[NFN-?\ -5;JWDA8$1/NX?DM\R[B
M. <<FJ'A_P 3:9HD^CJ7BFBM--O&E62%F1[F9' 1E[C B4]NM '*6^@:Q=SQ
MP6VEWDLLD/GHB0,2T9Z.!C[OOTJI=6ES8W#6]W;RV\RX+1RH589&1D'GH17I
MQNK3Q5:>()+&ZO8CJ2VEU<R+!+,+212X:!MH+&,D@H0"!A5.*YKXG'/CV]0S
M23-'#;1O)*,.66",-N'9L@Y'8YH Y"BBB@ HHHH **** +-A87&IWT-E:('G
MF;:@+!1^))  ]S5WQ)H4GAO7)=+EN8;EXDC<RP'*-O17X/<?-U[UDUO>,=2M
M-6\1-=V4AD@-M;1[BI7YDA1&&#[J10!77PMX@=(G71-1*RN$C/V9\,Q&0!QS
MQS4<'A[6KFZNK:#2;V6>U_X^(D@8M%_O#''XUV&L>,;2Z'BE;?49RM]86-O:
MC#@-Y?E;U]@-K_7GUK<EN8O%UO<#3[J_AC74;.47D%K)+YL@MDC*$+\P<,K%
M2>#EN10!PV@^#+S6KEK>67[#*+N.SVSQ-GS&#L01U& A)^HK(MM%U2\DMDMM
M.NY7N@S0!(6)E"\$KQR!SD^U>F:KXFTG2_B7 SW>^V@UN[O;UPI8!BVQ5X^]
MA4SQ_?-06VK6GBDZA+;/<6UU?Z,+:ZCMH'=-/\J2/!15Y\AU4 A<E2QR,4 >
M:7NGWFFSB"^M)[64C<$GC*-CIG!^AJO7:_$M/(U31;4W$MQ);Z-;1N\JE7S\
MQ&5/*\$8!YQBN*H **** "BBB@ HHHH LZ?87&J7\-E:('GE.%#.%'J222
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M4##;\#!R"0#7E^NRI-X@U*6-@R/=2LI4\$%R1B@"A1110 5]D_"'_DE.@?\
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MPA_Y)3H'_7%O_1C5\;5]D_"'_DE.@?\ 7%O_ $8U ';4444 ?!VM?\A[4?\
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M>:1\.-%L=0MWM[J*%A)$XPRDNQY_ B@#K**** "BBB@ HHHH **** "BBB@
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M0R.HR8^/]Z@"2BF;I/\ GG_X]1ND_P">?_CU #Z*9ND_YY_^/4;I/^>?_CU
M#Z*9ND_YY_\ CU&Z3_GG_P"/4 /HJ-9'89$?'^]2[I/^>?\ X]0 ^BF;I/\
MGG_X]1ND_P">?_CU #Z*9ND_YY_^/4;I/^>?_CU #Z*C$CDD"/I_M4NZ3_GG
M_P"/4 /HIFZ3_GG_ ./4;I/^>?\ X]0 ^BF;I/\ GG_X]1ND_P">?_CU #Z*
MC,C@@>7R?]JEW2?\\_\ QZ@!]%,W2?\ //\ \>HW2?\ //\ \>H ?13-TG_/
M/_QZC=)_SS_\>H ?14;2.HR8_P#QZEW2?\\__'J 'T4S=)_SS_\ 'J-TG_//
M_P >H ?13-TG_//_ ,>HW2?\\_\ QZ@!]%,W2?\ //\ \>I%D=@"(^#_ +5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<%XSD:'7HOM4)N;:2U_T:+^V!9;)5+%F W M\NWYN=N/<UWM<%XJTR]U'Q2
M6T=X_MMM9QW$JW%NLB,%:01HI+J0S$R9_A^49QW .D\+SZI-H5L-7MFBNHXT
M1I#.DOG?*,N"O')S6S65X8%JOA72A9/(]J+2,1-*,,5VC&1V/L*U: "L<^*=
M$$]U$U_&K6JR/*65@H"$!\,1AMI(!P3@G%;%>:3^#=9GN;PB%%D+7$AE>YS%
M.6E62-8X_P#EEG8 QP,\YW9S0!Z!I^IVFJV[3V<OF(KF-P5*LC#J&5@"#R."
M.XJ9_P#CYB_W6_I63H%G>13ZI?WL MI+^Y$JV_F!S&JQH@R1QD[,\>HK5D :
MXB!_NMW^E $U%,\I/?\ [Z-'E)[_ /?1H ?13/*3W_[Z-'E)[_\ ?1H ?3)?
M]6?J/YT>4GO_ -]&F2QJ$/7J.Y]: )J*9Y2^_P#WT:/*3W_[Z- #Z*9Y2>__
M 'T:/*3W_P"^C0 ^BF>4GO\ ]]&HYV@MHC+,Q1!U))H DB_U0I]4[&XM+V'=
M;RB51P2K'%6?*3W_ .^C0 ^BF>4GO_WT:/*3W_[Z- #Z*9Y2>_\ WT:/*3W_
M .^C0 )_K)/J/Y4^H5C7>_7J.Y]*?Y2>_P#WT: 'T4SRD]_^^C1Y2>__ 'T:
M 'T4SRD]_P#OHT>4GO\ ]]&@ ;_6)^-/J%HU\Q.O?N:?Y2>__?1H ?13/*3W
M_P"^C1Y2>_\ WT: 'T4SRD]_^^C1Y2>__?1H )?]6?J/YT^H9(U"'KU'<^M/
M\I/?_OHT /HIGE)[_P#?1H\I/?\ [Z- #Z*9Y2>__?1H\I/?_OHT /ID7^J6
MF2P;XV5)'C8]'4Y(_/BJ6C)+)IZ2W%P\S.3U 7&"1VQ0!IT4BJ%&!_.EH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\V^(=S9KKMA%J4=C#;% JSW-N[F7=OW*&5API5"4Y
MW;A7I->07/B!AK*Q3>*-2LFN;F[BU%1$[""-)"(A$-I6-BH W#.<D\G! !ZA
MH<LT^@Z?+/:+:3/;QE[=5VB([1\H'8#T[5?JKI@MQI=H+1WDMO)7RG=F9F7'
M!);DG'<\UQ-K>>)5OV.E7$+6A:7R[/6+I))IV0_,L1CY7!X.\MC/(% 'H%%1
MP.\EO&\D1BD906C)!*''(R.#BI* "HG_ ./F+_=;^E2U$_\ Q\Q?[K?TH EH
MHHH **** "F2_P"K/U'\Z?3)?]6?J/YT /HHHH **** "BHI;F&$X>0!NRCD
MG\!S5#5+B\;3I39P2JV/O'@X[X'6L*U>-.,I;M=%JS2%-S:6UR71?^01!_P+
M_P!"-7ZYKPT+^2VD5I62 'Y"5SSSG&:W?LF3EYYV_P"![?Y8K'#8IXBDJD8-
M7[V_K\"ZM%4YN#E>W8L5&T\2?>E1?JP%1BQMLY,08_[1+?SIZVT"_=AC'T45
MT7J=E^)G[OF--[:CK<1?]]BF_;[7_GJ#] 35@ #H /I2T6J=U]S_ ,P]WL5$
MO;?>YWL<D=$;T^E/^VP^LG_?IO\ "I5_UDGU'\J?1:IW7W?\$+Q[?B5_MD/_
M $T_[]-_A1]MA_Z:?]^F_P *L44[5._X?\$+Q[?B5_MUO_>;\4;_  I/M]M_
MST_\=/\ A5FBE:IW7W?\$+Q[%0WUJ9$_?(.O7BI/MMJ?^7B+_OL5(W^L3\:?
M@'M3M4[K[G_F'ND/VNV/2XB_[[%.%Q">DT9_X$*<8XSU13^%--O >L,9_P"
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MPOIDEW).R3[))A/);B=Q"\F0=QCSM)R >F,C-;-<BVHZU9^'8=2EU&UGEO\
M[.D0^S[8[=Y75=P(;+*-_0\G'7FKOVG4].UC2-/N;U+M;N2??(80C;5CW*.#
MC.<\C''YT =#17&)KFK:A<Z=:6UY;V_VJ\OX7E\H.0D+L%VC.-V .3D=>*@E
M\1:E)IJPI>.-2ADND(M+(2^>(9-GF$%L(N<9&>I(!XH [JBN*&MZWJI@:SNK
M:S1M%AU%@8/,)E?=\O)^[QSW]"*L:9J^J>(;S-M=0V,5O:VL[QF'S/-:5=Y!
M)(PH' QSG//&* .MHKE+/7M0N-5@T9C&+V&]F%VVSC[,@W(P&>"PDB&?7=Z5
M9U?4;^QUZU\Z9[;26\M1,D D5I6<J4D.<H#E I QDG)[4 ;-Y86]\(!<(6\B
M99X\$C#KT/%6:X?2[W5=.TMYIM2-V9==-K^]B V(;ID;&/4'CT[5:O\ Q!?K
MJ5[I]O+#&QU&WLH963=Y0>$2,2,\GJ!GN10!UBR([.JNK,APP!R5.,X/IP0:
M=7!6-_?Z+JVIS7=U!/!_;$<%[,L>S"/;1"-CSA2&V ]N<\5NVM]JU]X/GU&$
M(M]/'+/9HR<!228E8=R5VY^M '04@(.<$'%< _CF\N+F[-FD)M[JVC32V(R6
MN3L#JWJ 9DX_V'I;Z>_N+J..TO%L"OB$P.T$*_O1Y.<OZG_ZWI0!TMWX>TK4
M[RYF=I@\H$5VD%RZ+* .%D53@_*>_8^E;"(L:*B*%11A5 P /2N$ENM4TJ\\
M2:G;74(M[?4H0]NT.3-F*!6RV>.#QCOUSTKO: "BBB@ HHHH **** "BBB@
MHHHH *X;Q7%+/KYBT^UO6OA;12F:*YAB5"LC&-@) =S [P1C&'YZC'<UYOXY
M2T3Q4D\T%A>.NG@F&\TVXN_*0.V74Q@A >ASR=H]* .YT2U%CH=A:A'00P(F
MUY [# '5AP3[CBN L=0UJWU"RN/L>N75\)W%\OVNWDADCPW^KC\SY>=I& "
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M<JNQD=LD2!$+@#_:ZGUHDCPGWGZCO[U-3)?]6?J/YUJDDK(AN^K#R_\ ;?\
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M/MP.*B?Q*;:PUZ:[A59]*D=?*5L^:I4-$1[L& ^N:J1:_J\^NRZ:6TBV>W6
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M9(Y*'Y&ZCT]:8B:BF>8?^>;_ *4>8?\ GF_Z4 /HIGF'_GF_Z4>8?^>;_I0
M^BF>8?\ GF_Z4>8?^>;_ *4 $/\ JA3ZAB<B,?(]/\P_\\W_ $H ?13/,/\
MSS?]*/,/_/-_TH ?13/,/_/-_P!*/,/_ #S?]* !/]9)]1_*GU"KG>_R-U'\
MJ?YA_P">;_I0 ^BF>8?^>;_I1YA_YYO^E #Z*9YA_P">;_I1YA_YYO\ I0 -
M_K$_&GU"SGS$^1N]/\P_\\W_ $H ?13/,/\ SS?]*/,/_/-_TH ?13/,/_/-
M_P!*/,/_ #S?]* "7_5GZC^=/J&1R4/R/U'IZT_S#_SS?]* 'T4SS#_SS?\
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M] !1110 4444 ,;_ %B?C3Z8W^L3\:?0 4444 %%%% #)?\ 5GZC^=/IDO\
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MX3TPV\%O9PQV4"7L=[+' @ F9#D!OQ"G\!3-7\-3:O=N)=6N%TZ5XI)K/8K
MM&P8;&ZH"57/7IQC- '04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>avxl-20250331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +KIpo7xRiXgen8uAZHZcOa2NCbPtxZ97aekhsmR9bXlKbysoYBI5gSsGznDmEQEA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:avxl="http://anavex.com/20250331" elementFormDefault="qualified" targetNamespace="http://anavex.com/20250331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimBalanceSheets" id="InterimBalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimBalanceSheetsParenthetical" id="InterimBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" id="InterimStatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimStatementsOfCashFlows" id="InterimStatementsOfCashFlows">
          <link:definition>00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" id="InterimStatementsOfChangesInStockholdersEquity">
          <link:definition>00000006 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BusinessDescription" id="BusinessDescription">
          <link:definition>999012 - Disclosure - Business Description</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BasisOfPresentation" id="BasisOfPresentation">
          <link:definition>999013 - Disclosure - Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilities" id="AccruedLiabilities">
          <link:definition>999014 - Disclosure - Accrued Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
          <link:definition>999015 - Disclosure - Other Income</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
          <link:definition>999016 - Disclosure - Equity Offerings</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999017 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999018 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BasisOfPresentationPolicies" id="BasisOfPresentationPolicies">
          <link:definition>999019 - Disclosure - Basis of Presentation (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
          <link:definition>999020 - Disclosure - Accrued Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>999021 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
          <link:definition>999022 - Disclosure - Basis of Presentation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
          <link:definition>999023 - Disclosure - Accrued Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
          <link:definition>999024 - Disclosure - Other Income (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
          <link:definition>999025 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
          <link:definition>999026 - Disclosure - Commitments and Contingencies (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
          <link:definition>999027 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
          <link:definition>999028 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
          <link:definition>999029 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
          <link:definition>999030 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" id="CommitmentsAndContingenciesDetails5">
          <link:definition>999031 - Disclosure - Commitments and Contingencies (Details 5)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999032 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999033 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="avxl_ShareProceedsReceivableMember" name="ShareProceedsReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MichaelJFoxFoundationMember" name="MichaelJFoxFoundationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement2023Member" name="PurchaseAgreement2023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2022Member" name="StockOptionPlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice1Member" name="OptionPrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice2Member" name="OptionPrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice3Member" name="OptionPrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice4Member" name="OptionPrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice5Member" name="OptionPrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrants" name="NonOperatingIncomeFromGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome" name="DeferredGrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IssuanceOfCommonShares" name="IssuanceOfCommonShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashPaidForStateAndLocalFranchiseTaxes" name="CashPaidForStateAndLocalFranchiseTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommonStockIssuedUponCashlessExerciseOfStockOption" name="CommonStockIssuedUponCashlessExerciseOfStockOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseShares" name="PurchaseShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseSharesShares" name="PurchaseSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentShares" name="CommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesShares" name="CommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashlessExerciseOfStockOption" name="CashlessExerciseOfStockOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashlessExerciseOfStockOptionShares" name="CashlessExerciseOfStockOptionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesWithheldRelatedToAndTaxes" name="SharesWithheldRelatedToAndTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesWithheldRelatedToAndTaxesShares" name="SharesWithheldRelatedToAndTaxesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptions" name="SharesIssuedPursuantToExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ExerciseOfStockOptions" name="ExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" name="SharesIssuedPursuantToExerciseOfStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ExerciseOfStockOptionsShares" name="ExerciseOfStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ExerciseOfStockOption" name="ExerciseOfStockOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ExerciseOfStockOptionShares" name="ExerciseOfStockOptionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ExerciseOfStockOptionAndTaxes" name="ExerciseOfStockOptionAndTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ExerciseOfStockOptionAndTaxesShares" name="ExerciseOfStockOptionAndTaxesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureAccruedLiabilitiesAbstract" name="DisclosureAccruedLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccuredLiabilitiesTextBlock" name="AccuredLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingTextBlock" name="EquityOfferingTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DilutiveCommonShares" name="DilutiveCommonShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccruedInvestigatorPayments" name="AccruedInvestigatorPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MilestoneBasedContractAccruals" name="MilestoneBasedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome1" name="DeferredGrantIncome1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues1" name="StockIssuedDuringPeriodValueNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FairValueOfInitialCommitment" name="FairValueOfInitialCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncurredExpenses" name="IncurredExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AggregateCommonShares" name="AggregateCommonShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AggregatePurchasePrice" name="AggregatePurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentsShares" name="CommitmentsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesOfCommonStockIssued" name="SharesOfCommonStockIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionToPurchaseShares" name="OptionToPurchaseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WthheldShares" name="WthheldShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ExercisePriceConsideration" name="ExercisePriceConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommonStockAsConsideration" name="CommonStockAsConsideration" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WithholdingObligationsExercise" name="WithholdingObligationsExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccountsPayable" name="AccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WarrantsOutstandingWeightedAverageExercise" name="WarrantsOutstandingWeightedAverageExercise" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionIssued" name="OptionIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesOfCommonStockReservedForIssuance" name="SharesOfCommonStockReservedForIssuance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>avxl-20250331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheets" xlink:href="avxl-20250331.xsd#InterimBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:href="avxl-20250331.xsd#InterimBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20250331.xsd#InterimStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:href="avxl-20250331.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20250331.xsd#InterimStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20250331.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20250331.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20250331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20250331.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20250331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20250331.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20250331.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20250331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20250331.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20250331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20250331.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:href="avxl-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_IssuanceOfCommonShares" xlink:label="loc_avxlIssuanceOfCommonShares" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_avxlIssuanceOfCommonShares" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="999012 - Disclosure - Business Description" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="999013 - Disclosure - Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="999014 - Disclosure - Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="999015 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="999016 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="999017 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="999018 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="999019 - Disclosure - Basis of Presentation (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="999020 - Disclosure - Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="999021 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999022 - Disclosure - Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="999023 - Disclosure - Accrued Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="999024 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="999025 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="999026 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="999027 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="999028 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="999029 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="999030 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="999031 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999032 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:title="999033 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>avxl-20250331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheets" xlink:href="avxl-20250331.xsd#InterimBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:href="avxl-20250331.xsd#InterimBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20250331.xsd#InterimStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:href="avxl-20250331.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20250331.xsd#InterimStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20250331.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20250331.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20250331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20250331.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20250331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20250331.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20250331.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20250331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20250331.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20250331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20250331.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:href="avxl-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ShareProceedsReceivableMember" xlink:label="loc_avxlShareProceedsReceivableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_avxlShareProceedsReceivableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_PurchaseShares" xlink:label="loc_avxlPurchaseShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlPurchaseShares_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_PurchaseSharesShares" xlink:label="loc_avxlPurchaseSharesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlPurchaseSharesShares_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommitmentShares" xlink:label="loc_avxlCommitmentShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentShares_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CashlessExerciseOfStockOption" xlink:label="loc_avxlCashlessExerciseOfStockOption_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCashlessExerciseOfStockOption_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CashlessExerciseOfStockOptionShares" xlink:label="loc_avxlCashlessExerciseOfStockOptionShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCashlessExerciseOfStockOptionShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesWithheldRelatedToAndTaxes" xlink:label="loc_avxlSharesWithheldRelatedToAndTaxes_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesWithheldRelatedToAndTaxes_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesWithheldRelatedToAndTaxesShares" xlink:label="loc_avxlSharesWithheldRelatedToAndTaxesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesWithheldRelatedToAndTaxesShares_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptions" xlink:label="loc_avxlExerciseOfStockOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOptions_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionsShares" xlink:label="loc_avxlExerciseOfStockOptionsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOptionsShares_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOption" xlink:label="loc_avxlExerciseOfStockOption_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOption_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionShares" xlink:label="loc_avxlExerciseOfStockOptionShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOptionShares_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionAndTaxes" xlink:label="loc_avxlExerciseOfStockOptionAndTaxes_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOptionAndTaxes_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionAndTaxesShares" xlink:label="loc_avxlExerciseOfStockOptionAndTaxesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOptionAndTaxesShares_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="999012 - Disclosure - Business Description" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="999013 - Disclosure - Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="999014 - Disclosure - Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="999015 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="999016 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="999017 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="999018 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="999019 - Disclosure - Basis of Presentation (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="999020 - Disclosure - Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="999021 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999022 - Disclosure - Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="999023 - Disclosure - Accrued Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="999024 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="loc_avxlMichaelJFoxFoundationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxFoundationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AUD" xlink:label="loc_currencyAUD_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:label="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DeferredGrantIncome1" xlink:label="loc_avxlDeferredGrantIncome1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlDeferredGrantIncome1_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOtherReceivables_170" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="999025 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_PurchaseAgreement2023Member" xlink:label="loc_avxlPurchaseAgreement2023Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement2023Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlIncurredExpenses_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AggregateCommonShares" xlink:label="loc_avxlAggregateCommonShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlAggregateCommonShares_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AggregatePurchasePrice" xlink:label="loc_avxlAggregatePurchasePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlAggregatePurchasePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommitmentsShares" xlink:label="loc_avxlCommitmentsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlCommitmentsShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesOfCommonStockIssued" xlink:label="loc_avxlSharesOfCommonStockIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSharesOfCommonStockIssued_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionToPurchaseShares" xlink:label="loc_avxlOptionToPurchaseShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlOptionToPurchaseShares_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExercisePrice" xlink:label="loc_avxlExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlExercisePrice_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_WthheldShares" xlink:label="loc_avxlWthheldShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlWthheldShares_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExercisePriceConsideration" xlink:label="loc_avxlExercisePriceConsideration_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlExercisePriceConsideration_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommonStockAsConsideration" xlink:label="loc_avxlCommonStockAsConsideration_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlCommonStockAsConsideration_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_WithholdingObligationsExercise" xlink:label="loc_avxlWithholdingObligationsExercise_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlWithholdingObligationsExercise_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AccountsPayable" xlink:label="loc_avxlAccountsPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlAccountsPayable_60" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="999026 - Disclosure - Commitments and Contingencies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="999027 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="999028 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="999029 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="999030 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="999031 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999032 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2" xlink:label="loc_avxlSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_120" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:title="999033 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaapSubsegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaapSubsegmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsegmentsAxis" xlink:to="loc_us-gaapSubsegmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaapSubsegmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsegmentsAxis" xlink:to="loc_us-gaapSubsegmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsegmentsDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesOfCommonStockReservedForIssuance" xlink:label="loc_avxlSharesOfCommonStockReservedForIssuance_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesOfCommonStockReservedForIssuance_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>avxl-20250331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ShareProceedsReceivableMember" xlink:label="avxl_ShareProceedsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareProceedsReceivableMember" xlink:to="avxl_ShareProceedsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareProceedsReceivableMember_lbl" xml:lang="en-US">Share Proceeds Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="avxl_MichaelJFoxFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MichaelJFoxFoundationMember" xlink:to="avxl_MichaelJFoxFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MichaelJFoxFoundationMember_lbl" xml:lang="en-US">Michael J Fox Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_PurchaseAgreement2023Member" xlink:label="avxl_PurchaseAgreement2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement2023Member" xlink:to="avxl_PurchaseAgreement2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement2023Member_lbl" xml:lang="en-US">Purchase Agreement 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">Stock Option Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockOptionPlan2022Member" xlink:label="avxl_StockOptionPlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2022Member" xlink:to="avxl_StockOptionPlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2022Member_lbl" xml:lang="en-US">Stock Option Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice1Member" xlink:label="avxl_OptionPrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice1Member" xlink:to="avxl_OptionPrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice1Member_lbl" xml:lang="en-US">Option Price 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice2Member" xlink:label="avxl_OptionPrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice2Member" xlink:to="avxl_OptionPrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice2Member_lbl" xml:lang="en-US">Option Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice3Member" xlink:label="avxl_OptionPrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice3Member" xlink:to="avxl_OptionPrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice3Member_lbl" xml:lang="en-US">Option Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice4Member" xlink:label="avxl_OptionPrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice4Member" xlink:to="avxl_OptionPrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice4Member_lbl" xml:lang="en-US">Option Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice5Member" xlink:label="avxl_OptionPrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice5Member" xlink:to="avxl_OptionPrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice5Member_lbl" xml:lang="en-US">Option Price 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis" xlink:label="us-gaap_SubsegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsegmentsAxis_lbl" xml:lang="en-US">Subsegments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities - Note 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred grant income - Note 4</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 6</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 84,985,449 common shares (September 30, 2024 - 84,795,517)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="avxl_NonOperatingIncomeFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrants" xlink:to="avxl_NonOperatingIncomeFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrants_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss per share, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss per share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DeferredGrantIncome" xlink:label="avxl_DeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_DeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_IssuanceOfCommonShares" xlink:label="avxl_IssuanceOfCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IssuanceOfCommonShares" xlink:to="avxl_IssuanceOfCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IssuanceOfCommonShares_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Decrease in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CashPaidForStateAndLocalFranchiseTaxes" xlink:label="avxl_CashPaidForStateAndLocalFranchiseTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashPaidForStateAndLocalFranchiseTaxes" xlink:to="avxl_CashPaidForStateAndLocalFranchiseTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashPaidForStateAndLocalFranchiseTaxes_lbl" xml:lang="en-US">Cash paid for state and local franchise taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommonStockIssuedUponCashlessExerciseOfStockOption" xlink:label="avxl_CommonStockIssuedUponCashlessExerciseOfStockOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonStockIssuedUponCashlessExerciseOfStockOption" xlink:to="avxl_CommonStockIssuedUponCashlessExerciseOfStockOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonStockIssuedUponCashlessExerciseOfStockOption_lbl" xml:lang="en-US">Common stock issued upon cashless exercise of stock option</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance at beginning, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_PurchaseShares" xlink:label="avxl_PurchaseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseShares" xlink:to="avxl_PurchaseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseShares_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_PurchaseSharesShares" xlink:label="avxl_PurchaseSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseSharesShares" xlink:to="avxl_PurchaseSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseSharesShares_lbl" xml:lang="en-US">Purchase shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommitmentShares" xlink:label="avxl_CommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentShares" xlink:to="avxl_CommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentShares_lbl" xml:lang="en-US">Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommitmentSharesShares" xlink:label="avxl_CommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesShares" xlink:to="avxl_CommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesShares_lbl" xml:lang="en-US">Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CashlessExerciseOfStockOption" xlink:label="avxl_CashlessExerciseOfStockOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashlessExerciseOfStockOption" xlink:to="avxl_CashlessExerciseOfStockOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashlessExerciseOfStockOption_lbl" xml:lang="en-US">cashless exercise of stock option</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CashlessExerciseOfStockOptionShares" xlink:label="avxl_CashlessExerciseOfStockOptionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashlessExerciseOfStockOptionShares" xlink:to="avxl_CashlessExerciseOfStockOptionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashlessExerciseOfStockOptionShares_lbl" xml:lang="en-US">cashless exercise of stock option, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesWithheldRelatedToAndTaxes" xlink:label="avxl_SharesWithheldRelatedToAndTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesWithheldRelatedToAndTaxes" xlink:to="avxl_SharesWithheldRelatedToAndTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesWithheldRelatedToAndTaxes_lbl" xml:lang="en-US">and taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesWithheldRelatedToAndTaxesShares" xlink:label="avxl_SharesWithheldRelatedToAndTaxesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesWithheldRelatedToAndTaxesShares" xlink:to="avxl_SharesWithheldRelatedToAndTaxesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesWithheldRelatedToAndTaxesShares_lbl" xml:lang="en-US">Shares withheld related to cashless exercise of stock option and taxes, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xml:lang="en-US">exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptions" xlink:label="avxl_ExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExerciseOfStockOptions" xlink:to="avxl_ExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ExerciseOfStockOptions_lbl" xml:lang="en-US">exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionsShares" xlink:label="avxl_ExerciseOfStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExerciseOfStockOptionsShares" xlink:to="avxl_ExerciseOfStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ExerciseOfStockOptionsShares_lbl" xml:lang="en-US">exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOption" xlink:label="avxl_ExerciseOfStockOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExerciseOfStockOption" xlink:to="avxl_ExerciseOfStockOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ExerciseOfStockOption_lbl" xml:lang="en-US">exercise of stock option</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionShares" xlink:label="avxl_ExerciseOfStockOptionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExerciseOfStockOptionShares" xlink:to="avxl_ExerciseOfStockOptionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ExerciseOfStockOptionShares_lbl" xml:lang="en-US">exercise of stock option, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionAndTaxes" xlink:label="avxl_ExerciseOfStockOptionAndTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExerciseOfStockOptionAndTaxes" xlink:to="avxl_ExerciseOfStockOptionAndTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ExerciseOfStockOptionAndTaxes_lbl" xml:lang="en-US">exercise of stock option and taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionAndTaxesShares" xlink:label="avxl_ExerciseOfStockOptionAndTaxesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExerciseOfStockOptionAndTaxesShares" xlink:to="avxl_ExerciseOfStockOptionAndTaxesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ExerciseOfStockOptionAndTaxesShares_lbl" xml:lang="en-US">exercise of stock option and taxes, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance at ending, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="avxl_DisclosureAccruedLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureAccruedLiabilitiesAbstract" xlink:to="avxl_DisclosureAccruedLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AccuredLiabilitiesTextBlock" xlink:label="avxl_AccuredLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccuredLiabilitiesTextBlock" xlink:to="avxl_AccuredLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_AccuredLiabilitiesTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="avxl_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingsAbstract" xlink:to="avxl_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_EquityOfferingTextBlock" xlink:label="avxl_EquityOfferingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_LiquidityPolicyTextBlock" xlink:label="avxl_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LiquidityPolicyTextBlock" xlink:to="avxl_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of principal components of accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:to="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of contributions under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of summarizes information about stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:label="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:to="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DilutiveCommonShares" xlink:label="avxl_DilutiveCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DilutiveCommonShares" xlink:to="avxl_DilutiveCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DilutiveCommonShares_lbl" xml:lang="en-US">Dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AccruedInvestigatorPayments" xlink:label="avxl_AccruedInvestigatorPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccruedInvestigatorPayments" xlink:to="avxl_AccruedInvestigatorPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccruedInvestigatorPayments_lbl" xml:lang="en-US">Accrued investigator payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="avxl_MilestoneBasedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MilestoneBasedContractAccruals" xlink:to="avxl_MilestoneBasedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MilestoneBasedContractAccruals_lbl" xml:lang="en-US">Milestone-based contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">All other accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:label="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:to="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Non operating income from grant</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DeferredGrantIncome1" xlink:label="avxl_DeferredGrantIncome1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome1" xlink:to="avxl_DeferredGrantIncome1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome1_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Value of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Share issued for offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance or sale of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_FairValueOfInitialCommitment" xlink:label="avxl_FairValueOfInitialCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FairValueOfInitialCommitment" xlink:to="avxl_FairValueOfInitialCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FairValueOfInitialCommitment_lbl" xml:lang="en-US">Fair value of the initial commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_IncurredExpenses" xlink:label="avxl_IncurredExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncurredExpenses" xlink:to="avxl_IncurredExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncurredExpenses_lbl" xml:lang="en-US">Incurred expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AggregateCommonShares" xlink:label="avxl_AggregateCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AggregateCommonShares" xlink:to="avxl_AggregateCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AggregateCommonShares_lbl" xml:lang="en-US">Aggregate common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AggregatePurchasePrice" xlink:label="avxl_AggregatePurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AggregatePurchasePrice" xlink:to="avxl_AggregatePurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommitmentsShares" xlink:label="avxl_CommitmentsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentsShares" xlink:to="avxl_CommitmentsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_CommitmentsShares_lbl" xml:lang="en-US">Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesOfCommonStockIssued" xlink:label="avxl_SharesOfCommonStockIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesOfCommonStockIssued" xlink:to="avxl_SharesOfCommonStockIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesOfCommonStockIssued_lbl" xml:lang="en-US">[custom:SharesOfCommonStockIssued]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionToPurchaseShares" xlink:label="avxl_OptionToPurchaseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionToPurchaseShares" xlink:to="avxl_OptionToPurchaseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionToPurchaseShares_lbl" xml:lang="en-US">[custom:OptionToPurchaseShares]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExercisePrice" xlink:label="avxl_ExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExercisePrice" xlink:to="avxl_ExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ExercisePrice_lbl" xml:lang="en-US">[custom:ExercisePrice]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_WthheldShares" xlink:label="avxl_WthheldShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WthheldShares" xlink:to="avxl_WthheldShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WthheldShares_lbl" xml:lang="en-US">[custom:WthheldShares]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExercisePriceConsideration" xlink:label="avxl_ExercisePriceConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExercisePriceConsideration" xlink:to="avxl_ExercisePriceConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ExercisePriceConsideration_lbl" xml:lang="en-US">[custom:ExercisePriceConsideration]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommonStockAsConsideration" xlink:label="avxl_CommonStockAsConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonStockAsConsideration" xlink:to="avxl_CommonStockAsConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonStockAsConsideration_lbl" xml:lang="en-US">[custom:CommonStockAsConsideration]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_WithholdingObligationsExercise" xlink:label="avxl_WithholdingObligationsExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WithholdingObligationsExercise" xlink:to="avxl_WithholdingObligationsExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WithholdingObligationsExercise_lbl" xml:lang="en-US">[custom:WithholdingObligationsExercise]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AccountsPayable" xlink:label="avxl_AccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccountsPayable" xlink:to="avxl_AccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccountsPayable_lbl" xml:lang="en-US">[custom:AccountsPayable]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionContributions" xlink:label="us-gaap_PensionContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Contributions to 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted average grant date fair value, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, Outstanding beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value, Outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, Outstanding ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice_lbl" xml:lang="en-US">Weighted average grant date fair value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, upper range limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WarrantsOutstandingWeightedAverageExercise" xlink:to="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xml:lang="en-US">Warrants outstanding weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionIssued" xlink:label="avxl_OptionIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionIssued" xlink:to="avxl_OptionIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionIssued_lbl" xml:lang="en-US">Option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Option available issue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average contractual life of options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2" xlink:label="avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2" xlink:to="avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average contractual life of options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesOfCommonStockReservedForIssuance" xlink:label="avxl_SharesOfCommonStockReservedForIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesOfCommonStockReservedForIssuance" xlink:to="avxl_SharesOfCommonStockReservedForIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesOfCommonStockReservedForIssuance_lbl" xml:lang="en-US">Shares of common stock reserved for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome_2_lbl" xml:lang="en-US">DeferredGrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ExerciseOfStockOptions" xlink:to="avxl_ExerciseOfStockOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ExerciseOfStockOptions_2_lbl" xml:lang="en-US">ExerciseOfStockOptions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccuredLiabilitiesTextBlock" xlink:to="avxl_AccuredLiabilitiesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccuredLiabilitiesTextBlock_2_lbl" xml:lang="en-US">AccuredLiabilitiesTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingTextBlock" xlink:to="avxl_EquityOfferingTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingTextBlock_2_lbl" xml:lang="en-US">EquityOfferingTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:to="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_2_lbl" xml:lang="en-US">ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_2_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentsShares" xlink:to="avxl_CommitmentsShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentsShares_2_lbl" xml:lang="en-US">CommitmentsShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2" xlink:to="avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>avxl-20250331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheets" xlink:href="avxl-20250331.xsd#InterimBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:href="avxl-20250331.xsd#InterimBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20250331.xsd#InterimStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:href="avxl-20250331.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20250331.xsd#InterimStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20250331.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20250331.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20250331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20250331.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20250331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20250331.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20250331.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20250331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20250331.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20250331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20250331.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:href="avxl-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_IssuanceOfCommonShares" xlink:label="loc_avxlIssuanceOfCommonShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_avxlIssuanceOfCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CashPaidForStateAndLocalFranchiseTaxes" xlink:label="loc_avxlCashPaidForStateAndLocalFranchiseTaxes" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCashPaidForStateAndLocalFranchiseTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommonStockIssuedUponCashlessExerciseOfStockOption" xlink:label="loc_avxlCommonStockIssuedUponCashlessExerciseOfStockOption" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCommonStockIssuedUponCashlessExerciseOfStockOption" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ShareProceedsReceivableMember" xlink:label="loc_avxlShareProceedsReceivableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_avxlShareProceedsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_PurchaseShares" xlink:label="loc_avxlPurchaseShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlPurchaseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_PurchaseSharesShares" xlink:label="loc_avxlPurchaseSharesShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlPurchaseSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommitmentShares" xlink:label="loc_avxlCommitmentShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CashlessExerciseOfStockOption" xlink:label="loc_avxlCashlessExerciseOfStockOption" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCashlessExerciseOfStockOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CashlessExerciseOfStockOptionShares" xlink:label="loc_avxlCashlessExerciseOfStockOptionShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCashlessExerciseOfStockOptionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesWithheldRelatedToAndTaxes" xlink:label="loc_avxlSharesWithheldRelatedToAndTaxes" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesWithheldRelatedToAndTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesWithheldRelatedToAndTaxesShares" xlink:label="loc_avxlSharesWithheldRelatedToAndTaxesShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesWithheldRelatedToAndTaxesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptions" xlink:label="loc_avxlExerciseOfStockOptions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionsShares" xlink:label="loc_avxlExerciseOfStockOptionsShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOption" xlink:label="loc_avxlExerciseOfStockOption" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionShares" xlink:label="loc_avxlExerciseOfStockOptionShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOptionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionAndTaxes" xlink:label="loc_avxlExerciseOfStockOptionAndTaxes" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOptionAndTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExerciseOfStockOptionAndTaxesShares" xlink:label="loc_avxlExerciseOfStockOptionAndTaxesShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlExerciseOfStockOptionAndTaxesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="999012 - Disclosure - Business Description">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="999013 - Disclosure - Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccounting" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="999014 - Disclosure - Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AccuredLiabilitiesTextBlock" xlink:label="loc_avxlAccuredLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlAccuredLiabilitiesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="999015 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="999016 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_EquityOfferingTextBlock" xlink:label="loc_avxlEquityOfferingTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_avxlEquityOfferingTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="999017 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="999018 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="999019 - Disclosure - Basis of Presentation (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_LiquidityPolicyTextBlock" xlink:label="loc_avxlLiquidityPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="999020 - Disclosure - Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="999021 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:label="loc_us-gaapDefinedContributionPlanDisclosuresTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanDisclosuresTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:label="loc_avxlScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="999022 - Disclosure - Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DilutiveCommonShares" xlink:label="loc_avxlDilutiveCommonShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlDilutiveCommonShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="999023 - Disclosure - Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DisclosureAccruedLiabilitiesAbstract" xlink:label="loc_avxlDisclosureAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AccruedInvestigatorPayments" xlink:label="loc_avxlAccruedInvestigatorPayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlAccruedInvestigatorPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="loc_avxlMilestoneBasedContractAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_avxlMilestoneBasedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureAccruedLiabilitiesAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="999024 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="loc_avxlMichaelJFoxFoundationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:label="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DeferredGrantIncome1" xlink:label="loc_avxlDeferredGrantIncome1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_avxlDeferredGrantIncome1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="999025 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_DisclosureEquityOfferingsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_PurchaseAgreement2023Member" xlink:label="loc_avxlPurchaseAgreement2023Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlIncurredExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AggregateCommonShares" xlink:label="loc_avxlAggregateCommonShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlAggregateCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AggregatePurchasePrice" xlink:label="loc_avxlAggregatePurchasePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlAggregatePurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommitmentsShares" xlink:label="loc_avxlCommitmentsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlCommitmentsShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesOfCommonStockIssued" xlink:label="loc_avxlSharesOfCommonStockIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSharesOfCommonStockIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionToPurchaseShares" xlink:label="loc_avxlOptionToPurchaseShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlOptionToPurchaseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExercisePrice" xlink:label="loc_avxlExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_WthheldShares" xlink:label="loc_avxlWthheldShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlWthheldShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ExercisePriceConsideration" xlink:label="loc_avxlExercisePriceConsideration" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlExercisePriceConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_CommonStockAsConsideration" xlink:label="loc_avxlCommonStockAsConsideration" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlCommonStockAsConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_WithholdingObligationsExercise" xlink:label="loc_avxlWithholdingObligationsExercise" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlWithholdingObligationsExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_AccountsPayable" xlink:label="loc_avxlAccountsPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlAccountsPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="999026 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="999027 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapPensionContributions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="999028 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="999029 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="999030 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="999031 - Disclosure - Commitments and Contingencies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999032 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2" xlink:label="loc_avxlSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:title="999033 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaapSubsegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaapSubsegmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsegmentsAxis" xlink:to="loc_us-gaapSubsegmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsegmentsDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20250331.xsd#avxl_SharesOfCommonStockReservedForIssuance" xlink:label="loc_avxlSharesOfCommonStockReservedForIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesOfCommonStockReservedForIssuance" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">20th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock
    Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,371,852<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 115,771<span></span>
</td>
<td class="nump">$ 132,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">2,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">117,139<span></span>
</td>
<td class="nump">135,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,997<span></span>
</td>
<td class="nump">9,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities - Note 3</a></td>
<td class="nump">9,555<span></span>
</td>
<td class="nump">4,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred grant income - Note 4</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">17,381<span></span>
</td>
<td class="nump">15,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 84,985,449 common shares (September 30, 2024 - 84,795,517)</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">459,051<span></span>
</td>
<td class="nump">456,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(359,378)<span></span>
</td>
<td class="num">(336,071)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">99,758<span></span>
</td>
<td class="nump">120,263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 117,139<span></span>
</td>
<td class="nump">$ 135,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">85,333,652<span></span>
</td>
<td class="nump">84,795,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">85,333,652<span></span>
</td>
<td class="nump">84,795,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,621<span></span>
</td>
<td class="nump">$ 2,895<span></span>
</td>
<td class="nump">$ 5,767<span></span>
</td>
<td class="nump">$ 5,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,892<span></span>
</td>
<td class="nump">9,729<span></span>
</td>
<td class="nump">20,338<span></span>
</td>
<td class="nump">18,413<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">12,513<span></span>
</td>
<td class="nump">12,624<span></span>
</td>
<td class="nump">26,105<span></span>
</td>
<td class="nump">24,003<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(12,513)<span></span>
</td>
<td class="num">(12,624)<span></span>
</td>
<td class="num">(26,105)<span></span>
</td>
<td class="num">(24,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrants', window );">Grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1,210<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
<td class="nump">2,604<span></span>
</td>
<td class="nump">3,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">2,078<span></span>
</td>
<td class="nump">2,798<span></span>
</td>
<td class="nump">4,835<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (11,196)<span></span>
</td>
<td class="num">$ (10,546)<span></span>
</td>
<td class="num">$ (23,307)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per share, Basic</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per share, Diluted</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, Basic</a></td>
<td class="nump">85,073,769<span></span>
</td>
<td class="nump">82,464,226<span></span>
</td>
<td class="nump">84,938,400<span></span>
</td>
<td class="nump">82,269,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, Diluted</a></td>
<td class="nump">85,073,769<span></span>
</td>
<td class="nump">82,464,226<span></span>
</td>
<td class="nump">84,938,400<span></span>
</td>
<td class="nump">82,269,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,307)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">3,504<span></span>
</td>
<td class="nump">4,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">1,783<span></span>
</td>
<td class="num">(1,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">229<span></span>
</td>
<td class="num">(692)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(4,893)<span></span>
</td>
<td class="num">(596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">4,720<span></span>
</td>
<td class="num">(2,380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(17,976)<span></span>
</td>
<td class="num">(18,974)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IssuanceOfCommonShares', window );">Issuance of common shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">7,336<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Decrease in cash and cash equivalents during the period</a></td>
<td class="num">(16,416)<span></span>
</td>
<td class="num">(11,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">132,187<span></span>
</td>
<td class="nump">151,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">115,771<span></span>
</td>
<td class="nump">139,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CashPaidForStateAndLocalFranchiseTaxes', window );">Cash paid for state and local franchise taxes</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommonStockIssuedUponCashlessExerciseOfStockOption', window );">Common stock issued upon cashless exercise of stock option</a></td>
<td class="nump">$ 460<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashPaidForStateAndLocalFranchiseTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashPaidForStateAndLocalFranchiseTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommonStockIssuedUponCashlessExerciseOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommonStockIssuedUponCashlessExerciseOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IssuanceOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IssuanceOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Share Proceeds Receivable [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 434,839<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (293,069)<span></span>
</td>
<td class="nump">$ 141,852<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning, shares at Sep. 30, 2023</a></td>
<td class="nump">82,066,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PurchaseShares', window );">Purchase shares</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">7,410<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PurchaseSharesShares', window );">Purchase shares, shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentShares', window );">Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">3,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ExerciseOfStockOptions', window );">exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ExerciseOfStockOptionsShares', window );">exercise of stock options, shares</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,938<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,168)<span></span>
</td>
<td class="num">(19,168)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">447,345<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(312,237)<span></span>
</td>
<td class="nump">134,958<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Mar. 31, 2024</a></td>
<td class="nump">83,616,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">437,184<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(301,691)<span></span>
</td>
<td class="nump">135,575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning, shares at Dec. 31, 2023</a></td>
<td class="nump">82,086,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PurchaseShares', window );">Purchase shares</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">7,410<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PurchaseSharesShares', window );">Purchase shares, shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentShares', window );">Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">3,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,652<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,546)<span></span>
</td>
<td class="num">(10,546)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">447,345<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(312,237)<span></span>
</td>
<td class="nump">134,958<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Mar. 31, 2024</a></td>
<td class="nump">83,616,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">456,249<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(336,071)<span></span>
</td>
<td class="nump">120,263<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning, shares at Sep. 30, 2024</a></td>
<td class="nump">84,795,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CashlessExerciseOfStockOption', window );">cashless exercise of stock option</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CashlessExerciseOfStockOptionShares', window );">cashless exercise of stock option, shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesWithheldRelatedToAndTaxes', window );">and taxes</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,721)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,722)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesWithheldRelatedToAndTaxesShares', window );">Shares withheld related to cashless exercise of stock option and taxes, shares</a></td>
<td class="num">(282,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,560<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">320,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,504<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,307)<span></span>
</td>
<td class="num">(23,307)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2025</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">459,051<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(359,378)<span></span>
</td>
<td class="nump">99,758<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Mar. 31, 2025</a></td>
<td class="nump">85,333,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2024</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">459,012<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(348,182)<span></span>
</td>
<td class="nump">110,915<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning, shares at Dec. 31, 2024</a></td>
<td class="nump">84,985,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">130,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ExerciseOfStockOption', window );">exercise of stock option</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ExerciseOfStockOptionShares', window );">exercise of stock option, shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ExerciseOfStockOptionAndTaxes', window );">exercise of stock option and taxes</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,721)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,722)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ExerciseOfStockOptionAndTaxesShares', window );">exercise of stock option and taxes, shares</a></td>
<td class="num">(282,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,449<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,196)<span></span>
</td>
<td class="num">(11,196)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2025</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 459,051<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (359,378)<span></span>
</td>
<td class="nump">$ 99,758<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending, shares at Mar. 31, 2025</a></td>
<td class="nump">85,333,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashlessExerciseOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashlessExerciseOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashlessExerciseOfStockOptionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashlessExerciseOfStockOptionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ExerciseOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ExerciseOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ExerciseOfStockOptionAndTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ExerciseOfStockOptionAndTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ExerciseOfStockOptionAndTaxesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ExerciseOfStockOptionAndTaxesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ExerciseOfStockOptionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ExerciseOfStockOptionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PurchaseSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PurchaseSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesWithheldRelatedToAndTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesWithheldRelatedToAndTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesWithheldRelatedToAndTaxesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesWithheldRelatedToAndTaxesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (11,196)<span></span>
</td>
<td class="num">$ (10,546)<span></span>
</td>
<td class="num">$ (23,307)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z9R5f4dEeaZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 	<span id="xdx_82F_zTFTJfB8thWk">Business Description</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s focus is on developing innovative
treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--BasisOfAccounting_zexirGCAj3Nb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 2 	<span id="xdx_823_z36cN1o8XQ12">Basis of Presentation</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed consolidated
interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed consolidated
interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are
necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2024 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto
included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2024 filed with the SEC on December 23, 2024.
The Company follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the six months ended March 31,
2025 are not necessarily indicative of the results that may be expected for the year ending September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain immaterial amounts from prior periods have
been reclassified to conform to the current year&#8217;s presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_848_ecustom--LiquidityPolicyTextBlock_zICIurpE8pEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_zeR0VfVzmDJ9">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenue from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed consolidated interim financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. The Company will need to obtain effectiveness of a new registration
statement in order to access the funds under the 2023 Purchase Agreement. If the Company is not able to obtain the additional financing
on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--UseOfEstimates_zvoBFwCpEkv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zrQtwQDPhyT7">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zyMLo2kqnlP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zwYdubCxIUV4">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These unaudited condensed consolidated interim financial
statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex
Australia&#8221;), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany,
and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances
have been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zORTeRDCLXV" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zLXB3vMTixZ4">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025 and September 30, 2024, the Company
did not have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zEziszRJ3yNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zNJJ33As7Ie7">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025 loss per share excludes <span id="xdx_900_ecustom--DilutiveCommonShares_iI_pip0_c20250331_zd47XwkTDlq1" title="Dilutive common shares">15,710,622</span>
(March 31, 2024: <span id="xdx_90B_ecustom--DilutiveCommonShares_iI_pip0_c20240331_zSr7AeeGJm0c" title="Dilutive common shares">15,755,114</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv2UtPTYfkUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_86C_zhB6e4utZRmk">Recent Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2023, the Financial
Accounting Standards Board (FASB) issued ASU No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221;
This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our
fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30, 2026. The Company is currently
assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccuredLiabilitiesTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p id="xdx_80D_ecustom--AccuredLiabilitiesTextBlock_zfzFq0XHzQRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 3	<span id="xdx_822_zMut58cTdmi9">Accrued Liabilities</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zTR76Me0xrG8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B6_zAYunKXtNpH6" style="display: none">Schedule of principal components of accrued liabilities</span></td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_49C_20250331_zD5WUULJawa9" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_49E_20240930_zfej5vkDkEW2" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_405_ecustom--AccruedInvestigatorPayments_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">1,459</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">860</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">2,200</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,527</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">4,332</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">557</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">1,564</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">1,891</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_zGSWkP31omT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,555</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,835</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccuredLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccuredLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_80C_ecustom--OtherIncomeDisclosureTextBlock_zk66xjkPwUGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 4	<span id="xdx_823_z8t8ZdZUxhs9">Other Income</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of March 31, 2025, the
Company had received a $<span id="xdx_90D_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20241001__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zQMM4WfPKBi1" title="Research and development incentive income">1.0</span> million research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant
will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) related to Parkinson&#8217;s
disease. Of the total, $<span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20221001__20230930_zJRplDwq78Q8" title="Research and development incentive income">0.5</span> million was received during the year ended September 30, 2023 and $<span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20201001__20210930_z1MYgO9BrOEj" title="Research and development incentive income">0.5</span> million was received during the year
ended September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income was
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the three and six months ended March 31, 2025, the Company recognized $<span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20250101__20250331_zDkAYP2l8lVj" title="Non operating income from grant">0</span> and $<span id="xdx_906_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20241001__20250331_zHo2UpitGLWa" title="Non operating income from grant">12,275</span>, respectively (three and six months ended March 31,
2024: $<span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20240101__20240331_zrxVg7ZPsDB3" title="Non operating income from grant"><span id="xdx_906_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20231001__20240331_zUGWZElgf6F2" title="Non operating income from grant">0</span></span>) of this grant on its statements of operations within grant income. At March 31, 2025 an amount of $<span id="xdx_90E_ecustom--DeferredGrantIncome1_pn5n6_c20241001__20250331_zsnxobGOHehg" title="Deferred grant income">0.8</span> million (September 30,
2024: $<span id="xdx_90C_ecustom--DeferredGrantIncome1_pn5n6_c20231001__20240930_zuj6CigMDod5" title="Deferred grant income">0.8</span> million) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized
to other income. The Company will recognize this income on its statements of operations as the related expenditures are incurred to offset
the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#8217;s annual income tax return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the three and six
months ended March 31, 2025, the Company recorded research and development incentive income of $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20250101__20250331_zp30BaoA9U6g" title="Research and development incentive income">0.1</span> million (AUD <span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20250101__20250331__srt--CurrencyAxis__currency--AUD_zTDPeiu1kqm8" title="Research and development incentive income">0.2</span> million) and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250331_z8oUCNXbqTX9" title="Research and development incentive income">0.5</span>
million (AUD <span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250331__srt--CurrencyAxis__currency--AUD_zsRczMl4XLp1" title="Research and development incentive income">0.8</span> million), respectively (2024: $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331_za7nMLpByrd5" title="Research and development incentive income">0.5</span> million (AUD <span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331__srt--CurrencyAxis__currency--AUD_zgLVuvOeCura" title="Research and development incentive income">0.7</span> million) and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331_z4ZorWOIzI0k" title="Research and development incentive income">1.1</span> million (AUD <span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331__srt--CurrencyAxis__currency--AUD_zu6d9mEiJjA4" title="Research and development incentive income">1.6</span> million), respectively) in respect
of the Australia R&amp;D credit for eligible research and development expenses incurred during the period. This amount is included within
Other income (expense) on the condensed consolidated interim statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At March 31, 2025, Incentive
and tax receivables includes $<span id="xdx_90B_eus-gaap--OtherReceivables_iI_pn5n6_c20250331_z9JmJrCqRI49" title="Incentive and tax receivables">0.5</span> million (AUD <span id="xdx_903_eus-gaap--OtherReceivables_iI_pn5n6_c20250331__srt--CurrencyAxis__currency--AUD_zlLn9Cp3He5j" title="Incentive and tax receivables">0.8</span> million) (September 30, 2024: $<span id="xdx_902_eus-gaap--OtherReceivables_iI_pn5n6_c20240930_zEnZJCwyNmp" title="Incentive and tax receivables">2.3</span> million (AUD <span id="xdx_904_eus-gaap--OtherReceivables_iI_pn5n6_c20240930__srt--CurrencyAxis__currency--AUD_zNr0fI8Ex2wk" title="Incentive and tax receivables">3.3</span> million)) relating to Australia
R&amp;D credits earned during the period that are expected to be reimbursed upon filing of the Company&#8217;s annual claim under this
program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Australia R&amp;D credit
program is a self-assessment program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if specific R&amp;D activities are eligible and (iii) if the individual R&amp;D expenditures have nexus to such R&amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right
to review the Company&#8217;s qualifying programs and related expenditures for a period of four years. If such a review were to occur,
the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#8217;s assessments
and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#8217; claims already received.
Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess
penalties and interest on any such adjustments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Currently, the Company&#8217;s
tax incentive claims from 2020 to 2024 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_EquityOfferingTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_80D_ecustom--EquityOfferingTextBlock_zqtZmkPJVub6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5	<span id="xdx_82B_zTgkX6ypXsza">Equity Offerings</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board of Directors&#160;(the &#8220;Board&#8221;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2023 Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEO1Po9iJstg" title="Value of shares obligated to purchase">150</span>.0
million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zenXujBEivod" title="Share issued for offering, shares">75,000</span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
and agreed to issue up to an additional <span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z5vpIn8uL2r9" title="Pro rata basic number of shares obligated to purchase">75,000</span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion,
the $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zIIP2cMT7llb" title="Proceeds from issuance or sale of equity">150</span>.0 million aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_90C_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230930_zu9HE73auP5a" title="Fair value of the initial commitment">0.8</span> million with
reference to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $<span id="xdx_900_ecustom--IncurredExpenses_iI_pn5n6_c20230930_zIMJ8tyfr997" title="Incurred expenses">0.1</span> million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2025, the Company
did not issue any shares of common stock under the 2023 Purchase Agreement (2024: an aggregate of <span id="xdx_90A_ecustom--AggregateCommonShares_pip0_c20241001__20250331_zLIZcf0gdBFl" title="Aggregate common shares">1,503,707</span> shares of common stock including
<span id="xdx_901_ecustom--AggregateCommonShares_pip0_c20231001__20240331_zXOO9ZEfGZwe" title="Aggregate common shares">1,500,000</span> shares for an aggregate purchase price of $<span id="xdx_902_ecustom--AggregatePurchasePrice_pn5n6_c20241001__20250331_zYAdxQOcwO46" title="Aggregate purchase price">7.4</span> million and <span id="xdx_90D_ecustom--CommitmentsShares_pip0_c20241001__20250331_zUC4XvKkVTZi" title="Commitment shares">3,707</span> commitment shares).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025, there was an unused amount of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20241001__20250331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zFwiDzW8tU1" title="Amount of shares remain available">110.8</span>
million under the 2023 Purchase Agreement. The Company will need to obtain effectiveness of a new registration statement in order to access
funds under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2020 Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;2020 Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company could offer and sell shares of common
stock registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2024, no shares
were sold pursuant to the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2024, the Company terminated the 2020
Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and six months ended March 31,
2025, the Company issued a net <span id="xdx_902_ecustom--SharesOfCommonStockIssued_pip0_c20241001__20250331_z6SYGlKymyw7">217,503</span>
shares of common stock to the Company&#8217;s Chief Executive Officer upon a net exercise of an option to purchase <span id="xdx_90A_ecustom--OptionToPurchaseShares_pip0_c20241001__20250331_zHGO5UX7pvpj">500,000</span>
shares of common stock at an exercise price of $<span id="xdx_90D_ecustom--ExercisePrice_pip0_c20241001__20250331_zYD2xB8VJOta">0.92</span>
per share. In connection with the exercise, the Company withheld <span id="xdx_90D_ecustom--WthheldShares_pip0_c20241001__20250331_zX7fdpz2XgY2">47,745</span>
shares of common stock as consideration of the exercise price of $<span id="xdx_90B_ecustom--ExercisePriceConsideration_pn3n3_dm_c20241001__20250331_zxzDYQc6kEOe">0.46</span>
million and <span id="xdx_904_ecustom--CommonStockAsConsideration_pip0_c20241001__20250331_zh70B5Qc2s3g">234,752</span>
shares of common stock as consideration for the payment of $<span id="xdx_909_ecustom--WithholdingObligationsExercise_pn5n6_c20241001__20250331_zNY0nl0W2Yha">2.3</span>
million in connection with tax withholding obligations associated with the exercise. The shares withheld were based upon a market
price of $9.63 per share as determined by reference to the average high and low sales price reported on the Nasdaq stock exchange on
the date of exercise. At March 31, 2025, the amount of $<span id="xdx_90A_ecustom--AccountsPayable_pn3n3_dm_c20241001__20250331_zvear9CB18Pa">2.3</span>
million in connection with the tax withholding obligations was included in accounts payable on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsDisclosureTextBlock_z9XnvYLplbN" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 6	<span id="xdx_829_z42y3Yg8aavi">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lease</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company leases office space under an operating lease with an initial term of 12 months or less. Under the terms of the office lease, the
Company is required to pay its proportionate share of operating costs. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
operating lease costs were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"></p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LeaseCostTableTextBlock_pn3n3_zwSPOL4WLGye" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8BE_z306R9oBMXN" style="display: none">Schedule of operating lease costs</span></td>
<td style="font-style: normal">&#160;</td>
<td colspan="3" id="xdx_49A_20250101__20250331_zXvTohZieOh3" style="font-style: normal; text-align: center">&#160;</td>
<td style="color: gray; font-weight: bold; font-style: normal">&#160;</td>
<td colspan="3" id="xdx_493_20240101__20240331_ziUeuynH9xMc" style="font-weight: bold; text-align: center">&#160;</td>
<td style="color: gray; font-weight: bold; font-style: normal">&#160;</td>
<td colspan="3" id="xdx_495_20241001__20250331_zWoEmaQFPEE1" style="font-weight: bold; text-align: center">&#160;</td>
<td style="color: gray; font-weight: bold; font-style: normal">&#160;</td>
<td colspan="3" id="xdx_493_20231001__20240331_z2IVqBCiBZij" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-style: normal; text-align: center"><span style="font-weight: normal; font-size: 10pt; font-style: normal"><b>2025</b></span></td>
<td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_401_eus-gaap--OperatingLeaseCost_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Operating lease costs</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right">33</td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right">31</td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right">66</td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right">61</td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A8_zBV7Ud0dpqk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">The
Company made matching contributions under the 401(k) plan as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zoNuCoesb418" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
<tr style="vertical-align: bottom">
<td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B2_zgvvTFOaLGM5" style="display: none">Schedule of contributions under the plan</span></td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_498_20250101__20250331_zo7hRpAFbtJe" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_49C_20240101__20240331_zzIMjpSm5Ag" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_492_20241001__20250331_zvYnMorIwb5b" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_499_20231001__20240331_zt9xe4YEHub6" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months ended March 31</td></tr>
<tr style="vertical-align: bottom">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_401_eus-gaap--PensionContributions_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">67</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">94</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">115</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">167</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A4_zfSdE6CZo3m6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Litigation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="font-style: normal"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York and it
named the Company and an officer of the Company as Defendants. The complaint was amended on July 12, 2024 (the &#8220;Initial Action&#8221;).
The complaint alleged violations of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect
to certain clinical trials for ANAVEX<sup>&#174;</sup>2-73 related to Rett syndrome. The complaint seeks unspecified damages, as well as
costs, including counsel and expert witness fees, on behalf of a class of investors.&#160;The Company believes the lawsuit is without
merit and the Company denies any liability or wrongdoing and has filed a motion to dismiss the complaint, which is awaiting a decision
by the Court. No amount has been recorded in these condensed consolidated interim financial statements for any loss contingencies associated
with this lawsuit as the Company believes that it is not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants.
The Company believed that this lawsuit was also without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed this complaint subsequent to the filing of the motion to dismiss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the
Company&#8217;s Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint
asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding
the same or similar allegations at issue in the purported class action lawsuit related to disclosures and statements made about certain
clinical trials related to Rett Syndrome. On January 22, 2025, pursuant to a stipulation of the parties, the Court entered an order staying
this purported derivative lawsuit until the motion to dismiss filed by defendants in the Initial Action is decided by the U.S. District
Court for the Southern District of New York.&#160;No amount has been recorded in these condensed consolidated interim financial statements
for any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On February
14, 2025, another derivative lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations
was filed against the Company (as nominal defendant), an officer of the Company, and members of the Company&#8217;s Board of Directors
in the Supreme Court for the State of New York, County of New York, by another purported shareholder named Evan Levitan. The parties to
that action also have stipulated to a stay of the proceeding until the Court rules on the motion to dismiss in the putative class action
lawsuit pending in the U.S. District Court for the Southern District of New York. The New York state court has not yet entered an order
pursuant to the stipulation of the parties. No amount has been recorded in these condensed consolidated interim financial statements for
any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We know of no
other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which
our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any
of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Share Purchase Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025 and September 30, 2024, the Company
had <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20250331_zQNhL5vRDmm2" title="Warrants outstanding">10,000</span> share purchase warrants outstanding exercisable at $<span id="xdx_90B_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20250331_z99TI7K5dSrc" title="Warrants outstanding weighted average exercise price">12.00</span> per share until <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20250331_zMTbu586Lpxc" title="Expiry Date">April 21, 2026</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Share&#8211;based Compensation
Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2015 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the 2015 Plan was <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT078oDmSJQk" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the 2019 Plan was <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20241001__20250331__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zdlnRZjcpsEc" title="Additional shares of common stock available for issuance">6,000,000</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pip0_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zinupTm7xWrl" title="Option granted">406,453</span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20220324__20220325__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zArEo1H39uD5" title="Additional shares of common stock available for issuance">10,000,000</span> additional shares of Common Stock will be available for issuance under the 2022 Plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. As at March 31,
2025, <span id="xdx_905_ecustom--OptionIssued_pip0_c20241001__20250331_z6BLsQoqgdX3" title="Option issued">6,751,000</span> options had been issued under the 2022 Plan and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zwUxtbOJOy4" title="Option available issue">3,978,702</span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock option
activity during the six months ended March 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_pn3n3_z9S8O13eYfzg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_zS9TXJDkRItc" style="display: none">Schedule of stock option activity</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value <br/> ($)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value <br/> ($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2024</span></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoEaPYql32d4" style="width: 13%; text-align: right" title="Number of options, Outstanding beginning balance">15,037,754</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoToyiPYCpNa" style="width: 13%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance">6.80</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3KMRIQOoSy6" style="width: 13%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance">5.12</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7FOQOnkEFBb" style="width: 13%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance">15,825,791</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjgRAX6Toh8k" style="text-align: right" title="Number of options, Granted">1,483,500</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z55T64KzlfX5" style="text-align: right" title="Weighted average exercise price, Granted">8.58</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbB1KsasrkVc" style="text-align: right" title="Weighted average grant date fair value, Granted">6.22</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zb5a8BIaPsmg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Exercised">(820,632</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze0qcpoGZEj4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Exercised">2.46</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBIWuwS0o07c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Exercised">1.89</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT0rQLLEcxK3" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Exercised">6,785,518</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, March 31, 2025</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjgGMNZ5Achc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding beginning balance">15,700,622</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zapl6u6eG3ik" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance">7.19</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuLjeaneUI4j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Outstanding ending balance">5.39</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zddXQqjIO2Kj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance">38,630,198</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable, March 31, 2025</span></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_za09lPpzu9Fi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable">10,346,086</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMW0ks6U2uB" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">6.03</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvgz0pk0U7Pi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Exercisable">4.68</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJcdPGwunFEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable">34,276,704</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8AA_z67DJIQfLdm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at March 31, 2025 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlIRqgbamqfc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_8B0_zOvKWoDBishk" style="display: none">Schedule of summarizes information about stock options</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of exercises prices</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of outstanding </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average remaining contractual life (in</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of vested </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;options</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> years)&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; price</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;options</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; price</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zrnGbCei2rd3" style="width: 10%; text-align: right" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z52scwgkvHul" style="width: 12%; text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zSAurzpUAKbe" style="width: 11%; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,400,150</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z03dX8ExWOb5" title="Weighted average remaining contractual life (in years)">3.92</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxSls1sXj7db" style="width: 10%; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.69</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zPymBH2v5m15" style="width: 10%; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,400,150</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zCun6LKsZWab" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.69</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zBiOs6e9ODdl" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.01</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zyoEroYMf3u" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zffZhWgKcf9d" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,197,500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zurDYdWYyMXc" title="Weighted average remaining contractual life (in years)">3.44</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zSnbeNfoWgk4" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.41</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zTBZD18vTfej" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,027,916</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zp4vRIlaj22a" style="text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.31</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTaxbaDflOLj" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.01</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zWkAAlJQsaI1" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zvuSVhzoEaA" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,028,972</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zGGjzbtrmZm8" title="Weighted average remaining contractual life (in years)">6.36</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zmu2LkvBC4Ee" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.95</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zaNQFSp8JOn4" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,297,519</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zNcGZkFQBZAl" style="text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.39</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z69JunRT9rya" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.01</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zPJraIoaxcNg" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z1kQsNImJ2p9" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,609,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zvfOZMHD6tia" title="Weighted average remaining contractual life (in years)">6.81</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zO46Ji9l9SOg" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zFgDHNVAFGqa" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">998,834</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3cdhYlhr5z4" style="text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zXTCt5aJdsId" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.01</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zGqvDBOJrpa5" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zUkMsMVzpcQ5" style="border-bottom: black 1pt solid; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,465,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zqDDFS6JsUe3" title="Weighted average remaining contractual life (in years)">5.97</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zKKvCc09J06j" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.18</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zDZG5Pgw9TO1" style="border-bottom: black 1pt solid; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">621,667</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBLqMqPkvQC4" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.34</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZx9d33psFFi" style="border-bottom: black 2.25pt double; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,700,622</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm0Xt9SnbzZb" title="Weighted average remaining contractual life (in years)">5.59</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6fSVe9l7uT6" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.19</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKoKRgQHLD6i" style="border-bottom: black 2.25pt double; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,346,086</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPN9U7MMCaic" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.03</span></td>
    <td>&#160;</td></tr>
  </table>

<p id="xdx_8AA_zRtWEBMpp0w4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average per share fair value of options
vested at March 31, 2025 was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250331_zQTrzeDgURb6" title="Weighted average grant date fair value of options vested">4.68</span> (September 30, 2024: $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930_zObSEf6I3Arg" title="Weighted average grant date fair value of options vested">4.34</span>). At March 31, 2024, the weighted average contractual life of options outstanding
was <span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331_zazaen280lTe" title="Weighted average contractual life of options exercisable">5.59</span> years (September 30, 2024: <span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zluwOMal5HA3" title="Weighted average contractual life of options exercisable">5.48</span> years) and for options exercisable was <span id="xdx_90B_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331_zvyKflAdZpC9" title="Weighted average contractual life of options exercisable">4.16</span> years (September 30, 2024: <span id="xdx_90C_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zHJ8b0iGmcV3" title="Weighted average contractual life of options exercisable">4.03</span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">	The Company recognized share-based compensation expense of $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20241001__20250331_zMQ4RKqp3Old" title="Share based compensation expense">1.4</span> million
and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250331_z033PHgEgZIc" title="Share based compensation expense">3.5</span> million during the three and six months ended March 31, 2025, respectively (three and six months ended March 31, 2024: $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240331_zcoYkVYG7yZi" title="Share based compensation expense">2.7</span> million
and $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20240331_zkKqgmf3ij5i" title="Share based compensation expense">4.9</span> million, respectively) in connection with the issuance and vesting 	of stock options in exchange for services. These amounts
have been included in general and 	administrative expenses and research and development expenses on the Company&#8217;s condensed consolidated
interim statements of 	operations as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zRh3T6c8zy4j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zGd4iqBHJun4" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsdePd72fJP4" style="width: 10%; text-align: right" title="Total share based compensation">605</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvVUtKpGRobj" style="width: 10%; text-align: right" title="Total share based compensation">979</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zaJVYaJQ91ll" style="width: 10%; text-align: right" title="Total share based compensation">1,407</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIJV7N6wQDvd" style="width: 10%; text-align: right" title="Total share based compensation">1,905</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTkDsIk0arsg" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">844</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zPPYzqwN8CP1" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">1,673</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zsepTg66hEZh" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,097</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQLcSQjTkXWg" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,033</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331_zp2UQISywiD7" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">1,449</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zYLvizQYIEQi" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,652</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331_zDiBuuC3BI8a" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,504</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331_zsdD1RzD9ITf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">4,938</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>


<p id="xdx_8A1_zlExNPLG2s52" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20250331_zmJuvYORp40a" title="Remaining stock based compensation">14.5</span> million in share-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2029.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each stock option award is estimated
on the date of grant using the Black Scholes option pricing model. The fair value of share-based compensation charges recognized during
the three and six months ended March 31, 2025 was determined with reference to the quoted market price of the Company&#8217;s shares on
the grant date and based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zPvDuWDnFQRl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zqMPwOhpgEG" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20241001__20250331_zoyoowXnU3Bg" title="Risk-free interest rate">3.98</span></td>
<td style="width: 1%; text-align: left">%</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240331_z4ohS6cP5BEc" title="Risk-free interest rate">4.28</span></td>
<td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250331_zLU1pziZ19Re" title="Expected life of options (years)">5.56</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331_zfZGxXDHR0yg" title="Expected life of options (years)">5.74</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250331_zUu6KqaeQfKa" title="Annualized volatility">86.49</span></td>
<td style="text-align: left">%</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240331_z1RY5hnHofR7" title="Annualized volatility">84.84</span></td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20241001__20250331_zPt4K6lfFYX6" title="Dividend rate">0.00</span></td>
<td style="text-align: left">%</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240331_zA083g62GN2g" title="Dividend rate">0.00</span></td>
<td style="text-align: left">%</td></tr>
</table>


<p id="xdx_8AE_zQjOKf59jhb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zqshjQVK9aVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7	<span id="xdx_822_zAW7x0rQUdWi">Subsequent Events</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates subsequent events occurring
between the most recent balance sheet date and the date the financial statements are available to be issued in order to determine whether
the subsequent events are to be recorded and/or disclosed in the Company&#8217;s financial statements and footnotes. The financial statements
are considered to be available to be issued at the time they are filed with the Securities and Exchange Commission (SEC).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 17, 2025, the Board approved, subject to
stockholder approval, an amendment to the 2022 Plan (the &#8220;Amendment&#8221;). The Amendment, if approved by stockholders, will increase
the number of shares of common stock reserved for issuance under the 2022 Plan by <span id="xdx_904_ecustom--SharesOfCommonStockReservedForIssuance_iI_pip0_c20250417__us-gaap--SubsegmentsAxis__us-gaap--SubsequentEventMember_zxmnbP0IA1ai" title="Shares of common stock reserved for issuance">4,000,000</span> shares. In addition, the Amendment will establish
a minimum vesting period of one year for all awards granted under the Plan and limit the discretion to accelerate the vesting of awards
upon a separation from service, with limited exceptions permitted. Finally, the Amendment would prohibit liberal share recycling provisions.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_848_ecustom--LiquidityPolicyTextBlock_zICIurpE8pEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_zeR0VfVzmDJ9">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenue from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed consolidated interim financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. The Company will need to obtain effectiveness of a new registration
statement in order to access the funds under the 2023 Purchase Agreement. If the Company is not able to obtain the additional financing
on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--UseOfEstimates_zvoBFwCpEkv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zrQtwQDPhyT7">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zyMLo2kqnlP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zwYdubCxIUV4">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These unaudited condensed consolidated interim financial
statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex
Australia&#8221;), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany,
and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances
have been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zORTeRDCLXV" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zLXB3vMTixZ4">Fair Value Measurements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025 and September 30, 2024, the Company
did not have any Level 2 or Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>














<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zEziszRJ3yNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zNJJ33As7Ie7">Basic and Diluted Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025 loss per share excludes <span id="xdx_900_ecustom--DilutiveCommonShares_iI_pip0_c20250331_zd47XwkTDlq1" title="Dilutive common shares">15,710,622</span>
(March 31, 2024: <span id="xdx_90B_ecustom--DilutiveCommonShares_iI_pip0_c20240331_zSr7AeeGJm0c" title="Dilutive common shares">15,755,114</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv2UtPTYfkUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_86C_zhB6e4utZRmk">Recent Accounting Pronouncements</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2023, the Financial
Accounting Standards Board (FASB) issued ASU No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221;
This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our
fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30, 2026. The Company is currently
assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of principal components of accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zTR76Me0xrG8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B6_zAYunKXtNpH6" style="display: none">Schedule of principal components of accrued liabilities</span></td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_49C_20250331_zD5WUULJawa9" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_49E_20240930_zfej5vkDkEW2" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_405_ecustom--AccruedInvestigatorPayments_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued investigator payments</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">1,459</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">860</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">2,200</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,527</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone-based contract accruals</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">4,332</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">557</td>
<td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">1,564</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">1,891</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_zGSWkP31omT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,555</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
<td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,835</td>
<td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of operating lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LeaseCostTableTextBlock_pn3n3_zwSPOL4WLGye" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
<tr style="vertical-align: bottom">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8BE_z306R9oBMXN" style="display: none">Schedule of operating lease costs</span></td>
<td style="font-style: normal">&#160;</td>
<td colspan="3" id="xdx_49A_20250101__20250331_zXvTohZieOh3" style="font-style: normal; text-align: center">&#160;</td>
<td style="color: gray; font-weight: bold; font-style: normal">&#160;</td>
<td colspan="3" id="xdx_493_20240101__20240331_ziUeuynH9xMc" style="font-weight: bold; text-align: center">&#160;</td>
<td style="color: gray; font-weight: bold; font-style: normal">&#160;</td>
<td colspan="3" id="xdx_495_20241001__20250331_zWoEmaQFPEE1" style="font-weight: bold; text-align: center">&#160;</td>
<td style="color: gray; font-weight: bold; font-style: normal">&#160;</td>
<td colspan="3" id="xdx_493_20231001__20240331_z2IVqBCiBZij" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-style: normal; text-align: center"><span style="font-weight: normal; font-size: 10pt; font-style: normal"><b>2025</b></span></td>
<td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_401_eus-gaap--OperatingLeaseCost_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Operating lease costs</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right">33</td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right">31</td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right">66</td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td>
<td style="width: 3%; color: gray; font-style: normal">&#160;</td>
<td style="font-weight: normal; width: 1%; font-style: normal; text-align: left">$</td>
<td style="font-weight: normal; width: 10%; font-style: normal; text-align: right">61</td>
<td style="width: 1%; color: gray; font-style: normal; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock', window );">Schedule of contributions under the plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zoNuCoesb418" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
<tr style="vertical-align: bottom">
<td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B2_zgvvTFOaLGM5" style="display: none">Schedule of contributions under the plan</span></td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_498_20250101__20250331_zo7hRpAFbtJe" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_49C_20240101__20240331_zzIMjpSm5Ag" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_492_20241001__20250331_zvYnMorIwb5b" style="font-weight: bold; text-align: center">&#160;</td>
<td style="font-weight: bold">&#160;</td>
<td colspan="3" id="xdx_499_20231001__20240331_zt9xe4YEHub6" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months ended March 31</td></tr>
<tr style="vertical-align: bottom">
<td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr id="xdx_401_eus-gaap--PensionContributions_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">67</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">94</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">115</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">167</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_pn3n3_z9S8O13eYfzg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B2_zS9TXJDkRItc" style="display: none">Schedule of stock option activity</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td colspan="2" style="text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price <br/> ($)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value <br/> ($)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value <br/> ($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, September 30, 2024</span></td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoEaPYql32d4" style="width: 13%; text-align: right" title="Number of options, Outstanding beginning balance">15,037,754</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoToyiPYCpNa" style="width: 13%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance">6.80</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3KMRIQOoSy6" style="width: 13%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance">5.12</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7FOQOnkEFBb" style="width: 13%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance">15,825,791</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjgRAX6Toh8k" style="text-align: right" title="Number of options, Granted">1,483,500</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z55T64KzlfX5" style="text-align: right" title="Weighted average exercise price, Granted">8.58</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbB1KsasrkVc" style="text-align: right" title="Weighted average grant date fair value, Granted">6.22</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#8212;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zb5a8BIaPsmg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Exercised">(820,632</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze0qcpoGZEj4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Exercised">2.46</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBIWuwS0o07c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Exercised">1.89</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT0rQLLEcxK3" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Exercised">6,785,518</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding, March 31, 2025</span></td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjgGMNZ5Achc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding beginning balance">15,700,622</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zapl6u6eG3ik" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance">7.19</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuLjeaneUI4j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Outstanding ending balance">5.39</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zddXQqjIO2Kj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance">38,630,198</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable, March 31, 2025</span></td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_za09lPpzu9Fi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable">10,346,086</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMW0ks6U2uB" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">6.03</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvgz0pk0U7Pi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Exercisable">4.68</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJcdPGwunFEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable">34,276,704</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summarizes information about stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlIRqgbamqfc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_8B0_zOvKWoDBishk" style="display: none">Schedule of summarizes information about stock options</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Range of exercises prices</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of outstanding </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average remaining contractual life (in</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of vested </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average exercise</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;options</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> years)&#160;</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; price</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;options</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160; price</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zrnGbCei2rd3" style="width: 10%; text-align: right" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z52scwgkvHul" style="width: 12%; text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zSAurzpUAKbe" style="width: 11%; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,400,150</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z03dX8ExWOb5" title="Weighted average remaining contractual life (in years)">3.92</span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxSls1sXj7db" style="width: 10%; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.69</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zPymBH2v5m15" style="width: 10%; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,400,150</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zCun6LKsZWab" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.69</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zBiOs6e9ODdl" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.01</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zyoEroYMf3u" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zffZhWgKcf9d" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,197,500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zurDYdWYyMXc" title="Weighted average remaining contractual life (in years)">3.44</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zSnbeNfoWgk4" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.41</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zTBZD18vTfej" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,027,916</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zp4vRIlaj22a" style="text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.31</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTaxbaDflOLj" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.01</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zWkAAlJQsaI1" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zvuSVhzoEaA" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,028,972</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zGGjzbtrmZm8" title="Weighted average remaining contractual life (in years)">6.36</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zmu2LkvBC4Ee" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.95</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zaNQFSp8JOn4" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,297,519</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zNcGZkFQBZAl" style="text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.39</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z69JunRT9rya" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.01</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zPJraIoaxcNg" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z1kQsNImJ2p9" style="text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,609,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zvfOZMHD6tia" title="Weighted average remaining contractual life (in years)">6.81</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zO46Ji9l9SOg" style="text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zFgDHNVAFGqa" style="text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">998,834</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3cdhYlhr5z4" style="text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zXTCt5aJdsId" style="text-align: right" title="Range of exercise prices, lower range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.01</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zGqvDBOJrpa5" style="text-align: right" title="Range of exercise prices, upper range limit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zUkMsMVzpcQ5" style="border-bottom: black 1pt solid; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,465,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zqDDFS6JsUe3" title="Weighted average remaining contractual life (in years)">5.97</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zKKvCc09J06j" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.18</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zDZG5Pgw9TO1" style="border-bottom: black 1pt solid; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">621,667</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBLqMqPkvQC4" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.34</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZx9d33psFFi" style="border-bottom: black 2.25pt double; text-align: right" title="Number of outstanding options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,700,622</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm0Xt9SnbzZb" title="Weighted average remaining contractual life (in years)">5.59</span></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6fSVe9l7uT6" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.19</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKoKRgQHLD6i" style="border-bottom: black 2.25pt double; text-align: right" title="Number of vested options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,346,086</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPN9U7MMCaic" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price options vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.03</span></td>
    <td>&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zRh3T6c8zy4j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_zGd4iqBHJun4" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsdePd72fJP4" style="width: 10%; text-align: right" title="Total share based compensation">605</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvVUtKpGRobj" style="width: 10%; text-align: right" title="Total share based compensation">979</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zaJVYaJQ91ll" style="width: 10%; text-align: right" title="Total share based compensation">1,407</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIJV7N6wQDvd" style="width: 10%; text-align: right" title="Total share based compensation">1,905</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTkDsIk0arsg" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">844</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zPPYzqwN8CP1" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">1,673</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zsepTg66hEZh" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,097</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQLcSQjTkXWg" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,033</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total share-based compensation</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331_zp2UQISywiD7" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">1,449</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zYLvizQYIEQi" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,652</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331_zDiBuuC3BI8a" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,504</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td>
<td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331_zsdD1RzD9ITf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">4,938</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zPvDuWDnFQRl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zqMPwOhpgEG" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td>
<td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20241001__20250331_zoyoowXnU3Bg" title="Risk-free interest rate">3.98</span></td>
<td style="width: 1%; text-align: left">%</td>
<td style="width: 8%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240331_z4ohS6cP5BEc" title="Risk-free interest rate">4.28</span></td>
<td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250331_zLU1pziZ19Re" title="Expected life of options (years)">5.56</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331_zfZGxXDHR0yg" title="Expected life of options (years)">5.74</span></td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250331_zUu6KqaeQfKa" title="Annualized volatility">86.49</span></td>
<td style="text-align: left">%</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240331_z1RY5hnHofR7" title="Annualized volatility">84.84</span></td>
<td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20241001__20250331_zPt4K6lfFYX6" title="Dividend rate">0.00</span></td>
<td style="text-align: left">%</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240331_zA083g62GN2g" title="Dividend rate">0.00</span></td>
<td style="text-align: left">%</td></tr>
</table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation (Details Narrative) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DilutiveCommonShares', window );">Dilutive common shares</a></td>
<td class="nump">15,710,622<span></span>
</td>
<td class="nump">15,755,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DilutiveCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DilutiveCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureAccruedLiabilitiesAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccruedInvestigatorPayments', window );">Accrued investigator payments</a></td>
<td class="nump">$ 1,459<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_MilestoneBasedContractAccruals', window );">Milestone-based contract accruals</a></td>
<td class="nump">4,332<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">All other accrued liabilities</a></td>
<td class="nump">1,564<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 9,555<span></span>
</td>
<td class="nump">$ 4,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccruedInvestigatorPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccruedInvestigatorPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_MilestoneBasedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_MilestoneBasedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Non operating income from grant</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,275<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome1', window );">Deferred grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Incentive and tax receivables</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Incentive and tax receivables</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember', window );">Michael J Fox Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FairValueOfInitialCommitment', window );">Fair value of the initial commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncurredExpenses', window );">Incurred expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AggregateCommonShares', window );">Aggregate common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,503,707<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentsShares', window );">Commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesOfCommonStockIssued', window );">[custom:SharesOfCommonStockIssued]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OptionToPurchaseShares', window );">[custom:OptionToPurchaseShares]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ExercisePrice', window );">[custom:ExercisePrice]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WthheldShares', window );">[custom:WthheldShares]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ExercisePriceConsideration', window );">[custom:ExercisePriceConsideration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommonStockAsConsideration', window );">[custom:CommonStockAsConsideration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WithholdingObligationsExercise', window );">[custom:WithholdingObligationsExercise]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccountsPayable', window );">[custom:AccountsPayable]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member', window );">Purchase Agreement 2023 [Member] | Lincoln Park Capital Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Value of shares obligated to purchase</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues1', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AggregateCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AggregateCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommonStockAsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommonStockAsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ExercisePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ExercisePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FairValueOfInitialCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FairValueOfInitialCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncurredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncurredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OptionToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OptionToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WithholdingObligationsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WithholdingObligationsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WthheldShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WthheldShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contributions to 401(k) plan</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding beginning balance | shares</a></td>
<td class="nump">15,037,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding beginning balance</a></td>
<td class="nump">$ 6.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding beginning balance</a></td>
<td class="nump">$ 5.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding beginning balance | $</a></td>
<td class="nump">$ 15,825,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted | shares</a></td>
<td class="nump">1,483,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 8.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted</a></td>
<td class="nump">$ 6.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised | shares</a></td>
<td class="num">(820,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 2.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice', window );">Weighted average grant date fair value, Exercised</a></td>
<td class="nump">$ 1.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, Exercised | $</a></td>
<td class="nump">$ 6,785,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding beginning balance | shares</a></td>
<td class="nump">15,700,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding ending balance</a></td>
<td class="nump">$ 7.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Outstanding ending balance</a></td>
<td class="nump">$ 5.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding ending balance | $</a></td>
<td class="nump">$ 38,630,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable | shares</a></td>
<td class="nump">10,346,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 6.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice', window );">Weighted average grant date fair value, Exercisable</a></td>
<td class="nump">$ 4.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable | $</a></td>
<td class="nump">$ 34,276,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - Equity Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">15,700,622<span></span>
</td>
<td class="nump">15,037,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 7.19<span></span>
</td>
<td class="nump">$ 6.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">10,346,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option Price 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,400,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">3 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,400,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 2.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,197,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">3 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,027,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">5.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">8,028,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">4,297,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 6.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">9.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,609,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 10.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">998,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 10.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option Price 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">13.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">5 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">621,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 18.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">$ 1,449<span></span>
</td>
<td class="nump">$ 2,652<span></span>
</td>
<td class="nump">$ 3,504<span></span>
</td>
<td class="nump">$ 4,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">$ 844<span></span>
</td>
<td class="nump">$ 1,673<span></span>
</td>
<td class="nump">$ 2,097<span></span>
</td>
<td class="nump">$ 3,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 5)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.98%<span></span>
</td>
<td class="nump">4.28%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 6 months 21 days<span></span>
</td>
<td class="text">5 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">86.49%<span></span>
</td>
<td class="nump">84.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WarrantsOutstandingWeightedAverageExercise', window );">Warrants outstanding weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 21,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 21,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OptionIssued', window );">Option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,751,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">Stock Option Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member', window );">Stock Option Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Option available issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,978,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,978,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WarrantsOutstandingWeightedAverageExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WarrantsOutstandingWeightedAverageExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Apr. 17, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesOfCommonStockReservedForIssuance', window );">Shares of common stock reserved for issuance</a></td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesOfCommonStockReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesOfCommonStockReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .:#K5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( .:#K5HN&%03\0   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=XZ:34.4=?+T$Y#0F(2B%N4
M>%M$TT:)4;NW)PU;!X('X!C[S^?/DAOMI1X"/H7!8R"+\6YR71^E]FMV(O(2
M(.H3.A7+E.A3\S $IR@]PQ&\TN_JB%!Q?@\.21E%"F9@X1<B:QNCI0ZH: @7
MO-$+WG^$+L.,!NS084\11"F M?-$?YZZ!FZ &4887/PJH%F(N?HG-G> 79)3
MM$MJ',=RK',N[2#@]7'WG-<M;!])]1K3KV@EG3VNV77R2[UYV&]96_%J5?!5
M(>I]Q64MI!!OL^L/OYNP&XP]V']F7'\SO@JV#?RZB_834$L#!!0    ( .:#
MK5J97)PC$ 8  )PG   3    >&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^
M[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZ
MFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *
MI4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>
M+&A T%116F]?(+3E'S/X%<M4C66C 1-702:YB+3R^6S%_-K>/F7/Z3H=,H%N
M,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8
MSG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CV
MVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI
M)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN
M.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(
M@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\
M+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E,L_O^0KK3CQG'U:6L%W/S^2>C'(C
MN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6
MH8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V
M5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\'1,2S90+!D&&ER0F$JDY?DU($_XK
MI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:P4:O&W6':-(\>OX%^9PU"AR1&QT"
M9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:<K46@;9QJ81@6A+&T7A.TK01_%FL
M-9,^8,CLS9%USM:1#A&27C="/F+.BY 1OQZ&.$J:[:)Q6 3]GE[#2<'H@LMF
M_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >CFED)O816:I^JAS0^J!XR"@7QN1X^
MY7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK<W(WUGP=.+6]Y&
M;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?P.S]:#Z>\>WZV22$KYI9+2,6D$N!
MLT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T
M/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL<QP3A[+##MG/)(=MG>@'37[]EUV
MY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1
MT?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q
M+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW
M&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07
MIDJB\QE3ON<K2<15.+]%,[82EQB\X^;'<4Y3N!)VM@\",KF[.:EZ93%GIO+?
M+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_IN
MDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0!A,!S93)1/ "@F2F'("8^@N]\@RY
M*17.K3XY?T4L@X9.7M(E$A2*L P%(1=RX^_ODVIWC-?Z+(%MA%0R9-47RD.)
MP3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+PWING2TG_]M>U#VT%SU&\Z.9X!ZS
MAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT
M>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,
M>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*
M/-S^[PVPPL2.X>V+OP%02P,$%     @ YH.M6M_B DCZ!0  C2   !@   !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6RUFEUSXC88A>_[*S2TTVEGEF#+0,@V
M889X2<LT8=F033?M]$*Q!7AB6U26(?S[OK+!9E/YA7J67("_SD&/)4O'4B[7
M0KXD"\X5>8W".+EJ+)1:OF^U$F_!(Y:<B26/X<Q,R(@IV)7S5K*4G/F9* I;
MU+*ZK8@%<:-_F1V;R/ZE2%48Q'PB29)&$9.;:QZ*]57#;NP.W ?SA=('6OW+
M)9OS*5>?EQ,)>ZW"Q0\B'B>!B(GDLZO&P'[O.FTMR*YX#/@ZV=LF&N59B!>]
M,_*O&I8N$0^YI[0%@Z\5=WD8:B<HQS];TT;QFUJXO[USO\G@ >:9)=P5X1^!
MKQ97C5Z#^'S&TE#=B_5O? O4T7Z>")/LDZSS:]OM!O'21(EH*X821$&<?[/7
M[8W8$SA5 KH5T#<"VZD0.%N!DX'F)<NP/C#%^I=2K(G45X.;WLCN3:8&FB#6
MU3A5$LX&H%-]5ZRX)$V2+)CDR65+@:<^T_*V^NM<3ROT77(G8K5(R##VN?^U
MO@5E*0I$=P6ZIJCA'9-GQ+'?$6K1CJ$\[B'YAMB.2?U5:9SB]CB9G8/>GK\&
MSXF2T.+^-MV@W*%M=M"/X?MDR3Q^U8#G+.%RQ1O]'[^WN]8O)KIO9/85;+N
M;6/N_0_"2^$)5>1AL^0F4EQN6\U/)B1451.I4R!UT#(-@,?/F&Y"-C<QX?H9
M"Q/3K7!164VH;@'5/:Z>/J5,*B[##;GG2R&5B0^W4C(UXJ&JFGCG!=[YD<U0
M,A@NLMZ^F@_WJJP_5%83L%< ]HX#G' 9"%]WG00Z;^,CASL5G65E;XGJ:W)>
M%)P7QW'>!(G'PAWN#1PVCC2XVR=JXD,U-?ELJQP\K?]%^,29K.8[8%95A;BL
M+N->0+#18KFIE&\1L19[P*[9M"Z:CF4$195U06D)2M&2#6,5J UPAIR,T^B9
M2R,>;F)9=M,Y[UI=(R"JK0M89AD;30\[P'L^#W2<@3H=L\A<A[C18#QX''XA
MMZ.;(9FZH^'8'4Z)^_%^<F:D/D6FL<M08^.Q9$OM0AN6T'Y'D%-?R>]\8^3&
MK2RH7<=N6QUC5X2+ZW*62<?&H\J6\X&]DI$/L,$L\%@V>"*-&;>\Z#6MKM5K
M6VTC[RDRD%V&(!N/+EO>4>P)">$@0WU'I@JZ)2(D<44*%0[U+GQS$\?=QX]&
MY%/D(KL,1C:>9K;( ]\']^3=;H/<PG7D8VSFQ"V[CD4Z:D$&*QZ;HR!N4)>Y
MS$HV'G%0YH>U,#+CEM0"X)M0"-,SX>+BNKQE9K+QF/.6U]5[T)X?Q#HVLN)V
M8[XF3T*^&$E/$9YH&9XHGG?>DA:/[D2*51![QN9\P'/\9)PR.$6"HF6"HGCD
M^4^5YEV3$0]W^CPUXITB-]$R-]&C<E.!-Q&)@H'VSV!9V?D><+0MV[:-I*<(
M4+0,4!3//=FS.)"<58/A!KVV<23%576QRH1$\5AS*[*WLX6(L>![P*3;@UA_
MX5P8^4Z1C&B9C"@>8QX"!9%>S(A-?WK^F4RYETJH22,D[N2**() -57">_F.
MP-\$7H8>69AR\H-U!NG02'^*G$3+G$3Q)/,@F1_$<S+=1,\B-$+C!H/'+[=&
MKE.$(5J&(8HGEUTUDN&KMV#QG%>^S1PP&@^F'P;&F4M<6)>PC#[TJ.BS>P'/
MY\"RJH21TCS%<,#QR3C%[^*JNIQEY*%'19Y1K+C,EW7TY +;@1LY<<<JSE,$
M'J<,/,Y1@4=/,,#["82=N3"G@ ,^8Q$WF>=QL $3/S<T+B:<(O<X9>YQCLH]
MTXB%(;E.$SB=&%OM 9^J26I<5A>OS#W.4;EG&'$YUT_EK^  +Q8P1BQ9;*Y7
MW+!RLAK7U07=6P,[:MYHNN!0CQ@>;E.-=XKXXY3QQSEN@FAO;(>7D6P]E'Q,
M%8396 ^@1N)O%&RV]R%WZV1N>OU]U>]UG'.[I^>;5ON,K;T%7]W\LG7PA'CZ
MQ2)?^RV.%FOM@VR%N55>GB_4WS'=>A,2\AE(K;-S^'F9KWWG.THLL^7C9Z&4
MB++-!6<^E_H".#\30NUV] \4_X'0_Q=02P,$%     @ YH.M6L9RMJ%T!
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M+9J5;3T76S=2I\::3'?6WQ2IJ:4[;'D#%_NZ>PG[&0P@J>,YM-\61!#2">U
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ME$EC +_OA- O-^8%W0GH^C]02P,$%     @ YH.M6O5P;96)"0  U%   !@
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6R]7%UOXS86_2N"M^CN N.Q^"%9
MGDT"=&P1[4,7P:3=/A1]4"PF%D:67$E.IO]^*5MCF2)U;::W[4/'3BX/K^_A
ME70.&=^\EM7G>B-EXWW9YD5].]DTS>[#;%:O-W*;U._+G2S4;Y[*:ILTZFWU
M/*MWE4S2PZ!M/J.^'\ZV259,[FX./[NO[F[*?9-GA;ROO'J_W2;5'Q]E7K[>
M3LCDZP\^9<^;IOW![.YFESS+!]G\O+NOU+O9"27-MK*HL[+P*OET._F.?!!\
MT0XX1/PODZ_UV6NO_2B/9?FY??-#>COQVXQD+M=-"Y&H?U[D4N9YBZ3R^+T#
MG9SF; >>O_Z*+@X?7GV8QZ26RS+_)4N;S>TDFGBI?$KV>?.I?/U>=A\H:/'6
M95X?_N^]=K'^Q%OOZZ;<=H-5!MNL./Z;?.D*<3: TI$!M!M !P-8.#* =0/8
M<$ P,H!W _@PI?G(@* ;$ P&$#8R(.P&A(?:'XMUJ/0J:9*[FZI\]:HV6J&U
M+PYT'4:K F=%N[(>FDK]-E/CFKME6:1JG<C44Z_J,L_2I%%O?B@:665;[Z%1
M;]5":FJO?/*6FZ1XEK67%>H7Y?KSILQ36=7_].+?]UGSAS?U?GY8>?_ZYM_>
M-VW,3YMR7R=%6M_,&I5J.^%LW:7U\9@6'4UKNRV[6;Q??Y3;1UG]9H%9PC#?
MI6G6+N D]^Z3+)VJI);)+FO4>P!T!8,^;))*>O=5N98RK;U/<BVSE^0QEQ!F
M#&-^DHVZ"JC"QTE59,5S#6$)&.NG4GT^?=A,K8K3TJ"GI4$/.'P$YZ-\SHHV
M&=6Z>5*LY3OO)<GWTDL:[T'NWGO,?^=1GS(;O4?H\ #=7MU>[B)Z,WLYI\X,
MX8Q';*&'K< DVPOOAWJ7K.7M1%U9:UF]R,F=9R/ G&Y*%\P/!_,),XYP$@5]
M]EHQV:F8#"[FL81M[1Z_UO6=5[=+J;ZJH$?X0"NH'X8!(8.R@GG8Z_7M/TCH
M_\?6"9A@,2:80 +3R.0G,CE(YOV^6F_4[:SCST87-U;1</ES@] Y)_Y@\9M!
M4\JX'A2#R5[?(<*2$9E']G4?G$H5N)3J'5"RP)B>!'[[WZ!PX(2N"QP3+,8$
M$TA@&FOAB;409*V]_69->]\'^ (AKE]V2R2<%1).C(0C_CR.QMW\Q-W<C3NH
MY^9&S[&Y/Q\T'#B?:\-A@L688 ()3",M.I$6@:3)+[):9^HRJ9ZRZ\-#;[EK
M'URMI(%0#HT762ZXT> &A#17C(0CX)RUVB].M5^\K?90XRR,/'AHWJK B5T[
M!Q,LQ@032& :>\3O%:P/\G?48ZV]D'KK<KM3<C9I^;.J3A#*H7<Z(&T!+-BP
M>["FB[& Q*6\=0[.7 0"<O!?V7AY6=N5/CC4I>9(0"LLH+@#TI[/R8*$@W4@
M+L?I=>\E.H$U>ERD=H'^8U(I/4D.>I);6;$H](&P6'8QVF+A<\:#X3(WXRPR
MQ1;%"*5L/JR6&4@87XQ=YTFOP<G5(EP>"G>NP"]7S"+!64A"2J)AW5 U."I:
MC(HFL-!T0GL=3F A#EE4*[D^\6EU5(BIT0V/BIB:F+,Y&7;*"L[3Y8IB4?S,
M)^&"#)O$#"0L".;!2)/T@IW BOV24W6YKJ:0CZ@?6:PJ.!/G/D'5\JAH @M-
MY[27\P36\U<85AT"Y%AU(1<L*TN4[6: I;)M28VZ5J07T016T0Z^%3%%M-VX
M@J=T7NZH2AH536"AZ>3U8IK :OHJ^PK&<'DL10):80'%6$ " 4BGL-?D!!;E
M3BX6,=6XQ<:"9W1N/U0YCHHFL-#T;<->D%-8D#N963"60QM24]DNC+U$+#V.
M!23@K'4">C5.837^<'Q8R^IZ+U-OMZ_J?:(:J2F]-WE=U%2OU&)VP4FY]A<J
M6HR*)K#0='K/]N5AT>]B>,%0+NUEBG(:!G388&B[]4A XE+>.@>]E4!A*P$R
MO."A+C5' EIA <74]$"FQ ]X.#Q$<3%.KWNO^"FL^-]N>%&+W!\:7M0B]VV&
MER7.HG%L45;#RQ((&5ZTU_+T:BW_!L.+6H2\W?""TW"^]*,*>50T@86F$]H+
M>0H+^6O/9-GY-"5^% R9-.4T#T+*C2<IK-UVRX13QD)_/C2\+(%$?=*0C31)
M+_4I+/5=CF;9ZVH: !&?+X* #"4(G(ESGZ Z *AH @M-Y[1W "CL *R3>I/+
MNAY]X+7R&!G],70LJ;G_S .C-[!T/!:0L*4=^B.-TVMT"FOTBT4&186IV:VF
M&9R#<\N@JG94-(&%II]/[54[@U5[4J1>DWRQL]6-U4[/&@=/32D[I7,Z"%O!
M:3AT!Q:0&$E\[,1O+\/953+\-6LV&YFG7B7SP^%ZI<,OMHYWH@-J(F;95Z:1
MNEL/;SQPILZG@E&U.2J:P$+3.>^U.8.UN9/W!6,Y"$5FV3$/PN'.#-9T,1:0
MN)2W3L+967M8G"/[7\P4LXSZ(1ONC\%9.3<9[ME[W,/W?\6V/^M-  :; "X&
M& SETF.F2&>!/SP(@#5=C 4D+N6M<]!;"PRV%B ##![J4G,DH!464,Q,3V1*
M&1MN-HG+<7K=>P> P0[ 50988&7E"OG/;/)_X0?&0QR6_+=,.&7!@LV'1^@L
M@8O%?,PB8[WZ9U>K?]@BL]?4(OT#QICAC"_A-)QO#JC2'Q5-8*'IA/;2G\'2
M_]HS858KAYD6@-DC5@_ )\.]$#A/EQXQ)YPR'I'A:35A"23$7Y"1,V&L5_H,
M5OHN9\+L=375?L074<"'QN(2SL2Y3U#U/BJ:P$+3_X2QU_L<<9<>QG*XHW-3
M:T?&+B+6;#$6D+B0MDY!;Q#POW6?GIMN %%/'(:E!F?EVF*H:#$JFL!"T_GM
MS0#^-C/ 2I[E[\Z'O%F.XQOF,YR22^]@B7Q;VF,:G_<:G\,:_RV>,S>%O-5S
MAJ=V;A!4(8^*)K#0=!+/_HX>%O*7W4\KC>9.OF%&<]L.O6E&P_FY= N67!])
M?.Q>T^MU#NOU/V<T<YN<M1G-<!;.K8-Z$@ 536"AZ7SV/@"'?0 7#PR&<GEZ
ML^S!&X_P*ZSI8BP@<2EOG8/>.^"P=P!Y8/!0EYHC :VP@&)NFAY30LAB> CL
M<IQ>]U[B<UCBO]T#XU?H>TN,U0.#DW2IISFAW0.S! (>&._E/;]:WK_! ^,6
M;6_WP. TG&\.J-H>%4U@H1T)G9U]OUO[?7^*DN>LJ+U</BEX__U<U;XZ?H7>
M\4U3[@Y?^?98-DVY/;S<R"2551N@?O]4ELW7-^VWR)V^R/#N_U!+ P04
M" #F@ZU:)#<=38X"  #+!P  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;*U5;4_;,!#^*U:&)I &SEL+=&DDVG0:TI@J7K8/TSZXR;6)<.S,=EKX][.=
M-"LH5(CQI?&=[WG.S]F]BS9<W,L<0*&'DC(Y=G*EJA'&,LVA)/*$5\#TSI*+
MDBAMBA66E0"265!)L>^Z0UR2@CEQ9'US$4>\5K1@,!=(UF5)Q.,$*-^,'<_9
M.JZ+5:Z, \=1159P ^JNF@MMX8XE*TI@LN ,"5B.G0MO- M-O WX4<!&[JR1
M4;+@_-X8E]G8<<V!@$*J# /1GS5,@5)#I(_QI^5TNI0&N+O>LG^QVK66!9$P
MY?1GD:E\[)PY*(,EJ:FZYINOT.H9&+Z44VE_T::)'0P<E-92\;(%ZQ.4!6N^
MY*&MPP[ >PG@MP#_.2!\ 1"T@."U&<(6$+XVPZ %6.FXT6X+EQ!%XDCP#1(F
M6K.9A:V^1>MZ%<R\DQLE]&ZA<2J>DT>TEF@.PKXYE@)*"IE2+FL!Z!C=W23H
M\. (':""H=N<UY*P3$98Z=R& :=MGDF3QW\A3X"N.%.Y1#.60=:#3_;CAWOP
M6&ONA/M;X1-_+^$5$2<H\#XAW_4'/>>9OAX>]LGYO^RS-V=_4HR@>P6!Y0O>
M] I^W9(%A=]]E][0AOVTIL>-9$52&#NZB4D0:W#BCQ^\H?NYK^+O29:\)]GL
MG<B>W$W8W4VXCSW^KH?%)4MY">CP&Y?RJ.\>&HJAI3"C81T?>YYW/HSP>K?"
M?6'N('P6EO2$^4'@GCX-F_6QG7O#LRZLT8MWNE,)8F7'@D0IKYEJGFCG;2;/
MQ!M-;8=^YD_T1.KSZTEU81LT_D??C#G]/UD53"(*2YW*/3G5S5,THZ,Q%*]L
M;UQPI3NM7>9ZVH(P 7I_R;G:&B9!-[_COU!+ P04    " #F@ZU:C_G;ZTP"
M  "2!@  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;)V56V^;,!2 _XK%
MI#VUX9+;E %2TFU:'EI%:;8]3'LP< "KQF:V*>V_GVT(RZ:$2GD)MCGG\W<<
M^1"V7#S)$D"AEXHR&3FE4O7*=65:0H7EA-? ])N<BPHK/16%*VL!.+-)%74#
MSUNX%2;,B4.[MA-QR!M%"8.=0+*I*BQ>-T!Y&SF^<US8DZ)49L&-PQH7\ CJ
M6[T3>N8.E(Q4P"3A# G((V?MKS9+$V\#OA-HY<D8F4H2SI_,9)M%CF>$@$*J
M# 'KQS/< :4&I#5^]TQGV-(DGHZ/]"^V=EU+@B7<<?J#9*J,G \.RB#'#55[
MWGZ%OIZYX:6<2ON+VBYV-G-0VDC%JSY9&U2$=4_\TI_#28+FG$\(^H3 >G<;
M6<M/6.$X%+Q%PD1KFAG84FVVEB/,_"F/2NBW1.>I>*N/-P.!#@)GA!5H+01F
M!>AC5S)TE=[!Q+EI3]MTM. ";8'N.5.E1)]9!MF_^:XV&_2"H]XF& 7>8S%!
M4_\&!5XP'^%-AW*GEC>]P#M7Y@U*7M&69>299 VFZ.<!)Q1^G:N^@\_.P\W]
M6<D:IQ Y^H)($,_@Q._?^0OOXXCZ;%"?C='C?4,!^5XRO_5/]=$ZX[7Z_[ [
MW7%@CJF$$;'Y(#8?Y3QP=GN%W#CT+;G%(+>XZM0.(/1MPA?<QIEON2T'M^75
M!S?N-\Z]Z.>>](D*1&&[H40I;YCJ6L:P.C3<===G_H9WW5I?S((PB2CD.M6;
M+/7?*;H.V$T4KVW72;C2/<P.2_W1 &$"]/N<<W6<F V&SU#\!U!+ P04
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M\U,1/PM^F]$&!][/#=_?;A$2]*_]_#]02P,$%     @ YH.M6FB+1O<7#@
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MI#)HDD[BS6$Z"*GJ.M-HU\!@'!L>TS"B,:[2'7*(2D%"[.Z.5WQ.\,HYG'=
MV4="L\="AU@A+L=6'U2J330U]6R;B+)H]E#9. 0,X!3S<&]8D(&^ORD3X::L
MWG?W-QZ6B:S0X7J;<Y+2-L$'XI,S#AQ(;V=R/N2M+EL"P$?J+L#[XHZ;D+"
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MG5&U>9UXF9&=+GY(DW'<]ADBKT0T(,  H&3UZWLN0%)2[;AI'RB1 .ZYYZX
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MYQ:(B6+?<NTQB2%WQN&S'UPBON&=\L/HV9/ &XM#:%8;B-KGVL6Y3AM$_-9
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MQXT(7JD:G/.1^G36+H8K"GNRYS6Y/2:TF 4R["R\I0-_E":_MC8=<O\N<TK
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MRK)3RGPZ:7KX6Q*H2@^!S%:Y:@M)63;)()F1![45Q9.C2=F 3,2LZ=1<TP!
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M^-I82HD:/0BU<H2ZY)5"%<=QKJ$>FU72?2&0I^X /4V\V4C(C^]ZP/\\\9Z
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M5OQVH23:*1W \YD%YJ</)*#[&Y"K_P)02P,$%     @ YH.M6D'?<NV= @
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M062[AO(?+,YETS4C-LQ3[#0>17YOU1O4<P"R#E;N7 F\1(A';@*D84FHTO
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M7"K:@.NSMC7;"2GHW_23?P%02P,$%     @ YH.M6FR ].LZ @  -@4  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULK51-C],P$/TK5I 02$N=I!^+
M2A)IVVH%AX5J*^" .+C)I+'6L8/M-@N_GK&31JW4HCUPB;_FO9GW,G;2*OUD
M*@!+GFLA31I4UC9S2DU>0<W,2#4@\:14NF86EWI'3:.!%1Y4"QJ'X8S6C,L@
M2_S>6F>)VEO!):PU,?NZ9OKW H1JTR *CAN/?%=9MT&SI&$[V(#]VJPUKNC
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M_-WF,2[^,?;MCF1/A.G')- 57%":!TKS06D!*&T!2@NA:$T?'A9R[?[[3I-
M5W-!:1XHS0>E!:"T!2@MA*(U+7E8(+;;5XA_;)H$N:8Z!Z5YMF81VM(.L)!A
M U#: I060M%*JYE'>PHRPE;%_A*.(CFZBO*?6W5IN8?EQA[/BZT>K\H#M;=%
M4^[98U]7?FV/KXL=(.8A;+F1Y@ZS59)SE)*E;()U-90=9N7>E/)$T$VQT^&)
M"D&SXG!-<$R8JB"O+RD5+R<J0+U#:/8_4$L#!!0    ( .:#K5J&.63 [@4
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MI="F +MA89HP2.M@UE="Z-W$"G1M/?D+4$L#!!0    ( .:#K5K0C%!Y(@0
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MAFOLQ:!L 'XOI33'B=V@[>[97U!+ P04    " #F@ZU:],:*_M<&  "[.0
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MDJ(T6;8$5,V/R$.JS8-&3UU5! GS(&&^^8*ZZ)D2QM$89?OB"I:WY+.N/!1
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MP:YBWK G&$>2!$.@%OTU&L?(ZL3P\>\/]I1$49+X$<#\#J((0^!IQ!', 7C
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M^2N\ D.Y%%K.'&L/FSW^8-B*MVJTO@IEM^;&BG+[@VW[<_#B+U!+ P04
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MYH.M6BX85!/Q    *P(  !$              ( !PP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ YH.M6IE<G",0!@  G"<  !,
M ( !XP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #F@ZU:W^("
M2/H%  "-(   &               @($D"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ YH.M6L9RMJ%T!   G \  !@
M ("!5 X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .:#
MK5I;$4H)T0(  *L(   8              " @?X2  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " #F@ZU:$?S=NF0%  #Q&0  &
M        @($%%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ YH.M6I(,V,IU!0  #14  !@              ("!GQL  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .:#K5KU<&V5B0D  -10   8
M              " @4HA  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " #F@ZU:)#<=38X"  #+!P  &               @($)*P  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ YH.M6H_YV^M, @
MD@8  !@              ("!S2T  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( .:#K5K!$D;&F@,  /D'   8              " @4\P
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #F@ZU::(M&
M]Q<.  #=)0  &0              @($?-   >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( .:#K5I(["M'LP(  #8&   9
M  " @6U"  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
MYH.M6I"H#A40!@  JPX  !D              ("!5T4  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " #F@ZU:C1#Z30\%   L#   &0
M            @(&>2P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( .:#K5H>J;HLQ@\  .8J   9              " @>10  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ YH.M6A1HRPMB P
M@P<  !D              ("!X6   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " #F@ZU:JZ#92VT,   /(@  &0              @(%Z
M9   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .:#K5I!
MWW+MG0(  /T%   9              " @1YQ  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ YH.M6B+]6/"Y!0  WP\  !D
M     ("!\G,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .:#K5J4=Q&JE0(  -<'   9              "
M@6V*  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ YH.M
M6L1$QC6? @  X@<  !D              ("!.8T  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " #F@ZU:T(Q0>2($   ,$   &0
M        @($/D   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( .:#K5H.4_QQ\@8  $\R   9              " @6B4  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ YH.M6C*H._2# P  ,A
M !D              ("!D9L  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " #F@ZU:H'(3K- "  #I!P  &0              @(%+GP
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .:#K5KTQHK^
MUP8  +LY   9              " @5*B  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ YH.M6G1$W(+^ 0  *00  !D
M ("!8*D  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #F
M@ZU:GR936CD#  #L$P  #0              @ &5JP  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( .:#K5J7BKL<P    !,"   +              "  ?FN
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .:#K5JP]34 " ,  * 4   /
M          "  >*O  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #F@ZU:
M9(35>E<!  "1$@  &@              @ $7LP  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #F@ZU:.6DC=8(!  !,$P  $P
M        @ &FM   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     )@ F $$*
(  !9M@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>90</ContextCount>
  <ElementCount>189</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>20</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimBalanceSheets</Role>
      <ShortName>Condensed Consolidated Interim Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Interim Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Interim Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999012 - Disclosure - Business Description</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescription</Role>
      <ShortName>Business Description</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BasisOfPresentationPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Commitments and Contingencies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails5</Role>
      <ShortName>Commitments and Contingencies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="e6578_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/SubsequentEvents</ParentRole>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avxl-20250331.xsd</File>
    <File>avxl-20250331_cal.xml</File>
    <File>avxl-20250331_def.xml</File>
    <File>avxl-20250331_lab.xml</File>
    <File>avxl-20250331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="e6578_10q.htm">e6578_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="337">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>49
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "e6578_10q.htm": {
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "avxl-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "avxl-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "e6578_10q.htm"
     ]
    }
   },
   "keyStandard": 135,
   "keyCustom": 54,
   "axisStandard": 10,
   "axisCustom": 0,
   "memberStandard": 8,
   "memberCustom": 12,
   "hidden": {
    "total": 75,
    "http://fasb.org/us-gaap/2024": 32,
    "http://anavex.com/20250331": 38,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 90,
   "entityCount": 1,
   "segmentCount": 20,
   "elementCount": 377,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 337,
    "http://xbrl.sec.gov/dei/2024": 31,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://anavex.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://anavex.com/role/InterimBalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Interim Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://anavex.com/role/InterimBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Interim Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-03-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://anavex.com/role/InterimStatementsOfCashFlows",
     "longName": "00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:IncreaseDecreaseInIncomeTaxesReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity",
     "longName": "00000006 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity",
     "shortName": "Condensed Consolidated Interim Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://anavex.com/role/BusinessDescription",
     "longName": "999012 - Disclosure - Business Description",
     "shortName": "Business Description",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://anavex.com/role/BasisOfPresentation",
     "longName": "999013 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://anavex.com/role/AccruedLiabilities",
     "longName": "999014 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "avxl:AccuredLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "avxl:AccuredLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://anavex.com/role/OtherIncome",
     "longName": "999015 - Disclosure - Other Income",
     "shortName": "Other Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://anavex.com/role/EquityOfferings",
     "longName": "999016 - Disclosure - Equity Offerings",
     "shortName": "Equity Offerings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "avxl:EquityOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "avxl:EquityOfferingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "longName": "999017 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://anavex.com/role/SubsequentEvents",
     "longName": "999018 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://anavex.com/role/BasisOfPresentationPolicies",
     "longName": "999019 - Disclosure - Basis of Presentation (Policies)",
     "shortName": "Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "avxl:LiquidityPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "avxl:LiquidityPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://anavex.com/role/AccruedLiabilitiesTables",
     "longName": "999020 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "longName": "999021 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://anavex.com/role/BasisOfPresentationDetailsNarrative",
     "longName": "999022 - Disclosure - Basis of Presentation (Details Narrative)",
     "shortName": "Basis of Presentation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "19",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "avxl:DilutiveCommonShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "avxl:DilutiveCommonShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://anavex.com/role/AccruedLiabilitiesDetails",
     "longName": "999023 - Disclosure - Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "avxl:AccruedInvestigatorPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "avxl:AccruedInvestigatorPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "avxl:AccuredLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "longName": "999024 - Disclosure - Other Income (Details Narrative)",
     "shortName": "Other Income (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2022-10-012023-09-30",
      "name": "avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-012023-09-30",
      "name": "avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "longName": "999025 - Disclosure - Equity Offerings (Details Narrative)",
     "shortName": "Equity Offerings (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "avxl:FairValueOfInitialCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "avxl:FairValueOfInitialCommitment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:EquityOfferingTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "longName": "999026 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-03-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "999027 - Disclosure - Commitments and Contingencies (Details 1)",
     "shortName": "Commitments and Contingencies (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-03-31",
      "name": "us-gaap:PensionContributions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31",
      "name": "us-gaap:PensionContributions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "longName": "999028 - Disclosure - Commitments and Contingencies (Details 2)",
     "shortName": "Commitments and Contingencies (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "longName": "999029 - Disclosure - Commitments and Contingencies (Details 3)",
     "shortName": "Commitments and Contingencies (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012025-03-31_us-gaap_StockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "longName": "999030 - Disclosure - Commitments and Contingencies (Details 4)",
     "shortName": "Commitments and Contingencies (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-03-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails5",
     "longName": "999031 - Disclosure - Commitments and Contingencies (Details 5)",
     "shortName": "Commitments and Contingencies (Details 5)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999032 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2025-03-31",
      "name": "avxl:OptionIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://anavex.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999033 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-17_us-gaap_SubsequentEventMember",
      "name": "avxl:SharesOfCommonStockReservedForIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-17_us-gaap_SubsequentEventMember",
      "name": "avxl:SharesOfCommonStockReservedForIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6578_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "currency_AUD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AUD",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_AccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "AccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:AccountsPayable]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r321"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation and benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "avxl_AccruedInvestigatorPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "AccruedInvestigatorPayments",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued investigator payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails",
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities - Note 3",
        "verboseLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "avxl_AccuredLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "AccuredLiabilitiesTextBlock",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Liabilities",
        "label": "AccuredLiabilitiesTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r424",
      "r425",
      "r426",
      "r427",
      "r465",
      "r487"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r142"
     ]
    },
    "avxl_AggregateCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "AggregateCommonShares",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate common shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "AggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r350",
      "r361",
      "r371",
      "r396"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r353",
      "r364",
      "r374",
      "r399"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r385"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r392"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r354",
      "r365",
      "r375",
      "r392",
      "r400",
      "r404",
      "r412"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r70",
      "r78",
      "r88",
      "r112",
      "r114",
      "r115",
      "r116",
      "r118",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r185",
      "r187",
      "r201",
      "r225",
      "r273",
      "r316",
      "r317",
      "r321",
      "r331",
      "r436",
      "r437",
      "r481"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r403"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r77",
      "r310"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r87"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Decrease in cash and cash equivalents during the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r52"
     ]
    },
    "avxl_CashPaidForStateAndLocalFranchiseTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "CashPaidForStateAndLocalFranchiseTaxes",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for state and local franchise taxes"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CashlessExerciseOfStockOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "CashlessExerciseOfStockOption",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cashless exercise of stock option"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CashlessExerciseOfStockOptionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "CashlessExerciseOfStockOptionShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cashless exercise of stock option, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "avxl_CommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "CommitmentShares",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommitmentSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "CommitmentSharesShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies - Note 6",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r66",
      "r227",
      "r259"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "avxl_CommitmentsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "CommitmentsShares",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitment shares",
        "label": "CommitmentsShares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommonStockAsConsideration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "CommonStockAsConsideration",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:CommonStockAsConsideration]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum number of common shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "avxl_CommonStockIssuedUponCashlessExerciseOfStockOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "CommonStockIssuedUponCashlessExerciseOfStockOption",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon cashless exercise of stock option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r424",
      "r425",
      "r427",
      "r465",
      "r486",
      "r487"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r260"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r41",
      "r260",
      "r279",
      "r487",
      "r488"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 84,985,449 common shares (September 30, 2024 - 84,795,517)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r229",
      "r321"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r312"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DeferredGrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "DeferredGrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred grant income",
        "label": "DeferredGrantIncome"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DeferredGrantIncome1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "DeferredGrantIncome1",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income - Note 4",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanDisclosuresTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of contributions under the plan",
        "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r304",
      "r305",
      "r306",
      "r307",
      "r322",
      "r324",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r63",
      "r250",
      "r251",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r304",
      "r305",
      "r306",
      "r307",
      "r311",
      "r322",
      "r324",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "avxl_DilutiveCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "DilutiveCommonShares",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive common shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DisclosureAccruedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "DisclosureAccruedLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DisclosureEquityOfferingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "DisclosureEquityOfferingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "DisclosureOtherIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r345",
      "r357"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r103",
      "r105",
      "r107",
      "r108",
      "r109",
      "r111",
      "r180",
      "r183",
      "r196",
      "r197",
      "r224",
      "r235",
      "r313"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r105",
      "r107",
      "r108",
      "r109",
      "r111",
      "r180",
      "r183",
      "r196",
      "r197",
      "r224",
      "r235",
      "r313"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r110"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining stock based compensation",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r75",
      "r82",
      "r83",
      "r84",
      "r89",
      "r90",
      "r91",
      "r93",
      "r98",
      "r100",
      "r102",
      "r113",
      "r119",
      "r120",
      "r121",
      "r139",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r216",
      "r234",
      "r238",
      "r239",
      "r240",
      "r248",
      "r300"
     ]
    },
    "avxl_EquityOfferingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "EquityOfferingTextBlock",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity Offerings",
        "label": "EquityOfferingTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r350",
      "r361",
      "r371",
      "r396"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r347",
      "r358",
      "r368",
      "r393"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "avxl_ExerciseOfStockOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ExerciseOfStockOption",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "exercise of stock option"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ExerciseOfStockOptionAndTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ExerciseOfStockOptionAndTaxes",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "exercise of stock option and taxes"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ExerciseOfStockOptionAndTaxesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ExerciseOfStockOptionAndTaxesShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "exercise of stock option and taxes, shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ExerciseOfStockOptionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ExerciseOfStockOptionShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "exercise of stock option, shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "exercise of stock options",
        "label": "ExerciseOfStockOptions"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ExerciseOfStockOptionsShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "exercise of stock options, shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ExercisePrice",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ExercisePrice]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ExercisePriceConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ExercisePriceConsideration",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ExercisePriceConsideration]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_FairValueOfInitialCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "FairValueOfInitialCommitment",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the initial commitment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r297"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r354",
      "r365",
      "r375",
      "r400"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r354",
      "r365",
      "r375",
      "r400"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r354",
      "r365",
      "r375",
      "r400"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r354",
      "r365",
      "r375",
      "r400"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r354",
      "r365",
      "r375",
      "r400"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r283"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r198",
      "r199",
      "r200",
      "r236",
      "r237",
      "r284",
      "r309",
      "r319",
      "r485"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r198",
      "r199",
      "r200",
      "r236",
      "r237",
      "r284",
      "r309",
      "r319",
      "r485"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive and tax receivables",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r421"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Incentive and tax receivables",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in working capital balances related to operations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and deposits",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "avxl_IncurredExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "IncurredExpenses",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r354",
      "r365",
      "r375",
      "r392",
      "r400",
      "r404",
      "r412"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r410"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r346",
      "r415"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r346",
      "r415"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r346",
      "r415"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, net",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r429"
     ]
    },
    "avxl_IssuanceOfCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "IssuanceOfCommonShares",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of operating lease costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r88",
      "r118",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r186",
      "r187",
      "r188",
      "r201",
      "r258",
      "r314",
      "r331",
      "r436",
      "r481",
      "r482"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r67",
      "r231",
      "r321",
      "r423",
      "r433",
      "r477"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "LincolnParkCapitalFundLLCMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lincoln Park Capital Fund L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_LiquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "LiquidityPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r172",
      "r318",
      "r434",
      "r435"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r172",
      "r318",
      "r434",
      "r435"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "avxl_MichaelJFoxFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "MichaelJFoxFoundationMember",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J Fox Foundation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_MilestoneBasedContractAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "MilestoneBasedContractAccruals",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone-based contract accruals"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows",
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r54",
      "r68",
      "r76",
      "r80",
      "r81",
      "r84",
      "r88",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r106",
      "r118",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r180",
      "r183",
      "r197",
      "r201",
      "r233",
      "r281",
      "r298",
      "r299",
      "r330",
      "r436"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "NonOperatingIncomeFromGrant",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non operating income from grant"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_NonOperatingIncomeFromGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "NonOperatingIncomeFromGrants",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r315",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r320"
     ]
    },
    "avxl_OptionIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "OptionIssued",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "OptionPrice1Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "OptionPrice2Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "OptionPrice3Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "OptionPrice4Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "OptionPrice5Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 5 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "OptionToPurchaseShares",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:OptionToPurchaseShares]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/BusinessDescription"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r62",
      "r243",
      "r244"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "OtherIncomeDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Income",
        "label": "OtherIncomeDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Incentive and tax receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r268",
      "r317",
      "r484"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r352",
      "r363",
      "r373",
      "r398"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r366",
      "r376",
      "r401"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r366",
      "r376",
      "r401"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r380"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_PensionContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionContributions",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contributions to 401(k) plan",
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r138"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r260"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r228",
      "r321"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance or sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r246"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "avxl_PurchaseAgreement2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "PurchaseAgreement2023Member",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_PurchaseShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "PurchaseShares",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_PurchaseSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "PurchaseSharesShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r347",
      "r358",
      "r368",
      "r393"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r140",
      "r217",
      "r218",
      "r226",
      "r232",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r278",
      "r280",
      "r303"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r140",
      "r217",
      "r218",
      "r226",
      "r232",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r278",
      "r280",
      "r303",
      "r480"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development incentive income",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "avxl_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development incentive income",
        "label": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r309",
      "r316",
      "r483"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r348",
      "r359",
      "r369",
      "r394"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r349",
      "r360",
      "r370",
      "r395"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r356",
      "r367",
      "r377",
      "r402"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r58",
      "r230",
      "r241",
      "r242",
      "r247",
      "r261",
      "r321"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r89",
      "r90",
      "r91",
      "r93",
      "r98",
      "r100",
      "r102",
      "r119",
      "r120",
      "r121",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r189",
      "r191",
      "r192",
      "r194",
      "r195",
      "r213",
      "r214",
      "r238",
      "r240",
      "r248",
      "r487"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of principal components of accrued liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16",
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of general and administrative expenses and research and development expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of summarizes information about stock options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r59"
     ]
    },
    "avxl_ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock option activity",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation",
        "verboseLabel": "Total share based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average grant date fair value, Outstanding beginning balance",
        "periodEndLabel": "Weighted average grant date fair value, Outstanding ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value of options vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annualized volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional shares of common stock available for issuance",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option available issue",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, Outstanding beginning balance",
        "periodEndLabel": "Aggregate intrinsic value, Outstanding ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, Outstanding beginning balance",
        "periodEndLabel": "Number of options, Outstanding beginning balance",
        "label": "Number of outstanding options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding beginning balance",
        "periodEndLabel": "Weighted average exercise price, Outstanding ending balance",
        "label": "Weighted average exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price options vested",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169"
     ]
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices, lower range limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices, upper range limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "avxl_ShareProceedsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ShareProceedsReceivableMember",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Proceeds Receivable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of vested options",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average contractual life of options exercisable",
        "label": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average contractual life of options exercisable",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "SharesIssuedPursuantToExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "SharesIssuedPursuantToExerciseOfStockOptionsShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options, shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesOfCommonStockIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "SharesOfCommonStockIssued",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:SharesOfCommonStockIssued]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesOfCommonStockReservedForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "SharesOfCommonStockReservedForIssuance",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of common stock reserved for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning, shares",
        "periodEndLabel": "Balance at ending, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesWithheldRelatedToAndTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "SharesWithheldRelatedToAndTaxes",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "and taxes"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesWithheldRelatedToAndTaxesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "SharesWithheldRelatedToAndTaxesShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares withheld related to cashless exercise of stock option and taxes, shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r41",
      "r44",
      "r45",
      "r75",
      "r82",
      "r83",
      "r84",
      "r89",
      "r90",
      "r91",
      "r93",
      "r98",
      "r100",
      "r102",
      "r113",
      "r119",
      "r120",
      "r121",
      "r139",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r216",
      "r234",
      "r238",
      "r239",
      "r240",
      "r248",
      "r300"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r113",
      "r214",
      "r222",
      "r245",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r300",
      "r325"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r113",
      "r117",
      "r214",
      "r222",
      "r245",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r300",
      "r325"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r351",
      "r362",
      "r372",
      "r397"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issued for offering, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r40",
      "r41",
      "r58",
      "r246",
      "r300",
      "r308"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r40",
      "r41",
      "r58",
      "r152"
     ]
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "StockIssuedDuringPeriodValueNewIssues1",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of shares remain available",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "avxl_StockOptionPlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "StockOptionPlan2015Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2015 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_StockOptionPlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "StockOptionPlan2019Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_StockOptionPlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "StockOptionPlan2022Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets",
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r56",
      "r262",
      "r279",
      "r301",
      "r302",
      "r321",
      "r331",
      "r423",
      "r433",
      "r477",
      "r487"
     ]
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r220"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://anavex.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r221"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r71",
      "r72",
      "r73",
      "r74"
     ]
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "ValueOfSharesObligatedToPurchase",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of shares obligated to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ]
    },
    "avxl_WarrantsOutstandingWeightedAverageExercise": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "WarrantsOutstandingWeightedAverageExercise",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r109"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r109"
     ]
    },
    "avxl_WithholdingObligationsExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "WithholdingObligationsExercise",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:WithholdingObligationsExercise]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "avxl_WthheldShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20250331",
     "localname": "WthheldShares",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:WthheldShares]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "70",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0001731122-25-000724-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-25-000724-xbrl.zip
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M%Y\JS>?4]9T:?W/$7=U6P.UX"JH2,*#E39:6A+YP,Y30V'!4Q-&M-U;PS=-
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M9&W;(=J+I+MO+O4'L;\*Q2Y8DD8KO_P3=;W@'C!M;D%Z;9L]:VLUDOHTO=$
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M$RB6_F[GWB>=(#94/_X/4$L#!!0    ( .:#K5J\NH'K0 D  %!E   5
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M' BA6,BISQD<"B50"W3,SR%BETF=;Q7Q'&J(+VWHR+6:&#\'H04-*6F;77T
M%,.A&ABDY-M5@KQB1\AHLS.&^56 FN10!4,,("4HB6G4T&/YB3Y!%'%(/1.)
MLM,\P0__CA^U^9)P?C6AH3D4Q0@$2!5J9AI9-&#$T8C"@PCCDJ3KB#Q>I[&E
MJ9"!?J6A(SK4QA@%2!P::AIU-&AT?7H8LB6YB1Y.$RK4=)G6^T L*M'B_8K%
M0GNH&0T8D'3,##4*HD9H:!522&P[$=D40KC#8;&E#O#QL$CT/12+E5]1.65A
M*"VC"2"!N?#4R&Q@>E#'I*""76++$T LA2"*6R0)_5!E\S]G:8[?:O.OQ/I5
MEX'N4%,*(" EZ=EI]-,@#]H_$+-!%SD4T;R;D-5WX47SSE4T[T"+YMTNHKGY
M5@ 1S?L)67T?7C3O747S'K1HWN\D&EKP07W-(?WS@MP4WU3!V5ID$,G(5)6"
MZ6'PY")QLXF%&;#^##,)*1/>L;H@EZ2X3_-8WV76P8,(1D-:J9H1%IYTU 1M
M^NDZQ*U=4%]3=\JME:2%A?$R0Y)J%U-CX(ED2,SJ7&IT2$E<%F459?\WW1@'
MXFIP$'DH"2M%,D#"DXJ*GDTPM0VB1B$&UHU<V8*&<BO9Z+F_+< *6OT68.$A
M"!&H&,E;@.O9DQKDNYB91@F.-!YA^-A;(2M(=64L/(-1Q#(AJ81YO::8$!69
MG>J47=X5N3Y 0(9XNR1*0ZZ[)6KT'$2):TA)M_X4/-:,X0+-QC]4."_5[EMX
MYJUE']/I&O+V 8C2';.1CU=NGGLNS=](6M$W'Q;K]39O5GE4<8,:G*]2-M)L
M2UP) E'Z)F9C)318- 1[EL5UD:5Q6J7YZC,=?)(T4N5*!?(E"#W!5@TR H04
MM+2D4WLZ(&J1GD5P23 3(:8%P3<!8G:,_,5RJ6SM36!?HK 3;L6A1X(0B96>
M=-L;P:]BP0+5)HC;A)7-:5EN,9DD'H5)( EIR6N$).$ARDE'TBJJVC"DMJYQ
MO*7MX^/;=[<W:96I!I<RQ%N;I"'7M4BCYR"TH2$UU@)_QD[U??ONY>T/J+7R
M7/SGQ0V)$MHD7C^N;XM,<_J4$N5+! :*K0X4$!!2T/,:J^&\0 T4U=@0IU,-
MR"JR,WKN2P!*6FW1#QZ"*'05(ZGR#\HZD,L_?HCOV*5#F@T):IAOUZ\B.7;_
M(@:$! S$I$%) T4M-L2&A+[)6MD[ :M@G8"5I1.P@M@)6+EV E;!.@'M:^LC
M0JA?NKC-TE6D.9S0B/8M"@/EL3X44%!2T?/3^HS.!/4VOD^TY$><G>;+@JSY
M^T_H'XI<:G#>SK0TT>P.M52!0&C$Q$PZUK(^=$X (X;VK8MMDE8XJ<F<I'F4
MQVF4=<<CJF;$[2;>U.)(OA..!0]#0VXD)3G59NU9AIUA?]2E[ZGT.@#C-YQE
M_YX7W_)K')5%CI-Z+D6U4F3&^XV8L= >!LUHP"#DY,)0$SK#C%Y]95:H-6MF
MPH(HZ=<BV^951/A><J+R3!J<7^5H: X5,P(!4HJ:F48A'1C5Z# ;M.O3([I.
M%G-XRB-@S'#/V[6-I$>[MI580)HQ$M3MX6[._.C[QK55H"V6%6;W1:3W^"BJ
MHH:;-K\ZN.]-E2;2X]V4*BP@"1D):O=/=C;LJ)BHU52P(V/((>UJK0I#E/@(
MY?_@&(FB?'9,!P$D#Q4OPPDR!+78(%JX7D=9]FE;ICDN]0W1".57"TJ*0RT,
M(("TH.*ET0*'HA8;1 O':TQ6M'G[A13?JKOF?%9MWC1HO]HP4AYJ1 D%I!43
M/XUF6A-4V[1'ZH81ST-_H'A]RJ(^IPJH9]EHR8XT(^$@"49'3E)+AF,VWW)>
M5.BF0%]*C*H[=IUJQ8)$$O$D^#J=4#>-Q#';$%'WRO,D(BH)F<#>;QW1$I;N
M'I&0((1DI:>_AZ2S0*V)9]5<4 T3<1S'29Q6>*W=[6 W\:4@5_*MCFQX$&IR
M)"E==,_,AH-K;HB89<C3C,3#[?5=O '(<\]807#4,180(#2BI:7K%HMW!80Y
M.V][FZ7Q259$^EF6 <;SB7DRO=%A>3T D )D5KHC\C@0<620\O\4Y5_)=E/%
MCY>DB#%F459EYZUL\V^.UGXU,RE+0S4YF0+2V12^&@7V22 AC0.AQ0HYF<>"
MQMEI;D7\]?HNHA_P8EN5K 6EQ/2SX$8CS\L+#AD8+3(8+ !)SX&F;L&!6R)N
M>H!J8R18!QJ?E?TI@#CY]'B%EYBP?0<W^*'Z1%_TU3#"<+#U/7ISSLYX,&<U
M!"'"J6QU0[T2B0F@6Q8CUB2!?F>)()[*?N\O7T;E+<_GMGRUBJ)-K4R<567[
M2R_1YH<_NNB1BV474G)9U!,;FAOMIYGZ$.@NF6'ZG&(77)X[D)4"%EM3%NK:
M1Q"UUNCWUCZ\+A=EB:O2HL QR*?6U 1%50T18/2CI"5%FW$0$!4T/44G,4A8
M_YK0T)6E,0("4XB:G>9JE^!*.8S*NT6>L/\Y_MLVO8\RU@HOJL.(D$?:^_LU
MRK;C_103;7TJ:5)V1&4Y&8)1VA2VDO*H$:)=>Q2S/W!O'ER+K.NWQC?1 Z:#
MYAA37K?27AX+UJ?6C'1%;2F!8+1D8C?6#L52I;"X(B:@*GI I#,)KY]+@C=1
MFAP_;'!>8EH_^&3_P"MKOH&3I4]M3<B*J#0',S"Z<^>J.(: 62)<FY9<C 5?
MV(F;Z,D(4C_,V%T(T=/2=ZV\JJ,JJB@[LW:H='L/F34"TN$^2Z/;-*.C05Q2
M)?.YM+LB2S I6?M</5KZX.[F/L4R-5.BG%QMP;BCB82E4_AZ<^Z.Q 3^US_\
MZ=W;?_HSJA."I%6W$:+)() >'<:*>C1$S4T:-2+!,+B<FN"<\C)Z9-U <T=+
M!_;:!AH)#]I$)1*,?(STI)FI!HPV-1J";L@6)W(=T.=6A_>L'C/MD8#48$@:
M,C)4R(CA42:T=Z]8L"=&[X-+ZHBM%1&<U$-:LYPT6)]2,M(59:0$@I&0B9VT
MSM=@T8I?7IMRDU9 'X(+2*@&]B8[6.?'TMN!-8:3B:D'<I"Z-"PD(JWX>C2;
M92UXZ#'.8[TLC!9>)\#MU ?3WGHX&/]BYRA?==!9\,'8P*;U-O\87&:7I/&&
M?+!H6FE1(CW/1^JHCN8?QS P,M)SDU=(-BES224#HL6VNBM(^G><_/SVS<&;
M-_P_:-.F5J,.:+>:H'N6*/J?;WY\\^8MVF""2A9-%5QG0FR8<3E/@OEV7"J2
M8V\E8L!H2T/,65COWO3*BNMX/*NLT)\^''S\TT\''SY\[&SJX+V7U_1;8[:3
M ;U_<X"8'JC3H_!_^OC3P4]O_^F'X(I<) F/G(FRRRBE'<?FPPB?43=<<3#T
M.AITSLA@6&BU J-L9ZK20+$S1&RQYE6:H[BV#:Z^*UQ%:8Z3XXCD++J:CFFW
MZVW&(@[I^(2=L:_Y&"Z&/M7GGA%1?78K,.ISIJJ8IFB!**F1P64GKREH<JT"
M^@T'U1$=!G^.4; &GEI^ZO'G\UBP42Y-[;BB!6LQ<9=%1%B"<V1KG?Z OGXX
M'$C5&T;ZOJS3Z$LV"C>8U65 /ZX=6X!I+IUH*J)IAB/99A01=8; %'<9D0O"
M0_(3/MBZQ(1GU>FCZ(W#*="6(;T2=99 %6FA:U5F-Q@.KDAINYW5 1HM DVT
MN+@^ QR,RNP<53/$_20+/(\GY&BBNW.R#*2W*8[.P0RB_B:ZN$/U9!\D_=4U
MBI]O[.S;6G10OS:D;/1I-12BGA3\G'Q9RBW@Z4A_8(";25!%:0X+<,'#U9;]
MH "EP(J93@C8?>-0MTO7$LZJ1?O?/*2E+&\?DJ!@%&7FI]A"Q$)^^BW5@#9/
M7VPPB5BD0+,IQ;:/VH#WJ24K;5%-6C 8/=D82D>ZM?AN0U!P(?V"<\HI6^3)
M(EFG><KXLVUS38XT&;=:^1258Q9$:5E,P C,C>=89HT5GYV-!G;!Y7:%2TR_
M)=L2?(3O<59LF&<UB\UBXW<9TX'^< 738 !&9BXLQR)K;;C*DMXJN,0DI^SJ
MO ,WA4Y-(*QU)!T]]<)1 :_UZS)0]_7."NFP?R,RB%YDJDK%]#"@FI$(ZGM+
M6;'GH_]WT<IYD1=#[NV&<'/7V\'.IXZ<LR&JRFH$IBES9:H^;;G9Y?&R<5!/
M#C^,[A\RIJ2?WKQ__Y:KB?W"2(ZJP0DMHU_81I.Q_W' ^U"/,VVF&BLXN%I<
M&4H]:V$OT$S:4/?%NN-,:J*J[#@:>E/+I(QTLG&R@J&?*51=>\],6\VY-?M1
MV1YF+"M,/ULU<*;G6#]EJ8/[G;,TDQY.6JJQP47F2%">MJSAC8 .4([##\I.
M"H+355YON8P?^=4J[-ZW(O\E2G/6"?R$EQ1S$SUHOL*D%'QJ;8>LB?*;8 Y&
MD=,YCT7:I$!'@O$=_1VC%35$+UE'/_R>#VT?<FJ?$TC/?E*/'M9HT493,],@
M=.9A^#_JKJU3#".,5^FHZ WD(@* 241!;2P+BN&3"/5IDL5Z0_ =51'K9H&8
M6VAWC;0Q.)8I!3W<IVALI$7]Z+!@FC0+096@F-X [9T=Y^!35*:Q8VX;;$CU
M#.B:I,.!8'4CLK.+Y@!Q/#CM'*79MM(&T6G1(?4SHFQ24 ,%JZ$A/Q<5-1;!
M=?0;[=3?42*+>]IG6^'ZDKJ+I12^96G?IB?C4WF[9E*4Y-0TP&AU1^)C$;?)
MH*A.!^4\(79K!<"H/==,FYK<B6E %+2VB9Z4P+.3LJE)GZ1C**V])N--(^(:
M_3PY%0"2MF710=2Z)*#+VL+[B<*&T@$1KDYBMT><9,4W6VBLV230Y59:\II+
MK20\&#DZD#1>8L4O >%6D.*O:2><$;LDQ7V:L/OCOI3L6,EN/7D15^E]?4@I
M/]%M2W]K'A:Y39'[2MSS#.(>/\AHZG$/*8.I#WO-CO+&G+JR;&FR*,U1'T75
MIVRJ/G!FF=]!*C,%+]TD<W#GM$C^<UO6ATJ>TU*AFF!7QI<WQ15FI91F>)"A
MF\)1D+;KV69_K=_STOQ\Q.%I:_.^$TR%\I11^:2W[K6H*MB-4/7+V!)AO3Y$
M?V5_\PO'6@]:=-[WY^!5NYUCQLEAL68+H9R8KNNE 7OMTQH)#WJS2B08R1KI
M23U8?NSE+4/SY<86'EP_M$X13&D=X?I_A5K4G)=HWY+JG(#G7:H3,S;:N.IH
M#4:/DRE+?44>>%,R#_>M(%]9#[$Y]I(*ER)C^HS@^F!"ZA8A>4$Y[Q,O9'2S
M#JO?*9<VNICZ4>['6KDY7C'AF.(VIM%^7O<[RGD;WB'H_$G&9F$EJ<Z$68M#
M&_@B5/)UNM<QP1MVS3I$]8WN7W+^&))=6/UILF$6X,C(:P-^C\EM4>)I"E03
M!G]+EC(CHQN;IGP#R32X]C29L<IO9 >X"ZDEZW"YUDS[H=I[F/C6*_WN)R7,
MVUXG \EN9Y," Z4UM/!SNAHKN/]QGUA_\LP\U*65IRV?@ OKGL9;-1VOFL>C
MX]S(:24DI&I/TIR.P&=:2)R<. "U[_A!'&K"Q)3!M-Y[S8YA(7'3O #=/J(N
M<<?%Q">T^^P@238)=;%LS@'D42>JADN']-;ZFZEV'0 U++B>[-RDN9<&S,(S
M!O<Y!?>FM#+$&"<EV\C/#XZ\V'"U'S]@$J>EX<Q_JYW?0]<=LS$\;]UB%%QI
M4YG*LRZU'6)?"^$&S4/2^#5E19U,<!6Z>^8GNW:H;?/3VM]GT1/5\];V1,6F
M]&73+?T!+;M&%5"_E.68_8?=Y'(?96S)_ K3+D,:TS$D>[#(D^$/ O(2D[1(
MQM,+QP]QMDWX:6'UIN\K.AX]7BZQMO_JFX37(YN#?.#!(=!>&<"JTT'R+L^C
MU):(WSA8UH?!\#]P_S*4; GS#=4=9CN^Z(N?MV^8HT">4<W=>T7T6J]J 5Y7
M$:EFJUVF$:FJ@AR@6[Q*<[:#DG4%[77DOXXT_$;0UE_^.#<NN.XG0Q/$@>FO
M3K+P$[^WW6PROK<ARMKM$*?YLB!K/BUCVZKB:NTUPF]:E@8A?VZF8 :NT_A*
M08&"=;^M!0D)S#25QD<O49J<%/5]/[2*G5'S[(30<<<='4+SD!O5M)"KI;>I
MMFE9Z:;>W,R"ZVPZ5Z4CY*$I5%2H9/;<+S*Y9&C9)L$"IF:;N17N;:EO _JR
M*7)&+,-E-\=SL11F?I2?88=4_,EPYRSVDIR<!!!Y[LK;=%=/<PD4VM*T>!O.
M$M/.\(5OQ=L-BC>&:*HQ*,A.TAM=G-00$5Q:1EKZ_:&_<UCX[: =H[,TQWPK
MBRU_ C"(,"2B2G%T*'@"&5,SB(1!$<<:E3+K9]_QGOH0(SCK\-[ <UP*G[JA
M>;.GX #(M9&NIUP$/L?"Z:2*L&=1N(K&\>")3[5.4%3U\SH'>UI?UG18+VF6
M[Z(2ZT,,Q@AO'4TUM:X3.7P<W$GK.4E+N0W(9\&Z%F_@0G8J:K@%/J789Z[7
M;(21\NV^^J*7,5X'D2IZ@R&B"(!1W!I6JN%=#?-;R.Y%';S '8L=<N%/D\#<
M]7WR'!.4Z:1I,T?/8))HA_F@V:=]=E&-P9NXF,%0D,[/V&V>@9J,'LBJJ9D]
M4DWNM[2ZN\-9<E7OIK\I%GFB77*QFGC3E"/Y3D\6/ PMN9$<ZZC98QY*)WHO
MY&@(13,:3^1D]2ST8_1&]4/TK3$63]>P.BK42="+RZJ7=NAPC47Z5S>%TO4:
M%.EJ[UF8T[(UTJ>;,2293F(\5NML\?4:X;E+++B8'&4#0""& PCL%$,K8HJ(
M;4WDM%1 NB5CXSDEB>?GHER:U2:$8-,DQ5I5K6!G;D.G2A2(&"?)#K[ =I 2
M*,$XYRFT1-RT 5@4$]7@4P03G08,GS'%98#W&#LYC!#^PC2K9#$(*Q?MC)(1
M#5@REMDD^Q@_A&PF>II@4TP3,N$F)/ >R&ERR=_$T3[/I[\I%DF2,IY1QH+>
M3_/F\%J>U]OQ<<M7;&M/F5;X&I/[-,;U3DQV:/@JYZG\RH++1A_6WVL#G4\_
MZT?4G$\_RSNA3(UXSN\^3@^?,P9QU^#5]_"V'QI8CDOAF$<I3HA;G;,(=@L#
M!;C_4T_2$ B*FUO&9FB_2AS_N"KN7^,X:9JN..E;+/J//R[O-ZIM'L-'/CR_
MB@PK?_'WX+T8!1DI"#!Z1/<EHBZ1;WQD97R4EG%6E%OJ]N;8TF$O9-KOBK?L
M./'#J,*K@CPN'M)Q7]B \U7\1IJM%I0@$,(P,9/<;XM%+1C]SN"^E7%*?<]]
MFFRC3".),<"7%M3$6A$,GX(H?24E^5S_%A2FN&F7[Z9@/3E-:8^>^RIL):VV
MK </012UBI'^,B:V5"-VGL.4_&<<L09(4^Z#I[Y*74&I+7/A$8@2E_F,R[M!
MA"G<MDMR@Q^J3S3!KX9NBX#QW:V3Z(W[=QT 1*'K6$WJ\1V@F[W?7V 7Q&%Q
MC3/,SIAI='D>20?+&W"^A&&DV8I#"0(A$!,SQ6Z!390_HM8"M0Z#V7A6!WME
MTO5 +Y;+-,:D/,E-[L/!QI=JG.FW"K(:@%"3*TOI_$UFA_H!16MY@$Z*HLJ+
MRK>\+C$FOY!BN^'1+S9A&='>6B@[Y:ZMTD-!R,C.3VJ_J 7B)JBQ"2:=^M:^
MI,N#63I&M+<VS$ZY:\GT4!#2L?-3W[*8H%Y" ;U.<</.1>7CLO7XC#DEPI]W
M45+K/<K@,0@IJ#E)GN/X G'8<("[6+.[N_R7_R*NME&6/;(5+*,,E$"/:C 0
M%42A0$'1AIZ:2B(M&C$X *GP^1N:"\;$W,)HD5YGQO14!W-D,@R$7,S<#/-F
M-P5BZA'U$JQU.2]RFH5SJOS[E:69T4.]#9 L9+MQD08'0C86<M(HJ,A?,;6<
M,W]SCTFTPF":)C$K/!>"][1K2&D10DH&ZBI%*>#@A*7GZ**OH;(&C5RX=JW+
MGF/KIL=[;>-LM <MG0X,0E\N#,VK1:+6!AH+U/C5H40LIJL^"+HLMVL>?7F4
M+I>88%JZ9J%-3<!;P,%.&>LB$299@]#F3I2EV 6>".I207TRJ$\GW!S2R*?_
M6O)^  _-JF/CKBKSM-+$!/RMENR2L7X998HU"+7N1%FU\*)II._+'YL^HI D
MNL+5ENSW%.9=1'N.FVN*ITE5919.H/I,Z&4IVP 5HY;H1 FR"]1.]W_+]"ZB
MDU8TIXG/9!Y.A/9,Z<6HMP4J2BOAB>+4K5M[EJK"\?]:=@L5)I4Z6_H2Z,2L
MM-IT- ,ARVE<QXK4-<GHUU)8: KN*R^J.TQV<I,:RW >TI@5O7-4FH$0X#2N
M$UTB3RJ4'XQNMUE$SM*RLD;\&;#>?)V-;N?==$ 0<K*QDSQ8C4?,($P H,(#
MJV>:=<" K:%B7EF-@J$-$S7GIBW0DGG;(KNJQ6KA/6#+33\6. @AN7$T!&\]
M05PSE))POW@]N#TK2MW%Z3W \ZY:AUW2:GJJ2]!K&'K)@#^$#OA6UU\U+%BX
MMZ*FJC @JJ>!F'.L=Q OS[NK;'."41E*E"]A&"BVNE! 0,A"SVNLBGK8(.X2
M:4P. JX6Z\-8AH_][P24)2 ^ U'V"D+NVP #E3I;E5;O!>J>> R$5.WW:7X&
M4<)#+JK8Q@#;=\Q;NH)LY#)LWX*V:<N^52O$CJPB_X5V-AMN1[B,2<H7U(U;
MLAR,/,:).69 "!6S6("0BS--5<#8+XO%9=?Y$VR]M_3MV4X?WKR[[_>FFF/#
MK#;^^@2.]/N.@L4 A+)<6<I=BM8.4<.7]S\(NXU]=R;R,O^4+ZN2=G,LN_QT
M2&^=#3/5KO.AAH$0C)F;/#&4EVS]XA/.\3*M2B0<]Q8L-NN8$-8'9B?%W6/R
MJ#MY2@WS%A5H(-G%_BDP($1B(";%\1%2Y+C8EMDC6GR+2()'FW/:1 *=6G6%
MR_:6ZR/ZOYJC2Y0H7U(Q4&R5HH" $(J>UU@G I)V8BI,UFE>"X09ACGQ1&0O
M4F*,+)F5X2'4HB.MDLT8"TX_&H+3A.2[4[Q:58VSU$R C0#>NKM*8EW?=O 4
MA!*4E*1>ZVI%\(KYBZ[9 ; SJZ5-.]./95H:]S!HH9[[)5JRH[Z)A ,A%@LY
M;1]E));&W+-<KJNOER2^(#<E.2ZK=,W)?,;579&8I.-FYDM&4S+12LK%!H2\
M)A"5SJ7FQ\I?DC3&J"#HYOH*]4F@.@W?2W?]0<+6YLJ ];:,9Z/;+>;I@" T
M9&,G+>SU> 2SF1.R<5Y4_X&['ALV^BTWLP#](FLF%+TEK0T(S4T@.KEG11-$
M-$74)^E9?B?T&U!B[73":9YHUJYT0%\2,Q-M1:5&08E;LC($L-PUXG>TQ>QJ
M1*98?+$\SI<%_1QLE*ANZ299!Y*.2Y8T>C*9@O!5T_F.)=>DT$\P)EO,XB.:
M5-@E/T(Z@2(E5-G\-2TR[E0OEO]:K/$AHT4>SZ)O[DHU)Q%2KBZ9,VG69 ]6
MN ZD7=7;)<7TRQ)#36J()@=(Q$=I^;=ME*7+-&YR?A,]M,M$[D*V)Q-2S*Z9
M- G:E@9843L2=Q7V.#FF;YI@M[0(0]NT\:"Y:?)[NMZ0**XHX=LT2ZM'TS!G
MQW0"J7M:-C7R=DL$HKXG,;<)_  )R3%5CQ,,-]]C'RR9P %F?"R#)CT2TL#)
MRA+ X$G!T6E64 ('%(E]7G"$!.&*K/3,&XE#M)'B*FV!R_.BXG<WDLZ?FAK&
M*<8AUM#=,J1:43=;@A#;9+JFU?:$IH#RHD*D3J-K 7U/1+,PH_(PHR[XIOB<
M;U(6NJB+ C.!O4TZ6PEW4\U:) @Y6>E)T\K< '$+E.;H)EWSP<#G\\M3(>*T
MG"4X;*=[EQGA&_H"1:"8!N/U1F,5O<'UPR(@N&9,K)1200P4Z%8[SG&]ZF1M
M6M/28[WZ%!/=@4M1 8.KPX6=1B7IFJV3CKQ(*,%80S>T2.]B,0=H:&"PA.(4
MAC&428BHBY;O)<%)1=9Y<I)%*T.^1CC?RE#2'.MB  *E"A4SHR:80:B5;-'G
M'>9E0FS:& -#M#$R454#TZ- R4-)S=ZT'!9YF2:8!%/(OQ;?>NHN+8S.P+=B
MS,3'RE&C02G(2-&DI -$30/+J>M<T=%7<E+P *%?HTSC=8QH;WO![92[O>%Z
M* @)V?E)UP /^[5\U)R@94&&(5GL[/0@G5[E#(#5/=FLPL_&F!V5V02$U-QY
M[CI1$^8@0F6^](M:9GA0G6D6MDQ82$M;#CP!+&YQEE_RA&2/JVL<;TE:I5@3
ME&+ >A6*B>Y )2H@'.=C8#<6!H5BBF6][1X>0BG'#R3F.S9TF1( 7C4A$1L(
MH7L*I_3'E*2-6 ^8Q"EM83@H1%G_0J)ZJ_))E!+>@=+E187T6OIZJ@,9R# X
M>M!RDV)JZ/.Z/XNBDL70<,L0.WJ'#NSQ\]>*:_7P+E]=QJH&Q&;@2S-NQ%OI
MF-$@%.1$T=ZH/*+/$?F*JV937GW9M.^#M$G$-X(1\HF% NG6JM4P;X=H&TAV
M1V@K,"#$8B F'9]=0Q'%,BDT9]G</B)JE]ZGR3;* IU5TF="<TS)&.!?&JK#
M289/@<G!L.*L$$*8I>?/%<EN,%F7%\L;DE ZIKD4$]C;[)R5<#<YIT6"T(F5
MGC0U1WLD)*4>@EOQ&'991=[=!F.NGPX9/??G-!2T>I\A/(0TPZ$B!F!*HZ-U
MDU::OL,0X+V4!\2D8N9/051Y)26I:6#/?$?9;C/\]LWM3V]9JY44FPKKUH6U
M2&_QLV:J7;"L&@9"!F9N4A@L12,&?_5VT%UH+/T?].LN%A/8X\&^CI+1(T&H
MQDI/=8 O+/'4_H^_6W_4G0KDMT51$1RV*B("A#BTM.3#=XM-J!/K1/G>D'5>
MN30R(C!$&R,3534Q/0J$'(S47!N8F^9\P]!MC%$J!FR@%D8O&"T0A&9L[*8T
M+\&DTXZD;>>I:G!^VQD-S6%3<P/PZ%03,VDX$_:4U)KJ\<,F)78]C&%^Y: F
M.53#$ -(#$IB\AIL"PHGA:-MS4";DQ[@M_C'Q(8%WSX%5.0C2E)/4V@/6JCG
M$C^M@UZ;:=++(DOC%)>7I(C/TAR?5GBM6NEPLO*EC0E9: 7C8 )"1>X\Q])J
M++OY[]8617F"6 (XJ7=VLH003\GWNDJ7N43,F'FZQ,'&N^QL]"71Z0Q@2<["
M<E?!A9E64>?JO*@:.J8EO0FV8;5GR(Y9@PI#P%K4L]U5D^STU#ETN<L6]PNR
MBO+T[[POP+:D4,H)_\<B3RXI6=I7:$Y&.J%CACQ.H^RZ/0.B7-R6%3O<:/0M
M]YRVSRWU>_T<XE;\O20<O);,D1OI[&LA[0,T2+VI2'WZ;,F]>P/J7X%^;U\2
M_A"))WTK^\UZ\[WFV=0[R_U]<[WC^ZB-[K<$?MJ6M/->EK-=.[E+[?H4E6EY
ML5S$,3L*B[:ZFF^DP/G4MY:F*% )!$9A.F:21!B..651=D_52'3_D+&"_^G-
M^_=O>>&S7_[HA4MID2U.SM+ZB$6VST3=,9E@YT,<D[/!Q.)L%%P\4YE*TU6U
M 1(L9I(2?1,E*%+3M;9VN#?A.)#N]&+ 0@FW<^093B2]DB^J.TQ.\[A88S='
MHS0(X&$,Q!6N18&&YE/T%*51!4.B&CJ30 0R]FZ[DX4WB;A1[S1BAH/R*$Y4
M XBE)W/\MVU:/5XLEYC0CI5CUT5K%,"K6#*@\"P:"VC>Q4Q36DKE:-3!9Q+.
MD)31O6BAWD1B(=M)0X,#Y4G,'.=6PY,'RH?%>IW6=[4O\N2PX,,XG+/Y::&/
M;I[0G9B&SP'V3MD3!]^3$@CNJ9["6G&D>)L&GV =I"*>/ 1H4E7@[#Y%:C,*
MI%?'Z4NS!41%NG>XC!(,+K;K[6V)_[:E[([O'9:]]'"? K.1%J6EPX(1E86@
M=.]N!T<U'I+K&N?%YK4,^)!Z,OHJ+1BLHJQ7.8\E-5/W_BRE'<>$=AUY\(#V
M+@T+UEL'WT:WZ^'K@,$%X<)N+(8.'MR9?.$79-9WBF/=%05CD$^WH28H^HHA
M(K@>C+2D V::FT5;6' ]#)9_S2[$S<1OG]A.?M@CUN/!Z,B!Y%A5ER2E'=]-
MAOE2ZB"!X +KSN[ZC"/6LV=]]CI7;FJ;8.]3>I.S)>K0V1B,**<R-IS0)J00
MWOT=1R1GLVV7F%S?102[:=)JY5.)CED0]6<Q :,Z-YZJF)*8SPH<I=FV8FN]
M15FB#2:(IQ)<=.?X6Q\8<TF*G/Y97S->3O&,TY/Q*<M=,RGJ=&H:8(2[(W'Y
M^KR8G_30)86&:057\G5\AY-MAGFDURA8QWBL^RX)>)V\F)RQP6R&LS48Q4ZF
M+,UW- FP'NBF[H]&&8J+]:;(^8P:_3UJ8F^R_<7>/%G"9[0[@@^+LG+2JQ;M
M4YP6RJ(2-5 PLC/S,VFLH.UYQ'UBQM*@2BL!.,0CO&170K'E")+>;OD0CF9!
MN +!26;3D_&IOUTS*0IS:AI@%+LC<9.48R&M$FW9&<2HNL.(70L?7-%]PW!=
MT>Q<\"C^\JK(LI."\.N-IK7SCJF$:>PG95'=XCLE 4;-N_$VB;EDZ:#FA*HH
MKM)["-/>0C[9$) .$5D5[F]#$G._:$A/%?;."0?2^A,_A$;^.Z8*L48\+2O&
M2K)=KR.2_AV7*,V7!5DWNQ5OBVTUJ$'A>S3]]SA>;[+B$>-K3.[3&*L_SR+C
M-/CF,7;!^RJGN4PN,4F+A/7S[*O7\[TO3#V;Z;.IJ]^>7P:P5LZ30U-E7>&<
M#C4R/J,8)>LT3UED"*WY&.$']LIFPS[;P48_SQW_1X+O<59L^-$Y+6JF" "5
MQ[J,'MFK?\/IZJ["R>*>YF"%V01\_7U*ZH%J!V-LY69(WUNDP1R?I8M.V&?B
MP2O97#DR5:IO39HHJA-%49\8OZMRR5:,[OF*$87CB-:KME/)^J6S[;+(MJQF
ML_A"VM:S+S$.DC#@/.ZET-,4MD_((!A:,S ;:Z:%LIE$BD4E!\^WK9/-3Y[F
M][BLTA6S:ZJ 4@1&N,]MG3;2XK9.'1:&,NP$=?LY4\$$;1J;X+WGAMVG(M_2
M#L#AEA!*2]/'T6!]]EJ-=,4>IQ(87$(N['3ZB<6[D5D/[I9V^Y;I;'&;G].,
MZK7(V\YKSJ.-.9LH4[H;FX4WC^-&O7,Z9GAPT;ASE&[S:8U>W3*K>AZ7FM7K
M7-0NN/OA^U+E!3VS'[(9>3WFQRD#@T-[C!;!U3:)IN2KL@P5?*OQQ)74^9L,
MM\+19_@=E*V;[E2E8[*+BLT2 %SC[L=VS>K5I[IM8PM7Y7CERCH#XY1&F+FV
M"=E3SY\Y) #&A>S"6AI>U9:H,47,=I;K*Y^PF"YDJ\_5F>;TYXFV 9;-W;*C
M6"LW&X*1Y12V3G(4-Q2?[>\T:$V__*J9Q5WDR5$_ARN<A-YV#F^*2TS8VLU)
M07AK7HHST"QT%2=O57W-?;_!6[]_GD_3C1/VFSR4_L1\69.C137K#VG.PDC9
M)%HZYPDUYT5^T09EU4?AG%#M\*O85=_$"/>F:0?2G4 -V.#>UY&@X@8@(9*N
ME@=BGP>MF-5<L^QXB6E?.N',:J)*3ZG&^9ME-]#L9]D5(!AJ,#!3M+L<6I?Z
MGMS$D_M_>_6:FM[*GM_ALS\YR^<1^YU[?0&4]GC.S 5KD?<S4<BVFZ3W;.RG
M&U7),.^3@0J2TO2?@($F.PT_^6:(5B!,.E7T@$AO$UPM_<S#89%1&D4=#B-4
M'G:X%.U;Q)K'-_2OD@6'MJ$#UBF._;THS,S4OC^4>OIJ7V\)WH&9/6OR@5*"
M_> B3%8!Q7_79WU6=U&.AD90ILWV\*5LLVO[?87?(R/V_W&&1TSL+WTPM7"&
M3,U1_^:?'.0G&#01<N7%;<;"37!">XCT:]]%Y;@9<[3Q-J!UI=\-;FT&P14Z
MA>58<K^VP85U3!DJ6DM4%6C3V ;WYGR_P6E9;G%RM&4GP]91S'5FS_$W_DCG
MIUV-O?:))F5HT,]QL@RNR9WH2K&R#(52;LWC88OF8."#>4,@-:1Y7>DX*R?K
M7"W]!8!/RDH?VNUD%EQET[G*IT85B#:=$;KE!Z;DV_4M)N#](;\6$2<EF]EF
M^8NH""[(=<3WAO SM#75T<70IQ]TSXCH ^U6P94YF:I"F-RP7HA(&U-$G6 9
MU;L',#>?R05V9UU=+$_SM$JCK#]M6%4)S7AO[LZ%=N?D3.#@ G)EJ#QDK-LR
MPG;0I[4EWSQ0F\ZDF=,\9M%AR7&SU4N5(QGC31LZ>IT>Q@ 8&M"P4DR6<MC<
M&^T6JQ7!K$6T[0[2 /UM"3$1[3>#J% P"MY$30J*;;%^M@BU;VL'EY<DC97C
M?AW2OPJ45&49#&# =*#BIA="VUEE!U'%<X6["%<0Z#V! N2M_+4$NZ*7$%!6
MRXSL]'=![*GJSS5G4W=GV/3EM!D#T0[ 3(V<#8=)FMXHN&>9RE3R,VMV&J,P
M4"9X':4YBNZC-&-+0'--S=3SF\NF3>S9*V<&]&!_$S VPOV<BPX97"Q.],8*
M^3W>EE6Q_EEK-]?Z1'TN33_SK6^8=$A_-T@:J?8W1RIA,&1AY*;3A-IH+D$<
M/V 2IX9>Z@C@[Z(_%;'^>C_Q*8S"5E'2E?$ .U?1_E;=W>$LT5?Q$<!;T2J)
M=44[> JC:%64=$4[P'JIM>PZAS3A(=I%;E7F"!VF/BLIJROW  I##E9^3M5^
M8#B74(2.Q:*T"L6$]CHJ-5,>#$_54!A"L?+3"45O.%MCD5*_560)'>4T 1(L
M**<5K-(I6BS\-2=.U/OVQ0B'(1PGCMH6R&@\EX":.PC*R^A1$:^KAO@\ DE%
M3CSV2'P.0P1J4KI2'Z'#1YEV&\VZ(]PUTRPJH-== UJB@WT#$BJX2JS4QEKI
M@*".Q+_$M'TK<O' =%VXFAKJ-2C#0'80AJ' @1&,@9P\=RX>/5\5Z,.;MR^_
M_@#CZ/F+Y;+$%1/THJ1_&'>*:+!>'8V)[L#7J(!@U&-B)WF<#HMJ,)A-$.-<
MG%EV-!CP(34DT3;IZ S<Q@$;0P<]G>TOJ/_IZWKJPZ;[S0F?'J7#<Q?LM-KF
MO/B+;5564<ZZ[N<\VE*W,K7_]WA=-YSK,PW6&??]$J^59E.'@E<1J53KWW-G
M4CH&HHO];:X=.$""*;K%JS3/^5]1QF(QOZ>:.#K=VK1BXOWMS[36NGS2F>JR
MZ=7?>0UWR/JXWO\V/H4=-T9UY-1WZP7J\//3O*S(E@<8\7B/F[LH;S[K><&/
MD\;)Z*/RLU2.H@IWX<G[+M>]4GL6_F.&PMB+<]DCK^_*\^S_NUC=4GTL4<)B
M._M[(;Y;[R2[]E,V2Y.7:3R+R[&_[UGX$=?/-E//8_BR[ZK&.V96'Y"=MO#_
M&C67.[KR-*\#2G\A1:G=H#W'FYY3;35\JGW64\5KP$R2S9<WAV$^-\9/ODYI
M_BI73OH*<PSJ]\D 5!7=_Z>=5'7W]_KG4Z7WGN?)(_MG4_&?\J7F'Z[OR@*4
M YCG$\_7?L,:;_MKV^<>3X/Q"::3<\0+F%M/J#O==Y>$ .RP<\BH\[E(RE3\
MU(^/=?W(^1@P,8Y,=\V!0P^W,PDOZZ?V"MJL!.WF3B0!JJ&;Y0/OM;,[B<'S
M:>;FR/;D+N_>/(%I@ZZ/KU!JM_-YI^!W,['_CSO<HNSO_<&K=L!,[]I]?48M
M_=3/QN\6]+(*Y/9J4*WZ'C_F/L>L+N\-7LT#9';",I%3C08LO4"1C'XO4ZU7
M'X]S\PAOMDS.&<OX/*0%-=SN^Y:A4]:?%'"'&\4^3YW^5PCK^IX4/L=WV4=@
MU_.N!;""DKXGO3IG=L>P)'?=/:<A)=N=-^O>(\5[GN%@4?Y,,XP,^Y=\;\-
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MFGA(4%^$B>]%.4<7_'>)'FX).11RE#.G44Q4V/])/ 8&O40,A1SE&&H0L6?
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MGQ3L=B5@+/9=/[WU8R14\>'=R<E1I@[Q&Z&+FI%=<($^B\=Y99-+M-$WP4Y
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M=D)*B ^^SGQ*8$NY[[D0\S!+ ($ OY0#_@SE@.5I1%+"%F&<023FE'G9:+;
M+1AJN7!#0.C[4#";I84,:C=-C0:W7 @$(E4RCX+RA@%^VGA*PL24B*:DQBT0
M4D#9V)@HQ>P9];OT^X3Y-^P^8>=)&N9OYGXAZ9P&!@W 6N*6"!FU82-^WT[X
MW3T[D 5(0XY;(&34@5%0O.7^FJ;_)-LEE)BF!*PE;@6141TVXO>LF0LN+HW)
M9F?!-VQJ[[2*%K>>R(B^7L0#"MC6!#E;$7'MM7#@$+XC%.^S^]G^1+F@676
M6ZQDJU4(&+A3*^/P]Y!&&8(WT_^@"W)*5W'*GJZ\'U8ZT_>"6^EDN4]N"](
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M6GRS!X^H'!-T557$-$^X[6Y)UPJ<\72 :H3@A:[4;55[\0:V$"SG%:QABRZ
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MFVDI(:&4@Z!)ZM@>CP&-L?/PE)^NQED?C(35AK7XB_@_X4S@O_G_4$L#!!0
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MTA,D)?+]C8Y6DR09/0-# $&6FM#@C6134#"540Y0@MIT!%0#IQ+O43K)D$T
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MZ,]VXOM\K$I75_7]S_UTIB-PTZ_INJ ^8NQ=:9XUE GDDC P2$ ^O@*/@M+
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MS/SS/I2G@B&_@6/TUZ.3__??3(G^8J%F_[\+A<\+./A@[BPQ6G@ O<A"C^I
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M"J(R1CD62H![#2F^AW(WZQAH0V6BRZ8,U["0!SJ0J-NQ;HQ18LW4X$(X:+,
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M_L)R["?K@9PYD'%?V0CUE068*&I3$V7!.[,\P/CXKNU*SL.D-)8ZMV9<@)C
MUNC>)J51J4_$IE+^02AHY3R*J-[PK#,I% EK0NVE-8FI'* \"CD%+@DH012A
M<M %).%(7G3DT7G^E8*4+WA^8 RA5H%OT1TW #+#$!)UFD<.+%P.>GT(_$?J
M4==>S8'S\2>('<@AV"30EU7<TX_+=JB,P-)?_"#$'S-?G,<"'_"'SWD0.K$Y
M^V$?6)TG9=52?@S;*[".6^[VQ?=/W2R'3*G([4=J)'.R/Z5__# CEBNX6N9)
M# MFNS#YJ>0!7%1KZX#A^6U $S9SMX6]J^W5KI'HJDP 4K\B_/S$CEZ'%'[4
M_/IY]*G^\OKK3JA=]<GERO#+\7Z*]LM7TF8>[4P+T!Z=M+P,7(PDZC9XI;16
MJ'8NU0D#T/:SZ#N$:5DPZ@N"@2$^'1NR"@R?A(WYIZ8T;__0Z@^0[,%\SJ,#
M;@&^H$/Y>Z"F=LZB&0 -;T\Z12):61!1!]X+#&[=@M9;5">]L=+Z.]%_M^*7
M\L(=5.<\VCH] 0T^JYX5>,(&T_TU06L>AH!>L79.[GODX*S,&_0E5 TGSL8&
MP$_!U^)Y&UZGV6',C-ZE3-'+7V7X:OA:2H78:,CBO<@&]DU4015E04&Q"&I;
M1@^C88:2H$M&#IV!DZ6EK-V\L/1!^.@5N^XP=%TW<"(@3=:;<_Z[2N 8 QB2
M.VQ)?8#,AM,H<-,#DQ3O,BDZKQS]AN\GD5U=.=VP>!B@C39HK1UY.U-.W\Y_
MTY?/20\\X3S&*[CA0]&/K^78<Y%"W&^U(2-9L$:#4MK8Q.H2Z4WX5R"( Z=#
M5S:,,=!GO<PBZM8$.#'I[J+*H_/S]C<4^!K#I$8X<2WB_!D:1&0/X_!M,+&+
MJ'A1O*8UA?5F#EI7;F+.*=)%ANN^\:>70W%(G_9_EF;\<HY?"J%:*<ZN6?=H
M@;WF(XJ+!31K;H%Q*HLL!@DI::8$1!E&#$>4_8/Q[U&S=7Y$H0&F>$EGGFRE
MF.?*3+Z"Y@\OPKODF.2<?5FD\L(^602_%J;0A%FSF?9/CRW[+VM*P.P7RKJG
MS3A&K['-]Q>K;0]^?"@58A<)'.2_4&BZX3%5TX6>+'ZA4%N31:"6AM!F%\JZ
MSK?P?-N#KS=ON]=_MY-T\2*=VNE5 XW"JM^T.HU6ITUD53>6"W4/=YUCN0ZR
MU"B)AR(OIC_BB8P"^F9  S>.%9 N/J;&HQ%*=1K JSE:?^Q]8&D^SW*5/%LL
M?O0MF%279U)80#BM[Y;8BL/59G@LR\X?T9?P<W"S!6J@(_7_WT(7NCJ$AUO<
MUNX[5!-7]1CF"W7>;-5:]6;MBH*FY^;^NM99GO0KK&]R7<8>^R4AT2>)&A^0
M3TN"H5:YYN= -L'Z/)VU)/X+#((!@JK E49Q6:9L30]<X!F6,,\T.XUKBOGD
M8A8\0_O:4B+!O)+Q1WBMLF56X9)@%?83=5UKU2XPA]@A0)LZ:[;K#WB2.(4F
MC,,'KGZWFVUDD>:,!6W3&1[MB)^Y;[0?KCKXD9O;QCU63NU/^\)R3#45/)<.
MG<0GP6C<)^H.S?UL0G74_-' / /_<.7\CECNZJ;] /F(JIW>/'0@7]Y_;W2H
M^V;[^_XP$E=)!2.E3GD5D^ I_A-VD.]OKMJ8GV[O;^J-,\1"&;N0<JY#JR12
M7G0I$2]Z[D;?=+XU[J.ZT*G@E738J-2IEG)"+O15XP)Z.5BG-,Z:K8O]42KI
M8)1T.#.51+BC]@G[)=1YK=ZYN=\;SN#I5'!&ZE1(-:'0ZJ%UW[AHMCN-^\89
MU:Y=-7!\U+A[:'9^NT?<(^?EH8TS?K:^V1^68E+!4JE0-@R=4.1TUCBOX>CZ
MX1:&V^U&JWES[^*?C%?V6OTPI!/'3G!TW6PUH-HY;T!MXXJO,W;90]622**X
M^&E_PZ&=< ?ANE1B431#.EG<;EZT:IV]TA[<*G^0:0!-HEZ\IBV"RSH@(-K<
MN^J 2%M+0L \5M1 Y53 +:$+7[O>QLA.,F1<QI:=81M<=27S?M(8(4;VOU-[
M_87;6[S<9]T%2)N38I/+AK9]!]I-ZZS1:C?.4-VC?7/5/(-<=@9EJM.X;U[[
ML-\>7FP4\:7+]U<>/L8?'E1A+,&X1-J[H<)+PYK7.#Y\YOA M/EWY?@DS(H>
M0Q_6-3\Z+>P<W>@R#-,=J9S*==_&E[?T_12,?CX\'E'&> B7G^('X:ZBJR+0
MT#>J0-4UE M IY?@3Y@G\3%K//%%'E*G@B*@G6P/ # -RB721TL<OCHV8F&\
M!(PKUYQ&M;87/R-%IYQ-'<P&LW\9VGLX\'(*Q'T*,:$CGC&0V@)$<)O07_X]
MXN8\Q%<9]XG*T]]_Q_HW3BR!&+-%MCZK=)_(7$=DYNDJ%V=JR[8I:^<E0HKO
M#.'J$FH]39%2@%]-%5[ )'<E]Z%:$V5DJ RH_/31I\/%>:;E<R&T_.&2X8.L
MYLR!-C8$58*/@8D(D">&#CGAF:DCH#N_#='Y7</C%KC,BJ56O:9>D68TW+8Q
MLI_9.]D*J3!WR1PIT>DXKY+CF'Q&4$)SG*!-!.A@=HZC\YG]VYBE/*^MV0V?
M>2:C7%?5I(H/K31IM@&[W "/4VZ';GG3;2-VSQ4+6?U%L'="E]WYG[-L#KK@
M>6P4'@5A5"C4# /&T+4>F@HDFEWYM/MFMK4_S/.OL=9ACM;+3L@.G43L:V)2
M9U%D^\SBT[^T/842:532OB-]P*B]N_WTTG'5%1UG7P,P5W4T Y5=Z9L@_U(O
MKM7OI1C*SNECW2\-9U,B$XG#%8EL/P\+:2\5Q[E47%TP!C550O]I_!W++X*"
M+DFKF75!U]$04-ST 54>V^P.A?K;Z9]:]ZTJ_[GLE"YJTE7:W#P6*T&['%]<
M'NOO=3* N(J$A,RA&HL(?Z# G*2$0GP;M\H_J<T"^5SC29K5_X<PN,L7+1#7
M"MXC$VU!/ XEAWZ3$U=O-^)+(2<G%E"$"047X%AS-D+QH7UV=,(PQ7RYS/@/
M3]P+1B&3#-FAY*6(E@%"]R[DC2_0U0)'+\E;F82\<6R>J90CREN*V".<^U%S
MN1]-5=2&H"-,@'$/1 #WH:<LNQM/EY=*N7_VMUYF4Q%IL2M9W6TX%I!2Z*:9
M%X"]"U.84/J,8&2<B]1Z%+NV#K$ W;(^\Q2D"/Y"E8#^*I5*2?D*NV:!]$G/
M85!M3V3&T^87:0(RP^9YOIJ Q=^]F:^[S/RM#D:"+#4F(]2="?VN&W2SQ$)Z
M=<GHG].UOV/EY;'TDTMGDF';]M\F80Y8-#1P(Z>&+^@0+0I2@F<!:J]Z"9+O
M']BN'DP0D2TKRQ B'-[=*+($5&>97G.O W'FWP]KN@=2>P@">Z"RZNWF< 1D
MM<I%32/NB9AZ>3[\2@D9U8P[T+LQ;>_&'%Q4_ER6Y/(X3J=,HL7C+;HT'<T4
ME)QWVTSFM>PFD7LX#HO%5Q%\DB*1DDDYSW!1 [K,+TF!7.ZY2.ZO-'I['40*
MF%PQ7RPE45!)@2"&;%./GA[967M9UHUTZ-U(V7X>%M)!>=\K6>C)BFS*P(!1
M*+Y4<P!]': ;J.AN3N<]M>\X#'(1"==VW62R;X&B+')EHG2XHI3MYV$A[:4:
M&]ZJ<>6 P6GW[>YY>M$HZ3_95R%M]:_=:$F;2#D7W3+Q.5SQR?;SL) .\A1K
MHH@G$=T*4]2%,6L*L%H";LZT[MO3J//CC!]=T*\@%=[B;OH '$+E1A:ELM:_
M79\@V&56S5-JPN>\2SR)MK]\M1HUQY8*!L@:_W9T!F _),8S+UTB426JYDML
M$EGIW9OTQJ))U\= 6@UT%JQZ3SF?UIY^B<*YDK9 9V<&'I$MI\SI1A6HEF8"
MBLN,?>H W;[^\A:J"$:?Q%FE:KY8+&9&/ST0[0/5]DARO(U_A8#D\/D*%U5R
MTK?]7L:_Y#+^9Z /('4EZXR%E^$?LXW>Y=#D?SR)[SB<=^B4>]0%U:1D3"['
MWO.$].D>=-_L@6TXG-8X3^$,[T"421Q\JK!9E]P>RNDAB.C!2*>GDU)F2$@G
M'_5LS9X(II??PGB79;NRW;*/W!7DMIB#9O>-%[[=\=(OB6:EM.4K=MG%OZ8L
MFSDM:>X;W@=_Q<5<$;P4$N>6F'*>JR0V 2D%^C!S5-(IEGLND=Z>"8EJ(U/,
M<S1_Z,X)B7Q(UL>?=?-D^YGM)X&HJ*X-A[(YQ"/R5*D.%X2*!:@BCI*:KN!(
MX7M/ X-[?<J"(ZMK=4XXW-N_0#HGS5O*1.MP12O;S\-".O/1]F_/WB6C9OMY
M6$@G=MY[/QTK822CO+.!#DMF;'^X;)_MYV$A3=9_(M?SDUP_[]@<:#K\@W2<
M\?7A\G6VGX>%=%K=+6X+*LM:R4D%5A<&&M[J=GL*'E/1'@@Z,.8J#F4#1_*(
M[HJH+$MS'--]^Z--C(GYQ-V@88>F;"+P9JM0V('+4P9>B!)F*ZU"P<6#@J>K
M'-U]JU^#0>/FY^T3#:)!$31I<PT<$8K58>?O-UOGL]H8[:J-6:]. %S/2EXE
M;(]1$+@,G8?+H7\]*GI^)3[\G]QH>?-&@DZ]H&M;J/]99IVR+^O<"OJ-WC8%
M$TCXRI=;H&/8O!AY/%8:@^N?U2O-GX-F0*SR;WTS(&P^[CQ5=;XB/0M#*1P4
M$1C"#X[P?%P)VW3AQQ@/[;/;.+P<"71OG@Y[LB\,Z/0GFO9J&UG+TM0(Z)8*
M>D^.Q4Q *HRO@-BW$$)I4#F5P_6F&J>Y97/P6SPK5WCM=[,Z$PL[1V )!>7R
MP^=:AUJG1? FSC?%\RIN+Q_(QPVP2;*94;9?43" 6) GA8$L01_@F(($9.5)
M3U<@'Y<1J2LLPWY99*\4;/;[X./3.'QLJW>M]O#R\^9[_>VR]][YN)I./DY5
M F/7T0"J;VMJZ%#@^;M9+?U2ITUA'@I82T2( QHQWF]+U_2U<T,K+#N^>(SP
M_O47"?I#$-YMJI+RI\G"ZNDG53=U\1Q863J^\R\N;-H:S[_NS2Q1W/[)I%+[
M)OWJ__WAQ[1KG/ZS#=YO,RT_-7ZU&S]_2*<@Q/O#,L#FOGZ5I,.<#-S>#!SV
M_'OFZ&<9Q,SAS?8SY1GA'=U':QAH2@V^A6YL&B;\ 4&6"<#A"D"VGX>%]+N/
M9.EUD:2EX+P" O[US_T-9WP?W/371Y$R7F+UO>?KWGLSUZ9>+Q]\K]],&Q59
M>5G_;I=2CAP66JA'B 2V4[U:1ZK0P#(TJ5B[4LQS')<O%;V.RH<+7ZVM^H B
M%:I 14JT>+"G'2_JC8O.-Y;](W//\=B3C<.>]LO?5.GNO/&S^E?B=\*?7A$?
M0Y-*61#F3V]@-PVK9_S)Y\O58K[(>(V:7,N?'[,Y@ULI#K@8)KC"]<A-3?5:
M^7$Y>0JN#+AR:Y1OKFRI+D!!AJE"I<;S56I)0;7!R 3#'GR2H_.4K:[F_/7Q
MB,!.;/D$\S+M(Q@0$O,3*]GPQ!1!M&.=4(RL$YS4\+?;V^_7]Y<__U32KA,.
M01UXV^NPSB]1=9 ^G@Z:"%F#01]"3%!N!5EJJC:?N@CO'"5&3/XVTF[/[E2E
M_B@4LZ/$N(]\1K\<NMP;OH@2+1)FWEKJ -WV;-M V0KOWC DYL?QQ6J>+B8V
M.&G7/)$^<3H,JNVC$'DZ!0Q+1(A*>9:/.B8U?9P0Y!G< U.052 U!%V%QM:H
MB>)X.%90B?\,]&51-A<\ [ZMOO9O&%-Y?L^WAKJ(E),L*F6#%U.D\O9I^N*'
M]8HQ6#XC>!?Q9L 9$''XMV4-R4$W@RM7#F8^8T#B]4"D]Q $]T!EUMN9B7?G
ME9_,<J4\78X:&J1?7+V\''>R?_7V\]F :>36S&:HM1[K$KCZ>?5GPF:)C_F
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MIN8G3QR)<G$Q7_8L0F7RY+TKG+4K?O+$D2@-%O/%JM?(WICRY&6GZ87C809
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M7-'2)/BP0F(&3J68\5[&>ZN\M[; N<2'1"[O*%;S=)@Y_!DSIIL90S9%5^G
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M)=EMX??0.OJ+H@$UECN0'#O^(&(*V^$470XG9'W+X>S/'$YCYN90 ZA;J1X
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MQP;/ #EO?W^]"XEE&(^:LQAOA%JD#.PT8YEQ2R%D#2RVFF'"&',FV*8\Q!$
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M-OIM!UL .C0TY@ZG1:@LRN2P!#=)XQ=%^0PS7\O^U\$D(,I<0-M"'V*^ A\
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MI"#K^M0$@U;S?>=G7,F=RLWF9VV9:BMR4FZYBGQM1]6NU'JI^_$JJ,6_M5P
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M%3+T!\W0^T#U0NZ26.Z0&J4[?3(>X=.18NN6YX0BR#E?+.?"^-/5L2B,85N
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M_ST0C/5#P.TR=+NN7A:=HYKGNSU1R^%R'3\%]H'>% JXD;;5Z0.GTSN2X.U
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M=X7JC&&'I9; ,XH@(QL&KK)9\OXLHG)^E.Z,%L8HV?:,:=CW%-5O:4#K B"
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M")&!!5#6#26;-A;WF*D./#?*H&<91H4CK$+,)F8/$^L5N6UF+K9EEBS4"Q.
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MULI (K7KF=RFU9W$RD=;M,4ZI2:8(AX %#DCFK.*X[? ]:-&B*FO,Z7_)S$
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MG/PR^7W1*NBSL??%Y46GCRZ5R'%WYHTWO_:-][9W]J;>^1_E !Y4,/]7*R^
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MUT1XA[9K<);S#"_5XXN%0EZ/O(52SI@V-G]#YT">3)*;Q@@.YOY6;(Q.BIZ
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M\BH56S++\/NA+DEK-)0*$7%MV&^&W9S8&H9[J.<$=]VQ#J&0(= <F48QP7B
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M!5-YIL<PNWW&4CAH+F[<"A\;<*#W\56#TY4.:Z2299FWS;LO0W@6C <QDO.
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M%.YM(]2W>U$XI+00QH828Q;]IF+6;<HR=!3)S*$\UY,F:"5CL%-?>':5#/W
M_*E!Z\[!Z"K$@K-$8:F9KM<N91>)&1<9H<<>CNJ#;:)9OSA%4J*Q2(>5&(EW
M;QTUS"\_\PW#_'D<O1BKS@%[$TTO<IO""Z"!O?@R[D!IZ_&1$UP!\U)S6D)F
M1)HI #6*VQNYL#Q.$N'3QX\]&_6I@N5]E.(C[!#]T08&+2>W&098J\  2X>\
M1PVTQIE>-"%C-KWK(\O,<L^LWL!WL9CL,I[S%T^1/GCZA,6*I2@P76X<_23.
M6/@,E?PWSP&L0:2YMU,$_L^]R_IWL.Q=6/8#^2+7O\>L14Y8! /<16B5S,:>
M+S K$]27MK9_5B3_3JG1*!ZQ'RF?<6"$0"3--+87_X(C?F\='R>5KW*,OU;;
M+FW6%K_$F3%^46>NU-/72MO_AN\HHWH?F>CGB2:GJB+=T]Q@'NQT^QEVBK#3
M[6?8Z5-*_[YR6A8XN(^\C*=X6NVCS7O2*=B4:5![A4[=3>?PY@=@[ADC>HV\
M07%8U6SH2PH,1;,<!C) V"-82Y=S:XS6(WC_G90C5)HMAZ;#:4RX@LCMN-Y(
M ^R<($CF\3RF*+VQ<P\?ZR4X/-1X(,F3"A0'YP>ZN%P[3O!J0_!?QK1;=-];
MWGIXB&C6%$$]&RD/TG$ZG2B![_MI:= R(3W&4/0"J-''QH7<++ H"19E&-4T
M1$H:XD,$X=B>N+@KMZ'709C/.(=;7N4TKZD/%L<P/X!.V$]C-JH53'O0HDJP
M9I]<#5O?GJX72 'IK9U]3ZQZ[*3 N^D:Q"H @7^P8;H'2^=;J8*D-(QE[K\.
M9FBS\5+N/4[RX^H1#UR3*68HZICJ=X<C/YRX*]WHM/36;9:R0FG-..\DV"F6
MTAF/(Z^=<+)6";96\7JOO3A.N+S34_SFA &-47'>PJ7")%8X<[@XUH3 OKB,
M<X?5->R+!!:+%J#9CUP73=(*OQ6SW^=(;?*/5W9I_SGCU?T0P/7SP#YRVU&"
MY<,&G2'X+\KK/FKF8&)3D$2.#K5?_%K;JI:J5?J?-5)[XJ@]L=?PNSAVLE[]
M8\:^T6]K?ZRS.W."@&,_@+ )O!(%<3V"<U.R3T[V[36YEODQ=8&2#0O (SG&
MNJB,>C:6#K=E)Q%3!C3AE#HZ@BZ=9#KIYF5Y$&IF/>":AFW8,>66J0<NV<F(
M/>.M:NH:(ZK[%L->5!#>.%;: ?ZUS^JB11J:%0J\)AK[BW_2<$]'F@:HOB\V
M$/Q-S\^_H>T55AKG."YT8K>3&*<;@^?O,$H[3MJ?W Z]I8%S2]HZL-U>ST6=
M[8)KW)<.952Z8W@?)&VY;W;<:.R@B82[P>)@PW# -PUWCK-2/83;=KT(OY=Y
MX<8[EE=<9UF7=VGEW^4:10;J.W 7D==+MY^ GZ[%/U9"R]&0A!((^;#S'Z7%
MZ5B!+$CZ9%[428:P =BJ)%W-,AW=-#PJ'C*7^H>VBB5[$-Y!5!3AGCC9'= 3
M8]' >6.4>SD!N/.\&-S _*(MV!\X7!A2N/<=%[[VZV9Z,B0$5 ^HUSCC@-S!
MM^RV&HT3JK&P;H#PAEL'XB60CZRAQ8O!F[!2@TS?H<,%OW)\BJ0@&(P[8.I5
MX#;;+.."(WA/\+\@A"AMB.<Y5+._B1M%MX 4-M'"-SAR)AEQRCPA;^3<!1P'
M>C)YR?9Z!<W&XNMV9PHPN1V]!%6>EK;,(AS<2O)Y*+HNR"&V!-I].'X!'E-8
MQ'BI<Z-6[:@;Q]CT*><"XE[7QU0%+'R4.QMTG-7GC(M,^TI)?<=U,#('70NR
M ,$-6)0%;W9U=>?5[*=2$FH(B3K)%@K_G,.6LX+X[]I6:;NZ7=JL;\_X4@F\
MXQ%F60)*.=7V*GM[ORFEDWXEKX*L,!FC[L(,O3I,U.$DGYWU<$G@HZW I _%
M.(/0)SV$:#DPN&RF43^RE6;K/@SY: :9Y V$OS2JFK)%H (Q]:G5$6HPN*CO
M=1@W0UICT7XM/,I8<$( 6!B):N37!($ZA :8RVIR+JOCAS%NS$P-KK;LS(F[
MSF?M+)VR(O2&0[?K,7)PA,%+5\5,A_=N)R']?4";#5OPDF\I.V"I_M1_MP*5
M6^AA@NVELO 'SB1>>G$_Z.F4AN9PX+5SI]0B9Y!5*F[);*T*:G_&"2;C$,;J
MY%'6$E1W'V[?-_*&FEUS^F4L,K!M-W![7L>#3T_L\"[@G%EF5>1 PU,XO1Y8
M8H2/PAW#Q.^J_"PHX 5?4#Y>>C>Z5Q0/O%')<L;\M/ )S"R''F5NR9B7<-7I
MR=XT]0ZM?TQ$9J:>F:7!L-/3\3N)KPP+11*XYRU\%^#.UQIKW75U=?AA$G'R
MX/!>VLJ;'3*JM;W&)O=[#RDGP8'$90*+KS6ZY09^/W))3ZRP?"]1]MMY+OMA
MV6_GN>SW^.)XC,,%@QC9"3DV0>M#KQ8//64K"C;9TAHY&PV2P] M6/:=+2/R
M*WK/Z#-SE$0ZON>ZF>R'%X"V<'SS(WPE%0F:A:=YF'Z&AE.*Q7!O.#K-+A$L
M#');./8:XD$Y= 8U3NJ?$IBSEE2RC(7/7+ R+*C.>Z7L7BD[A<IO/,T-I6[R
MR.5P!G^?S9VDYLI*[[_"VC*;LIY+39!Q![I>EX)H?LE9HZ]RSLM&D-/6,*^X
MDEW)C$/A&*^*C%]IJ]HH[51W9IV3A0LE8C<_(6.-5YN;;\%3GEE",:GPZTYI
MLU:#)55)5'EQ!:%>8=F:TG)$'@:/R,(L#:$"TJC_UUJMFC8=+2,Z5X9VI&Q,
M(,J'XZPT,T<N/J6Q GB<&6DZQ"=$=,^0HODXMK#R'B^QDA5/L$\#/JI&@?:?
MY[U>^27S#MFM@0LA5#.*T+,<,CCQFZSK<:5WSHVOL6WNEO)M(6R,$#+!<86-
ML1QC8SCA1I]%;1"Y BF!H'UB^]X-VCS.([MHH@73D39$L?!B+(L%4JD/DED,
M5+[-0*),^[T5N2#ZB2M!/1-FEB3^8;HQW3Q7@B4)'TE)PUDR5"SAU&XR?$9\
M-FP&Q XR.GU)9&9 'D^)/8U\S#L;^Y?'5\?[S1.[N;]__O[LZOCLE7UQ?G*\
M?WS8^FHGX[L\!*J%CYH(0T0U@S;''D2*DBA:)>(S;VC(IE:VL:"+0.'2\>'8
M'_Z=<*Y.<%B8V>HS"2P6P$$IC\9I5OP].(KHBHXI6 =Q;@[A?AV'9C@.G1LX
M0_ @0TVCYH"O,!3< 0NN'#%X!'B:,!IK>\36@OI02R;Z"4\/G2FZ8'JF\%^,
M].) '=U(/XP3<0ZX-;//*5!]L8I]S=4#AD#HM<*1'X"!"B-JS,2;1![%9G@7
M3HX4'N4.KN3ZGGOK9E6-(MJR,C69"B8%!(-&NH SYK =D082Q,;VK?@)?MB-
MN:9">KGM0B0!FCZ&KWH]>!W!V#*4+F4C,=W2X0* EEXX AU/I"Y]KYFR#E'G
M,1#PDF0/7_L1MLS6JN6W.DLY*^2RV!7&4:.>KY)GE $ZW,<K';@=_FR]\<B8
MI._Q%8)FOCS</SR[RNCER_,S^/O^X2G\XNMIYQ79D@N?"K61VV,/]RR$L*2>
M%H(QX60U4QF^B,( _MYA=:WJ6-BI'THK/DKPOM+\^+=4\Q^+YC_2FK]E:GZ,
MHS0J-=92_VZE990A/]1]ZW7_^XOSOVIU4S?:'E\=GMJ-BOWN?1.$\:IY=?S7
MH=T\.\ ?G*A_'QRW]D_.6^\O#UMV\^7Y^RO[M'GY]O#*OCQNO6U5OAHAW%.Q
M389C$#=P*A&8@_HL'H(9=Y6M)=PT!6_>:L2Y4U[P5O8%;U;L_?.SJ\OSDQ:]
M7- X^X<'^#Y7Z]W-UZP'VK?!0S^.0I]Y&D%C=-PNNCP_FVZ]QO@'O%W,.:2>
M'WE]N#L6<_BJW4F#)G (X X"VF+8B^FYH9,7D7M,W] AEA<@M0:G+_0!@TNT
M777WU,7@1)K7D4,76^PNI"F-3)G(HYX!S()T2[SBF)*EFIM!JD;:6T:W0QPA
M0K$H$M!XY'; 84I]=7!+=(XU2L"OITW!YV O::D=H!*Y^?3(PMP!MU;*8]0\
M&0Z'"5*:"!@.-P'>M=.7+![%*P//[2$H&6NZMUA8!M]..$UITW072!JZR&=*
ME!U"Y@IZ8(A*NO"DS-^-N;Z($H3ZK:32L-*V[<%:8G$5;O>Y"H=5N-WG*MSW
M*,"@T3M.%*$""Y,QH3P1,^MP7BW5GG$RPB%D,=6& B,,&SG880XZ1/&HY_50
M6DW(:ARME6Q3*TW12);62%+[+V2[";A$)H8UFTKVJ>5,,55VUE0QP;+;(\P2
M:')!"SCEVM::NV[T#9A6A+ZDUH3W[1F47'"G6T)JMR?L_+_CCC1_,B4,?E>Q
M7Z;@2OBP\1)F;9NU8-OTML(C2QQ"MF6Y#>$I/GJGY4FS=8Z?2],SGU6:$Z'0
M+P#Q%-^04>-I('BIG/_';HKX'G?+J'6J3DS*[5@S*F4N WM5RDG<&4^V6 DI
M;W$JX6E\Y2'9A/;#4O6C7;'T0&6Z%/"<QWC0;3CHB"Z*X"]=^)]M8(TRGF/&
M0\5<+1T1]!?G%3\*7RAE'M#2IW#6$Z[N61-GHNA*3*=R*H2>VSKTO&A>7MG'
MQY3*J=7^L,^O7A]>VL=G1^>7I\VKX_.S1SEEQL*^:D ZY5%WLE%VK6*?'+YJ
MGG!X?7AP?/9JQ>)KAF&FN)Y,=XCO>!(3\? X,CZ$1(TMB1RQDS+3G@I'ET %
MJF$E6QJ'&TAY$<Z9<:NQR<)G^\Y=G'CC^/<52,7\*^X[#4RH-70:G>$6@MB&
M5Q#'U(>) _AP&@X&]X1;X.AY:OWI #$%'NSL/KR.%&;< O\1E'F0_A[>$S[A
MW]C@;D*QCAGW9#7IQME.G.PJ.@Z5?N#>+_UD:-]6[&;@W+KW]HG7@SMVJ%H$
MV[8?1J.*[2*RMT(]IV!-$JH*U'ZO;Y8[M^5J;:]6+0GVU0X@.NEFX#4TFF(0
M835JA'6G4R^.J:\%5G'@]L!X@<6(\VO$-%\?KG3KA3Z7EZ?@4_'2TS"J!2H!
MLY9&K51I*GGH=*5V"+\<Y?NK'DAM:A ;7+IC"#0G03>B^7#&2V+F 2)-V%?/
MF[ZJ)CR[/7"=2%H'T/:U,8!XDP3H.&<13"@FO.5.P&4]L,&26%%GUY#+$OC*
M:!GCV+%?)^ZDA TKONN ?TK+\'J]PE[@C5C8LTM&B<%R*166]J>(.+GG+O89
M(+ 9*2"R-X*'>Y. .JG5U1GBSD:LF4:(HD81D'=O;&SZ@%G9$# S:(&U]D(P
M\]CCBQF"80B-I6,PFBV:EX+\6V[)6^9#P ^!+R6#?[?GG8-N[AS(MEKIML:N
M>X,PHC0KUG6&X(K%F0E>-+W:# RQ%A.[OBXU1S@8;$S1'4X4+>%+:+L#Q^\Q
MMHGU%G9U!K<NUH_AVH-0][]V5>M]MDM+-4LT6P?-=T4.Y;2MDYW3.O9_ADE_
M8+]Q N/GFQ76[E<4=*H=$6ER[&%(8'5^:T/8/4VL(/*(W^,/V<:'P'1A;]BD
MW(98O"<I/N?.\9A$1B??E+S2H?H!6(*7-V03>U>TB@56S!MZV!PWQVCQH2#=
M WOVU@T"%X[+07@7X(ZNL9$(*V@AJF(C&EOUO74TDNGI-<UE5IY@&7VX<SQ.
M[V:(@_0Z3U=)<T7'GBTZ%UHKJ<>X#?TD&#-YN'P)+H49A'1GP!&**=V6^D+<
MLBG/4[CM3R16RFY9*%^IV<+S%GFW#J4^Q%\T),Q\\4J[K!&#S]##<%6_6Q"F
M:<J45?"0< MQ3JQTG^#+T(DHIW1 W4BHY)0[5FE59GEA6>?KUNDZ-(.Y8'9-
MN6;3?. &Z&X?N&A^?"].U9QE.#QB]12]AF"@88N4/[^6JG7,WH+T$P53-P&C
M!3JTFXPGZ_3XVBYFS.+FFC//+*+/:)0?],G#HJNH!-,@.PJYK4HW=Z9ESKB_
M*BHP[6;&[F8<,HL<,G9Y9KEALPQPQ0;!4S:E7E>9$+/E"13<V!LEZ?[H3*L;
M&TZ5I=@@'(7HA15.>&-P.IU^TBG2S%0&4\]_ZAD92DIVD$;/E0E<@;ZW;*(E
MF[B6==S6]=T\FMNI.)\6"?'<4.('T$Z+BT9[ST4C+!KM/1>-OB-CJ1QDJ[:I
ME)8R+%,4#)L*:OE$M4DV8I9%(.V:!+@DVPW@Q ^H44%,"O-.)"-L8B@J>>MI
M[;(]TRY;K604@7G(*[.QM.8H!8;I"M"^D^S/EK32A[?PKD[<6V_L*!H/-@OL
MVSECI8JIQYFPG<J4J)'-:".T3=$Y-\,@\/H)O*#93(H!BY!O)&-^[=.,J46H
M>NK_^Y<ZGYY4)Y-8H-BW'QC,B05S:*;ZR5>8:557W:K,JUPM.6''N@G".]P6
M[/@@0=1 '/4>.5$+;ZR/=8H #VDV<5N2;U([>(A.&AYQN-\8Q]L@&ERH:[!<
MV>6O2[%'I71+*7L4 R\E>H^XW0*"&:\+BH,R:T@)0V^0?]]3N9E ";B'I5.L
M!X_-]'..3D9.7?H4Q'B*5[+D2EPSE>->4I55:A4QV^Y#)N/AMBN21/B)T51O
MLF7@'\2;H[OGMWY3MU+$ 7(]G?*QA%8',Q8Q];)XU&'F=.%MQ&ZZ$P/JAC5P
M5#*877U0MGS*GHJ:TU]Y['/QC0"KN[E*2[-"V%/[J+E_=7ZYBE66/))?OWRC
MIDJ-&UY\8R-1+4BRE8Z4!HE7"&G\P!%_P$!#7X!LV<<E^Q@B(-@O):I+(/N%
M?W?NG+22M22ZGSA;1N-L26>5*SGM/W'#8]A!;:(ECB< ";M&!REI,NJ <]2+
M:H8<_/J(&^DNHA"<*C"L2+6!^/1'Q:<^F7 _-G4E)62),H=2K8K%2%"A),8C
M4,A#I^,FU %CC7BC*6OK@%$,^N/!A,EX??>>7LG ZP]H+'Q?,9K(Y2CYCJ"K
M +T6<!B[7H?%&8PDSGJG%#<6,U$#LS\5I^="+AB"%^Z PQ1*?@362&0 =R[W
M!PM;ZI3G(O(RATI7E1^-'/0JLT&%5YFR8!V>-BF-8AT=-$M&MYG!H([1(P'*
MC%U&?T&_;43%EK$-,!DR/R(J4=3#5'U. GFU>+&T;:X@72 'F$R;6$;G%6%M
ME<LE#KCY6+*B2065AGN+.:.!Z_C86&@L=H@<<3GBO6+R5_BU%&6'Y9@BPU?[
MHG!HD8VB'!FE$P]['&X]]PZD:C@*J>V& ,%&8W"',(6A?RN\FK@6L_C#WZ#[
M:9(Y*Y=+*PFU9*?PB+!3OD,^#]+'LVO3CW!+U%97["8":B1?* "X"^IKK[<W
M&E(IQ<)HN7E0KE8W=2+/&K/WA/Y@G*#/YTD2/4Y&9.\H/R^*>,:^H>UL^E]@
MKX9N9+)O4)=2AXB:J.28D(GF+!D\;V_,T#UL6Z0+65+R+,@!YP1#LQ9 ^J(;
M0<2-#WO:;)(6:T/DW,&*'_C9J]"',IMJ)J(N+G(IX'M3A%]<(=*GPMV)]%43
MJQ=V$@%:BA:W8Z?G2@I"'3:PR!OLMZ.*#M$WP0.3-0/J K$J"1LO$R%?Z-BW
MDPC;QG 9C-F/\70KT;12Q82_#2BE01PQ1L,N=]%.#+:':2J.K)0R2PS;-28M
M5- M ]?)00-52F/QHS"D2J-U$"5]N]D%39821IAH -"3FB=8Z;+#!",K.-VG
MJ.@P=K.;?3?H3#+?!%6;$M:D'JJ'*QD*8:$$_*;NH'D4J<UBE#'R8?H3RB:X
MV$\A.@P%G_5;%]EVD!M#\O?N$ X0/@_%B;P]*2003[33$<);$H(5/A5"_TT2
MHNR1ZM5A-5L0&G0E39V@XDWA95#GHZ/=2>JU@<]] @,0HW&C\0&ARQF8(<J"
MZM%6G+&@LU'">XE/7VX7EV-I&0X5<=Z,.Y.)-N\=_W >S(/>GYU[?P0:^A<O
ML)\X:#E=M_ 6%1._** P2MO ILF5QZS2Q1=&FA+;G2 "]7Q<8QB)!9\A'0:K
MZ)2EHP,@O")*>:9T(E;>;\K[7DJFD"4@\SM&P*-;ABP)L)Z,T,GHNH &M:!;
MD_%YZ!T8BI38LM%%TBUC3#] '&7(0, 9<5R'Z149A+M(T*G<H7@,OQ:.DH*+
M%!=*D,A7D7282<*:NGOXWO$%*\:)]F2&BS'K!"(Q\A#?=G:/D/(1>]R4J3&>
MS8+XU.DZ[-.IXFGVVY(O/GQ?2O5V*L;V$.L$;>5-2],MN.O#-N)#J73 Y1_$
M^N&;RG\6J60M3[25>6MZ'#+7':(UEB2YUTG/A)Y#CID5G/S3DS1:)BK$[+N!
M0-7.Z H;F(55R\WJ<]42'GNS^ERU?'QQO)RII:8KHK!G:;>73$9&:YO>)GGZ
M1=-)X9>,[!(51 D?9%#VPHB[/%0(R(/98[=H.2R*8@T=FUF'2@?@4&F, \A"
M$%5%1!& _+5BIXX"*^4I=BY6;<(0X:?<0_F/6]G[YXB#C:P$VVEX06B_T!?7
MX&;"<](6)NH'?!6Z\ -,F:5,F1E/M5T=-J':+69=^&,Z#S BXB*.S3WLJL$7
M:30#IFHZ2*$[M*W$5(1X)Y7[F>\\D/&/F<BYI^/&XH0XB)V,9,2U"PX7F5V2
M0H/T:*%_[ 6J84BVD^6-LW]I?WH&K0\&K8?RBOX6"Q")[)1\8E80\_>RT%$#
MNPBGKZ/O"[N_@<:/O4+38S5YVXLYR)B[G\9H/E7B1/N:$;A?'0' YN)?4)&^
M]\68I"!?'85CC"2+'O'BB$;=%2-[M[O*YGE*(0'K!(KX_<<H!>2;,$F=<^K5
M/!C@>7==S4Y%\S^D](GI@^'(D=R*GGMCM W3X2.RL!\NNKQ2!C MWU.IF,",
M1K<)*5KGQ@TL57](*1Y]&3:H-*>\"S[\$YW],I2^48!<ZG7EDE47\#8(*F!=
M1<EP1 OF9'.789]]N(10,7,.VK%C-^))A[RSF!3M]6+^1YBJ?6T*TN&=W >?
MABZF+C5CF!FI0"8-<>YT^34UPA!^*4]C9AY1VI,\3.$A&@-A""X9;*$.N</W
M *^6*G]ZBZ<\Y5H866SJD0@6\3B<(^\+_"5>3X/[;CA2#:QCW5XOY"W8F4-I
M=U6((F/+9)\!VGL)?CP(-&/R3%KX\23H.;<A3Y(TA$WSQ85Y4T8B4))[Q6@6
M,;^NVF)3ILZT43;*/'6)I,]12W=)%J*Q:BF!OV*V*_M6TGRIP2/3Q4SH[-3I
MG939'1^,47>"E73Z+H^'4KY0W@6@'1HR+PVF*?$>^NXR;1?>$RLGDFQY+-PH
M#I?),XG34\+/BV&F\=!==RAL,Z:K8]B[DFXI (M,R0FXG3?%/<I\AT18^6W9
M0;=T.[:NB 7'Z9=$$:A&.Y+_@5($CY=[8?EW;/F(FQ%TEK@6AL!2]4VGC45>
M/62W\6+2VJQ%].R[6+JQ [<?COE=\!?&4[0@:CM$;(.(>>QUR=5$[.4=49DV
MZ(?I[> DQDPK2Z*K=%TG/28&/B?+=*L!3],X;85]B.R0E2&P704?90KB9B^+
MN*E7[/=GEX>OCEM7AY>'!W:K>7+8LL^/[,-W[X^O_D;\QWNDG#UD@K'WK4/\
MI31"KQP^YZ#0;+:('<0RV4%2M8-Q0QSZG.9%?QT<XSAMDY <5<0?-'!H*9&+
MT521]J(V<M_$& K[.WP,#P6+BDZ]1IWD\#Z[Y;>K*9:U:H&Y\.#PJ/G^Y*IE
MO[\X/P,Y/#L^OS3$<;5$;PZ\[BQ\Q"KPMX'UU6H%FL+3X[-#4"Y'AZ!3#-K)
MU7J+3#&9AM0K>M;JV;>S57DT!H^G#$B/>>J-?07^ /')^D[P8T3;J"$*Z&=T
MHG2WWG8*A6:V0K=K);HNG[[]^^[]__:JA_]SW4ZW7$;2G5JUO55K1E&3@X\C
MW^G_K]L^^E\'09ZU:K7VO_]AATFUT:C][\O.]OV7M^[IP#_T?_DS?]4]N2JL
M]L$7WO]R_.'-U<?N_A92KWCWOP=A<)80N3KYI; KEV[OO[\<1>&0NH3!&E=K
MXQ"O4*XVRHW:+S:3-/[W%^]^_'L[#"$ AMC'C]U?:(T(I*U6J[L[V[]0!\=_
M?X'%_CYCH8^]AAUS#;/WZY<_*22$-_R?C<QZ_BS^6\#A] ?$8&&7LL4<4$0%
M"3B8(@%7T3 8+WA/M:-NI_/F?6]PV2D*0&.Z "QSW;UDLWH=A_7Z*_^Q]WYW
MUOM/U_G82]B;\_K-52"XQN/(_&$"P.P,"D=.%'IP^7*-8B6*%M.Q(0I:#E(B
M7X#+EI?[DK6&,V^P;HY5VCQW'R'4-ZN[TDE\J4-(NU5^NVX2/_" [T6#F!Z/
MY^Z[*-K6GHNV6+2M/1=MO[;W1U[>=L4^_/#Z^.7Q5YM$P)[E5[N6V1U'FP)Z
M)XA1I?YN)R-0"ZAC"C[7UVJ*>M "BK<F>#F<#M^'GW9 K_WWE^HO].\1IH?E
MWP]>WIW7'0_PH]7?())C!8 S#)U1#'*N_O8+RN=_QI&Z_BWV^W8<7XD5'(%?
M1(3'W:PZ47JDENH1N>?.;[DMP567>\[0\R>_+UHW?3;VOKC\F+1IA_<TYI?6
M<4:D8)EM''=G+)%/<&&9\LO(ZP_&LW^=U9;%IZQ]U:=4@OE-'VFO_MLR#>;_
M]G4>T&P9\4ZS[Q'^$RT6R6FIB?^WOW]X>'0T2UK_\=;([WVW5_SV5]Z7M<;Z
MDG+]SQ[FF\CK/]WWQQ?#)LH5LOOCPL'+/ XZ(7;MZ^J%_7*"5;>O)Z.2/EM1
M"6U4:L^B.5LT'1M"$8CR!N/QZ/>-C;N[NTKL=BK]\':C":&(=^O&&VZW[T0;
MV.*P46O4-JM;]0T(ZVK;M:V=G<W:7K6ZTZAO;L2UVFZU#C'Q?:-<JPS&PZ^Y
M.TKJ"Q)OSELG"BCYE4(4"UT0UM#$'ML@$:H/_5^,!\, K2;T'_#%L_!6^H69
MHJ2VKE^E\[,;B4:E_GP$'^4(5G>WJHV=ZDX5!&YO;\-E"6_\[^N?/SEA:%\N
M74+L*$/S\%,WNY:7GJ?F*/)\6_A^&E_Q,*VV-2-_J_;L<#VAPX6905HT3>5
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M&W?NFX]_[W]B3;[1#KL3_',P'OI__G]02P,$%     @ YH.M6J9P4"%*!P
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M]B8"3/)0IM(NJ*QLDTO1[1SO?.HKX!IIH_%P4/I0[:@H=8&@,JX.1A$.E:1
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M?%J%--,F8]*"5; 5?6L?Y]&'Z%BH4A*S/;V81(&'ICO43,^8Y*8VNDOX"KS
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ME/GQ?4._ M#I?_YS /UJ\"]02P,$%     @ YH.M6K)6'R\98   >6L   T
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M5]^H5\&1@5 MC_'B_DD/"$!6#@$XH8:U1UO<6M]6VC2P.1:3(HZ@'L3<BB$
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MNBD?3A3V:K9:+5KL!F337&I5?>T0F@=U)LX$>71839+3VC:?SI1VL,"^D'5
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M;AUS'HCC#CVW88L?CR]5@["_J?=43I G*0[S%U)/5@0<:8H@+S7H&<][^EA
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M$=9# .*@^SSXT3!\$#L,MW/6G%>:'5 .$8#MUZ#[(_=R"$"F,P'P2Y6O@Z+
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M8'NDXFQGR2T+>/,5\%:MTPW=S9Q8'IF9%S@?SY$@^8R!3=="D'^;'^Z44&=
M_3+L6^SEQ_'-@B\_AE_KI+[R,?#/^]J[=2,3-W&A@HE/X?@GCT6#.8;*C"J<
MS$E#Q+UI=2-;@\D?G"ZD$C4PCG'\PMW9&]()NEF:^]:(\WUDH*:&^P\D<YOO
M?(RI6T3(CU/(71/XNT_SM</FMD*;FYUA'%;3<5VHH*<!5LA#SY[L^G7GD4L_
M?:.K32:*H=!]T078>34J=?0;1E;DM@_#V$Z6:FG-]<*ZIR^_602KD-*)C::4
MUUR'?;OK0'W Y[49O85)-8UL\,3R2]:=2A& "T_)9KUA<^H$(%:A1$X(2T8
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M_G[8] *\@ZF5)IU>=-:% S'J\@\G.DP#-VFP,[ULAHVQ'<";89/P0/#6$JV
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ML;HY4V9SMH/Z]2NC]DLN(GO]RM86#;@M;ZPMW5MKBZL8[,5IN,+^0;^/K\$
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M;JKGFNOHRNP%=H=S0TL&5?5Y-SXJV]B8);2PDJEP'S 13?T#(W(0AA0!P]R
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MZBJGFJC\UZ/G=X6@U_:$?2SAO<>6!CZL[UZ&,HP8+R;R<3_78C.7[GB:&=P
M&VELGFU-FNE%5)?#^YL7[6APM)+SI:8DZT<JR/U<V:@WX]-EINF<$1,(BK$2
MJRK\6TY+&FF41URE,7%'/]&6H4NL"-S(CV6&2^^>+Z_HQI,43W.GSLW,S RY
MY>A#9R!I!T4 @BB.1L70"\?_7S/?'=54T_5[Z"I2%$60$FFB%)$N" F@%$&*
M"$A'Z44(O4.""**$JA3I@D@'D5XCO?=.J-)%2@ )(22Y\?F>=]WON>N]=ZWO
MKN^N=?^8==8YLV?/9)^9O7^_,[-S;1:CZ*[AY".D39FJ(H-WZ-(9H1<OG4_S
M'"A"GTX^;QAF^9IXJ8&N6NW'?;_O ((^+=9MVR@E+?'R$-O6)KKKJR!/]$K4
M8D3+Z7HANWC2(U2\QGI/H@]"_:QO5U5M:I8)#C*I>RY+8=\%*I'>,0>1EEX[
M$3BA7%PQ#;M:=EJ02 0$B<#WCR#4R>*ZA;LL$:CRA1%"F8C $A.,M.Q)RPE/
M_2?S]B9IX:_>RL'K]<$2\+]@J).]?RN.^0]I*9)TQVC>*%=(V)FP4 <FM$:
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M'0@R8FK@JK^_SD4'&@61YI8 =\'X07Z,D8R# _)2N*V,8?D78TH4"RQKMT[
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MVY!H[3ZM.0(95W0*?O+_^74)F=*E*..PU=,)!H@0B%RB,@^=+5X1<K-=7R?
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MM_4%K]&-X+72:TH^_/5[QD/]\QR0W:;G5UR\D#VCZ!QZ\S*Y+N]G,;)5$+Y
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MPRF%46U#FX.I^3:,9_E')::443*P]O=O0:L,#.P*%\5-S/PVDVHR6?"\::.
M"VZ7CF2\=)(INM'U^L#U%>FY/KA>GE/PT@4%K]Y9C/8"^W@IMPT.]WQLH#0&
MM-HC).X*@B=)*+PC 8#UT5S]1NEUGR@Q,W\,NTLZ[)=\1>K0S4U*3CY99EU6
MFCEJ8Y(^=2],+4U8K7^ ;G<Y95#BVC6ZY9IG=4;4NZBA,3L3QH>Q?J4]-8U1
M?K8Y64M7']HY>8$ :F@-Y!Y_O_XT2JN'+86R1KH7N_6%;6^GS-)Z/1Y<NYDP
M>M-DF=:"IG<[0V/$T/LC'L\NS Z<\;=4]#O,U+,2$VRT-7)6 OO@!O1AQ(#@
M6#;$<E*_01#4_5WQBA6]W&4"@M#"C1EW8^/L%*H&,FL%.+(YX,W1W8FBML5D
M.J/ QYHA.RLGGQPTRX*]3!=YD5Z(()[:YG<GQ4<Z<2SV[*_(S3WR%\RK/K&5
MTD-CP]OHPW*,/MMZ!Q9/61ZQ"H:K2$!Y<>=D;'*T)0^8XCQO.TQ S&V$**F&
M=47_\$*Z*G]:QR+A\(<6I=LZG^(@GCM$AA) X><>D5]RL_*4*#2OU4HK<9ZQ
M:M"9UV<P#6-FPJG&U(BA+CC;':V7/45KQ=ZZ3H>NH*DW'[- =84G'Y7-/&,F
M_5)"OZ'(:_6,1\?7@SP6KF<WF;;A>199?=)SPW2\NIIT2K$!DK!BP VE B4+
M437GFQZ-.768F4#Z5>BCJ9_E\31E?'OJMZ BC?D==QT>3J(]QUD&*Z2N;RWF
MRIJ)"-])$E<%EU 7IFZ-++T%-<^]9)<'LTK:'*PNNBY5!C9GB2+]MX08$"*J
MA[E3COBK1LNMA0=GGQUGOCN>'5ZR]2J6DCV,O8Y/<W"\8'P_?)>#(QWDX(9#
M1'MMM$ZA7BY;E<SVY#((U#*V7UY::GC$=<$NCU\2EB F%=Y0/N>$@.*-/)9Z
M*.&PO;+')G=$&4W[865A84C1JE),C]':E .[Y&69(%2H+A,3=[']>F#^6YM-
MGEX?IQ@]3BZZ1I>[,/L%R&BA2&=F3E.'NWD<MTW R-$^2UTG+,Q_2(QY3&]E
MK),GG=)+>/^>JD#&W$.P#['**UET \'Z1M0P)4+)EV9=T=;RP<S:6JAV_ ?<
M9!\II=T?F03@U_I H^R%'%Z1AO_9>OX#B!MX8BP+2ONG9J M:3;63UFI$US>
M\<%AV\_W" &WS&:7F'(O4Z;/O+3&0($+>^\ASN!HD[@$VZ\(5&)1,D(<?$/X
M:<N!E2$KVD&3^C+CF<QT<>V2>BS'A#S#&J38HD $I@<87&+I37+$._,S0X78
MT[P@[V F_<>14Z(2O6W(8_5W\LL**/V2$H!MK0#W71E4.&)R5.@6MXD5758G
M7MG!5^"4^^6E=@=.L-Q6<LB5DMNH=8T=5*3)=<G6[5PX;EC#M6R@A54D>-.T
MIMJC/E]]1C,*_VT3YFU$G(O844!<MJOH\[/'W[:/%X2FJ:;9DBY\%H:@@%V%
M&7''M<MYF(#:SWA]]ANQ5YTOFA5^&B&@')<^.PSX>C@]$?"MZLJVYUSQ8PL=
MY/4;]YCUF%/J9H0W?I\KY77WR]]G@U!EWELMS-]6(K+X=?BO30^<&+VL3342
MG-2+69UG?CW.7:\D/ ;GP>S!Q= 6AATHZ3I[28MVPBB$]L[W(03SENDT]XKF
M+/9.EE8Z1<PG=BW.OT5!F:G*#5^)SHDF(GNLKDY(&9$9<K:(H2GA]=R/(*U0
M/U1>1 \B7;9:'1U_RAZV%GU!J_AB]O"%_6-@*F&W,G>!<CPOW)]F7K97]5#4
M7I(!_K=W#%XQAT'W,@I^,$!'&P9(<GM:_7.Q\8H,^MO'52SUC\G'?79W0 ]%
M)_%_4G3^$\!W3MRMG]#HZ0[9*CEG)8O=2&4.B:IM9?O20YL;*E(&J^J3%W2,
M/#GPWKL;J[+T_]1,K&+OH5U[*+2 O\K-/P#?</+^N*.^NC%][GNC3CN5?/OP
M:D'1J2*<\NS<D*G D)5@U)M69^G48JPL?'P\X.I=_ HXWIQ<AG0];1K2/1[S
MYM]\PJ8"Z6Z]1+G3QD60O9^=6HI*<778;[)X1 ( F7NX&##&#^Y8NCV:;2%"
M)?W%8F=B%:Y&*L1C]!_MYN^!0'C1[9RMPJO,I])Z?LTMZ)V7\^D ^+^B])MX
M_U A31Q!_WFS .?Q!S1/LG_8#,NZB7OBRU%=BWOI6^X" >Z.L)(*8VR-8PQE
M&!!@LNIS3<#-=G-LAA";W=!ZJ:['"P.RC!X>M3Z+_(>_?/EEF8O_8<;_3/^?
MZ?\S_7^F_^]-+Z_TQH8!/8S#(KNA/EM=Y8D^RYJNB_<!X7+WM\G7.<OQ*6ZY
MGGPC[YW07&H;0@AP7Z^BYS:2^\ S()3\!\'E_SS4PP#<^1UU%RU.+9U._)+:
M(W';ST)#E$;AF>EX[D<9>?:U+<\F2UEQK]AD+"\:0WM<Q_/R$UZ$Z[H.]7(V
MVE'&S/@*,86T'YX-C.E8G#_E97-DL?ZH-$2IV%^**TQB!D3IA*U^9C99F]G)
MLM=X,C7J2R'!Z9AQ,@0#R'/^&#-11M[,T]^>P(#N@C]'N%,57AD8( @#CG;$
M:0IZ(B,O"N!E&5-R84"ZS^49R1\C(!SR;EMD,^->2/+WX156=E(#Z&H3!D0J
M_3$J(FP53$H91%-0'"COQ]R[P8#5<>#ZO[54#BX_[:-K'ZC<WY;Z;/W'$M;_
MY5)AWY?\UH]]9O+^5P+]]0O@A3<PZC,D<NL>_OOPH!W)48&PQ%\/=?^Z]9\J
M3")Z&IYF"09 7^$J2>=&?^]>E?NWD?Z_!?;7,"!XOTFH1++J1^?S-$&:7A^H
M.%JP/UG[15EC(,_I]N74KV^A"BEC7<KNWW^G@:RS$BPLLU5[A'Y4FULC_/$T
M=6W-\3V;(#%P2N)&;.FZ[IK\U G=R/"QF)28*,TQ-]T[5V<<F^5F#OPG 7(:
MXV@??SR#CVQJCJRU&,M\E _]L"5)'TQ[O(;[;#FM1 !GGREQF"O:P<7N+LUJ
M8[Y09KH+*S&_0$0'_7HU>23;EVG:?-)=MZ"FHC;BD2@K%)D#I.P%:I9]4,S)
MTYO2.R:MX(=MVV"[T+Y61*S^,SGK\9G(*+AWO#9NW1D:]Q%XV)B_B8\>=*>8
M/_:08ZHRGO[5'>Z  9KTXSY,7NPBDS)G%+T9?T.W.0N^'-L.OZ\0(?;Z*_7C
MT#\SW1%)$TYBNZXZHQC\&SH2!]N9'.BSQ'VA&=RITK_FC/\)X+>Y#DH&Z87N
M*::DF+/ZC&3?3Q-HTREW)F)\K>VKW=BT%AIP@;:Y%K]I'O=4UI9RO9^U,B7K
M*+:SKJ1!,D<TRVV(ZG^3=$\1:TKV50"$-E0DGZ6-H?<CNR&"2S)J$'*UR-#W
MH<G>09L[;MG/H@5_-"#F^WGV*/L3V1>=SF'&SL+?H&9 B<-*&C;(Z8E^5ZE%
MI6!>W ??CRCM.($STBB(2ZGJG6ZY]QB3IO5-U'B::#K2)AZIG?SFZM*3?#!@
M/=X9Z$80W'1V>$7NE[_CG%S:"#)E2PS9X$62K7RQ0Z0!CT7SX65(TI^;IZ[@
M9^J&=YUW]Q-^1NXFFFGVRJ_?HB(;/;I+H?]HAUG]%?$*I4_#_'TL'#?>$*,0
M##C(D8I-AP$7([_,YSAF\?Z:RTWF  9X$0->?^P.N;('#%B43&*QP#[;>9FA
M!22'F,:V_)J3TPORN=D:?K#_/^8(YE[ @);P!U,W_7W5@DTSUFR._DYL)]ID
M ,)V)I:A^M.:E<U@WH8A3@JQF%0MXW<F?GFH=?K6NU.SWWEX\!_IOY.-_ ,!
MWJ<D9D<D3CA+8\KC%QNR/O^6[W^6#*YUDGX55*#%??*DW'LCXW<Z#Z[A#V[_
MD.^72_E-GI'?$8"$.\WKR$U0@7&X&'FSE,,NZ-^Q]B^\&^OOQ">QD*R:R)#S
M")$I2-]>%FEQR#U+A\SI"/:OG<'9?9!ZKXB<AA>2)8ERDO?_[ O;3;,K9 /)
MNS4X%DK3[>\5F88<K/=-YEOM ]5)&57I^.?KP+E343J7?H&5%?(KX;(]9=;6
M*^.JKW]2AM-24V'/J/,P 7.<J3$];0!Y5E8?US5F!LMYJ#GG;)?>/-CLTQX%
M YGOZ1YXIRR1M2O!C)5LK>88W.OR[IU)-V+\6JJ+X-032[<5M5:C/!VQR8"\
MXY]GH;D0\Q]8_16$5SKDF,?3#S$/)5-)Z>L!79,-K20CD:A9#V)6-PV-?PC$
M%_4OGZ,*??+@KOOU]VM/,Q^;_5&_,4)@0+&(TNWVZ1]^"/CK_X\P,5H;?%Q>
M@VMD6,OXZJ#*+1?:-9;'8RM;&MGDRG?@-_FE5(]KE=%Z2J*8*X"7)WZ*;L1G
M#0?E%NW7ZR7O^G(,M"O67/4X". M!A8\27U7Z]T3DY#N# /\]NXU2FRG\S_E
M%DEBZ#>WEG]MJ%;CK^/7FP_%)P'A>FTK>9<@2;)85<5@&]V/L-YN[UK!WTT;
M44C@C[BG):R8[E^%\];DE';H7TQ_OFN9NG?W/T6<\ 6V@&OE$8NTJ3D8T"^T
MT/FZN79ATX,T>H1D;!MT\UZXTF?Q,PQ C?/YW6=*%+GHN]QB-WEXT_G4B,,
M>9&#,9\ "JN@^^3?$2LD7JH>7/JTH777KH!OG%HO4HXD'VZ#:F=]AD"WC@\I
MFV9VW)^+X&.<%4:+>/J7ZS&!:F8RKEQ#[V_P:7Q*0%T9OAXJ4(7=?9\-\FVL
MF;U(N4^M!Q4*3['38R1]EL12C<+.)$0"N&:_NK<3P0#?$/VFXUOQN9-;%!3Q
MD823?*<"[Y[W/NL+;#=+*O+AA3 @P14&(.7_4@/Y01++[Q'#2Q72-4U%C4\:
MD42V#0,,:N]WL7)J+T>;%?H>;-67(-*^$U__IV)$^MMKV<55J1]/[MU!,, G
MY=;\!'3E0W$)9W9QBX:GYE-1?GN6<7\/I3#2O]H3N;OEJL^_;8V\!:H][A$'
M=XF?.J,6<<CPP5>=,AK%R(;1%..S$"*,;3P+%Y?E=586B^DEJ@C?EUZZ*-(C
M'%N8^;%/UG;BBOKR;;1.97FP1N*8ZET7U&7ZATK>S]3ZYOVN.SPEW<T7O\(9
M+D";"J=)D$XW9I,3+V?D0&O7O1%$4+GR^BQL[PH&+/$/6/2JOEYO8\#;!TQI
MMA>:Y@_>" @7?M[BO>"=439W$'S;L2+W5 <Q7!^($GW/V/=\L"X32W97PBU@
MMM-CE=G/?8.V=B+[AQOS %21VA 'ZMG$^62BH9:&KYAC6YY?.]_K%8CW$YW?
M#],HBJH$6\6W1T2 X_6&KQ!QR$E*#\V7ZKHQ>BBK,;<YM=]^;D*/GV">+>:"
M!L$[5 '35D!]\:.^5DJ[@'@2U30""PRPD!$<S99$(.*G8*#PH)_TY?EYUOQ2
M<?QY">OS>,M0Q<\FKZ1U("A"CWNC;%V[N;-TTB**\WN.D,\?6>-5:4J@%BC#
M.4$,>S'9HZ- DWDM8U.*1^MU=4^:FP1\DC^1Q8MPR;Z0)L5]:3H^C *2< L*
M"LR]P.D[OXS1D<[GY>E\=V(28V2@;S>-)SSZB/ K8&L!XAB_E$F1@IS<2.>U
MGF?%##U_VJ_/5T=ZT'6[=U61ZIR))5>P41<X1Y6L%O;RTWA%ET8J(#3@ECJ
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M:@L0;O)? %!+ 0(4 Q0    ( .:#K5K(QD?_>@L  -%V   1
M  "  0    !A=GAL+3(P,C4P,S,Q+GAS9%!+ 0(4 Q0    ( .:#K5J\NH'K
M0 D  %!E   5              "  :D+  !A=GAL+3(P,C4P,S,Q7V-A;"YX
M;6Q02P$"% ,4    " #F@ZU:[;V(^805   K2@$ %0              @ $<
M%0  879X;"TR,#(U,#,S,5]D968N>&UL4$L! A0#%     @ YH.M6DH^,YL#
M0@  6\T# !4              ( !TRH  &%V>&PM,C R-3 S,S%?;&%B+GAM
M;%!+ 0(4 Q0    ( .:#K5H]K+?(FRT  (/O @ 5              "  0EM
M  !A=GAL+3(P,C4P,S,Q7W!R92YX;6Q02P$"% ,4    " #F@ZU:I_!+W0X]
M 0"0#0L #0              @ '7F@  938U-SA?,3!Q+FAT;5!+ 0(4 Q0
M   ( .:#K5JF<% A2@<  (8@   0              "  1#8 0!E-C4W.%]E
M>#,Q+3$N:'1M4$L! A0#%     @ YH.M6JW7Q"9 !P   B   !
M     ( !B-\! &4V-3<X7V5X,S$M,BYH=&U02P$"% ,4    " #F@ZU:FW+)
M]/X%   \&   $               @ 'VY@$ 938U-SA?97@S,BTQ+FAT;5!+
M 0(4 Q0    ( .:#K5JR5A\O&6   'EK   -              "  2+M 0!I
M;6%G95\P,#$N:G!G4$L! A0#%     @ YH.M6F XJSU^7   4&\   T
M         ( !9DT" &EM86=E7S P,BYJ<&=02P4&      L "P"V @  #ZH"
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>e6578_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20250331"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20250331.xsd" xlink:type="simple"/>
    <context id="From2024-10-01to2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2025-05-13</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_custom_MichaelJFoxFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-03-242022-03-25_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-17_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-17</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-10-01to2025-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-10-01to2025-03-31" id="Fact000004">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-10-01to2025-03-31" id="Fact000005">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-10-01to2025-03-31" id="Fact000006">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-10-01to2025-03-31" id="Fact000007">0001314052</dei:EntityCentralIndexKey>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0087"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2025-01-012025-03-31"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0154"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2023-10-012024-03-31"
      id="xdx2ixbrl0156"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:DeferredGrantIncome
      contextRef="From2023-10-012024-03-31"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:IssuanceOfCommonShares
      contextRef="From2024-10-01to2025-03-31"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommonStockIssuedUponCashlessExerciseOfStockOption
      contextRef="From2023-10-012024-03-31"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:ExerciseOfStockOption
      contextRef="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:ExerciseOfStockOption
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:ExerciseOfStockOptionAndTaxes
      contextRef="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:ExerciseOfStockOptionAndTaxes
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:PurchaseShares
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CashlessExerciseOfStockOption
      contextRef="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CashlessExerciseOfStockOption
      contextRef="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesWithheldRelatedToAndTaxes
      contextRef="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesWithheldRelatedToAndTaxes
      contextRef="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-012025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:PurchaseShares
      contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentShares
      contextRef="From2023-10-012024-03-31"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:ExerciseOfStockOptions
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:ExerciseOfStockOptions
      contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:ExerciseOfStockOptions
      contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-10-01to2025-03-31" id="Fact000013">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-10-01to2025-03-31" id="Fact000014">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-10-01to2025-03-31" id="Fact000015">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-10-01to2025-03-31" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-10-01to2025-03-31" id="Fact000017">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-10-01to2025-03-31" id="Fact000018">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-10-01to2025-03-31" id="Fact000019">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-10-01to2025-03-31" id="Fact000020">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-10-01to2025-03-31" id="Fact000021">630 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-10-01to2025-03-31" id="Fact000022">20th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-10-01to2025-03-31" id="Fact000023">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-10-01to2025-03-31" id="Fact000024">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2024-10-01to2025-03-31" id="Fact000025">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2024-10-01to2025-03-31" id="Fact000026">10111</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-10-01to2025-03-31" id="Fact000027">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-10-01to2025-03-31" id="Fact000028">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-10-01to2025-03-31" id="Fact000029">Common Stock     Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-10-01to2025-03-31" id="Fact000030">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-10-01to2025-03-31" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-10-01to2025-03-31" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-10-01to2025-03-31" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-10-01to2025-03-31" id="Fact000034">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-10-01to2025-03-31" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-10-01to2025-03-31" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-10-01to2025-03-31" id="Fact000037">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-05-13"
      decimals="INF"
      id="Fact000038"
      unitRef="Shares">85371852</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000046"
      unitRef="USD">115771000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000047"
      unitRef="USD">132187000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000049"
      unitRef="USD">666000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000050"
      unitRef="USD">2449000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000052"
      unitRef="USD">702000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000053"
      unitRef="USD">931000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000055"
      unitRef="USD">117139000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000056"
      unitRef="USD">135567000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000064"
      unitRef="USD">6997000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000065"
      unitRef="USD">9627000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000067"
      unitRef="USD">9555000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000068"
      unitRef="USD">4835000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000070"
      unitRef="USD">829000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000071"
      unitRef="USD">842000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">17381000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">15304000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000079"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000081"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000083"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000085"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000091"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000093"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000095"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000097"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000099"
      unitRef="Shares">85333652</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000101"
      unitRef="Shares">85333652</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000103"
      unitRef="Shares">84795517</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000105"
      unitRef="Shares">84795517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000107"
      unitRef="USD">85000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">85000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000111"
      unitRef="USD">459051000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">456249000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000114"
      unitRef="USD">-359378000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">-336071000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000117"
      unitRef="USD">99758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000118"
      unitRef="USD">120263000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000120"
      unitRef="USD">117139000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000121"
      unitRef="USD">135567000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">2621000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000129"
      unitRef="USD">2895000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000130"
      unitRef="USD">5767000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">5590000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">9892000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">9729000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">20338000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">18413000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">12513000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">12624000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">26105000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000141"
      unitRef="USD">24003000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000143"
      unitRef="USD">-12513000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000144"
      unitRef="USD">-12624000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000145"
      unitRef="USD">-26105000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000146"
      unitRef="USD">-24003000</us-gaap:OperatingIncomeLoss>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000155"
      unitRef="USD">12000</avxl:NonOperatingIncomeFromGrants>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">96000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">472000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000160"
      unitRef="USD">508000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000161"
      unitRef="USD">1064000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000163"
      unitRef="USD">1210000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">1756000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000165"
      unitRef="USD">2604000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000166"
      unitRef="USD">3764000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000168"
      unitRef="USD">11000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000169"
      unitRef="USD">-150000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">-326000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">7000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000173"
      unitRef="USD">1317000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000174"
      unitRef="USD">2078000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000175"
      unitRef="USD">2798000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000176"
      unitRef="USD">4835000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">-11196000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">-10546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000180"
      unitRef="USD">-23307000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000181"
      unitRef="USD">-19168000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact000188"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact000190"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000192"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000196"
      unitRef="USDPShares">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000198"
      unitRef="USDPShares">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-10-012024-03-31"
      decimals="INF"
      id="Fact000200"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-012024-03-31"
      decimals="INF"
      id="Fact000202"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact000209"
      unitRef="Shares">85073769</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact000211"
      unitRef="Shares">85073769</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000213"
      unitRef="Shares">82464226</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000215"
      unitRef="Shares">82464226</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000217"
      unitRef="Shares">84938400</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000219"
      unitRef="Shares">84938400</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-10-012024-03-31"
      decimals="INF"
      id="Fact000221"
      unitRef="Shares">82269965</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-012024-03-31"
      decimals="INF"
      id="Fact000223"
      unitRef="Shares">82269965</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">-23307000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">-19168000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">3504000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000235"
      unitRef="USD">4938000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">-1783000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000241"
      unitRef="USD">1076000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">-229000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">692000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">-4893000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000247"
      unitRef="USD">-596000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">4720000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000250"
      unitRef="USD">-2380000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <avxl:DeferredGrantIncome
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">12000</avxl:DeferredGrantIncome>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000255"
      unitRef="USD">-17976000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000256"
      unitRef="USD">-18974000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <avxl:IssuanceOfCommonShares
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000262"
      unitRef="USD">7178000</avxl:IssuanceOfCommonShares>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">1560000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000265"
      unitRef="USD">158000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000267"
      unitRef="USD">1560000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000268"
      unitRef="USD">7336000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">-16416000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000271"
      unitRef="USD">-11638000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000273"
      unitRef="USD">132187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">151024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000276"
      unitRef="USD">115771000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000277"
      unitRef="USD">139386000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <avxl:CashPaidForStateAndLocalFranchiseTaxes
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">36000</avxl:CashPaidForStateAndLocalFranchiseTaxes>
    <avxl:CashPaidForStateAndLocalFranchiseTaxes
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000283"
      unitRef="USD">220000</avxl:CashPaidForStateAndLocalFranchiseTaxes>
    <avxl:CommonStockIssuedUponCashlessExerciseOfStockOption
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000285"
      unitRef="USD">460000</avxl:CommonStockIssuedUponCashlessExerciseOfStockOption>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000294"
      unitRef="Shares">84985449</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000288"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000289"
      unitRef="USD">459012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">-348182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">110915000</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000302"
      unitRef="Shares">130700</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">852000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">852000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:ExerciseOfStockOptionShares
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000310"
      unitRef="Shares">500000</avxl:ExerciseOfStockOptionShares>
    <avxl:ExerciseOfStockOption
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">1000</avxl:ExerciseOfStockOption>
    <avxl:ExerciseOfStockOption
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000305"
      unitRef="USD">459000</avxl:ExerciseOfStockOption>
    <avxl:ExerciseOfStockOption
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">460000</avxl:ExerciseOfStockOption>
    <avxl:ExerciseOfStockOptionAndTaxesShares
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000318"
      unitRef="Shares">-282497</avxl:ExerciseOfStockOptionAndTaxesShares>
    <avxl:ExerciseOfStockOptionAndTaxes
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">-1000</avxl:ExerciseOfStockOptionAndTaxes>
    <avxl:ExerciseOfStockOptionAndTaxes
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">-2721000</avxl:ExerciseOfStockOptionAndTaxes>
    <avxl:ExerciseOfStockOptionAndTaxes
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000316"
      unitRef="USD">-2722000</avxl:ExerciseOfStockOptionAndTaxes>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000321"
      unitRef="USD">1449000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">1449000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000329"
      unitRef="USD">-11196000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000330"
      unitRef="USD">-11196000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000338"
      unitRef="Shares">85333652</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000332"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000333"
      unitRef="USD">459051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">-359378000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000336"
      unitRef="USD">99758000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000346"
      unitRef="Shares">82086511</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000341"
      unitRef="USD">437184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000343"
      unitRef="USD">-301691000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000344"
      unitRef="USD">135575000</us-gaap:StockholdersEquity>
    <avxl:PurchaseSharesShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000354"
      unitRef="Shares">1500000</avxl:PurchaseSharesShares>
    <avxl:PurchaseShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000348"
      unitRef="USD">2000</avxl:PurchaseShares>
    <avxl:PurchaseShares
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">7410000</avxl:PurchaseShares>
    <avxl:PurchaseShares
      contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember"
      decimals="-3"
      id="Fact000350"
      unitRef="USD">-234000</avxl:PurchaseShares>
    <avxl:PurchaseShares
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">7178000</avxl:PurchaseShares>
    <avxl:CommitmentSharesShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000362"
      unitRef="Shares">3707</avxl:CommitmentSharesShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000370"
      unitRef="Shares">26000</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000365"
      unitRef="USD">99000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">99000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000373"
      unitRef="USD">2652000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">2652000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">-10546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000382"
      unitRef="USD">-10546000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000390"
      unitRef="Shares">83616218</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">84000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000385"
      unitRef="USD">447345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_ShareProceedsReceivableMember"
      decimals="-3"
      id="Fact000386"
      unitRef="USD">-234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000387"
      unitRef="USD">-312237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000388"
      unitRef="USD">134958000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000398"
      unitRef="Shares">84795517</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000392"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000393"
      unitRef="USD">456249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000395"
      unitRef="USD">-336071000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000396"
      unitRef="USD">120263000</us-gaap:StockholdersEquity>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000406"
      unitRef="Shares">320632</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">1560000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000404"
      unitRef="USD">1560000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:CashlessExerciseOfStockOptionShares
      contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000414"
      unitRef="Shares">500000</avxl:CashlessExerciseOfStockOptionShares>
    <avxl:CashlessExerciseOfStockOption
      contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000408"
      unitRef="USD">1000</avxl:CashlessExerciseOfStockOption>
    <avxl:CashlessExerciseOfStockOption
      contextRef="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000409"
      unitRef="USD">459000</avxl:CashlessExerciseOfStockOption>
    <avxl:CashlessExerciseOfStockOption
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000412"
      unitRef="USD">460000</avxl:CashlessExerciseOfStockOption>
    <avxl:SharesWithheldRelatedToAndTaxesShares
      contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000422"
      unitRef="Shares">-282497</avxl:SharesWithheldRelatedToAndTaxesShares>
    <avxl:SharesWithheldRelatedToAndTaxes
      contextRef="From2024-10-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000416"
      unitRef="USD">-1000</avxl:SharesWithheldRelatedToAndTaxes>
    <avxl:SharesWithheldRelatedToAndTaxes
      contextRef="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000417"
      unitRef="USD">-2721000</avxl:SharesWithheldRelatedToAndTaxes>
    <avxl:SharesWithheldRelatedToAndTaxes
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000420"
      unitRef="USD">-2722000</avxl:SharesWithheldRelatedToAndTaxes>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-10-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000425"
      unitRef="USD">3504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">3504000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000433"
      unitRef="USD">-23307000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000434"
      unitRef="USD">-23307000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000442"
      unitRef="Shares">85333652</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000436"
      unitRef="USD">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000437"
      unitRef="USD">459051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">-359378000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000440"
      unitRef="USD">99758000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000450"
      unitRef="Shares">82066511</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">434839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">-293069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">141852000</us-gaap:StockholdersEquity>
    <avxl:PurchaseSharesShares
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000458"
      unitRef="Shares">1500000</avxl:PurchaseSharesShares>
    <avxl:PurchaseShares
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000452"
      unitRef="USD">2000</avxl:PurchaseShares>
    <avxl:PurchaseShares
      contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">7410000</avxl:PurchaseShares>
    <avxl:PurchaseShares
      contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">-234000</avxl:PurchaseShares>
    <avxl:PurchaseShares
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000456"
      unitRef="USD">7178000</avxl:PurchaseShares>
    <avxl:CommitmentSharesShares
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000466"
      unitRef="Shares">3707</avxl:CommitmentSharesShares>
    <avxl:ExerciseOfStockOptionsShares
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000474"
      unitRef="Shares">46000</avxl:ExerciseOfStockOptionsShares>
    <avxl:ExerciseOfStockOptions
      contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">158000</avxl:ExerciseOfStockOptions>
    <avxl:ExerciseOfStockOptions
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000472"
      unitRef="USD">158000</avxl:ExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">4938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000480"
      unitRef="USD">4938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000485"
      unitRef="USD">-19168000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000486"
      unitRef="USD">-19168000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000494"
      unitRef="Shares">83616218</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000488"
      unitRef="USD">84000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000489"
      unitRef="USD">447345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_ShareProceedsReceivableMember"
      decimals="-3"
      id="Fact000490"
      unitRef="USD">-234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">-312237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000492"
      unitRef="USD">134958000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000496">&lt;p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z9R5f4dEeaZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Note 1 	&lt;span id="xdx_82F_zTFTJfB8thWk"&gt;Business Description&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Anavex Life Sciences Corp. (&#x201c;Anavex&#x201d; or
the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s focus is on developing innovative
treatments for Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
including Rett syndrome, and other central nervous system (CNS) disorders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2024-10-01to2025-03-31" id="Fact000498">&lt;p id="xdx_80C_eus-gaap--BasisOfAccounting_zexirGCAj3Nb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Note 2 	&lt;span id="xdx_823_z36cN1o8XQ12"&gt;Basis of Presentation&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited condensed consolidated
interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited condensed consolidated
interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are
necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2024 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto
included in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2024 filed with the SEC on December 23, 2024.
The Company follows the same accounting policies in the preparation of interim reports.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating results for the six months ended March 31,
2025 are not necessarily indicative of the results that may be expected for the year ending September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain immaterial amounts from prior periods have
been reclassified to conform to the current year&#x2019;s presentation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--LiquidityPolicyTextBlock_zICIurpE8pEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zeR0VfVzmDJ9"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenue from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
condensed consolidated interim financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. The Company will need to obtain effectiveness of a new registration
statement in order to access the funds under the 2023 Purchase Agreement. If the Company is not able to obtain the additional financing
on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zvoBFwCpEkv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zrQtwQDPhyT7"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zyMLo2kqnlP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zwYdubCxIUV4"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These unaudited condensed consolidated interim financial
statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex
Australia&#x201d;), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany,
and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances
have been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zORTeRDCLXV" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zLXB3vMTixZ4"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2025 and September 30, 2024, the Company
did not have any Level 2 or Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zEziszRJ3yNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zNJJ33As7Ie7"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2025 loss per share excludes &lt;span id="xdx_900_ecustom--DilutiveCommonShares_iI_pip0_c20250331_zd47XwkTDlq1" title="Dilutive common shares"&gt;15,710,622&lt;/span&gt;
(March 31, 2024: &lt;span id="xdx_90B_ecustom--DilutiveCommonShares_iI_pip0_c20240331_zSr7AeeGJm0c" title="Dilutive common shares"&gt;15,755,114&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv2UtPTYfkUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zhB6e4utZRmk"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2023, the Financial
Accounting Standards Board (FASB) issued ASU No. 2023-07, &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d;
This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our
fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30, 2026. The Company is currently
assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In December 2023, the FASB
issued ASU No. 2023-09, &#x201c;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#x201d; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccounting>
    <avxl:LiquidityPolicyTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000500">&lt;p id="xdx_848_ecustom--LiquidityPolicyTextBlock_zICIurpE8pEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zeR0VfVzmDJ9"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenue from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
condensed consolidated interim financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. The Company will need to obtain effectiveness of a new registration
statement in order to access the funds under the 2023 Purchase Agreement. If the Company is not able to obtain the additional financing
on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:LiquidityPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-10-01to2025-03-31" id="Fact000507">&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zvoBFwCpEkv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zrQtwQDPhyT7"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive and tax receivables, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000509">&lt;p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zyMLo2kqnlP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zwYdubCxIUV4"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These unaudited condensed consolidated interim financial
statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex
Australia&#x201d;), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany,
and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances
have been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000511">&lt;p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zORTeRDCLXV" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zLXB3vMTixZ4"&gt;Fair Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2025 and September 30, 2024, the Company
did not have any Level 2 or Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000518">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zEziszRJ3yNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zNJJ33As7Ie7"&gt;Basic and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2025 loss per share excludes &lt;span id="xdx_900_ecustom--DilutiveCommonShares_iI_pip0_c20250331_zd47XwkTDlq1" title="Dilutive common shares"&gt;15,710,622&lt;/span&gt;
(March 31, 2024: &lt;span id="xdx_90B_ecustom--DilutiveCommonShares_iI_pip0_c20240331_zSr7AeeGJm0c" title="Dilutive common shares"&gt;15,755,114&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <avxl:DilutiveCommonShares
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000520"
      unitRef="Shares">15710622</avxl:DilutiveCommonShares>
    <avxl:DilutiveCommonShares
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000522"
      unitRef="Shares">15755114</avxl:DilutiveCommonShares>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000524">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zv2UtPTYfkUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zhB6e4utZRmk"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2023, the Financial
Accounting Standards Board (FASB) issued ASU No. 2023-07, &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d;
This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our
fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30, 2026. The Company is currently
assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In December 2023, the FASB
issued ASU No. 2023-09, &#x201c;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#x201d; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:AccuredLiabilitiesTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000526">&lt;p id="xdx_80D_ecustom--AccuredLiabilitiesTextBlock_zfzFq0XHzQRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 3	&lt;span id="xdx_822_zMut58cTdmi9"&gt;Accrued Liabilities&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The principal components of accrued liabilities consist of (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zTR76Me0xrG8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zAYunKXtNpH6" style="display: none"&gt;Schedule of principal components of accrued liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_49C_20250331_zD5WUULJawa9" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_49E_20240930_zfej5vkDkEW2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--AccruedInvestigatorPayments_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued investigator payments&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;1,459&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;860&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,200&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,527&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Milestone-based contract accruals&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,332&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;557&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,564&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,891&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_zGSWkP31omT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total accrued liabilities&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;9,555&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;4,835&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 18pt"&gt;&lt;/p&gt;

</avxl:AccuredLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000528">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zTR76Me0xrG8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Liabilities (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zAYunKXtNpH6" style="display: none"&gt;Schedule of principal components of accrued liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_49C_20250331_zD5WUULJawa9" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_49E_20240930_zfej5vkDkEW2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--AccruedInvestigatorPayments_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued investigator payments&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;1,459&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;860&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccruedBonusesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,200&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,527&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--MilestoneBasedContractAccruals_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Milestone-based contract accruals&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,332&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;557&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,564&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,891&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_zGSWkP31omT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total accrued liabilities&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;9,555&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;4,835&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avxl:AccruedInvestigatorPayments
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000530"
      unitRef="USD">1459000</avxl:AccruedInvestigatorPayments>
    <avxl:AccruedInvestigatorPayments
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000531"
      unitRef="USD">860000</avxl:AccruedInvestigatorPayments>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000533"
      unitRef="USD">2200000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">1527000</us-gaap:AccruedBonusesCurrent>
    <avxl:MilestoneBasedContractAccruals
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000536"
      unitRef="USD">4332000</avxl:MilestoneBasedContractAccruals>
    <avxl:MilestoneBasedContractAccruals
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">557000</avxl:MilestoneBasedContractAccruals>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000539"
      unitRef="USD">1564000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000540"
      unitRef="USD">1891000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000542"
      unitRef="USD">9555000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">4835000</us-gaap:AccruedLiabilitiesCurrent>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000545">&lt;p id="xdx_80C_ecustom--OtherIncomeDisclosureTextBlock_zk66xjkPwUGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 4	&lt;span id="xdx_823_z8t8ZdZUxhs9"&gt;Other Income&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Grant income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of March 31, 2025, the
Company had received a $&lt;span id="xdx_90D_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20241001__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zQMM4WfPKBi1" title="Research and development incentive income"&gt;1.0&lt;/span&gt; million research grant awarded by the Michael J. Fox Foundation for Parkinson&#x2019;s Research. The grant
will be used to fund a clinical trial of the Company&#x2019;s lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 (blarcamesine) related to Parkinson&#x2019;s
disease. Of the total, $&lt;span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20221001__20230930_zJRplDwq78Q8" title="Research and development incentive income"&gt;0.5&lt;/span&gt; million was received during the year ended September 30, 2023 and $&lt;span id="xdx_90B_ecustom--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1_pn5n6_c20201001__20210930_z1MYgO9BrOEj" title="Research and development incentive income"&gt;0.5&lt;/span&gt; million was received during the year
ended September 30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The grant income was
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the three and six months ended March 31, 2025, the Company recognized $&lt;span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20250101__20250331_zDkAYP2l8lVj" title="Non operating income from grant"&gt;0&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20241001__20250331_zHo2UpitGLWa" title="Non operating income from grant"&gt;12,275&lt;/span&gt;, respectively (three and six months ended March 31,
2024: $&lt;span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20240101__20240331_zrxVg7ZPsDB3" title="Non operating income from grant"&gt;&lt;span id="xdx_906_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20231001__20240331_zUGWZElgf6F2" title="Non operating income from grant"&gt;0&lt;/span&gt;&lt;/span&gt;) of this grant on its statements of operations within grant income. At March 31, 2025 an amount of $&lt;span id="xdx_90E_ecustom--DeferredGrantIncome1_pn5n6_c20241001__20250331_zsnxobGOHehg" title="Deferred grant income"&gt;0.8&lt;/span&gt; million (September 30,
2024: $&lt;span id="xdx_90C_ecustom--DeferredGrantIncome1_pn5n6_c20231001__20240930_zuj6CigMDod5" title="Deferred grant income"&gt;0.8&lt;/span&gt; million) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized
to other income. The Company will recognize this income on its statements of operations as the related expenditures are incurred to offset
the income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research and development
incentive income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#x2019;s annual income tax return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;During the three and six
months ended March 31, 2025, the Company recorded research and development incentive income of $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20250101__20250331_zp30BaoA9U6g" title="Research and development incentive income"&gt;0.1&lt;/span&gt; million (AUD &lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20250101__20250331__srt--CurrencyAxis__currency--AUD_zTDPeiu1kqm8" title="Research and development incentive income"&gt;0.2&lt;/span&gt; million) and $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250331_z8oUCNXbqTX9" title="Research and development incentive income"&gt;0.5&lt;/span&gt;
million (AUD &lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20241001__20250331__srt--CurrencyAxis__currency--AUD_zsRczMl4XLp1" title="Research and development incentive income"&gt;0.8&lt;/span&gt; million), respectively (2024: $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331_za7nMLpByrd5" title="Research and development incentive income"&gt;0.5&lt;/span&gt; million (AUD &lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331__srt--CurrencyAxis__currency--AUD_zgLVuvOeCura" title="Research and development incentive income"&gt;0.7&lt;/span&gt; million) and $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331_z4ZorWOIzI0k" title="Research and development incentive income"&gt;1.1&lt;/span&gt; million (AUD &lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331__srt--CurrencyAxis__currency--AUD_zu6d9mEiJjA4" title="Research and development incentive income"&gt;1.6&lt;/span&gt; million), respectively) in respect
of the Australia R&amp;amp;D credit for eligible research and development expenses incurred during the period. This amount is included within
Other income (expense) on the condensed consolidated interim statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;At March 31, 2025, Incentive
and tax receivables includes $&lt;span id="xdx_90B_eus-gaap--OtherReceivables_iI_pn5n6_c20250331_z9JmJrCqRI49" title="Incentive and tax receivables"&gt;0.5&lt;/span&gt; million (AUD &lt;span id="xdx_903_eus-gaap--OtherReceivables_iI_pn5n6_c20250331__srt--CurrencyAxis__currency--AUD_zlLn9Cp3He5j" title="Incentive and tax receivables"&gt;0.8&lt;/span&gt; million) (September 30, 2024: $&lt;span id="xdx_902_eus-gaap--OtherReceivables_iI_pn5n6_c20240930_zEnZJCwyNmp" title="Incentive and tax receivables"&gt;2.3&lt;/span&gt; million (AUD &lt;span id="xdx_904_eus-gaap--OtherReceivables_iI_pn5n6_c20240930__srt--CurrencyAxis__currency--AUD_zNr0fI8Ex2wk" title="Incentive and tax receivables"&gt;3.3&lt;/span&gt; million)) relating to Australia
R&amp;amp;D credits earned during the period that are expected to be reimbursed upon filing of the Company&#x2019;s annual claim under this
program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Australia R&amp;amp;D credit
program is a self-assessment program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if specific R&amp;amp;D activities are eligible and (iii) if the individual R&amp;amp;D expenditures have nexus to such R&amp;amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the ATO has the right
to review the Company&#x2019;s qualifying programs and related expenditures for a period of four years. If such a review were to occur,
the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#x2019;s assessments
and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#x2019; claims already received.
Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO could also assess
penalties and interest on any such adjustments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Currently, the Company&#x2019;s
tax incentive claims from 2020 to 2024 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1
      contextRef="From2024-10-012025-03-31_custom_MichaelJFoxFoundationMember"
      decimals="-5"
      id="Fact000547"
      unitRef="USD">1000000.0</avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1>
    <avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1
      contextRef="From2022-10-012023-09-30"
      decimals="-5"
      id="Fact000549"
      unitRef="USD">500000</avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1>
    <avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1
      contextRef="From2020-10-012021-09-30"
      decimals="-5"
      id="Fact000551"
      unitRef="USD">500000</avxl:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned1>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2025-01-012025-03-31"
      decimals="0"
      id="Fact000553"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2024-10-01to2025-03-31"
      decimals="0"
      id="Fact000555"
      unitRef="USD">12275</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000557"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2023-10-012024-03-31"
      decimals="0"
      id="Fact000559"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:DeferredGrantIncome1
      contextRef="From2024-10-01to2025-03-31"
      decimals="-5"
      id="Fact000561"
      unitRef="USD">800000</avxl:DeferredGrantIncome1>
    <avxl:DeferredGrantIncome1
      contextRef="From2023-10-012024-09-30"
      decimals="-5"
      id="Fact000563"
      unitRef="USD">800000</avxl:DeferredGrantIncome1>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2025-01-012025-03-31"
      decimals="-5"
      id="Fact000570"
      unitRef="USD">100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2025-01-012025-03-31_currency_AUD"
      decimals="-5"
      id="Fact000572"
      unitRef="USD">200000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2024-10-01to2025-03-31"
      decimals="-5"
      id="Fact000574"
      unitRef="USD">500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2024-10-012025-03-31_currency_AUD"
      decimals="-5"
      id="Fact000576"
      unitRef="USD">800000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2024-01-012024-03-31"
      decimals="-5"
      id="Fact000578"
      unitRef="USD">500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2024-01-012024-03-31_currency_AUD"
      decimals="-5"
      id="Fact000580"
      unitRef="USD">700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-10-012024-03-31"
      decimals="-5"
      id="Fact000582"
      unitRef="USD">1100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-10-012024-03-31_currency_AUD"
      decimals="-5"
      id="Fact000584"
      unitRef="USD">1600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:OtherReceivables
      contextRef="AsOf2025-03-31"
      decimals="-5"
      id="Fact000586"
      unitRef="USD">500000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2025-03-31_currency_AUD"
      decimals="-5"
      id="Fact000588"
      unitRef="USD">800000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000590"
      unitRef="USD">2300000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="AsOf2024-09-30_currency_AUD"
      decimals="-5"
      id="Fact000592"
      unitRef="USD">3300000</us-gaap:OtherReceivables>
    <avxl:EquityOfferingTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000594">&lt;p id="xdx_80D_ecustom--EquityOfferingTextBlock_zqtZmkPJVub6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 5	&lt;span id="xdx_82B_zTgkX6ypXsza"&gt;Equity Offerings&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s Board of Directors&#160;(the &#x201c;Board&#x201d;)&#160;has
the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number
of shares constituting any series or the designation of the series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2023 Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#x201c;2023 Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $&lt;span id="xdx_90F_ecustom--ValueOfSharesObligatedToPurchase_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zEO1Po9iJstg" title="Value of shares obligated to purchase"&gt;150&lt;/span&gt;.0
million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zenXujBEivod" title="Share issued for offering, shares"&gt;75,000&lt;/span&gt; shares of common stock as a commitment fee (the &#x201c;initial commitment shares&#x201d;)
and agreed to issue up to an additional &lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z5vpIn8uL2r9" title="Pro rata basic number of shares obligated to purchase"&gt;75,000&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchased, at the Company&#x2019;s discretion,
the $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zIIP2cMT7llb" title="Proceeds from issuance or sale of equity"&gt;150&lt;/span&gt;.0 million aggregate commitment. The Company determined the fair value of the initial commitment shares was $&lt;span id="xdx_90C_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230930_zu9HE73auP5a" title="Fair value of the initial commitment"&gt;0.8&lt;/span&gt; million with
reference to the closing price of the Company&#x2019;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $&lt;span id="xdx_900_ecustom--IncurredExpenses_iI_pn5n6_c20230930_zIMJ8tyfr997" title="Incurred expenses"&gt;0.1&lt;/span&gt; million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended March 31, 2025, the Company
did not issue any shares of common stock under the 2023 Purchase Agreement (2024: an aggregate of &lt;span id="xdx_90A_ecustom--AggregateCommonShares_pip0_c20241001__20250331_zLIZcf0gdBFl" title="Aggregate common shares"&gt;1,503,707&lt;/span&gt; shares of common stock including
&lt;span id="xdx_901_ecustom--AggregateCommonShares_pip0_c20231001__20240331_zXOO9ZEfGZwe" title="Aggregate common shares"&gt;1,500,000&lt;/span&gt; shares for an aggregate purchase price of $&lt;span id="xdx_902_ecustom--AggregatePurchasePrice_pn5n6_c20241001__20250331_zYAdxQOcwO46" title="Aggregate purchase price"&gt;7.4&lt;/span&gt; million and &lt;span id="xdx_90D_ecustom--CommitmentsShares_pip0_c20241001__20250331_zUC4XvKkVTZi" title="Commitment shares"&gt;3,707&lt;/span&gt; commitment shares).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2025, there was an unused amount of $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueOther_pn5n6_c20241001__20250331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zFwiDzW8tU1" title="Amount of shares remain available"&gt;110.8&lt;/span&gt;
million under the 2023 Purchase Agreement. The Company will need to obtain effectiveness of a new registration statement in order to access
funds under the 2023 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2020 Sales Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#x201c;2020 Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp;
Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant to which the Company could offer and sell shares of common
stock registered under an effective registration statement from time to time through the Sales Agents (the &#x201c;Offering&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended March 31, 2024, no shares
were sold pursuant to the Offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 24, 2024, the Company terminated the 2020
Sales Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three and six months ended March 31,
2025, the Company issued a net &lt;span id="xdx_902_ecustom--SharesOfCommonStockIssued_pip0_c20241001__20250331_z6SYGlKymyw7"&gt;217,503&lt;/span&gt;
shares of common stock to the Company&#x2019;s Chief Executive Officer upon a net exercise of an option to purchase &lt;span id="xdx_90A_ecustom--OptionToPurchaseShares_pip0_c20241001__20250331_zHGO5UX7pvpj"&gt;500,000&lt;/span&gt;
shares of common stock at an exercise price of $&lt;span id="xdx_90D_ecustom--ExercisePrice_pip0_c20241001__20250331_zYD2xB8VJOta"&gt;0.92&lt;/span&gt;
per share. In connection with the exercise, the Company withheld &lt;span id="xdx_90D_ecustom--WthheldShares_pip0_c20241001__20250331_zX7fdpz2XgY2"&gt;47,745&lt;/span&gt;
shares of common stock as consideration of the exercise price of $&lt;span id="xdx_90B_ecustom--ExercisePriceConsideration_pn3n3_dm_c20241001__20250331_zxzDYQc6kEOe"&gt;0.46&lt;/span&gt;
million and &lt;span id="xdx_904_ecustom--CommonStockAsConsideration_pip0_c20241001__20250331_zh70B5Qc2s3g"&gt;234,752&lt;/span&gt;
shares of common stock as consideration for the payment of $&lt;span id="xdx_909_ecustom--WithholdingObligationsExercise_pn5n6_c20241001__20250331_zNY0nl0W2Yha"&gt;2.3&lt;/span&gt;
million in connection with tax withholding obligations associated with the exercise. The shares withheld were based upon a market
price of $9.63 per share as determined by reference to the average high and low sales price reported on the Nasdaq stock exchange on
the date of exercise. At March 31, 2025, the amount of $&lt;span id="xdx_90A_ecustom--AccountsPayable_pn3n3_dm_c20241001__20250331_zvear9CB18Pa"&gt;2.3&lt;/span&gt;
million in connection with the tax withholding obligations was included in accounts payable on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:EquityOfferingTextBlock>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-6"
      id="Fact000601"
      unitRef="USD">150000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000603"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000605"
      unitRef="Shares">75000</avxl:StockIssuedDuringPeriodValueNewIssues1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-6"
      id="Fact000607"
      unitRef="USD">150000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <avxl:FairValueOfInitialCommitment
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000609"
      unitRef="USD">800000</avxl:FairValueOfInitialCommitment>
    <avxl:IncurredExpenses
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000611"
      unitRef="USD">100000</avxl:IncurredExpenses>
    <avxl:AggregateCommonShares
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000613"
      unitRef="Shares">1503707</avxl:AggregateCommonShares>
    <avxl:AggregateCommonShares
      contextRef="From2023-10-012024-03-31"
      decimals="INF"
      id="Fact000615"
      unitRef="Shares">1500000</avxl:AggregateCommonShares>
    <avxl:AggregatePurchasePrice
      contextRef="From2024-10-01to2025-03-31"
      decimals="-5"
      id="Fact000617"
      unitRef="USD">7400000</avxl:AggregatePurchasePrice>
    <avxl:CommitmentsShares
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000619"
      unitRef="Shares">3707</avxl:CommitmentsShares>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-10-012025-03-31_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      id="Fact000621"
      unitRef="USD">110800000</us-gaap:StockIssuedDuringPeriodValueOther>
    <avxl:SharesOfCommonStockIssued
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000622"
      unitRef="Shares">217503</avxl:SharesOfCommonStockIssued>
    <avxl:OptionToPurchaseShares
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000623"
      unitRef="Shares">500000</avxl:OptionToPurchaseShares>
    <avxl:ExercisePrice
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000624"
      unitRef="USDPShares">0.92</avxl:ExercisePrice>
    <avxl:WthheldShares
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000625"
      unitRef="Shares">47745</avxl:WthheldShares>
    <avxl:ExercisePriceConsideration
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000626"
      unitRef="USD">460000</avxl:ExercisePriceConsideration>
    <avxl:CommonStockAsConsideration
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">234752</avxl:CommonStockAsConsideration>
    <avxl:WithholdingObligationsExercise
      contextRef="From2024-10-01to2025-03-31"
      decimals="-5"
      id="Fact000628"
      unitRef="USD">2300000</avxl:WithholdingObligationsExercise>
    <avxl:AccountsPayable
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000629"
      unitRef="USD">2300000</avxl:AccountsPayable>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000631">&lt;p id="xdx_805_eus-gaap--CommitmentsDisclosureTextBlock_z9XnvYLplbN" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 6	&lt;span id="xdx_829_z42y3Yg8aavi"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company leases office space under an operating lease with an initial term of 12 months or less. Under the terms of the office lease, the
Company is required to pay its proportionate share of operating costs. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Anavex Life Sciences Corp.&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
operating lease costs were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LeaseCostTableTextBlock_pn3n3_zwSPOL4WLGye" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_z306R9oBMXN" style="display: none"&gt;Schedule of operating lease costs&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_49A_20250101__20250331_zXvTohZieOh3" style="font-style: normal; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_493_20240101__20240331_ziUeuynH9xMc" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_495_20241001__20250331_zWoEmaQFPEE1" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_493_20231001__20240331_z2IVqBCiBZij" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-style: normal; text-align: center"&gt;&lt;span style="font-weight: normal; font-size: 10pt; font-style: normal"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Operating lease costs&lt;/td&gt;
&lt;td style="width: 3%; color: gray; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: normal; width: 1%; font-style: normal; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"&gt;33&lt;/td&gt;
&lt;td style="width: 1%; color: gray; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; color: gray; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: normal; width: 1%; font-style: normal; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"&gt;31&lt;/td&gt;
&lt;td style="width: 1%; color: gray; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; color: gray; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: normal; width: 1%; font-style: normal; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"&gt;66&lt;/td&gt;
&lt;td style="width: 1%; color: gray; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; color: gray; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: normal; width: 1%; font-style: normal; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"&gt;61&lt;/td&gt;
&lt;td style="width: 1%; color: gray; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A8_zBV7Ud0dpqk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Employee 401(k) Benefit Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees. United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the
Internal Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing
employees. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-style: normal"&gt;The
Company made matching contributions under the 401(k) plan as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zoNuCoesb418" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zgvvTFOaLGM5" style="display: none"&gt;Schedule of contributions under the plan&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_498_20250101__20250331_zo7hRpAFbtJe" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_49C_20240101__20240331_zzIMjpSm5Ag" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_492_20241001__20250331_zvYnMorIwb5b" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_499_20231001__20240331_zt9xe4YEHub6" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended March 31,&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six Months ended March 31&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--PensionContributions_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Contributions to 401(k) plan&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;67&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;94&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;115&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;167&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A4_zfSdE6CZo3m6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Litigation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;span style="font-style: normal"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there
can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter
will not have a material adverse effect upon the Company&#x2019;s consolidated financial statements. The Company does not believe that
any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On March 13,
2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York and it
named the Company and an officer of the Company as Defendants. The complaint was amended on July 12, 2024 (the &#x201c;Initial Action&#x201d;).
The complaint alleged violations of the Securities and Exchange Act of 1934 associated with disclosures and statements made with respect
to certain clinical trials for ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 related to Rett syndrome. The complaint seeks unspecified damages, as well as
costs, including counsel and expert witness fees, on behalf of a class of investors.&#160;The Company believes the lawsuit is without
merit and the Company denies any liability or wrongdoing and has filed a motion to dismiss the complaint, which is awaiting a decision
by the Court. No amount has been recorded in these condensed consolidated interim financial statements for any loss contingencies associated
with this lawsuit as the Company believes that it is not probable that any loss will occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On May 8, 2024,
a similar complaint was filed in the same court by Kenneth Downing, a purported shareholder of the Company, against the same defendants.
The Company believed that this lawsuit was also without merit and filed a motion to dismiss the complaint. Plaintiff Downing voluntarily
dismissed this complaint subsequent to the filing of the motion to dismiss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On or about
May 13, 2024, a derivative lawsuit was filed against the Company (as nominal defendant), an officer of the Company, and members of the
Company&#x2019;s Board of Directors in the U.S. District Court for the District of Nevada by another purported shareholder. The complaint
asserts various common law claims (including breach of fiduciary duty) and violation of Section 14(a)of the Securities Exchange Act regarding
the same or similar allegations at issue in the purported class action lawsuit related to disclosures and statements made about certain
clinical trials related to Rett Syndrome. On January 22, 2025, pursuant to a stipulation of the parties, the Court entered an order staying
this purported derivative lawsuit until the motion to dismiss filed by defendants in the Initial Action is decided by the U.S. District
Court for the Southern District of New York.&#160;No amount has been recorded in these condensed consolidated interim financial statements
for any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On February
14, 2025, another derivative lawsuit asserting state law breach of fiduciary duty and unjust enrichment claims based upon similar allegations
was filed against the Company (as nominal defendant), an officer of the Company, and members of the Company&#x2019;s Board of Directors
in the Supreme Court for the State of New York, County of New York, by another purported shareholder named Evan Levitan. The parties to
that action also have stipulated to a stay of the proceeding until the Court rules on the motion to dismiss in the putative class action
lawsuit pending in the U.S. District Court for the Southern District of New York. The New York state court has not yet entered an order
pursuant to the stipulation of the parties. No amount has been recorded in these condensed consolidated interim financial statements for
any loss contingencies associated with this lawsuit as the Company believes that it is not probable that any loss will occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;We know of no
other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business, to which
our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which any
of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#x2019; interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Share Purchase Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2025 and September 30, 2024, the Company
had &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20250331_zQNhL5vRDmm2" title="Warrants outstanding"&gt;10,000&lt;/span&gt; share purchase warrants outstanding exercisable at $&lt;span id="xdx_90B_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20250331_z99TI7K5dSrc" title="Warrants outstanding weighted average exercise price"&gt;12.00&lt;/span&gt; per share until &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20250331_zMTbu586Lpxc" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Share&#x2013;based Compensation
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2015 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 18, 2015, the Company&#x2019;s Board approved
a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the 2015 Plan was &lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zT078oDmSJQk" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2019 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the 2019 Plan was &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20241001__20250331__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zdlnRZjcpsEc" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2022, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pip0_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zinupTm7xWrl" title="Option granted"&gt;406,453&lt;/span&gt;
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2022 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20220324__20220325__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zArEo1H39uD5" title="Additional shares of common stock available for issuance"&gt;10,000,000&lt;/span&gt; additional shares of Common Stock will be available for issuance under the 2022 Plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. As at March 31,
2025, &lt;span id="xdx_905_ecustom--OptionIssued_pip0_c20241001__20250331_z6BLsQoqgdX3" title="Option issued"&gt;6,751,000&lt;/span&gt; options had been issued under the 2022 Plan and &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zwUxtbOJOy4" title="Option available issue"&gt;3,978,702&lt;/span&gt; options were available for issue under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock option
activity during the six months ended March 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_pn3n3_z9S8O13eYfzg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zS9TXJDkRItc" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price &lt;br/&gt; ($)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value &lt;br/&gt; ($)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate intrinsic value &lt;br/&gt; ($)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoEaPYql32d4" style="width: 13%; text-align: right" title="Number of options, Outstanding beginning balance"&gt;15,037,754&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoToyiPYCpNa" style="width: 13%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance"&gt;6.80&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3KMRIQOoSy6" style="width: 13%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance"&gt;5.12&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7FOQOnkEFBb" style="width: 13%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance"&gt;15,825,791&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjgRAX6Toh8k" style="text-align: right" title="Number of options, Granted"&gt;1,483,500&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z55T64KzlfX5" style="text-align: right" title="Weighted average exercise price, Granted"&gt;8.58&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbB1KsasrkVc" style="text-align: right" title="Weighted average grant date fair value, Granted"&gt;6.22&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zb5a8BIaPsmg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Exercised"&gt;(820,632&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze0qcpoGZEj4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Exercised"&gt;2.46&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBIWuwS0o07c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Exercised"&gt;1.89&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT0rQLLEcxK3" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Exercised"&gt;6,785,518&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, March 31, 2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjgGMNZ5Achc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding beginning balance"&gt;15,700,622&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zapl6u6eG3ik" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance"&gt;7.19&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuLjeaneUI4j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Outstanding ending balance"&gt;5.39&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zddXQqjIO2Kj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance"&gt;38,630,198&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable, March 31, 2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_za09lPpzu9Fi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable"&gt;10,346,086&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMW0ks6U2uB" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable"&gt;6.03&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvgz0pk0U7Pi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Exercisable"&gt;4.68&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJcdPGwunFEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable"&gt;34,276,704&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AA_z67DJIQfLdm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock options
at March 31, 2025 by a range of exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlIRqgbamqfc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_8B0_zOvKWoDBishk" style="display: none"&gt;Schedule of summarizes information about stock options&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Range of exercises prices&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of outstanding &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average remaining contractual life (in&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average exercise&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of vested &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average exercise&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;options&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; years)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160; price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;options&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160; price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zrnGbCei2rd3" style="width: 10%; text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.92&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z52scwgkvHul" style="width: 12%; text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zSAurzpUAKbe" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,400,150&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z03dX8ExWOb5" title="Weighted average remaining contractual life (in years)"&gt;3.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxSls1sXj7db" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.69&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zPymBH2v5m15" style="width: 10%; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,400,150&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zCun6LKsZWab" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.69&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zBiOs6e9ODdl" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.01&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zyoEroYMf3u" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zffZhWgKcf9d" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,197,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zurDYdWYyMXc" title="Weighted average remaining contractual life (in years)"&gt;3.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zSnbeNfoWgk4" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.41&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zTBZD18vTfej" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,027,916&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zp4vRIlaj22a" style="text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.31&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTaxbaDflOLj" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.01&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zWkAAlJQsaI1" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zvuSVhzoEaA" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,028,972&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zGGjzbtrmZm8" title="Weighted average remaining contractual life (in years)"&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zmu2LkvBC4Ee" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.95&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zaNQFSp8JOn4" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,297,519&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zNcGZkFQBZAl" style="text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.39&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z69JunRT9rya" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.01&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zPJraIoaxcNg" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z1kQsNImJ2p9" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,609,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zvfOZMHD6tia" title="Weighted average remaining contractual life (in years)"&gt;6.81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zO46Ji9l9SOg" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.29&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zFgDHNVAFGqa" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;998,834&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3cdhYlhr5z4" style="text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.42&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zXTCt5aJdsId" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.01&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zGqvDBOJrpa5" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zUkMsMVzpcQ5" style="border-bottom: black 1pt solid; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,465,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zqDDFS6JsUe3" title="Weighted average remaining contractual life (in years)"&gt;5.97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zKKvCc09J06j" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.18&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zDZG5Pgw9TO1" style="border-bottom: black 1pt solid; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;621,667&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBLqMqPkvQC4" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.34&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZx9d33psFFi" style="border-bottom: black 2.25pt double; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,700,622&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm0Xt9SnbzZb" title="Weighted average remaining contractual life (in years)"&gt;5.59&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6fSVe9l7uT6" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.19&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKoKRgQHLD6i" style="border-bottom: black 2.25pt double; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,346,086&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPN9U7MMCaic" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.03&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zRtWEBMpp0w4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average per share fair value of options
vested at March 31, 2025 was $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250331_zQTrzeDgURb6" title="Weighted average grant date fair value of options vested"&gt;4.68&lt;/span&gt; (September 30, 2024: $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240930_zObSEf6I3Arg" title="Weighted average grant date fair value of options vested"&gt;4.34&lt;/span&gt;). At March 31, 2024, the weighted average contractual life of options outstanding
was &lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331_zazaen280lTe" title="Weighted average contractual life of options exercisable"&gt;5.59&lt;/span&gt; years (September 30, 2024: &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zluwOMal5HA3" title="Weighted average contractual life of options exercisable"&gt;5.48&lt;/span&gt; years) and for options exercisable was &lt;span id="xdx_90B_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331_zvyKflAdZpC9" title="Weighted average contractual life of options exercisable"&gt;4.16&lt;/span&gt; years (September 30, 2024: &lt;span id="xdx_90C_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240930_zHJ8b0iGmcV3" title="Weighted average contractual life of options exercisable"&gt;4.03&lt;/span&gt; years).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#x2019;s stock for the options
that were in-the-money at March 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;	The Company recognized share-based compensation expense of $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20241001__20250331_zMQ4RKqp3Old" title="Share based compensation expense"&gt;1.4&lt;/span&gt; million
and $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20250101__20250331_z033PHgEgZIc" title="Share based compensation expense"&gt;3.5&lt;/span&gt; million during the three and six months ended March 31, 2025, respectively (three and six months ended March 31, 2024: $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240331_zcoYkVYG7yZi" title="Share based compensation expense"&gt;2.7&lt;/span&gt; million
and $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20240331_zkKqgmf3ij5i" title="Share based compensation expense"&gt;4.9&lt;/span&gt; million, respectively) in connection with the issuance and vesting 	of stock options in exchange for services. These amounts
have been included in general and 	administrative expenses and research and development expenses on the Company&#x2019;s condensed consolidated
interim statements of 	operations as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zRh3T6c8zy4j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zGd4iqBHJun4" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsdePd72fJP4" style="width: 10%; text-align: right" title="Total share based compensation"&gt;605&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvVUtKpGRobj" style="width: 10%; text-align: right" title="Total share based compensation"&gt;979&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zaJVYaJQ91ll" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,407&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIJV7N6wQDvd" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,905&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTkDsIk0arsg" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;844&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zPPYzqwN8CP1" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;1,673&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zsepTg66hEZh" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,097&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQLcSQjTkXWg" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,033&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total share-based compensation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331_zp2UQISywiD7" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;1,449&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zYLvizQYIEQi" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,652&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331_zDiBuuC3BI8a" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,504&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331_zsdD1RzD9ITf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;4,938&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A1_zlExNPLG2s52" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An amount of approximately $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20250331_zmJuvYORp40a" title="Remaining stock based compensation"&gt;14.5&lt;/span&gt; million in share-based
compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal 2029.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of each stock option award is estimated
on the date of grant using the Black Scholes option pricing model. The fair value of share-based compensation charges recognized during
the three and six months ended March 31, 2025 was determined with reference to the quoted market price of the Company&#x2019;s shares on
the grant date and based on the following weighted average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zPvDuWDnFQRl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zqMPwOhpgEG" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20241001__20250331_zoyoowXnU3Bg" title="Risk-free interest rate"&gt;3.98&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240331_z4ohS6cP5BEc" title="Risk-free interest rate"&gt;4.28&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250331_zLU1pziZ19Re" title="Expected life of options (years)"&gt;5.56&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331_zfZGxXDHR0yg" title="Expected life of options (years)"&gt;5.74&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250331_zUu6KqaeQfKa" title="Annualized volatility"&gt;86.49&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240331_z1RY5hnHofR7" title="Annualized volatility"&gt;84.84&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20241001__20250331_zPt4K6lfFYX6" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240331_zA083g62GN2g" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AE_zQjOKf59jhb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000638">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--LeaseCostTableTextBlock_pn3n3_zwSPOL4WLGye" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_z306R9oBMXN" style="display: none"&gt;Schedule of operating lease costs&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_49A_20250101__20250331_zXvTohZieOh3" style="font-style: normal; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_493_20240101__20240331_ziUeuynH9xMc" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_495_20241001__20250331_zWoEmaQFPEE1" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_493_20231001__20240331_z2IVqBCiBZij" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-style: normal; text-align: center"&gt;&lt;span style="font-weight: normal; font-size: 10pt; font-style: normal"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="color: gray; font-weight: bold; font-style: normal; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Operating lease costs&lt;/td&gt;
&lt;td style="width: 3%; color: gray; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: normal; width: 1%; font-style: normal; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"&gt;33&lt;/td&gt;
&lt;td style="width: 1%; color: gray; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; color: gray; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: normal; width: 1%; font-style: normal; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"&gt;31&lt;/td&gt;
&lt;td style="width: 1%; color: gray; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; color: gray; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: normal; width: 1%; font-style: normal; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"&gt;66&lt;/td&gt;
&lt;td style="width: 1%; color: gray; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; color: gray; font-style: normal"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: normal; width: 1%; font-style: normal; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-weight: normal; width: 10%; font-style: normal; text-align: right"&gt;61&lt;/td&gt;
&lt;td style="width: 1%; color: gray; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000640"
      unitRef="USD">33000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000641"
      unitRef="USD">31000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000642"
      unitRef="USD">66000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000643"
      unitRef="USD">61000</us-gaap:OperatingLeaseCost>
    <us-gaap:DefinedContributionPlanDisclosuresTableTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000645">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zoNuCoesb418" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zgvvTFOaLGM5" style="display: none"&gt;Schedule of contributions under the plan&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_498_20250101__20250331_zo7hRpAFbtJe" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_49C_20240101__20240331_zzIMjpSm5Ag" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_492_20241001__20250331_zvYnMorIwb5b" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_499_20231001__20240331_zt9xe4YEHub6" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 11pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended March 31,&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six Months ended March 31&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--PensionContributions_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Contributions to 401(k) plan&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;67&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;94&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;115&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;167&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:DefinedContributionPlanDisclosuresTableTextBlock>
    <us-gaap:PensionContributions
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000647"
      unitRef="USD">67000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000648"
      unitRef="USD">94000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000649"
      unitRef="USD">115000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000650"
      unitRef="USD">167000</us-gaap:PensionContributions>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000657"
      unitRef="Shares">10000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000659"
      unitRef="USDPShares">12.00</avxl:WarrantsOutstandingWeightedAverageExercise>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2025-03-31" id="Fact000661">2026-04-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-03-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      id="Fact000663"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2024-10-012025-03-31_custom_StockOptionPlan2019Member"
      decimals="INF"
      id="Fact000665"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000667"
      unitRef="Shares">406453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2022-03-242022-03-25_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000669"
      unitRef="Shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <avxl:OptionIssued
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000676"
      unitRef="Shares">6751000</avxl:OptionIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-31_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000678"
      unitRef="Shares">3978702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000680">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_pn3n3_z9S8O13eYfzg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_zS9TXJDkRItc" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price &lt;br/&gt; ($)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value &lt;br/&gt; ($)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate intrinsic value &lt;br/&gt; ($)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, September 30, 2024&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoEaPYql32d4" style="width: 13%; text-align: right" title="Number of options, Outstanding beginning balance"&gt;15,037,754&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoToyiPYCpNa" style="width: 13%; text-align: right" title="Weighted average exercise price, Outstanding beginning balance"&gt;6.80&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3KMRIQOoSy6" style="width: 13%; text-align: right" title="Weighted average grant date fair value, Outstanding beginning balance"&gt;5.12&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7FOQOnkEFBb" style="width: 13%; text-align: right" title="Aggregate intrinsic value, Outstanding beginning balance"&gt;15,825,791&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjgRAX6Toh8k" style="text-align: right" title="Number of options, Granted"&gt;1,483,500&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z55T64KzlfX5" style="text-align: right" title="Weighted average exercise price, Granted"&gt;8.58&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbB1KsasrkVc" style="text-align: right" title="Weighted average grant date fair value, Granted"&gt;6.22&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zb5a8BIaPsmg" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Exercised"&gt;(820,632&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ze0qcpoGZEj4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Exercised"&gt;2.46&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBIWuwS0o07c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Exercised"&gt;1.89&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT0rQLLEcxK3" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Exercised"&gt;6,785,518&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding, March 31, 2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjgGMNZ5Achc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Outstanding beginning balance"&gt;15,700,622&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zapl6u6eG3ik" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding ending balance"&gt;7.19&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuLjeaneUI4j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, Outstanding ending balance"&gt;5.39&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zddXQqjIO2Kj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, Outstanding ending balance"&gt;38,630,198&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable, March 31, 2025&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_za09lPpzu9Fi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, Exercisable"&gt;10,346,086&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMW0ks6U2uB" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable"&gt;6.03&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvgz0pk0U7Pi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Exercisable"&gt;4.68&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zJcdPGwunFEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Exercisable"&gt;34,276,704&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000682"
      unitRef="Shares">15037754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000684"
      unitRef="USDPShares">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000686"
      unitRef="USDPShares">5.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000688"
      unitRef="USD">15825791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000690"
      unitRef="Shares">1483500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000692"
      unitRef="USDPShares">8.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000694"
      unitRef="USDPShares">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000696"
      unitRef="Shares">820632</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000698"
      unitRef="USDPShares">2.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000700"
      unitRef="USDPShares">1.89</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000702"
      unitRef="USD">6785518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000704"
      unitRef="Shares">15700622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000706"
      unitRef="USDPShares">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000708"
      unitRef="USDPShares">5.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000710"
      unitRef="USD">38630198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000712"
      unitRef="Shares">10346086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000714"
      unitRef="USDPShares">6.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000716"
      unitRef="USDPShares">4.68</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisablePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000718"
      unitRef="USD">34276704</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000720">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlIRqgbamqfc" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_8B0_zOvKWoDBishk" style="display: none"&gt;Schedule of summarizes information about stock options&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Range of exercises prices&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of outstanding &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average remaining contractual life (in&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average exercise&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of vested &lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average exercise&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;options&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; years)&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160; price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;options&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160; price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zrnGbCei2rd3" style="width: 10%; text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.92&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z52scwgkvHul" style="width: 12%; text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zSAurzpUAKbe" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,400,150&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z03dX8ExWOb5" title="Weighted average remaining contractual life (in years)"&gt;3.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zxSls1sXj7db" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.69&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zPymBH2v5m15" style="width: 10%; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,400,150&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zCun6LKsZWab" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.69&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zBiOs6e9ODdl" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.01&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zyoEroYMf3u" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zffZhWgKcf9d" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,197,500&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zurDYdWYyMXc" title="Weighted average remaining contractual life (in years)"&gt;3.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zSnbeNfoWgk4" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.41&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zTBZD18vTfej" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,027,916&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zp4vRIlaj22a" style="text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.31&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zTaxbaDflOLj" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.01&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zWkAAlJQsaI1" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zvuSVhzoEaA" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,028,972&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zGGjzbtrmZm8" title="Weighted average remaining contractual life (in years)"&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zmu2LkvBC4Ee" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.95&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zaNQFSp8JOn4" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,297,519&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zNcGZkFQBZAl" style="text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.39&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z69JunRT9rya" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.01&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zPJraIoaxcNg" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z1kQsNImJ2p9" style="text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,609,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zvfOZMHD6tia" title="Weighted average remaining contractual life (in years)"&gt;6.81&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zO46Ji9l9SOg" style="text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.29&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zFgDHNVAFGqa" style="text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;998,834&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z3cdhYlhr5z4" style="text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.42&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zXTCt5aJdsId" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.01&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zGqvDBOJrpa5" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zUkMsMVzpcQ5" style="border-bottom: black 1pt solid; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,465,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zqDDFS6JsUe3" title="Weighted average remaining contractual life (in years)"&gt;5.97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zKKvCc09J06j" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.18&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zDZG5Pgw9TO1" style="border-bottom: black 1pt solid; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;621,667&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zBLqMqPkvQC4" style="border-bottom: black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18.34&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZx9d33psFFi" style="border-bottom: black 2.25pt double; text-align: right" title="Number of outstanding options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,700,622&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm0Xt9SnbzZb" title="Weighted average remaining contractual life (in years)"&gt;5.59&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6fSVe9l7uT6" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.19&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20241001__20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKoKRgQHLD6i" style="border-bottom: black 2.25pt double; text-align: right" title="Number of vested options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10,346,086&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPN9U7MMCaic" style="border-bottom: black 2.25pt double; text-align: right" title="Weighted average exercise price options vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.03&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000722"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000724"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000726"
      unitRef="Shares">2400150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      id="Fact000728">P3Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000730"
      unitRef="USDPShares">2.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000732"
      unitRef="Shares">2400150</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000734"
      unitRef="USDPShares">2.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000736"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000738"
      unitRef="USDPShares">5.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000740"
      unitRef="Shares">2197500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      id="Fact000742">P3Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000744"
      unitRef="USDPShares">3.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000746"
      unitRef="Shares">2027916</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000748"
      unitRef="USDPShares">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000750"
      unitRef="USDPShares">5.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000752"
      unitRef="USDPShares">9.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000754"
      unitRef="Shares">8028972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      id="Fact000756">P6Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000758"
      unitRef="USDPShares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000760"
      unitRef="Shares">4297519</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000762"
      unitRef="USDPShares">6.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000764"
      unitRef="USDPShares">9.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000766"
      unitRef="USDPShares">13.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000768"
      unitRef="Shares">1609000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      id="Fact000770">P6Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000772"
      unitRef="USDPShares">10.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000774"
      unitRef="Shares">998834</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000776"
      unitRef="USDPShares">10.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000778"
      unitRef="USDPShares">13.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000780"
      unitRef="USDPShares">25.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000782"
      unitRef="Shares">1465000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      id="Fact000784">P5Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000786"
      unitRef="USDPShares">18.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000788"
      unitRef="Shares">621667</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000790"
      unitRef="USDPShares">18.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000792"
      unitRef="Shares">15700622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember"
      id="Fact000794">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000796"
      unitRef="USDPShares">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-10-012025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000798"
      unitRef="Shares">10346086</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000800"
      unitRef="USDPShares">6.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000802"
      unitRef="USDPShares">4.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-012024-09-30"
      decimals="INF"
      id="Fact000804"
      unitRef="USDPShares">4.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2024-10-01to2025-03-31" id="Fact000806">P5Y7M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2023-10-012024-09-30" id="Fact000808">P5Y5M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <avxl:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2 contextRef="From2024-10-01to2025-03-31" id="Fact000810">P4Y1M28D</avxl:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2>
    <avxl:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2 contextRef="From2023-10-012024-09-30" id="Fact000812">P4Y10D</avxl:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-10-01to2025-03-31"
      decimals="-5"
      id="Fact000819"
      unitRef="USD">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-03-31"
      decimals="-5"
      id="Fact000821"
      unitRef="USD">3500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-10-012024-03-31"
      decimals="-5"
      id="Fact000823"
      unitRef="USD">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-5"
      id="Fact000825"
      unitRef="USD">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000827">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zRh3T6c8zy4j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zGd4iqBHJun4" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsdePd72fJP4" style="width: 10%; text-align: right" title="Total share based compensation"&gt;605&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zvVUtKpGRobj" style="width: 10%; text-align: right" title="Total share based compensation"&gt;979&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zaJVYaJQ91ll" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,407&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIJV7N6wQDvd" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,905&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTkDsIk0arsg" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;844&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zPPYzqwN8CP1" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;1,673&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zsepTg66hEZh" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,097&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQLcSQjTkXWg" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,033&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total share-based compensation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--ShareBasedCompensation_pn3n3_c20250101__20250331_zp2UQISywiD7" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;1,449&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zYLvizQYIEQi" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,652&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20241001__20250331_zDiBuuC3BI8a" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,504&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331_zsdD1RzD9ITf" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;4,938&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000829"
      unitRef="USD">605000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000831"
      unitRef="USD">979000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-012025-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000833"
      unitRef="USD">1407000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000835"
      unitRef="USD">1905000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000837"
      unitRef="USD">844000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000839"
      unitRef="USD">1673000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-012025-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000841"
      unitRef="USD">2097000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000843"
      unitRef="USD">3033000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000845"
      unitRef="USD">1449000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000847"
      unitRef="USD">2652000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2025-03-31"
      decimals="-3"
      id="Fact000849"
      unitRef="USD">3504000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-03-31"
      decimals="-3"
      id="Fact000851"
      unitRef="USD">4938000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2025-03-31"
      decimals="-5"
      id="Fact000853"
      unitRef="USD">14500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000855">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock_zPvDuWDnFQRl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zqMPwOhpgEG" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20241001__20250331_zoyoowXnU3Bg" title="Risk-free interest rate"&gt;3.98&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240331_z4ohS6cP5BEc" title="Risk-free interest rate"&gt;4.28&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241001__20250331_zLU1pziZ19Re" title="Expected life of options (years)"&gt;5.56&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331_zfZGxXDHR0yg" title="Expected life of options (years)"&gt;5.74&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20241001__20250331_zUu6KqaeQfKa" title="Annualized volatility"&gt;86.49&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240331_z1RY5hnHofR7" title="Annualized volatility"&gt;84.84&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20241001__20250331_zPt4K6lfFYX6" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240331_zA083g62GN2g" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</avxl:ScheduleOfShareBasedPaymentWeightedAverageValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000857"
      unitRef="Pure">0.0398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-10-012024-03-31"
      decimals="INF"
      id="Fact000859"
      unitRef="Pure">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-10-01to2025-03-31" id="Fact000861">P5Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-10-012024-03-31" id="Fact000863">P5Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000865"
      unitRef="Pure">0.8649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-10-012024-03-31"
      decimals="INF"
      id="Fact000867"
      unitRef="Pure">0.8484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-10-01to2025-03-31"
      decimals="INF"
      id="Fact000869"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-10-012024-03-31"
      decimals="INF"
      id="Fact000871"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-10-01to2025-03-31" id="Fact000873">&lt;p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zqshjQVK9aVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Note 7	&lt;span id="xdx_822_zAW7x0rQUdWi"&gt;Subsequent Events&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates subsequent events occurring
between the most recent balance sheet date and the date the financial statements are available to be issued in order to determine whether
the subsequent events are to be recorded and/or disclosed in the Company&#x2019;s financial statements and footnotes. The financial statements
are considered to be available to be issued at the time they are filed with the Securities and Exchange Commission (SEC).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 17, 2025, the Board approved, subject to
stockholder approval, an amendment to the 2022 Plan (the &#x201c;Amendment&#x201d;). The Amendment, if approved by stockholders, will increase
the number of shares of common stock reserved for issuance under the 2022 Plan by &lt;span id="xdx_904_ecustom--SharesOfCommonStockReservedForIssuance_iI_pip0_c20250417__us-gaap--SubsegmentsAxis__us-gaap--SubsequentEventMember_zxmnbP0IA1ai" title="Shares of common stock reserved for issuance"&gt;4,000,000&lt;/span&gt; shares. In addition, the Amendment will establish
a minimum vesting period of one year for all awards granted under the Plan and limit the discretion to accelerate the vesting of awards
upon a separation from service, with limited exceptions permitted. Finally, the Amendment would prohibit liberal share recycling provisions.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <avxl:SharesOfCommonStockReservedForIssuance
      contextRef="AsOf2025-04-17_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000875"
      unitRef="Shares">4000000</avxl:SharesOfCommonStockReservedForIssuance>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-01to2025-03-31" id="Fact000876">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-01to2025-03-31" id="Fact000877">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-01to2025-03-31" id="Fact000878">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-01to2025-03-31" id="Fact000879">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
